Novel carboxylesterase nucleic acid molecules, proteins and uses thereof

ABSTRACT

The present invention relates to arthropod esterase proteins; to arthropod esterase nucleic acid molecules, including those that encode such esterase proteins; to antibodies raised against such esterase proteins; and to other compounds that inhibit arthropod esterase activity. The present invention also includes methods to obtain such proteins, nucleic acid molecules, antibodies, and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, nucleic acid molecules, antibodies and/or inhibitory compounds as well as the use of such therapeutic compositions to protect animals from hematophagous arthropod infestation.

FIELD OF THE INVENTION

[0001] The present invention relates to arthropod esterase nucleic acid molecules, proteins encoded by such nucleic acid molecules, antibodies raised against such proteins, and inhibitors of such proteins. The present invention also includes therapeutic compositions comprising such nucleic acid molecules, proteins, antibodies, and/or other inhibitors, as well as their use to protect an animal from hematophagous arthropod infestation.

BACKGROUND OF THE INVENTION

[0002] Hematophagous arthropod infestation of animals is a health and economic concern because hematophagous arthropods are known to cause and/or transmit a variety of diseases. Hematophagous arthropods directly cause a variety of diseases, including allergies, and also carry a variety of infectious agents including, but not limited to, endoparasites (e.g., nematodes, cestodes, trematodes and protozoa), bacteria and viruses. In particular, the bites of hematophagous arthropods are a problem for animals maintained as pets because the infestation becomes a source of annoyance not only for the pet but also for the pet owner who may find his or her home generally contaminated with insects. As such, hematophagous arthropods are a problem not only when they are on an animal but also when they are in the general environment of the animal.

[0003] Bites from hematophagous arthropods are a particular problem because they not only can lead to disease transmission but also can cause a hypersensitive response in animals which is manifested as disease. For example, bites from fleas can cause an allergic disease called flea allergic (or allergy) dermatitis (FAD). A hypersensitive response in animals typically results in localized tissue inflammation and damage, causing substantial discomfort to the animal.

[0004] The medical importance of arthropod infestation has prompted the development of reagents capable of controlling arthropod infestation. Commonly encountered methods to control arthropod infestation are generally focused on use of insecticides. While some of these products are efficacious, most, at best, offer protection of a very limited duration. Furthermore, many of the methods are often not successful in reducing arthropod populations. In particular, insecticides have been used to prevent hematophagous arthropod infestation of animals by adding such insecticides to shampoos, powders, collars, sprays, foggers and liquid bath treatments (i.e., dips). Reduction of hematophagous arthropod infestation on the pet has been unsuccessful for one or more of the following reasons: (1) failure of owner compliance (frequent administration is required); (2) behavioral or physiological intolerance of the pet to the pesticide product or means of administration; and (3) the emergence of hematophagous arthropod populations resistant to the prescribed dose of pesticide. However, hematophagous arthropod populations have been found to become resistant to insecticides.

[0005] Prior investigators have described insect carboxylesterase (CE) protein biochemistry, for example, Chen et al., Insect Biochem. Molec. Biol., 24:347-355, 1994; Whyard et al., Biochemical Genetics, 32:924, 1994 and Argentine et al., Insect Biochem. Molec Biol, 25:621-630, 1995. Other investigators have disclosed certain insect CE amino acid sequences, for example, Mouches et al., Proc Natl Acad Sci USA, 87:2574-2578, 1990 and Cooke et al., Proc Natl Acad Sci USA, 86:1426-1430, 1989, and nucleic acid sequence (Vaughn et al., J. Biol. Chem., 270:17044-17049, 1995).

[0006] Prior investigators have described certain insect juvenile hormone esterase (JHE) nucleic acid and amino acid sequences: for example, sequence for Heliothis virescens is disclosed by Hanzlik et al., J. Biol. Chem., 264:12419-12425, 1989; Eldridge et al., App Environ Microbiol, 58:1583-1591, 1992; Bonning et al., Insect Biochem. Molec. Biol., 22:453-458, 1992; Bonning et al., Natural and Engineered Pest Management Agents, pp. 368-383, 1994 and Harshman et al., Insect Biochem. Molec. Biol, 24:671-676, 1994; sequence for Manduca sexta

-s disclosed by Vankatesh et al., J Biol Chem, 265:21727-21732, 1990; sequence for Trichopulsia ni is disclosed by Venkataraman et al., Dev. Genet., 15:391-400, 1994 and Jones et al., Biochem. J., 302:827-835, 1994; and sequence for Lymantria dispar is disclosed by Valaitis, Insect Biochem. Molec. Biol., 22:639-648, 1992.

[0007] Identification of an esterase of the present invention is unexpected, however, because even the most similar nucleic acid sequence identified by previous investigators could not be used to identify an esterase of the present invention. In addition, identification of an esterase protein of the present invention is unexpected because a protein fraction from flea prepupal larvae that was obtained by monitoring for serine protease activity surprisingly also contained esterase proteins of the present invention.

[0008] In summary, there remains a need to develop a reagent and a method to protect animals or plants from hematophagous arthropod infestation.

SUMMARY OF THE INVENTION

[0009] The present invention relates to a novel product and process for protection of animals or plants from arthropod infestation. According to the present invention there are provided arthropod esterase proteins and mimetopes thereof; arthropod nucleic acid molecules, including those that encode such proteins; antibodies raised against such esterase proteins (i.e., anti-arthropod esterase antibodies); and compounds that inhibit arthropod esterase activity (i.e, inhibitory compounds or inhibitors).

[0010] The present invention also includes methods to obtain such proteins, mimetopes, nucleic acid molecules, antibodies and inhibitory compounds. Also included in the present invention are therapeutic compositions comprising such proteins, mimetopes, nucleic acid molecules, antibodies, and/or inhibitory compounds, as well as use of such therapeutic compositions to protect animals from arthropod infestation.

[0011] Identification of an esterase of the present invention is unexpected, however, because the most similar nucleic acid sequence identified by previous investigators could not be used to identify an esterase of the present invention. In addition, identification of an esterase protein of the present invention is unexpected because a protein fraction from flea prepupal larvae that was obtained by monitoring for serine protease activity surprisingly also contained esterase proteins of the present invention.

[0012] One embodiment of the present invention is an isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene comprising a nucleic acid sequence including SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74.

[0013] The present invention also includes a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule encoding a protein comprising at least one of the following amino acid sequences:SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and/or SEQ ID NO:74; and particularly a nucleic acid molecule that hybridizes with a nucleic acid sequence that is a complement of a nucleic acid sequence encoding any of the amino acid sequences. A preferred nucleic acid molecule of the present invention includes a nucleic acid molecule comprising a nucleic acid sequence including SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74, and allelic variants thereof.

[0014] The present invention also includes an isolated carboxylesterase nucleic acid molecule comprising a nucleic acid sequence encoding a protein comprising an amino acid sequence including SEQ ID NO:5, SEQ ID NO:19, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44 and/or SEQ ID NO:53. SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43 and SEQ ID NO:44 represent N-terminal amino acid sequences of carboxylesterases isolated from prepupal flea larvae, the production of which are described in the Examples of the present application.

[0015] The present invention also relates to recombinant molecules, recombinant viruses and recombinant cells that include a nucleic acid molecule of the present invention. Also included are methods to produce such nucleic acid molecules, recombinant molecules, recombinant viruses and recombinant cells.

[0016] Another embodiment of the present invention includes an isolated esterase protein that is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to (a) a nucleic acid molecule that includes at least one of the following nucleic acid sequences:SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:38, SEQ ID NO:52, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:69, and SEQ ID NO:71; and/or (b) a nucleic acid molecule encoding a protein including at least one of the following amino acid sequences: SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55 and SEQ ID NO:74. One embodiment is a carboxylesterase protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to a nucleic acid molecule that encodes a protein comprising at least one of the following amino acid sequences: SEQ ID NO:5, SEQ ID NO:19; SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44 and/or SEQ ID NO:53. Preferred proteins of the present invention are isolated flea proteins including at least one of the following amino acid sequences:SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; also included are proteins encoded by allelic variants of nucleic acid molecules encoding proteins comprising any of the above-listed amino acid sequences.

[0017] The present invention also relates to mimetopes of arthropod esterase proteins as well as to isolated antibodies that selectively bind to arthropod esterase proteins or mimetopes thereof. Also included are methods, including recombinant methods, to produce proteins, mimetopes and antibodies of the present invention.

[0018] The present invention also includes a formulation of flea carboxylesterase proteins, in which the proteins, when submitted to 14% Tris-glycine SDS-PAGE, comprise a fractionation profile as depicted in FIG. 3, in which the proteins have carboxylesterase activity.

[0019] Also included in the present invention is a formulation of flea carboxylesterase proteins, in which the proteins, when submitted to IEF-PAGE, comprise a fractionation profile as depicted in FIG. 4, lane 3, lane 4, lane 5, lane 6 and/or lane 7, wherein the proteins have carboxylesterase activity.

[0020] Another embodiment of the present invention is an isolated flea protein or a formulation of flea proteins that hydrolyzes α-napthyl acetate to produce α-napthol, when the protein is incubated in the presence of α-napthyl acetate contained in 20 mM Tris at pH 8.0 for about 15 minutes at about 37° C.

[0021] Yet another embodiment of the present invention is an isolated flea protein or a formulation of flea proteins that hydrolyzes the methyl ester group of juvenile hormone to produce a juvenile hormone acid.

[0022] Another embodiment of the present invention is a method to identify a compound capable of inhibiting flea carboxylesterase activity, the method comprising: (a) contacting an isolated flea carboxylesterase with a putative inhibitory compound under conditions in which, in the absence of the compound, the protein has carboxylesterase activity; and (b) determining if the putative inhibitory compound inhibits the activity. Also included in the present invention is a test kit to identify a compound capable of inhibiting flea carboxylesterase activity, the test kit comprising an isolated flea carboxylesterase protein having esterase activity and a means for determining the extent of inhibition of the activity in the presence of a putative inhibitory compound.

[0023] Yet another embodiment of the present invention is a therapeutic composition that is capable of reducing hematophagous ectoparasite infestation. Such a therapeutic composition includes at least one of the following protective compounds: an isolated hematophagous ectoparasite carboxylesterase protein or a mimetope thereof, an isolated carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene, an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein, and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase. A therapeutic composition of the present invention can also include an excipient, an adjuvant and/or a carrier. Preferred esterase nucleic acid molecule compounds of the present invention include naked nucleic acid vaccines, recombinant virus vaccines and recombinant cell vaccines. Also included in the present invention is a method to protect an animal from hematophagous ectoparasite infestation, comprising the step of administering to the animal a therapeutic composition of the present invention.

BRIEF DESCRIPTION OF THE FIGURES

[0024]FIG. 1 depicts SDS-PAGE analysis of DFP-labeled esterase proteins.

[0025]FIG. 2 depicts carboxylesterase activity of certain esterase proteins of the present invention.

[0026]FIG. 3 depicts SDS-PAGE analysis of carboxylesterase activity of certain esterase proteins of the present invention.

[0027]FIG. 4 depicts IEF analysis of certain esterase proteins of the present invention.

[0028]FIG. 5 depicts juvenile hormone esterase activity of certain esterase proteins of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

[0029] The present invention provides for isolated arthropod esterase proteins, isolated arthropod esterase nucleic acid molecules, antibodies directed against arthropod esterase proteins and other inhibitors of arthropod esterase activity. As used herein, the terms isolated arthropod esterase proteins and isolated arthropod esterase nucleic acid molecules refers to esterase proteins and esterase nucleic acid molecules derived from arthropods and, as such, can be obtained from their natural source or can be produced using, for example, recombinant nucleic acid technology or chemical synthesis. Also included in the present invention is the use of these proteins, nucleic acid molecules, antibodies and inhibitors as therapeutic compositions to protect animals from hematophagous ectoparasite infestation as well as in other applications, such as those disclosed below.

[0030] Arthropod esterase proteins and nucleic acid molecules of the present invention have utility because they represent novel targets for anti-arthropod vaccines and drugs.

[0031] The products and processes of the present invention are advantageous because they enable the inhibition of arthropod development, metamorphosis, feeding, digestion and reproduction processes that involve esterases. While not being bound by theory, it is believed that expression of arthropod esterase proteins are developmentally regulated, thereby suggesting that esterase proteins are involved in arthropod development and/or reproduction. The present invention is particularly advantageous because the proteins of the present invention were identified in larval fleas, thereby suggesting the importance of the proteins as developmental proteins.

[0032] One embodiment of the present invention is an esterase formulation that includes one or more esterase proteins capable of binding to diisopropylfluorophosphate (DFP). A preferred embodiment of an esterase formulation of the present invention comprises one or more arthropod esterase proteins that range in molecular weight from about 20 kilodaltons (kD) to about 200 kD, more preferably from about 40 kD to about 100 kD, and even more preferably from about 60 kD to about 75 kD, as determined by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis). An even more preferred formulation includes one or more flea esterase proteins having elution (or migration) patterns as shown in FIG. 1.

[0033] Another embodiment of the present invention is a formulation comprising one or more hematophagous ectoparasite carboxylesterase (CE) proteins. The present invention includes the discovery that such a formulation has general CE activity. General CE activity can be identified using methods known to those of skill in the art and described in the Examples section herein. A suitable formulation of the present invention comprises one or more flea proteins capable of hydrolyzing α-napthyl acetate to produce α-napthol when the proteins are incubated in the presence of α-napthyl acetate contained in 20 mm Tris at pH 8.0 for about 15 minutes at about 37° C. General CE activity can be identified following such incubation by detecting the production of from about 0.3 to about 2.5 absorbance units in the presence of Fast Blue when measured at 590 nm.

[0034] A preferred CE formulation of the present invention includes one or more flea CE proteins having acidic to neutral isoelectric points, or pI values. An isoelectric pH, or pI, value refers to the pH value at which a molecule has no net electric charge and fails to move in an electric field. A preferred formulation of the present invention includes one or more proteins having a pI value ranging from about pI 2 to about 10, more preferably from about pI 3 to about 8, and even more preferably from about pI 4.7 to about 5.2, as determined by IEF-PAGE.

[0035] An esterase formulation, including a CE formulation, of the present invention can be prepared by a method that includes the steps of: (a) preparing an extract by isolating flea tissue, homogenizing the tissue by sonication and clarifying the extract by centrifugation at a low speed spin, e.g., about 18,000 rpm for about 30 minutes; (b) recovering soluble proteins from said centrifuged extract and applying the proteins to a p-aminobenzamidine agarose bead column; (c) recovering unbound protein from the column and clarifying by filtration; (d) applying the clarified protein to a gel filtration column and eluting and collecting fractions with esterase activity; (e) dilayzing the eluate against 20 mM MES buffer, pH 6.0, containing 10 mM NaCl; (f) applying the dialysate to a cation exchange chromatography column, eluting protein bound to the column with a linear gradier of from about 10 mM NaCl to about 1 M NaCl in 20 mM MES buffer, pH 6, and collecting fractions having esterase activity; (g) adjusting the pH of the resulting fractions to pH 7 and applying the fractions to an anion exchange chromatography column; (h) eluting protein bound to the column with a linear gradient of from about 0 to about 1 M NaCl in 25 mM Tris buffer, pH 6.8 and collecting fractions having esterase activity, such activity elutes from the column at about 170 mM NaCl.

[0036] Tissue can be obtained from unfed fleas or from fleas that recently consumed a blood meal (i.e., blood-fed fleas). Such flea tissues are referred to herein as, respectively, unfed flea and fed flea tissue. Preferred flea tissue from which to obtain an esterase formulation of the present invention includes pre-pupal larval tissue, wandering flea larvae, 3rd instar tissue, fed adult tissue and unfed adult tissue.

[0037] In a preferred embodiment, a CE formulation of the present invention comprises a flea protein comprising amino acid sequence SEQ ID NO:5, SEQ ID NO:19, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44 and/or SEQ ID NO:53.

[0038] Another embodiment of the present invention is a juvenile hormone esterase (JHE) formulation comprising one or more arthropod JHE proteins, the arthropod being of the order Hemiptera, Anoplura, Mallophaga, Diptera, Siphonaptera, Parasitiformes, Acariformes and Acarina. The present invention includes the discovery that such a formulation has JHE activity. JHE activity can be identified using methods known to those of skill in the art and described in the Examples section herein. A suitable formulation of the present invention comprises one or more arthropod proteins capable of hydrolyzing a methyl ester group of juvenile hormone to produce a juvenile hormone acid. Preferably, such a protein is capable of releasing of at least about 120 counts per minute when such a protein is incubated in the presence of ³H-juvenile hormone to create a reaction mixture, the reaction mixture is combined with isooctane, the aqueous phase is recovered and the amount of ³H-juvenile hormone present in that phase is determined. Such a protein is also preferably capable of causing release of methane thiol when such protein is incubated in the presence of methyl 1-heptylthioacetothioate (HEPTAT) using the method generally disclosed in McCutchen et al., Insect Biochem. Molec. Biol., Vol. 25, No. 1, pg 119-126, 1995, which is incorporated in its entirety by this reference.

[0039] In one embodiment, a juvenile hormone esterase formulation of the present invention comprises a protein comprising amino acid sequence SEQ ID NO:74.

[0040] According to the present invention, an arthropod that is not of the order lepidoptera includes an arthropod of the order Hemiptera, Anoplura, Mallophaga, Diptera, Siphonaptera, Parasitiformes, Acariformes and Acarina. Preferred arthropods include Hemiptera cimicidae, Hemiptera reduviidae, Anoplura pediculidae, Anoplura pthiridae, Diptera culicidae, Diptera simuliidae, Diptera psychodidae, Diptera ceratopogonidae, Diptera chaoboridae, Diptera tabanidae, Diptera rhagionidae, athericidae, Diptera chloropidae, Diptera muscidae, Diptera hippoboscidae, Diptera calliphoridae, Diptera sarcophagidae, Diptera oestridae, Diptera gastrophilidae, Diptera cuterebridae, Siphonaptera ceratophyllidae, Siphonaptera leptopsyllidae, Siphonaptera pulicidae, Siphonaptera tungidae, Parasitiformes dermanyssidae, Acariformes tetranychidae, Acariformes cheyletide, Acariformes demodicidae, Acariformes erthraeidae, Acariformes trombiculidae, Acariformes psoroptidae, Acariformes sarcoptidae, Acarina argasidae and Acarina ixodidae. Preferred Diptera muscidae include Musca, Hydrotaea, Stomoxys Haematobia. Preferred Siphonaptera include Ceratophyllidae nosopsyllus, Ceratophyllidae diamanus, Ceratophyllidae ceratophyllus, Leptopsyllidae leptopsylla, Pulicidae pulex, Pulicidae ctenocephalides, Pulicidae xenopsylla, Pulicidae echidnophaga and Tungidae tunga. Preferred Parasitiformes dermanyssidae include Ornithonyssus and Liponyssoides. Preferred Acarina include Argasidae argas, Argasidae ornithodoros, Argasidae otobius Ixodidae ixodes, Ixodidae hyalomma, Ixodidae nosomma, Ixodidae rhipicephalus, Ixodidae boophilus, Ixodidae dermacentor; Ixodidae haemaphysalus, Ixodidae amblyomma and Ixodidae anocentor.

[0041] One embodiment of a JHE formulation of the present invention is one or more arthropod JHE proteins that range in molecular weight from about 20 kD to about 200 kD, more preferably from about 40 kD to about 100 kD, and even more preferably from about 60 kD to about 75 kD, as determined by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis).

[0042] A JHE formulation of the present invention can be prepared by a method (hat includes the steps of: (a) preparing soluble proteins from arthropod extracts as described above for CE purification and purifying such soluble proteins by gel filtration; (b) collecting fractions having JHE activity from the gel filtration step, loading the fractions onto a cation exchange column, eluting the cation exchange column with a linear gradient of from about 10 mM NaCl to about 1 M NaCl in 20 mM MES buffer, pH 6 and collecting fractions having JHE activity; (c) adjusting the pH of the collected fractions to about pH 7 are dialyzed against about 10 mM phosphate buffer (pH 7.2) containing about 10 mM NaCl; (d) applying the dialysate to a hydroxyapatite column, eluting protein bound to the column with a linear gradient of from about 10 mM phosphate buffer (pH 7.2) containing 10 mM NaCl to about 0.5 M phosphate buffer (pH 6.5) containing 10 mM NaCl and collecting fractions having JHE activity; (e) dialyzing the fractions against 20 mM Tris buffer (pH 8.0) containing 10 mM NaCl; (f) applying the dialysate an anion exchange chromatography column and eluting protein bound to the column with a linear gradient of from about 10 mM to about 1 M NaCl in 20 mM Tris buffer, pH 8 and collecting fractions containing JHE activity.

[0043] A JHE formulation of the present invention can be prepared by a method that includes the steps of: (a) preparing flea extracts as described herein in the Examples section and applying the extract to p-aminobenzamidine linked agarose beads and collecting protein not bound to the beads; (b) applying the unbound protein to a Superdex 200 HR gel filtration column and collecting fractions having JHE activity; (c) applying the fractions to an anion exchange chromatography column, eluting the anion exchange column with a linear gradient of 0 to 1 M NaCl in 25 mM Tris buffer, pH 6.8 and collecting fractions having JHE activity; (d) dialyzing the fractions overnight against about 1 L of 20 mM Tris buffer, pH 8.0, containing 10 mM NaCl; (e) applying the dialysate to a Poros 10 HQ anion exchange column, eluting the column with buffer containing about 120 mM NaCl and collecting fractions having JHE activity.

[0044] Suitable arthropods from which to isolate a JHE formulation of the present invention include, but are not limited to agricultural pests, stored product pests, forest pests, structural pests or animal health pests. Suitable agricultural pests of the present invention include, but are not limited to Colorado potato beetle., corn earworms, fleahoppers, weevils, pink boll worms, cotton aphids, beet armyworms, lygus bugs, hessian flies, sod webworms, whites grubs, diamond back moths, white flies, planthoppers, leafhoppers, mealy bugs, mormon crickets and mole crickets. Suitable stored product pests of the present invention include, but are not limited to dermestids, anobeids, saw toothed grain beetles, indian mealmoths, flour beetles, long-horn wood boring beetles and metallic wood boring beetles. Suitable forest pests of the present invention include, but are not limited to southern pine bark bettles, gypsy moths, elm beetles, ambrosia bettles, bag worms, tent worms and tussock moths. Suitable structural pests of the present invention include, but are not limited to, bess beetles, termites, fire ants, carpenter ants, wasps, hornets, cockroaches, silverfish, Musca domestica and Musca autumnalis. Suitable animal health pests of the present invention include, but are not limited to fleas, ticks, mosquitoes, black flies, lice, true bugs, sand flies, Psychodidae, tsetse flies, sheep blow flies, cattle grub, mites, horn flies, heel flies, deer flies, Culicoides and warble flies. Preferred arthropods from which to isolate a JHE formulation of the present invention include fleas, midges, mosquitos, sand flies, black flies, horse flies, snipe flies, louse flies, horn flies, deer flies, tsetse flies, buffalo flies, blow flies, stable flies, myiasis-causing flies, biting gnats, lice, mites, bee, wasps, ants, true bugs and ticks, preferably fleas, ticks and blow flies, and more preferably fleas. Preferred fleas from which to isolate JHE proteins include Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla. More preferred fleas include Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla (Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans, with C. felis being even more preferred.

[0045] Suitable tissue from which to isolate a JHE formulation of the present invention includes unfed fleas or fleas that recently consumed a blood meal (i.e., blood-fed fleas). Such flea tissues are referred to herein as, respectively, unfed flea and fed flea tissue. Preferred flea tissue from which to obtain a JHE formulation of the present invention includes pre-pupal larval tissue, 3rd instar tissue, fed or unfed adult tissue, with unfed adult gut tissue being more preferred than fed or unfed whole adult tissue. It is of note that a JHE formulation of the present invention obtained from pre-pupal larval tissue does not hydrolyze α-napthyl acetate.

[0046] Another embodiment of the present invention is an esterase formulation comprising a combination of one or more arthropod CE and JHE proteins of the present invention. Suitable arthropods from which to isolate a combined CE and JHE formulation include those arthropods described herein for the isolation of a JHE formulation of the present invention. Preferred arthropods from which to isolate a combined CE and JHE formulation include fleas, midges, mosquitos, sand flies, black flies, horse flies, horn flies, deer flies, tsetse flies, buffalo flies, blow flies, stable flies, myiasis-causing flies, biting gnats, lice, bee, wasps, ants, true bugs and ticks, preferably fleas, ticks and blow flies, and more preferably fleas. Suitable flea tissue from which to isolate a combined CE and JHE formulation of the present invention includes 3rd instar tissue, fed or unfed adult tissue and unfed adult tissue, with unfed adult gut tissue being more preferred than fed or unfed whole adult tissue.

[0047] In one embodiment, a formulation of the present invention comprises an esterase having both CE and JHE activity. Preferably, a formulation of the present invention that comprises an esterase having both CE and JHE activity comprises a flea protein comprising amino acid sequence SEQ ID NO:8 and/or SEQ ID NO:37.

[0048] Another embodiment of the present invention is an isolated protein comprising an arthropod esterase protein. It is to be noted that the term “a” or “an” entity refers to one or more of that entity; for example, a protein refers to one or more proteins or at least one protein. As such, the terms “a” (or “an”), “one or more” and “at least one” can be used interchangeably herein. It is also to be noted that the terms “comprising”, “including”, and “having” can be used interchangeably. Furthermore, a compound “selected from the group consisting of” refers to one or more of the compounds in the list that follows, including mixtures (i.e., combinations) of two or more of the compounds. According to the present invention, an isolated, or biologically pure, protein, is a protein that has been removed from its natural milieu. As such, “isolated” and “biologically pure” do not necessarily reflect the extent to which the protein has been purified. An isolated protein of the present invention can be obtained from its natural source, can be produced using recombinant DNA technology or can be produced by chemical synthesis.

[0049] As used herein, an isolated arthropod esterase protein can be a full-length protein or any homolog of such a protein. An isolated protein of the present invention, including a homolog, can be identified in a straight-forward manner by the protein's ability to elicit an immune response against arthropod esterase proteins, to hydrolyze α-napthyl acetate, to hydrolyze the methyl ester group of juvenile hormone or bind to DFP. Esterase proteins of the present invention include CE and JHE proteins. As such, an esterase protein of the present invention can comprise a protein capable of hydrolyzing α-napthyl acetate, hydrolyzing the methyl ester group of juvenile hormone and/or binding to DFP. Examples of esterase homologs include esterase proteins in which amino acids have been deleted (e.g., a truncated version of the protein, such as a peptide), inserted, inverted, substituted and/or derivatized (e.g., by glycosylation, phosphorylation, acetylation, myristoylation, prenylation, palmitoylation, amidation and/or addition of glycerophosphatidyl inositol) such that the homolog includes at least one epitope capable of eliciting an immune response against an arthropod esterase protein. That is, when the homolog is administered to an animal as an immunogen, using techniques known to those skilled in the art, the animal will produce an immune response against at least one epitope of a natural arthropod esterase protein. The ability of a protein to effect an immune response, can be measured using techniques known to those skilled in the art. Esterase protein homologs of the present invention also include esterase proteins that hydrolyze α-napthyl acetate and/or that hydrolyze the methyl ester group of juvenile hormone.

[0050] Arthropod esterase protein homologs can be the result of natural allelic variation or natural mutation. Esterase protein homologs of the present invention can also be produced using techniques known in the art including, but not limited to, direct modifications to the protein or modifications to the gene encoding the protein using, for example, classic or recombinant nucleic acid techniques to effect random or targeted mutagenesis.

[0051] Isolated esterase proteins of the present invention have the further characteristic of being encoded by nucleic acid molecules that hybridize under stringent hybridization conditions to a gene encoding a Ctenocephalides felis protein (i.e., a C. felis esterase gene). As used herein, stringent hybridization conditions refer to standard hybridization conditions under which nucleic acid molecules, including oligonucleotides, are used to identify similar nucleic acid molecules. Such standard conditions are disclosed, for example, in Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Labs Press, 1989; Sambrook et al., ibid., is incorporated by reference herein in its entirety. Stringent hybridization conditions typically permit isolation of nucleic acid molecules having at least about 70% nucleic acid sequence identity with the nucleic acid molecule being used to probe in the hybridization reaction. Formulae to calculate the appropriate hybridization and wash conditions to achieve hybridization permitting 30% or less mismatch of nucleotides are disclosed, for example, in Meinkoth et al., 1984, Anal. Biochem. 138, 267-284; Meinkoth et al., ibid., is incorporated by reference herein in its entirety.

[0052] As used herein, a C. felis esterase gene includes all nucleic acid sequences related to a natural C. felis esterase gene such as regulatory regions that control production of the C. felis esterase protein encoded by that gene (such as, but not limited to, transcription, translation or post-translation control regions) as well as the coding region itself. In one embodiment, a C. felis esterase gene of the present invention includes the nucleic acid sequence SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74. Nucleic acid sequence SEQ ID NO:1 represents the deduced sequence of the coding strand of a PCR amplified nucleic acid molecule denoted herein as nfE1₄₀₁, the production of which is disclosed in the Examples. The complement of SEQ ID NO:1 (represented herein by SEQ ID NO:3) refers to the nucleic acid sequence of the strand complementary to the strand having SEQ ID NO:1, which can easily be determined by those skilled in the art. Likewise, a nucleic acid sequence complement of any nucleic acid sequence of the present invention refers to the nucleic acid sequence of the nucleic acid strand that is complementary to (i.e., can form a complete double helix with) the strand for which the sequence is cited.

[0053] Nucleic acid sequence SEQ ID NO:4 represents the deduced sequence of the coding strand of a PCR amplified nucleic acid molecule denoted herein as nfE2₃₆₄, the production of which is disclosed in the Examples. The complement of SEQ ID NO:4 is represented herein by SEQ ID NO:6.

[0054] Nucleic acid sequence SEQ ID NO:7 represents the deduced sequence of the coding strand of a PCR amplified nucleic acid molecule denoted herein as nfE3₄₂₁, the production of which is disclosed in the Examples. The complement of SEQ ID NO:7 is represented herein by SEQ ID NO:9.

[0055] Nucleic acid sequence SEQ ID NO:10 represents the deduced sequence of the coding strand of a PCR amplified nucleic acid molecule denoted herein as nfE4₅₂₄, the production of which is disclosed in the Examples. The complement of SEQ ID NO:10 is represented herein by SEQ ID NO:12. Nucleic acid sequence SEQ ID NO:13 represents the deduced sequence of the coding strand of an apparent coding region of a complementary DNA (cDNA) nucleic acid molecule denoted herein as nfE5₁₉₈₂, the production of which is disclosed in the Examples. The complement of SEQ ID NO:13 is represented herein by SEQ ID NO:15.

[0056] Nucleic acid sequence SEQ ID NO:18 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE6₁₇₉₂, the production of which is disclosed in the Examples. The complement of SEQ ID NO:18 is represented herein by SEQ ID NO:20.

[0057] Nucleic acid sequence SEQ ID NO:24 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE7₂₉₃₆, the production of which is disclosed in the Examples. The complement of SEQ ID NO:24 is represented herein by SEQ ID NO:26.

[0058] Nucleic acid sequence SEQ ID NO:30 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE8₂₈₀₁, the production of which is disclosed in the Examples. The complement of SEQ ID NO:30 is represented herein by SEQ ID NO:32.

[0059] Nucleic acid sequence SEQ ID NO:36 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE9₂₀₀₇, the production of which is disclosed in the Examples. The complement of SEQ ID NO:36 is represented herein by SEQ ID NO:38.

[0060] Nucleic acid sequence SEQ ID NO:57 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE5₂₁₄₄, the production of which is disclosed in the Examples. The complement of SEQ ID NO:57 is represented herein by SEQ ID NO:59.

[0061] Nucleic acid sequence SEQ ID NO:67 represents the deduced sequence of the coding strand of an apparent coding region of a cDNA nucleic acid molecule denoted herein as nfE10₁₉₈₇, the production of which is disclosed in the Examples. The complement of SEQ ID NO:67 is represented herein by SEQ ID NO:69.

[0062] It should be noted that since nucleic acid sequencing technology is not entirely error-free, the nucleic acid sequences and amino acid sequences presented herein represent, respectively, apparent nucleic acid sequences of nucleic acid molecules of the present invention and apparent amino acid sequences of esterase proteins of the present invention.

[0063] In another embodiment, a C. felis esterase gene can be an allelic variant that includes a similar but not identical sequence to SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74. An allelic variant of a C. felis esterase gene is a gene that occurs at essentially the same locus (or loci) in the genome as the gene including SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74, but which, due to natural variations caused by, for example, mutation or recombination, has a similar but not identical sequence. Allelic variants typically encode proteins having similar activity to that of the protein encoded by the gene to which they are being compared. Allelic variants can also comprise alterations in the 5′ or 3′ untranslated regions of the gene (e.g., in regulatory control regions). Allelic variants are well known to those skilled in the art and would be expected to be found within a given arthropod since the genome is diploid and/or among a group of two or more arthropods.

[0064] The minimal size of an esterase protein homolog of the present invention is a size sufficient to be encoded by a nucleic acid molecule capable of foiling a stable hybrid (i.e., hybridize under stringent hybridization conditions) with the complementary sequence of a nucleic acid molecule encoding the corresponding natural protein. As such, the size of the nucleic acid molecule encoding such a protein homolog is dependent on nucleic acid composition and percent homology between the nucleic acid molecule and complementary sequence. It should also be noted that the extent of homology required to form a stable hybrid can vary depending on whether the homologous sequences are interspersed throughout the nucleic acid molecules or are clustered (i.e., localized) in distinct regions on the nucleic acid molecules. The minimal size of such nucleic acid molecules is typically at least about 12 to about 15 nucleotides in length if the nucleic acid molecules are GC-rich and at least about 15 to about 17 bases in length if they are AT-rich. As such, the minimal size of a nucleic acid molecule used to encode an esterase protein homolog of the present invention is from about 12 to about 18 nucleotides in length. Thus, the minimal size of an esterase protein homolog of the present invention is from about 4 to about 6 amino acids in length. There is no limit, other than a practical limit, on the maximal size of such a nucleic acid molecule in that the nucleic acid molecule can include a portion of a gene, an entire gene, multiple genes, or portions thereof. The preferred size of a protein encoded by a nucleic acid molecule of the present invention depends on whether a full-length, fusion, multivalent, or functional portion of such a protein is desired.

[0065] One embodiment of the present invention includes an arthropod esterase protein having CE enzyme activity. Such a CE protein preferably includes: a catalytic triad of serine—lhistidine—glutamic acid as well as the essential amino acids arginine and aspartic acid at positions similar to those described for juvenile hormone esterase, for example by Ward et al., 1992, Int J Biochem 24: 1933-1941; this reference is incorporated by reference herein in its entirety. Analysis of the apparent full-length protein sequences disclosed herein indicates that each of these amino acid sequences includes these amino acid motifs, as well as surrounding consensus sequences.

[0066] Suitable arthropods from which to isolate esterase proteins having general CE activity of the present invention (including isolation of the natural protein or production of the protein by recombinant or synthetic techniques) preferably include insects and acarines but not Culicidae, Drosophilidae, Calliphoridae, Sphingidae, Lymantriidae, Noctuidae, Fulgoroidae and Aphididae. Preferred arthropods from which to isolate CE proteins having general CE activity include fleas, ticks, black flies, lice, true bugs, sand flies, Psychodidae, tsetse flies, cattle grub, mites, horn flies, heel flies, deer flies, Culicoides and warble flies. Preferred arthropods from which to isolate an esterase proteins having general CE activity include fleas, midges, sand flies, black flies, horse flies, snipe flies, louse flies, hlo'n flies, deer flies, tsetse flies, buffalo flies, blow flies, stable flies, myiasis-causing flies, biting gnats, lice, mites, bee, wasps, ants, true bugs and ticks, preferably fleas, ticks and blow flies, and more preferably fleas. Preferred fleas from which to isolate esterase proteins having general CE activity include Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla. More preferred fleas include Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla(Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans, with C. felis being even more preferred.

[0067] A preferred arthropod esterase protein of the present invention is a compound that when administered to an animal in an effective manner, is capable of protecting that animal from hematophagous ectoparasite infestation. In accordance with the present invention, the ability of an esterase protein of the present invention to protect an animal from hematophagous ectoparasite infestation refers to the ability of that protein to, for example, treat, ameliorate and/or prevent infestation caused by hematophagous arthropods. In particular, the phrase “to protect an animal from hematophagous ectoparasite infestation” refers to reducing the potential for hematophagous ectoparasite population expansion on and around the animal (i.e., reducing the hematophagous ectoparasite burden). Preferably, the hematophagous ectoparasite population size is decreased, optimally to an extent that the animal is no longer bothered by hematophagous ectoparasites. A host animal, as used herein, is an animal from which hematophagous ectoparasites can feed by attaching to and feeding through the skin of the animal. Hematophagous ectoparasites, and other ectoparasites, can live on a host animal for an extended period of time or can attach temporarily to an animal in order to feed. At any given time, a certain percentage of a hematophagous ectoparasite population can be on a host animal whereas the remainder can be in the environment of the animal. Such an environment can include not only adult hematophagous ectoparasites, but also hematophagous ectoparasite eggs and/or hematophagous ectoparasite larvae. The environment can be of any size such that hematophagous ectoparasites in the environment are able to jump onto and off of a host animal. For example, the environment of an animal can include plants, such as crops, from which hematophagous ectoparasites infest an animal. As such, it is desirable not only to reduce the hematophagous ectoparasite burden on an animal per se, but also to reduce the hematophagous ectoparasite burden in the environment of the animal. In one embodiment, an esterase protein of the present invention can elicit an immune response (including a humoral and/or cellular immune response) against a hematophagous ectoparasite.

[0068] Suitable hematophagous ectoparasites to target include any hematophagous ectoparasite that is essentially incapable of infesting an animal administered an esterase protein of the present invention. As such, a hematophagous ectoparasite to target includes any hematophagous ectoparasite that produces a protein having one or more epitopes that can be targeted by a humoral and/or cellular immune response against an esterase protein of the present invention and/or that can be targeted by a compound that otherwise inhibits esterase activity (e.g., a compound that inhibits hydrolysis of α-napthyl acetate, hydrolysis of the methyl ester group of juvenile hormone, and/or binds to DFP), thereby resulting in the decreased ability of the hematophagous ectoparasite to infest an animal. Preferred hematophagous ectoparasite to target include ectoparasites disclosed herein as being useful in the production of esterase proteins of the present invention.

[0069] The present invention also includes mimetopes of esterase proteins of the present invention. As used herein, a mimetope of an esterase protein of the present invention refers to any compound that is able to mimic, the activity of such a protein (e.g., ability to elicit an immune response against an arthropod esterase protein of the present invention and/or ability to inhibit esterase activity), often because the mimetope has a structure that mimics the esterase protein. It is to be noted, however, that the mimetope need not have a structure similar to an esterase protein as long as the mimetope functionally mimics the protein. Mimetopes can be, but are not limited to: peptides that have been modified to decrease their susceptibility to degradation; anti-idiotypic and/or catalytic antibodies, or fragments thereof; non-proteinaceous immunogenic portions of an isolated protein (e.g., carbohydrate signatures); synthetic or natural organic or inorganic molecules, including nucleic acids; and/or any other peptidomimetic compounds.

[0070] Mimetopes of the present invention can be designed using computer-generated structures of esterase proteins of the present invention. Mimetopes can also be obtained by generating random samples of molecules, such as oligonucleotides, peptides or other organic molecules, and screening such samples by affinity chromatography techniques using the corresponding binding partner, (e.g., an esterase substrate, an esterase substrate analog, or an anti-esterase antibody). A preferred mimetope is a peptidomimetic compound that is structurally and/or functionally similar to an esterase protein of the present invention, particularly to the active site of the esterase protein.

[0071] The present invention also includes mimetopes of esterase proteins of the present invention. As used herein, a mimetope of an esterase protein of the present invention refers to any compound that is able to mimic the activity of such an esterase protein, often because the mimetope has a structure that mimics the esterase protein. Mimetopes can be, but are not limited to: peptides that have been modified to decrease their susceptibility to degradation; anti-idiotypic and/or catalytic antibodies, or fragments thereof, non-proteinaceous immunogenic portions of an isolated protein (e.g., carbohydrate structures); and synthetic or natural organic molecules, including nucleic acids. Such mimetopes can be designed using computer-generated structures of proteins of the present invention. Mimetopes can also be obtained by generating random samples of molecules, such as oligonucleotides, peptides or other organic molecules, and screening such samples by affinity chromatography techniques using the corresponding binding partner.

[0072] One embodiment of an arthropod esterase protein of the present invention is a fusion protein that includes an arthropod esterase protein-containing domain attached to one or more fusion segments. Suitable fusion segments for use with the present invention include, but are not limited to, segments that can: enhance a protein's stability; act as an immunopotentiator to enhance an immune response against an esterase protein; and/or assist purification of an esterase protein (e.g., by affinity chromatography). A suitable fusion segment can be a domain of any size that has the desired function (e.g., imparts increased stability, imparts increased immunogenicity to a protein, and/or simplifies purification of a protein). Fusion segments can be joined to amino and/or carboxyl termini of the esterase-containing domain of the protein and can be susceptible to cleavage in order to enable straight-forward recovery of an esterase protein. Fusion proteins are preferably produced by culturing a recombinant cell transformed with a fusion nucleic acid molecule that encodes a protein including the fusion segment attached to either the carboxyl and/or amino terminal end of an esterase-containing domain. Preferred fusion segments include a metal binding domain (e.g., a polyhistidine segment); an immunoglobulin binding domain (e.g., Protein A; Protein G; T cell; B cell; Fc receptor or complement protein antibody-binding domains); a sugar binding domain (e.g., a maltose binding domain); and/or a “tag” domain (e.g., at least a portion of β-galactosidase, a strep tag peptide, other domains that can be purified using compounds that bind to the domain, such as monoclonal antibodies). More preferred fusion segments include metal binding domains, such as a poly-histidine segment; a maltose binding domain; a strep tag peptide, such as that available from Biometra in Tampa, Fla.; and an S10 peptide. Examples of particularly preferred fusion proteins of the present invention include PHIS-PfE6₅₄₀, PHIS-PfE7₂₇₅, PHIS-PfE7₅₇₀, PHIS-PfE8₅₇₀ and PHIS-PfE9₅₂₈, production of which are disclosed herein.

[0073] In another embodiment, an arthropod esterase protein of the present invention also includes at least one additional protein segment that is capable of protecting an animal from hematophagous ectoparasite infestations. Such a multivalent protective protein can be produced by culturing a cell transformed with a nucleic acid molecule comprising two or more nucleic acid domains joined together in such a manner that the resulting nucleic acid molecule is expressed as a multivalent protective compound containing at least two protective compounds, or portions thereof, capable of protecting an animal from hematophagous ectoparasite infestation by, for example, targeting two different arthropod proteins.

[0074] Examples of multivalent protective compounds include, but are not limited to, an esterase protein of the present invention attached to one or more compounds protective against one or more arthropod compounds. Preferred second compounds are proteinaceous compounds that effect active immunization (e.g., antigen vaccines), passive immunization (e.g., antibodies), or that otherwise inhibit a arthropod activity that when inhibited can reduce hematophagous ectoparasite burden on and around an animal. Examples of second compounds include a compound that inhibits binding between an arthropod protein and its ligand (e.g., a compound that inhibits flea ATPase activity or a compound that inhibits binding of a peptide or steroid hormone to its receptor), a compound that inhibits hormone (including peptide or steroid hormone) synthesis, a compound that inhibits vitellogenesis (including production of vitellin and/or transport and maturation thereof into a major egg yolk protein), a compound that inhibits fat body function, a compound that inhibits muscle action, a compound that inhibits the nervous system, a compound that inhibits the immune system and/or a compound that inhibits hematophagous ectoparasite feeding. Examples of second compounds also include proteins obtained from different stages of hematophagous ectoparasite development. Particular examples of second compounds include, but are not limited to, serine proteases, cysteine proteases, aminopeptidases, serine protease inhibitor proteins, calreticulins, larval serum proteins and echdysone receptors, as well as antibodies to and inhibitors of such proteins. In one embodiment, an arthropod esterase protein of the present invention is attached to one or more additional compounds protective against hematophagous ectoparasite infestation. In another embodiment, one or more protective compounds, such as those listed above, can be included in a multivalent vaccine comprising an arthropod esterase protein of the present invention and one or more other protective molecules as separate compounds.

[0075] A preferred isolated protein of the present invention is a protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecules nfE1₄₀₁, nfE2₃₆₄, nfE3₄₂₁, nfE4₅₂₄, nfE5₁₉₈₂, nfE5₁₅₁₅, nfE5₂₁₄₄, nfE5₁₆₅₀, nfE6₁₄₈₈, nfE6₁₇₉₂, nfE6₁₆₅₀, nfE7₂₈₃₆, nfE7₁₇₈₈, nfE7₁₇₁₀, nfE7₆₅₀, nfE8₂₈₀₁, nfE8₁₇₈₅, nfE8₁₇₁₀, nfE9₂₀₀₇, nfE9₁₅₈₄, nfE9₁₅₄₀, nfE10₁₉₈₇ and/or nfE10₁₅₉₀. A further preferred isolated protein is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ TD NO:17, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:38, SEQ ID NO:52, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:69 and/or SEQ ID NO:71.

[0076] Translation of SEQ ID NO:1 suggests that nucleic acid molecule nfE1₄₀₁ encodes a non-full-length arthropod esterase protein of about 103 amino acids, referred to herein as PfE1₁₀₃, represented by SEQ ID NO:2, assuming the first codon spans from nucleotide 92 through nucleotide 94 of SEQ ID NO:1.

[0077] Comparison of amino acid sequence SEQ ID NO:2 (i.e., the amino acid sequence of PfE1₁₀₃) with amino acid sequences reported in GenBank indicates that SEQ ID NO:2, showed the most homology, i.e., about 33% identity, between SEQ ID NO:2 and alpha esterase protein from Drosophila melanogaster.

[0078] Translation of SEQ ID NO:4 suggests that nucleic acid molecule nfE2₃₆₄ encodes a non-full-length arthropod esterase protein of about 121 amino acids, referred to herein as PfE2₁₂₁, represented by SEQ ID NO:5, assuming the first codon spans from nucleotide 2 through nucleotide 4 of SEQ ID NO:4.

[0079] Comparison of amino acid sequence SEQ ID NO:5 (i.e., the amino acid sequence of PfE2₁₂₁) with amino acid sequences reported in GenBank indicates that SEQ ID NO:5, showed the most homology, i.e., about 38% identity, between SEQ ID NO:5 and alpha esterase protein from Drosophila melanogaster.

[0080] Translation of SEQ ID NO:7 suggests that nucleic acid molecule nfE3₄₂₁, encodes a non-full-length arthropod esterase protein of about 103 amino acids, referred to herein as PfE3₁₀₃, represented by SEQ ID NO:8, assuming the first codon spans from nucleotide 113 through nucleotide 115 of SEQ ID NO:7.

[0081] Comparison of amino acid sequence SEQ ID NO:8 (i.e., the amino acid sequence of PfE3₁₀₃) with amino acid sequences reported in GenBank indicates that SEQ ID NO:5, showed the most homology, i.e., about 39% identity, between SEQ ID NO:5 and alpha esterase protein from Drosophila melanogaster.

[0082] Translation of SEQ ID NO:10 suggests that nucleic acid molecule nfE4₅₂₄ encodes a non-full-length arthropod esterase protein of about 137 amino acids, referred to herein as PfE4₁₃₇, represented by SEQ ID NO:11, assuming the first codon spans from nucleotide 113 through nucleotide 115 of SEQ ID NO:10.

[0083] Comparison of amino acid sequence SEQ ID NO:11 (i.e., the amino acid sequence of PfE4₁₃₇) with amino acid sequences reported in GenBank indicates that SEQ ID NO:11, showed the most homology, i.e., about 30% identity, between SEQ ID NO:11 and Leptinotarsa decemlineata acetylcholinesterase.

[0084] Translation of SEQ ID NO:57 suggests that nucleic acid molecule nfE5₂₁₄₄ encodes a full-length arthropod esterase protein of about 550 amino acids, referred to herein as PfE5₅₅₀, represented by SEQ ID NO:58, assuming an open reading frame in which the initiation codon spans from nucleotide 30 through nucleotide 32 of SEQ ID NO:57 and the termination (stop) codon spans from nucleotide 1680 through nucleotide 1682 of SEQ ID NO:57. The complement of SEQ ID NO:57 is represented herein by SEQ ID NO:59. The coding region encoding PfE5₅₅₀ is represented by the nucleic acid molecule nfE5₁₆₅₀, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:60 and a complementary strand with nucleic acid sequence SEQ ID NO:61. The deduced amino acid sequence of PfE5₅₅₀ (i.e., SEQ ID NO:58) predicts that PfE5₅₅₀ has an estimated molecular weight of about 61.8 kD and an estimated pI of about 5.5.

[0085] Comparison of amino acid sequence SEQ ID NO:58 (i.e., the amino acid sequence of PfE5₅₅₀) with amino acid sequences reported in GenBank indicates that SEQ ID NO:58 showed the most homology, i.e., about 36% identity between SEQ ID NO:58 and Drosophila melanogaster alpha esterase protein.

[0086] Translation of SEQ ID NO:18 suggests that nucleic acid molecule nfE6₁₇₉₂ encodes a full-length arthropod esterase protein of about 550 amino acids, referred to herein as PfE6₅₅₀, represented by SEQ ID NO:19, assuming an open reading frame having an initiation codon spanning from nucleotide 49 through nucleotide 51 of SEQ ID NO:18 and a stop codon spanning from nucleotide 1699 through nucleotide 1701 of SEQ ID NO:18. The coding region encoding PfE6₅₅₀, is represented by nucleic acid molecule nfE6₁₆₅₀, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:21 and a complementary strand with nucleic acid sequence SEQ ID NO:22. The proposed mature protein, denoted herein as PfE6₅₃₀, contains about 530 amino acids which is represented herein as SEQ ID NO:53. The nucleic acid molecule encoding PfE6₅₃₀ is denoted herein as nfE6₁₅₉₀ and has a coding strand having the nucleic acid sequence SEQ ID NO:23. The deduced amino acid sequence SEQ ID NO:19 suggests a protein having a molecular weight of about 61.8 kD and an estimated pI of about 5.5.

[0087] Comparison of amino acid sequence SEQ ID NO:19 (i.e., the amino acid sequence of PfE6₅₅₀) with amino acid sequences reported in GenBank indicates that SEQ ID NO:19 showed the most homology, i.e., about 28% identity between SEQ ID NO:19 and Drosophila melanogaster alpha esterase protein.

[0088] Translation of SEQ ID NO:24 suggests that nucleic acid molecule nfE7₂₈₃, encodes a full-length arthropod esterase protein of about 596 amino acids, referred to herein as PfE7₅₉₆, represented by SEQ ID NO:25, assuming an open reading frame having an initiation codon spanning from nucleotide 99 through nucleotide 101 of SEQ ID NO:24 and a stop codon spanning from nucleotide 1887 through nucleotide 1889 of SEQ ID NO:24. The coding region encoding PfE7₅₉₆, is represented by nucleic acid molecule nfE7₁₇₈₈, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:28 and a complementary strand with nucleic acid sequence SEQ ID NO:29. The proposed mature protein, denoted herein as PfE7₅₇₀, contains about 570 amino acids which is represented herein as SEQ ID NO:54. The nucleic acid molecule encoding PfE7₅₇₀ is denoted herein as nfE7₁₇₁₀ and has a coding strand having the nucleic acid sequence SEQ ID NO:27. The deduced amino acid sequence SEQ ID NO:25 suggests a protein having a molecular weight of about 68.7 kD and an estimated pI of about 6.1.

[0089] Comparison of amino acid sequence SEQ ID NO:25 (i.e., the amino acid sequence of PfE7₅₉₆) with amino acid sequences reported in GenBank indicates that SEQ ID NO:25 showed the most homology, i.e., about 27% identity between SEQ ID NO:25 and Drosophila melanogaster alpha esterase protein.

[0090] Translation of SEQ ID NO:30 suggests that nucleic acid molecule nfE8₂₈₀₁, encodes a full-length arthropod esterase protein of about 595 amino acids, referred to herein as PfE8₅₉₅, represented by SEQ ID NO:31, assuming an open reading frame having an initiation codon spanning from nucleotide 99 through nucleotide 101 of SEQ ID NO:30 and a stop codon spanning from nucleotide 1884 through nucleotide 1886 of SEQ ID NO:30. The coding region encoding PfE8₅₉₅, is represented by nucleic acid molecule nfE8₁₇₈₅, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:34 and a complementary strand with nucleic acid sequence SEQ ID NO:35. The proposed mature protein, denoted herein as PfE8₅₇₀, contains about 570 amino acids which is represented herein as SEQ ID NO:55. The nucleic acid molecule encoding PfE8₅₇₀ is denoted herein as nfE8₁₇₁₀ and has a coding strand having the nucleic acid sequence SEQ ID NO:33. The deduced amino acid sequence SEQ ID NO:31 suggests a protein having a molecular weight of about 68.6 kD and an estimated pI of about 6.1.

[0091] Comparison of amino acid sequence SEQ ID NO:31 (i.e., the amino acid sequence of PfE8₅₉₅) with amino acid sequences reported in GenBank indicates that SEQ ID NO:31 showed the most homology, i.e., about 28% identity between SEQ ID NO:31 and estalpha-2 esterase of Culex pipiens quinquefasciatus.

[0092] Translation of SEQ ID NO:36 suggests that nucleic acid molecule nfE9₂₀₀₇ encodes a full-length arthropod esterase protein of about 528 amino acids, referred to herein as PfE9₅₂₈, represented by SEQ ID NO:37, assuming an open reading frame having an initiation codon spanning from nucleotide 11 through nucleotide 13 of SEQ ID NO:36 and a stop codon spanning from nucleotide 1595 through nucleotide 1597 of SEQ ID NO:36. The coding region encoding PfE9₅₂₈, is represented by nucleic acid molecule nfE9₁₅₈₄, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:51 and a complementary strand with nucleic acid sequence SEQ ID NO:52. The deduced amino acid sequence SEQ ID NO:37 suggests a protein having a molecular weight of about 60 kD and an estimated pI of about 5.43.

[0093] Comparison of amino acid sequence SEQ ID NO:37 (i.e., the amino acid sequence of PfE9₅₂₈) with amino acid sequences reported in GenBank indicates that SEQ ID NO:37 showed the most homology, i.e., about 37% identity between SEQ ID NO:37 and alpha esterase protein from Drosophila melanogaster.

[0094] Translation of SEQ ID NO:67 suggests that nucleic acid molecule nfE10₁₉₉₇ encodes a full-length flea esterase protein of about 530 amino acids, referred to herein as PfE10₅₃₀, having amino acid sequence SEQ ID NO:68, assuming an open reading frame in which the initiation codon spans from nucleotide 231 through nucleotide 233 of SEQ ID NO:67 and a stop codon spanning from nucleotide 1821 through nucleotide 1823 of SEQ ID NO:67. The complement of SEQ ID NO:67 is represented herein by SEQ ID NO:69. The coding region encoding PfE10₅₃₀, is represented by nucleic acid molecule nfE10₅₉₀, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:70 and a complementary strand with nucleic acid sequence SEQ ID NO:71. The amino acid sequence of PfE10₅₃₀ (i.e., SEQ ID NO:68) predicts that PfE10₅₃₀ has an estimated molecular weight of about 59.5 kD and an estimated pI of about 5.5.

[0095] Comparison of amino acid sequence SEQ ID NO:68 (i.e., the amino acid sequence of PfE10₅₃₀) with amino acid sequences reported in GenBank indicates that SEQ ID NO:68 showed the most homology, i.e., about 30% identity between SEQ ID NO:68 and Culex pipens esterase b1 precurser protein (swissprot #16854).

[0096] More preferred arthropod esterase proteins of the present invention include proteins comprising amino acid sequences that are at least about 40%, preferably at least about 45%, more preferably at least about 50%, even more preferably at least about 55%, even more preferably at least about 60%, even more preferably at least about 70%, even more preferably at least about 80%, even more preferably at least about 90%, and even more preferably at least about 95%, identical to amino acid sequence SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and/or SEQ ID NO:74.

[0097] More preferred arthropod esterase proteins of the present invention include proteins encoded by a nucleic acid molecule comprising at least a portion of nfE1₄₀₁, nfE2₃₆₄, nfE3₄₂₁, nfE4₅₂₄, nfE5₁₉₈₂, nfE5₁₅₁₅, nfE5₂₁₄₄, nfE5₁₆₅₀, nfE6₁₄₈₈, nfE6₁₇₉₂, nfE6₁₆₅₀, nfE7₂₈₃₆, nfE7₁₇₈₈, nfE7₁₇₁₀, nfE7₆₅₀, nfE8₂₈₀₁, nfE8₁₇₈₅, nfE8₁₇₁₀, nfE9₂₀₀₇, nfE9₁₅₈₄, nfE9₁₅₄₀, nfE10₉₈₇ and/or nfE10₁₅₉₀, or of allelic variants of such nucleic acid molecules.

[0098] More preferred is an esterase protein encoded by nfE1₄₀₁, nfE2₃₆₄, nfE3₄₂₁, nfE4₅₂₄, nfE5₁₉₈₂, nfE5₁₅₁₅, nfE5₂₁₄₄, nfE5₁₆₅₀, nfE6₁₄₈₈, nfE6₁₇₉₂, nfE6₁₆₅₀, nfE7₂₈₃₆, nfE7)₇₈₈, nfE7₁₇₁₀, nfE7₆₅₀, nfE8₂₈₀₁, nfE8₁₇₈₅, nfE8₁₇₁₀, nfE9₂₀₀₇, nfE9₁₅₈₄, nfE9₁₅₄₀, nfE10

19

7 and/or nfE10₁₅₉₀, or by an allelic variant of such nucleic acid molecules. Particularly preferred arthropod esterase proteins are PfE1₁₀₃, PfE2₁₂₁, PfE3₁₀₃, PfE4₁₃₇, PfE5₅₀₅, PfE5₅₅₀, PfE6₅₅₀, PfE6₅₃₀, PfE7₅₉₆, PfE7₅₇₀, PfE8₅₉₅, PfE8₅₇₀, PfE9₅₂₈ and PfE10₅₃₀.

[0099] In one embodiment, a preferred esterase protein of the present invention is encoded by at least a portion of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:60 and/or SEQ ID NO:67, and, as such, has an amino acid sequence that includes at least a portion of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58 and/or SEQ ID NO:68. Also preferred is a protein encoded by an allelic variant of a nucleic acid molecule comprising at least a portion of the above-listed nucleic acid sequences. Particularly preferred esterase proteins of the present invention include SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID

[0100] NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and/or SEQ ID NO:74. (including, but not limited to, the proteins consisting of such sequences, fusion proteins and multivalent proteins) and proteins encoded by allelic variants of SEQ ID NO:1, SEQ ID NO:4, SEQ ID NO:7, SEQ ID NO:10, SEQ ID NO:13, SEQ ID NO:16, SEQ ID NO:18, SEQ ID NO:21, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:30, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:36, SEQ ID NO:51, SEQ ID NO:57, SEQ ID NO:60 and/or SEQ ID NO:67.

[0101] Another embodiment of the present invention is an isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a C. felis esterase gene. The identifying characteristics of such a gene are heretofore described. A nucleic acid molecule of the present invention can include an isolated natural arthropod esterase gene or a homolog thereof, the latter of which is described in more detail below. A nucleic acid molecule of the present invention can include one or more regulatory regions, full-length or partial coding regions, or combinations thereof. The minimal size of a nucleic acid molecule of the present invention is the minimal size that can form a stable hybrid with a C. felis esterase gene under stringent hybridization conditions.

[0102] In accordance with the present invention, an isolated nucleic acid molecule is a nucleic acid molecule that has been removed from its natural milieu (i.e., that has been subject to human manipulation) and can include DNA, RNA, or derivatives of either DNA or RNA. As such, “isolated” does not reflect the extent to which the nucleic acid molecule has been purified. An isolated arthropod esterase nucleic acid molecule of the present invention can be isolated from its natural source or can be produced using recombinant DNA technology (e.g., polymerase chain reaction (PCR) amplification, cloning) or chemical synthesis. Isolated esterase nucleic acid molecules can include, for example, natural allelic variants and nucleic acid molecules modified by nucleotide insertions, deletions, substitutions, and/or inversions in a manner such that the modifications do not substantially interfere with the nucleic acid molecule's ability to encode an esterase protein of the present invention or to form stable hybrids under stringent conditions with natural gene isolates.

[0103] An arthropod esterase nucleic acid molecule homolog can be produced using a number of methods known to those skilled in the art (see, for example, Sambrook et al., ibid.). For example, nucleic acid molecules can be modified using a variety of techniques including, but not limited to, classic mutagenesis and recombinant DNA techniques (e.g., site-directed mutagenesis, chemical treatment, restriction enzyme cleavage, ligation of nucleic acid fragments and/or PCR amplification), synthesis of oligonucleotide mixtures and ligation of mixture groups to “build” a mixture of nucleic acid molecules and combinations thereof. Nucleic acid molecule homologs can be selected by hybridization with a C. felis esterase gene or by screening for the function of a protein encoded by the nucleic acid molecule (e.g., ability to elicit an immune response against at least one epitope of an arthropod esterase protein, hydrolyze α-napthyl acetate, hydrolyze the methyl ester group of juvenile hormone and/or blind to DFP).

[0104] An isolated nucleic acid molecule of the present invention can include a nucleic acid sequence that encodes at least one arthropod esterase protein of the present invention, examples of such proteins being disclosed herein. Although the phrase “nucleic acid molecule” primarily refers to the physical nucleic acid molecule and the phrase “nucleic acid sequence” primarily refers to the sequence of nucleotides on the nucleic acid molecule, the two phrases can be used interchangeably, especially with respect to a nucleic acid molecule, or a nucleic acid sequence, being capable of encoding an arthropod esterase protein.

[0105] A preferred nucleic acid molecule of the present invention, when administered to an animal, is capable of protecting that animal from infestation by a hematophagous ectoparasite. As will be disclosed in more detail below, such a nucleic acid molecule can be, or can encode, an antisense RNA, a molecule capable of triple helix formation, a ribozyme, or other nucleic acid-based drug compound. In additional embodiments, a nucleic acid molecule of the present invention can encode a protective esterase protein (e.g., an esterase protein of the present invention), the nucleic acid molecule being delivered to the animal, for example, by direct injection (i.e, as a naked nucleic acid) or in a vehicle such as a recombinant virus vaccine or a recombinant cell vaccine.

[0106] One embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE1₄₀₁ and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:1 and/or SEQ ID NO:3.

[0107] Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE2₃₆₄ and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:4 and/or SEQ ID NO:6.

[0108] Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE3₄₂₄ and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:7 and/or SEQ ID NO:9. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE4₅₂₄ and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:10 and/or SEQ ID NO:12.

[0109] Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE5₂₁₄₄ and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:57 and/or SEQ ID NO:59.

[0110] Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE6₁₇₉₂ and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:18 and/or SEQ ID NO:20.

[0111] Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE7₂₈₃₆ and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:24 and/or SEQ ID NO:26.

[0112] Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE8₂₈₀, and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:30 and/or SEQ ID NO:32. Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE9₂₀₀₇ and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:36 and/or SEQ ID NO:38.

[0113] Another embodiment of the present invention is an esterase nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE10₁₉₈₇ and preferably with a nucleic acid molecule having nucleic acid sequence SEQ ID NO:67 and/or SEQ ID NO:69.

[0114] Comparison of nucleic acid sequence SEQ ID NO:1 (i.e., the nucleic acid sequence of nfE1₄₀₁) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:1 showed no identifiable identity with any sequence reported in GenBank.

[0115] Comparison of nucleic acid sequence SEQ ID NO:4 (i.e., the coding strand of nucleic acid sequence of nfE2₃₆₄) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:4 showed the most homolog, i.e., about 43% identity, between SEQ ID NO:4 and a H. virescens juvenile hormone esterase gene.

[0116] Comparison of nucleic acid sequence SEQ ID NO:7 (i.e., the coding strand of nucleic acid sequence of nfE3₄₂₁) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:7 showed the most homolog, i.e., about 53% identity, between SEQ ID NO:7 and a Torpedo marmorata acetylcholinesterase gene.

[0117] Comparison of nucleic acid sequence SEQ ID NO:10 (i.e., the coding strand of nucleic acid sequence of nfE4₅₂₄) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:10 showed the most homolog, i.e., about 47% identity, between SEQ ID NO:10 and an Anas platyrhynos thioesterase B gene.

[0118] Comparison of nucleic acid sequence SEQ ID NO:57 (i.e., the coding strand of nucleic acid sequence of nfE5₂₁₄₄) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:57 showed the most homolog, i.e., about 41% identity, between SEQ ID NO:57 and a esterase mRNA from Myzus persicae.

[0119] Comparison of nucleic acid sequence SEQ ID NO:18 (i.e., the coding strand of nucleic acid sequence of nfE6₁₇₉₂) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:18 showed the most homolog, i.e., about 41% identity, between SEQ ID NO:18 and a esterase gene from Myzus persicae.

[0120] Comparison of nucleic acid sequence SEQ ID NO:24 (i.e., the coding strand of nucleic acid sequence of nfE7₂₈₃₆) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:24 showed the most homolog, i.e., about 48% identity, between SEQ ID NO:24 and an Anas platychyncos thioesterase B gene.

[0121] Comparison of nucleic acid sequence SEQ ID NO:30 (i.e., the coding strand of nucleic acid sequence of nfE8₂₈₀₁) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:30 showed the most homolog, i.e., about 46% identity, between SEQ ID NO:30 and a Mus musculus carboxyl ester lipase gene.

[0122] Comparison of nucleic acid sequence SEQ ID NO:36 (i.e., the coding strand of nucleic acid sequence of nfE9₂₀₀₇) with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:36 showed the most homolog, i.e., about 47% identity, between SEQ ID NO:36 and a hamster mRNA for CE precursor gene.

[0123] Comparison of nucleic acid sequence SEQ ID NO:67 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:67 showed the most homology, i.e., about 48% identity, between SEQ ID NO:67 and a Lucilia cuprina alpha esterase gene (genembl #U56636) gene.

[0124] Preferred arthropod esterase nucleic acid molecules include nucleic acid molecules having a nucleic acid sequence that is at least about 55%, preferably at least about 60%, more preferably at least about 65%, more preferably at least about 70%, more preferably at least about 75%, more preferably at least about 80%, more preferably at least about 90%, and even more preferably at least about 95% identical to nucleic acid sequence SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74.

[0125] Another preferred nucleic acid molecule of the present invention includes at least a portion of nucleic acid sequence SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74, that is capable of hybridizing to a C. felis esterase gene of the present invention, as well as allelic variants thereof. A more preferred nucleic acid molecule includes the nucleic acid sequence SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and/or a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74, as well as allelic variants thereof. Such nucleic acid molecules can include nucleotides in addition to those included in the SEQ ID NOs, such as, but not limited to, a full-length gene, a full-length coding region, a nucleic acid molecule encoding a fusion protein, or a nucleic acid molecule encoding a multivalent protective compound. Particularly preferred nucleic acid molecules include nfE1₄₀₁, nfE2₃₆₄, nfE3₄₂₁, nfE4₅₂₄, nfE5₁₉₈₂, nfE5₁₅₁₅, nfE5₂₁₄₄, nfE5₁₆₅₀, nfE6₁₄₈₈, nfE6₁₇₉₂, nfE6₁₆₅₀, nfE7₂₈₃₆, nfE7₁₇₈₈, nfE7₁₇₁₀, nfE7₆₅₀, nfE8₂₈₀₁, nfE8₁₇₈₅, nfE8₁₇₁₀, nfE9₂₀₀₇, nfE9₁₅₈₄, nfE9₁₅₄₀, nfE10₁₉₈₇ and nfE10₁₅₉₀.

[0126] The present invention also includes a nucleic acid molecule encoding a protein having at least a portion of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:5, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and/or SEQ ID NO:74, including nucleic acid molecules that have been modified to accommodate codon usage properties of the cells in which such nucleic acid molecules are to be expressed.

[0127] Knowing the nucleic acid sequences of certain arthropod esterase nucleic acid molecules of the present invention allows one skilled in the art to, for example, (a) make copies of those nucleic acid molecules, (b) obtain nucleic acid molecules including at least a portion of such nucleic acid molecules (e.g., nucleic acid molecules including full-length genes, full-length coding regions, regulatory control sequences, truncated coding regions), and (c) obtain esterase nucleic acid molecules from other arthropods. Such nucleic acid molecules can be obtained in a variety of ways including screening appropriate expression libraries with antibodies of the present invention; traditional cloning techniques using oligonucleotide probes of the present invention to screen appropriate libraries or DNA; and PCR amplification of appropriate libraries or DNA using oligonucleotide primers of the present invention. Preferred libraries to screen or from which to amplify nucleic acid molecule include flea pre-pupal, 3rd instar or adult cDNA libraries as well as genomic DNA libraries. Similarly, preferred DNA sources to screen or from which to amplify nucleic acid molecules include flea pre-pupal, 3rd instar or adult cDNA and genomic DNA. Techniques to clone and amplify genes are disclosed, for example, in Sambrook et al., ibid.

[0128] The present invention also includes nucleic acid molecules that are oligonucleotides capable of hybridizing, under stringent hybridization conditions, with complementary regions of other, preferably longer, nucleic acid molecules of the present invention such as those comprising arthropod esterase genes or other arthropod esterase nucleic acid molecules. Oligonucleotides of the present invention can be RNA, DNA, or derivatives of either. The minimum size of such oligonucleotides is the size required for formation of a stable hybrid between an oligonucleotide and a complementary sequence on a nucleic acid molecule of the present invention. Minimal size characteristics are disclosed herein. The present invention includes oligonucleotides that can be used as, for example, probes to identify nucleic acid molecules, primers to produce nucleic acid molecules or therapeutic reagents to inhibit esterase protein production or activity (e.g., as antisense-, triplex formation-, ribozyme- and/or RNA drug-based reagents). The present invention also includes the use of such oligonucleotides to protect animals from disease using one or more of such technologies. Appropriate oligonucleotide-containing therapeutic compositions can be administered to an animal using techniques known to those skilled in the art.

[0129] One embodiment of the present invention includes a recombinant vector, which includes at least one isolated nucleic acid molecule of the present invention, inserted into any vector capable of delivering the nucleic acid molecule into a host cell. Such a vector contains heterologous nucleic acid sequences, that is nucleic acid sequences that are not naturally found adjacent to nucleic acid molecules of the present invention and that preferably are derived from a species other than the species from which the nucleic acid molecule(s) are derived. The vector can be either RNA or DNA, either prokaryotic or eukaryotic, and typically is a virus or a plasmid. Recombinant vectors can be used in the cloning, sequencing, and/or otherwise manipulation of arthropod esterase nucleic acid molecules of the present invention.

[0130] One type of recombinant vector, referred to herein as a recombinant molecule, comprises a nucleic acid molecule of the present invention operatively linked to an expression vector. The phrase operatively linked refers to insertion of a nucleic acid molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell. As used herein, an expression vector is a DNA or RNA vector that is capable of transforming a host cell and of effecting expression of a specified nucleic acid molecule. Preferably, the expression vector is also capable of replicating within the host cell. Expression vectors can be either prokaryotic or eukaryotic, and are typically viruses or plasmids. Expression vectors of the present invention include any vectors that function (i.e., direct gene expression) in recombinant cells of the present invention, including in bacterial, fungal, endoparasite, insect, other animal, and plant cells. Preferred expression vectors of the present invention can direct gene expression in bacterial, yeast, insect and mammalian cells and more preferably in the cell types disclosed herein.

[0131] In particular, expression vectors of the present invention contain regulatory sequences such as transcription control sequences, translation control sequences, origins of replication, and other regulatory sequences that are compatible with the recombinant cell and that control the expression of nucleic acid molecules of the present invention. In particular, recombinant molecules of the present invention include transcription control sequences. Transcription control sequences are sequences which control the initiation, elongation, and termination of transcription. Particularly important transcription control sequences are those which control transcription initiation, such as promoter, enhancer, operator and repressor sequences. Suitable transcription control sequences include any transcription control sequence that can function in at least one of the recombinant cells of the present invention. A variety of such transcription control sequences are known to those skilled in the art. Preferred transcription control sequences include those which function in bacterial, yeast, insect and mammalian cells, such as, but not limited to, tac, lac, trp, trc, oxy-pro, omp/lpp, rrnB, bacteriophage lambda (such as lambda P_(L) and lambda P_(R) and fusions that include such promoters), bacteriophage T7, T7lac, bacteriophage T3, bacteriophage SP6, bacteriophage SP01, metallothionein, alpha-mating factor, Pichia alcohol oxidase, alphavirus subgenomic promoters (such as Sindbis virus subgenomic promoters), antibiotic resistance gene, baculovirus, Heliothis zea insect virus, vaccinia virus, herpesvirus, raccoon poxvirus, other poxvirus, adenovirus, cytomegalovirus (such as intermediate early promoters), simian virus 40, retrovirus, actin, retroviral long terminal repeat, Rous sarcoma virus, heat shock, phosphate and nitrate transcription control sequences as well as other sequences capable of controlling gene expression in prokaryotic or eukaryotic cells. Additional suitable transcription control sequences include tissue-specific promoters and enhancers as well as lymphokine-inducible promoters (e.g., promoters inducible by interferons or interleukins). Transcription control sequences of the present invention can also include naturally occurring transcription control sequences naturally associated with arthropods, such as, C. felis.

[0132] Suitable and preferred nucleic acid molecules to include in recombinant vectors of the present invention are as disclosed herein. Preferred nucleic acid molecules to include in recombinant vectors, and particularly in recombinant molecules, include nfE1₄₀₁, nfE2₃₆₄, nfE3₄₂₁, nfE4₅₂₄, nfE5₁₉₈₂, nfE5₅₁₅, nfE5₂₁₄₄, nfE5₁₆₅₀, nfE6₁₄₈₈, nfE6₁₇₉₂, nfE6₁₆₅₀, nfE7₂₈₃₆, nfE7₁₇₈₈, nfE7₁₇₁₀, nfE7₆₅₀, nfE8₂₈₀₁, nfE8₁₇₈₅, nfE8₁₇₁₀, nfE9₂₀₀₇, nfE9₁₅₈₄, nfE9₁₅₄₀, nfE10₁₉₈₇ and/or nfE10₁₅₉₀ Particularly preferred recombinant molecules of the present invention include pCro-nfE6₁₄₈₈, pTrc-nfE7₆₅₀, pTrc-nfE7₁₇₁₀, pTrc-nfE8₁₇₁₀, pTrc-nfE5₁₆₅₀, pTrc-nfE9₁₅₄₀, pFB-nfE6₁₆₇₉, pVL-nfE7₁₈₀₂, pVL-nfE8₁₇₉₂ and pVL-nfE9₁₆₀₀, the production of which are described in the Examples section.

[0133] Recombinant molecules of the present invention may also (a) contain secretory signals (i.e., signal segment nucleic acid sequences) to enable an expressed arthropod protein of the present invention to be secreted from the cell that produces the protein and/or (b) contain fusion sequences which lead to the expression of nucleic acid molecules of the present invention as fusion proteins. Examples of suitable signal segments include any signal segment capable of directing the secretion of a protein of the present invention. Preferred signal segments include, but are not limited to, tissue plasminogen activator (t-PA), interferon, interleukin, growth hormone, histocompatibility and viral envelope glycoprotein signal segments, as well as natural signal sequences. Suitable fusion segments encoded by fusion segment nucleic acids are disclosed herein. In addition, a nucleic acid molecule of the present invention can be joined to a fusion segment that directs the encoded protein to the proteosome, such as a ubiquitin fusion segment. Recombinant molecules may also include intervening and/or untranslated sequences surrounding and/or within the nucleic acid sequences of nucleic acid molecules of the present invention.

[0134] Another embodiment of the present invention includes a recombinant cell comprising a host cell transformed with one or more recombinant molecules of the present invention. Transformation of a nucleic acid molecule into a cell can be accomplished by any method by which a nucleic acid molecule can be inserted into the cell. Transformation techniques include, but are not limited to, transfection, electroporation, microinjection, lipofection, adsorption, and protoplast fusion. A recombinant cell may remain unicellular or may grow into a tissue, organ or a multicellular organism. Transformed nucleic acid molecules of the present invention can remain extrachromosomal or can integrate into one or more sites within a chromosome of the transformed (i.e., recombinant) cell in such a manner that their ability to be expressed is retained. Preferred nucleic acid molecules with which to transform a cell include arthropod esterase nucleic acid molecules disclosed herein. Particularly preferred nucleic acid molecules with which to transform a cell include, nfE1₄₀₁, nfE2₃₆₄, nfE3₄₂₁, nfE4₅₂₄, nfE5₁₉₈₂, nfE5₁₅₁₅, nfE5₂₁₄₄, nfE5₁₆₅₀, nfE6₁₄₈₈, nfE6₁₇₉₂, nfE6₁₆₅₀, nfE7₂₈₃₆, nfE7₁₇₈₈, nfE7₁₇₁₀, nfE7₆₅₀, nfE8₂₈₀₁, nfE8₁₇₈₅, nfE8₁₇₁₀, nfE9₂₀₀₇, nfE9)₅₈₄, nfE9₁₅₄₀, nfE10₁₉₈₇ and/or nfE10₁₅₉₀.

[0135] Suitable host cells to transform include any cell that can be transformed with a nucleic acid molecule of the present invention. Host cells can be either untransformed cells or cells that are already transformed with at least one nucleic acid molecule (e.g., nucleic acid molecules encoding one or more proteins of the present invention and/or other proteins useful in the production of multivalent vaccines). Host cells of the present invention either can be endogenously (i.e., naturally) capable of producing arthropod esterase proteins of the present invention or can be capable of producing such proteins after being transformed with at least one nucleic acid molecule of the present invention. Host cells of the present invention can be any cell capable of producing at least one protein of the present invention, and include bacterial, fungal (including yeast), parasite, other insect, other animal and plant cells. Preferred host cells include bacterial, mycobacterial, yeast, insect and mammalian cells. More preferred host cells include Salmonella, Escherichia, Bacillus, Listeria, Saccharomyces, Spodoptera, Mycobacteria, Trichoplusia, BHK (baby hamster kidney) cells, MDCK cells (normal dog kidney cell line for canine herpesvirus cultivation), CRFK cells (normal cat kidney cell line for feline herpesvirus cultivation), CV-1 cells (African monkey kidney cell line used, for example, to culture raccoon poxvirus), COS (e.g., COS-7) cells, and Vero cells. Particularly preferred host cells are Escherichia coli, including E. coli K-12 derivatives; Salmonella typhi; Salmonella typhimurium, including attenuated strains such as UK-1 _(X) 3987 and SR-11 _(X) 4072; Spodoptera frugiperda; Trichoplusia ni; BHK cells; MDCK cells; CRFK cells; CV-1 cells; COS cells; Vero cells; and non-tumorigenic mouse myoblast G8 cells (e.g., ATCC CRL 1246). Additional appropriate mammalian cell hosts include other kidney cell lines, other fibroblast cell lines (e.g., human, murine or chicken embryo fibroblast cell lines), myeloma cell lines, Chinese hamster ovary cells, mouse NIH/3T3 cells, LMTK³¹ cells and/or HeLa cells. In one embodiment, the proteins may be expressed as heterologous proteins in myeloma cell lines employing immunoglobulin promoters.

[0136] A recombinant cell is preferably produced by transforming a host cell with one or more recombinant molecules, each comprising one or more nucleic acid molecules of the present invention operatively linked to an expression vector containing one or more transcription control sequences. The phrase operatively linked refers to insertion of a nucleic acid molecule into an expression vector in a manner such that the molecule is able to be expressed when transformed into a host cell.

[0137] A recombinant molecule of the present invention is a molecule that can include at least one of any nucleic acid molecule heretofore described operatively linked to at least one of any transcription control sequence capable of effectively regulating expression of the nucleic acid molecule(s) in the cell to be transformed, examples of which are disclosed herein. Particularly preferred recombinant molecules include pCro-nfE6₁₄₈₈, pTrc-nfE7₆₅₀, pTrc-nfE7₁₇₁₀, pTrc-nfE8₁₇₁₀, pTrc-nfE5₁₆₅₀, pTrc-nfE9₁₅₄₀, pFB-nfE6₁₆₇₉, pVL-nfE7₁₈₀₂, pVL-nfE8₁₇₉₂ and pVL-nfE9₁₆₀₀.

[0138] A recombinant cell of the present invention includes any cell transformed with at least one of any nucleic acid molecule of the present invention. Suitable and preferred nucleic acid molecules as well as suitable and preferred recombinant molecules with which to transform cells are disclosed herein. Particularly preferred recombinant cells include E. coli:pCro-nfE6₁₄₈₈ , E. coli:pTrc-nfE7₁₇₁₀ , E coli:pTrc-nfE7₆₅₀ , E. coli:pTrc-nfE8₁₇₁₀ , E. coli:pTrc-nfE5₁₆₅₀ , E. coli:pTrc-nfF9₁₅₄₀ , S. frugiperda:pVL-nfE7 ₁₀₂ , S. frugiperda:pVL-nfE8₁₇₉₂ , S. frugiperda:pVL-nfE9₁₆₀₀ and S. frugiperda:pFB-nfE6₁₆₇₉. Details regarding the production of these recombinant cells are disclosed herein.

[0139] Recombinant cells of the present invention can also be co-transformed with one or more recombinant molecules including arthropod esterase nucleic acid molecules encoding one or more proteins of the present invention and one or more other nucleic acid molecules encoding other protective compounds, as disclosed herein (e.g., to produce multivalent vaccines).

[0140] Recombinant DNA technologies can be used to improve expression of transformed nucleic acid molecules by manipulating, for example, the number of copies of the nucleic acid molecules within a host cell, the efficiency with which those nucleic acid molecules are transcribed, the efficiency with which the resultant transcripts are translated, and the efficiency of post-translational modifications. Recombinant techniques useful for increasing the expression of nucleic acid molecules of the present invention include, but are not limited to, operatively linking nucleic acid molecules to high-copy number plasmids, integration of the nucleic acid molecules into one or more host cell chromosomes, addition of vector stability sequences to plasmids, substitutions or modifications of transcription control signals (e.g., promoters, operators, enhancers), substitutions or modifications of translational control signals (e.g., ribosome binding sites, Shine-Dalgarno sequences), modification of nucleic acid molecules of the present invention to correspond to the codon usage of the host cell, deletion of sequences that destabilize transcripts, and use of control signals that temporally separate recombinant cell growth from recombinant enzyme production during fermentation. The activity of an expressed recombinant protein of the present invention may be improved by fragmenting, modifying, or derivatizing nucleic acid molecules encoding such a protein.

[0141] Isolated esterase proteins of the present invention can be produced in a variety of ways, including production and recovery of natural proteins, production and recovery of recombinant proteins, and chemical synthesis of the proteins. In one embodiment, an isolated protein of the present invention is produced by culturing a cell capable of expressing the protein under conditions effective to produce the protein, and recovering the protein. A preferred cell to culture is a recombinant cell of the present invention. Effective culture conditions include, but are not limited to, effective media, bioreactor, temperature, pH and oxygen conditions that permit protein production. An effective medium refers to any medium in which a cell is cultured to produce an arthropod esterase protein of the present invention. Such medium typically comprises an aqueous medium having assimilable carbon, nitrogen and phosphate sources, and appropriate salts, minerals, metals and other nutrients, such as vitamins. Cells of the present invention can be cultured in conventional fermentation bioreactors, shake flasks, test tubes, microtiter dishes, and petri plates. Culturing can be carried out at a temperature, pH and oxygen content appropriate for a recombinant cell. Such culturing conditions are within the expertise of one of ordinary skill in the art. Examples of suitable conditions are included in the Examples section.

[0142] Depending on the vector and host system used for production, resultant proteins of the present invention may either remain within the recombinant cell; be secreted into the fermentation medium; be secreted into a space between two cellular membranes, such as the periplasmic space in E. coli; or be retained on the outer surface of a cell or viral membrane. The phrase “recovering the protein”, as well as similar phrases, refers to collecting the whole fermentation medium containing the protein and need not imply additional steps of separation or purification. Proteins of the present invention can be purified using a variety of standard protein purification techniques, such as, but not limited to, affinity chromatography, ion exchange chromatography, filtration, electrophoresis, hydrophobic interaction chromatography, gel filtration chromatography, reverse phase chromatography, concanavalin A chromatography, chromatofocusing and differential solubilization. Proteins of the present invention are preferably retrieved in “substantially pure” form. As used herein, “substantially pure” refers to a purity that allows for the effective use of the protein as a therapeutic composition or diagnostic. A therapeutic composition for animals, for example, should exhibit no substantial toxicity and preferably should be capable of stimulating the production of antibodies in a treated animal.

[0143] The present invention also includes isolated (i.e., removed from their natural milieu) antibodies that selectively bind to an arthropod esterase protein of the present invention or a mimetope thereof (i.e., anti-arthropod esterase antibodies). As used herein, the term “selectively binds to” an esterase protein refers to the ability of antibodies of the present invention to preferentially bind to specified proteins and mimetopes thereof of the present invention. Binding can be measured using a variety of methods standard in the art including enzyme immunoassays (e.g., ELISA), immunoblot assays, etc.; see, for example, Sambrook et al., ibid. An anti-arthropod esterase antibody preferably selectively binds to an arthropod esterase protein in such a way as to reduce the activity of that protein.

[0144] Isolated antibodies of the present invention can include antibodies in a bodily fluid such as, but not limited to, serum), or antibodies that have been purified to varying degrees. Antibodies of the present invention can be polyclonal or monoclonal, functional equivalents such as antibody fragments and genetically-engineered antibodies, including single chain antibodies or chimeric antibodies that can bind to more than one epitope.

[0145] A preferred method to produce antibodies of the present invention includes (a) administering to an animal an effective amount of a protein, peptide or mimetope thereof of the present invention to produce the antibodies and (b) recovering the antibodies. In another method, antibodies of the present invention are produced recombinantly using techniques as heretofore disclosed to produce arthropod esterase proteins of the present invention. Antibodies raised against defined proteins or mimetopes can be advantageous because such antibodies are not substantially contaminated with antibodies against other substances that might otherwise cause interference in a diagnostic assay or side effects if used in a therapeutic composition.

[0146] Antibodies of the present invention have a variety of potential uses that are within the scope of the present invention. For example, such antibodies can be used (a) as therapeutic compounds to passively immunize an animal in order to protect the animal from arthropods susceptible to treatment by such antibodies and/or (b) as tools to screen expression libraries and/or to recover desired proteins of the present invention from a mixture of proteins and other contaminants. Furthermore, antibodies of the present invention can be used to target cytotoxic agents to hematophagous ectoparasites such as those discloses herein, in order to directly kill such hematophagous ectoparasites. Targeting can be accomplished by conjugating (i.e., stably joining) such antibodies to the cytotoxic agents using techniques known to those skilled in the art. Suitable cytotoxic agents are known to those skilled in the art.

[0147] One embodiment of the present invention is a therapeutic composition that, when administered to an animal in an effective manner, is capable of protecting that animal from infestation by hematophagous ectoparasite. Therapeutic compositions of the present invention include at least one of the following protective compounds: an isolated hematophagous arthropod esterase protein (including a peptide); a mimetope of such a protein; an isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis esterase gene; an isolated antibody that selectively binds to an hematophagous arthropod esterase protein; and inhibitors of hematophagous arthropod esterase activity (including esterase substrate analogs). As used herein, a protective compound refers to a compound that, when administered to an animal in an effective manner, is able to treat, ameliorate, and/or prevent disease caused by an arthropod of the present invention. Preferred arthropods to target are heretofore disclosed. Examples of proteins, nucleic acid molecules, antibodies and inhibitors of the present invention are disclosed herein.

[0148] A preferred therapeutic composition of the present invention includes at least one of the following protective compounds: an isolated hematophagous ectoparasite carboxylesterase protein (including a peptide); a mimetope of such a protein; an isolated hematophagous ectoparasite carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene; an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein; and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase (including a substrate analog).

[0149] Suitable inhibitors of esterase activity are compounds that interact directly with an esterase protein's active site, thereby inhibiting that esterase's activity, usually by binding to or otherwise interacting with or otherwise modifying the esterase's active site. Esterase inhibitors can also interact with other regions of the esterase protein to inhibit esterase activity, for example, by allosteric interaction. Inhibitors of esterases are usually relatively small compounds and as such differ from anti-esterase antibodies. Preferably, an esterase inhibitor of the present invention is identified by its ability to bind to, or otherwise interact with, a flea esterase protein, thereby inhibiting the activity of the flea esterase.

[0150] Esterase inhibitors can be used directly as compounds in compositions of the present invention to treat animals as long as such compounds are not harmful to host animals being treated. Esterase inhibitors can also be used to identify preferred types of arthropod esterases to target using compositions of the present invention, for example by affinity chromatography. Preferred esterase inhibitors of the present invention include, but are not limited to, flea esterase substrate analogs, and other molecules that bind to a flea esterase (e.g., to an allosteric site) in such a manner that esterase activity of the flea esterase is inhibited; examples include, but are not limited to, juvenile hormone analogs and cholinesterase inhibitors as well as other neural transmission inhibitors. An esterase substrate analog refers to a compound that interacts with (e.g., binds to, associates with, modifies) the active site of an esterase protein. A preferred esterase substrate analog inhibits esterase activity. Esterase substrate analogs can be of any inorganic or organic composition, and, as such, can be, but are not limited to, peptides, nucleic acids, and peptidomimetic compounds. Esterase substrate analogs can be, but need not be, structurally similar to an esterase's natural substrate as long as they can interact with the active site of that esterase protein. Esterase substrate analogs can be designed using computer-generated structures of esterase proteins of the present invention or computer structures of esterases' natural substrates. Substrate analogs can also be obtained by generating random samples of molecules, such as oligonucleotides, peptides, peptidomimetic compounds, or other inorganic or organic molecules, and screening such samples by affinity chromatography techniques using the corresponding binding partner, (e.g., a flea esterase). A preferred esterase substrate analog is a peptidomimetic compound (i.e., a compound that is structurally and/or functionally similar to a natural substrate of an esterase of the present invention, particularly to the region of the substrate that interacts with the esterase active site, but that inhibits esterase activity upon interacting with the esterase active site).

[0151] Esterase peptides, mimetopes and substrate analogs, as well as other protective compounds, can be used directly as compounds in compositions of the present invention to treat animals as long as such compounds are not harmful to the animals being treated.

[0152] The present invention also includes a therapeutic composition comprising at least one arthropod esterase-based compound of the present invention in combination wraith at least one additional compound protective against hematophagous ectoparasite infestation. Examples of such compounds are disclosed herein.

[0153] In one embodiment, a therapeutic composition of the present invention can be used to protect an animal from hematophagous ectoparasite infestation by administering such composition to a hematophagous ectoparasite, such as to a flea, in order to prevent infestation. Such administration could be oral, or by application to the environment (e.g., spraying). Examples of such compositions include, but are not limited to, transgenic vectors capable of producing at least one therapeutic composition of the present invention. In another embodiment, a hematophagous ectoparasite, such as a flea, can ingest therapeutic compositions, or products thereof, present in the blood of a host animal that has been administered a therapeutic composition of the present invention.

[0154] Compositions of the present invention can be administered to any animal susceptible to hematophagous ectoparasite infestation (i.e., a host animal), including warm-blooded animals. Preferred animals to treat include mammals and birds, with cats, dogs, humans, cattle, chinchillas, ferrets, goats, mice, minks, rabbits, raccoons, rats, sheep, squirrels, swine, chickens, ostriches, quail and turkeys as well as other furry animals, pets, zoo animals, work animals and/or food animals, being more preferred. Particularly preferred animals to protect are cats and dogs.

[0155] In accordance with the present invention, a host animal (i.e., an animal that is or is capable of being infested with a hematophagous ectoparasite) is treated by administering to the animal a therapeutic composition of the present invention in such a manner that the composition itself (e.g., an esterase inhibitor, an esterase synthesis suppressor (i.e., a compound that decreases the production of esterase in the hematophagous ectoparasite), an esterase mimetope, or an anti-esterase antibody) or a product generated by the animal in response to administration of the composition (e.g., antibodies produced in response to administration of an arthropod esterase protein or nucleic acid molecule, or conversion of an inactive inhibitor “prodrug” to an active esterase inhibitor) ultimately enters the hematophagous ectoparasite. A host animal is preferably treated in such a way that the compound or product thereof enters the blood stream of the animal. Hematophagous ectoparasites are then exposed to the composition or product when they feed from the animal. For example, flea esterase inhibitors administered to an animal are administered in such a way that the inhibitors enter the blood stream of the animal, where they can be taken up by feeding fleas. In another embodiment, when a host animal is administered an arthropod esterase protein or nucleic acid molecule, the treated animal mounts an immune response resulting in the production of antibodies against the esterase (i.e., anti-esterase antibodies) which circulate in the animal's blood stream and are taken up by hematophagous ectoparasites upon feeding. Blood taken up by hematophagous ectoparasites enters the hematophagous ectoparasites where compounds of the present invention, or products thereof, such as anti-esterase antibodies, esterase inhibitors, esterase mimetopes and/or esterase synthesis suppressors, interact with, and reduce esterase activity in the hematophagous ectoparasite.

[0156] The present invention also includes the ability to reduce larval hematophagous ectoparasite infestation in that when hematophagous ectoparasites feed from a host animal that has been administered a therapeutic composition of the present invention, at least a portion of compounds of the present invention, or products thereof, in the blood taken up by the hematophagous ectoparasite are excreted by the hematophagous ectoparasite in feces, which is subsequently ingested by hematophagous ectoparasite larvae. In particular, it is of note that flea larvae obtain most, if not all, of their nutrition from flea feces.

[0157] In accordance with the present invention, reducing esterase activity in a hematophagous ectoparasite can lead to a number of outcomes that reduce hematophagous ectoparasite burden on treated animals and their surrounding environments. Such outcomes include, but are not limited to, (a) reducing the viability of hematophagous ectoparasites that feed from the treated animal, (b) reducing the fecundity of female hematophagous ectoparasites that feed from the treated animal, (c) reducing the reproductive capacity of male hematophagous ectoparasites that feed from the treated animal, (d) reducing the viability of eggs laid by female hematophagous ectoparasites that feed from the treated animal, (e) altering the blood feeding behavior of hematophagous ectoparasites that feed from the treated animal (e.g., hematophagous ectoparasites take up less volume per feeding or feed less frequently), (f) reducing the viability of hematophagous ectoparasite larvae, for example due to the feeding of larvae from feces of hematophagous ectoparasites that feed from the treated animal and

so- (g) altering the development of hematophagous ectoparasite larvae (e.g., by decreasing feeding behavior, inhibiting growth, inhibiting (e.g., slowing or blocking) molting, and/or otherwise inhibiting maturation to adults).

[0158] Therapeutic compositions of the present invention also include excipients in which protective compounds are formulated. An excipient can be any material that the animal to be treated can tolerate. Examples of such excipients include water, saline, Ringer's solution, dextrose solution, Hank's solution, and other aqueous physiologically balanced salt solutions. Nonaqueous vehicles, such as fixed oils, sesame oil, ethyl oleate, or triglycerides may also be used. Other useful formulations include suspensions containing viscosity enhancing agents, such as sodium carboxymethylcellulose, sorbitol, or dextran. Excipients can also contain minor amounts of additives, such as substances that enhance isotonicity and chemical stability. Examples of buffers include phosphate buffer, bicarbonate buffer and Tris buffer, while examples of preservatives include thimerosal or o-cresol, formalin and benzyl alcohol. Standard formulations can either be liquid injectables or solids which can be taken up in a suitable liquid as a suspension or solution for injection. Thus, in a non-liquid formulation, the excipient can comprise dextrose, human serum albumin, dog serum albumin, cat serum albumin, preservatives, etc., to which sterile water or saline can be added prior to administration.

[0159] In one embodiment of the present invention, a therapeutic composition can include an adjuvant. Adjuvants are agents that are capable of enhancing the immune response of an animal to a specific antigen. Suitable adjuvants include, but are not limited to, cytokinies, chemokines, and compounds that induce the production of cytokines and chemokines (e.g., granulocyte macrophage colony stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), macrophage colony stimulating factor (M-CSF), colony stimulating factor (CSF), erythropoietin (EPO), interleukin 2 (IL-2), interleukin-3 (IL-3), interleukin 4 (IL-4), interleukin 5 (IL-5), interleukin 6 (IL-6), interleukin 7 (IL-7), interleukin 8 (IL-8), interleukin 10 (IL-10), interleukin 12 (IL-12), interferon gamma, interferon gamma inducing factor I (IGIF), transforming growth factor beta, RANTES (regulated upon activation, normal T cell expressed and presumably secreted), macrophage inflammatory proteins (e.g., MIP-1 alpha and MIP-1 beta), and Leishmania elongation initiating factor (LEIF); bacterial components (e.g., endotoxins, in particular superantigens, exotoxins and cell wall components); aluminum-based salts; calcium-based salts; silica; polynucleotides; toxoids; serum proteins, viral coat proteins; block copolymer adjuvants (e.g., Hunter's Titermax™ adjuvant (Vaxcel™, Inc. Norcross, Ga.), Ribi adjuvants (Ribi ImmunoChem Research, Inc., Hamilton, Mont.); and saponins and their derivatives (e.g., Quil A (Superfos Biosector A/S, Denmark). Protein adjuvants of the present invention can be delivered in the form of the protein themselves or of nucleic acid molecules encoding such proteins using the methods described herein.

[0160] In one embodiment of the present invention, a therapeutic composition can include a carrier. Carriers include compounds that increase the half-life of a therapeutic composition in the treated animal. Suitable carriers include, but are not limited to, polymeric controlled release vehicles, biodegradable implants, liposomes, bacteria, viruses, other cells, oils, esters, and glycols.

[0161] One embodiment of the present invention is a controlled release formulation that is capable of slowly releasing a composition of the present invention into an animal. As used herein, a controlled release formulation comprises a composition of the present invention in a controlled release vehicle. Suitable controlled release vehicles include, but are not limited to, biocompatible polymers, other polymeric matrices, capsules, microcapsules, microparticles, bolus preparations, osmotic pumps, diffusion devices, liposomes, lipospheres, and transdermal delivery systems. Other controlled release formulations of the present invention include liquids that, upon administration to an animal, form a solid or a gel in situ. Preferred controlled release formulations are biodegradable (i.e., bioerodible).

[0162] A preferred controlled release formulation of the present invention is capable of releasing a composition of the present invention into the blood of an animal at a constant rate sufficient to attain therapeutic dose levels of the composition to protect an animal from hematophagous ectoparasite infestation. The therapeutic composition is preferably released over a period of time ranging from about 1 to about 12 months. A preferred controlled release formulation of the present invention is capable of effecting a treatment preferably for at least about 1 month, more preferably for at least about 3 months, even more preferably for at least about 6 months, even more preferably for at least about 9 months, and even more preferably for at least about 12 months.

[0163] Acceptable protocols to administer therapeutic compositions of the present invention in an effective manner include individual dose size, number of doses, frequency of dose administration, and mode of administration. Determination of such protocols can be accomplished by those skilled in the art. A suitable single dose is a dose that is capable of protecting an animal from disease when administered one or more times over a suitable time period. For example, a preferred single dose of a protein, mimetope or antibody therapeutic composition is from about 1 microgram (μg) to about 10 milligrams (mg) of the therapeutic composition per kilogram body weight of the animal. Booster vaccinations can be administered from about 2 weeks to several years after the original administration. Booster administrations preferably are administered when the immune response of the animal becomes insufficient to protect the animal from disease. A preferred administration schedule is one in which from about 10 μg to about 1 mg of the therapeutic composition per kg body weight of the animal is administered from about one to about two times over a time period of from about 2 weeks to about 12 months. Modes of administration can include, but are not limited to, subcutaneous, intradermal, intravenous, intranasal, oral, transdermal, intraocular and intramuscular routes.

[0164] According to one embodiment, a nucleic acid molecule of the present invention can be administered to an animal in a fashion to enable expression of that nucleic acid molecule into a protective protein or protective RNA (e.g., antisense RNA, ribozyme, triple helix forms or RNA drug) in the animal. Nucleic acid molecules can be delivered to an animal in a variety of methods including, but not limited to, (a) administering a naked (i.e., not packaged in a viral coat or cellular membrane) nucleic acid vaccine (e.g., as naked DNA or RNA molecules, such as is taught, for example in Wolff et al., 1990, Science 247, 1465-1468) or (b) administering a nucleic acid molecule packaged as a recombinant virus vaccine or as a recombinant cell vaccine (i.e., the nucleic acid molecule is delivered by a viral or cellular vehicle).

[0165] A naked nucleic acid vaccine of the present invention includes a nucleic acid molecule of the present invention and preferably includes a recombinant molecule of the present invention that preferably is replication, or otherwise amplification, competent. A naked nucleic acid vaccine of the present invention can comprise one or more nucleic acid molecules of the present invention in the form of, for example, a bicistronic recombinant molecule having, for example one or more internal ribosome entry sites. Preferred naked nucleic acid vaccines include at least a portion of a viral genome (i.e., a viral vector). Preferred viral vectors include those based on alphaviruses, poxviruses, adenoviruses, herpesviruses, and retroviruses, with those based on alphaviruses (such as Sindbis or Semliki virus), species-specific herpesviruses and species-specific poxviruses being particularly preferred. Any suitable transcription control sequence can be used, including those disclosed as suitable for protein production. Particularly preferred transcription control sequence include cytomegalovirus intermediate early (preferably in conjunction with Intron-A), Rous Sarcoma Virus long terminal repeat, and tissue-specific transcription control sequences, as well as transcription control sequences endogenous to viral vectors if viral vectors are used. The incorporation of “strong” poly(A) sequences are also preferred.

[0166] Naked nucleic acid vaccines of the present invention can be administered in a variety of ways, with intramuscular, subcutaneous, intradermal, transdermal, intranasal and oral routes of administration being preferred. A preferred single dose of a naked nucleic acid vaccines ranges from about 1 nanogram (ng) to about 100 μg, depending on the route of administration and/or method of delivery, as can be determined by those skilled in the art. Suitable delivery methods include, for example, by injection, as drops, aerosolized and/or topically. Naked DNA of the present invention can be contained in an aqueous excipient (e.g., phosphate buffered saline) alone or a carrier (e.g., lipid-based vehicles).

[0167] A recombinant virus vaccine of the present invention includes a recombinant molecule of the present invention that is packaged in a viral coat and that can be expressed in an animal after administration. Preferably, the recombinant molecule is packaging-deficient and/or encodes an attenuated virus. A number of recombinant viruses can be used, including, but not limited to, those based on alphaviruses, poxviruses, adenoviruses, herpesviruses, and retroviruses. Preferred recombinant virus vaccines are those based on alphaviruses (such as Sindbis virus), raccoon poxviruses, species-specific herpesviruses and species-specific poxviruses. An example of methods to produce and use alphavirus recombinant virus vaccines is disclosed in PCT Publication No. WO 94/17813, by Xiong et al., published Aug. 18, 1994, which is incorporated by reference herein in its entirety.

[0168] When administered to an animal, a recombinant virus vaccine of the present invention infects cells within the immunized animal and directs the production of a protective protein or RNA nucleic acid molecule that is capable of protecting the animal from hematophagous ectoparasite infestation. For example, a recombinant virus vaccine comprising an arthropod CE nucleic acid molecule of the present invention is administered according to a protocol that results in the animal producing a sufficient immune response to protect itself from hematophagous ectoparasite infestation. A preferred single dose of a recombinant virus vaccine of the present invention is from about 1×10⁴ to about 1×10⁷ virus plaque forming units (pfu) per kilogram body weight of the animal. Administration protocols are similar to those described herein for protein-based vaccines, with subcutaneous, intramuscular, intranasal and oral administration routes being preferred.

[0169] A recombinant cell vaccine of the present invention includes recombinant cells of the present invention that express at least one protein of the present invention.

[0170] Preferred recombinant cells for this embodiment include Salmonella, E. coli, Listeria, Mycobacterium, S. frugiperda, yeast, (including Saccharomyces cerevisiae), BHK, CV-1, myoblast G8, COS (e.g., COS-7), Vero, MDCK and CRFK recombinant cells. Recombinant cell vaccines of the present invention can be administered in a variety of ways but have the advantage that they can be administered orally, preferably at doses ranging from about 10⁸ to about 10¹² cells per kilogram body weight. Administration protocols are similar to those described herein for protein-based vaccines. Recombinant cell vaccines can comprise whole cells, cells stripped of cell walls or cell lysates.

[0171] The efficacy of a therapeutic composition of the present invention to protect an animal from hematophagous ectoparasite infestation can be tested in a variety of ways including, but not limited to, detection of anti-arthropod esterase antibodies (using, for example, proteins or mimetopes of the present invention), detection of cellular immunity within the treated animal, or challenge of the treated animal with hematophagous ectoparasites to determine whether, for example, the feeding, fecundity or viability of hematophagous ectoparasites feeding from the treated animal is disrupted. Challenge studies can include attachment of chambers containing hematophagous ectoparasites onto the skin of the treated animal. In one embodiment, therapeutic compositions can be tested in animal models such as mice. Such techniques are known to those skilled in the art.

[0172] One preferred embodiment of the present invention is the use of arthropod protective compounds, such as proteins, mimetopes, nucleic acid molecules, antibodies and inhibitory compounds of the present invention, to protect an animal from hematophagous ectoparasite, and particularly flea, infestation. Preferred protective compounds of the present invention include, but are not limited to, C. felis esterase nucleic acid molecules, C. felis esterase proteins and mimetopes thereof, anti-C. felis esterase antibodies, and inhibitors of C. felis esterase activity. More preferred protective compounds of the present invention include, but are not limited to, CE or JHE formulations of the present invention, C. felis CE nucleic acid molecules, C. felis CE proteins and mimetopes thereof, anti-flea CE antibodies, anti-flea JHE antibodies, inhibitors of C. felis CE activity and inhibitors of flea JHE activity. Additional protection may be obtained by administering additional protective compounds, including other proteins, mimetopes, nucleic acid molecules, antibodies and inhibitory compounds, as disclosed herein.

[0173] One therapeutic composition of the present invention includes an inhibitor of arthropod esterase activity, i.e., a compound capable of substantially interfering with the function of an arthropod esterase susceptible to inhibition by an inhibitor of arthropod esterase activity. An inhibitor of esterase activity can be identified using arthropod esterase proteins of the present invention. One embodiment of the present invention is a method to identify a compound capable of inhibiting esterase activity of an arthropod. Such a method includes the steps of (a) contacting (e.g., combining, mixing) an isolated flea esterase protein, preferably a C. felis esterase protein of the present invention, with a putative inhibitory compound under conditions in which, in the absence of the compound, the protein has esterase activity, and (b) determining if the putative inhibitory compound inhibits the esterase activity. Putative inhibitory compounds to screen include small organic molecules, antibodies (including mimetopes thereof) and substrate analogs. Methods to determine esterase activity are known to those skilled in the art; see, for example, the Examples section of the present application.

[0174] The present invention also includes a test kit to identify a compound capable of inhibiting esterase activity of an arthropod. Such a test kit includes an isolated flea esterase protein, preferably a C. felis esterase protein, having esterase activity and a means for determining the extent of inhibition of esterase activity in the presence of (i.e., effected by) a putative inhibitory compound. Such compounds are also screened to identify those that are substantially not toxic in host animals.

[0175] Esterase inhibitors isolated by such a method, and/or test kit, can be used to inhibit any esterase that is susceptible to such an inhibitor. Preferred esterase proteins to inhibit are those produced by arthropods. A particularly preferred esterase inhibitor of the present invention is capable of protecting an animal from hematophagous ectoparasite infestation. Effective amounts and dosing regimens can be determined using techniques known to those skilled in the art.

[0176] The following examples are provided for the purposes of illustration and are not intended to limit the scope of the present invention.

EXAMPLES

[0177] It is to be noted that the Examples include a number of molecular biology, microbiology, immunology and biochemistry techniques considered to be known to those skilled in the art. Disclosure of such techniques can be found, for example, in Sambrook et al., ibid., Borovsky, Arch Insect Biochem. and Phys., 7:187-210, 1988, and related references.

Example 1

[0178] This example describes labeling of proteases and esterases with radiolabeled diisopropylfuorophosphate.

[0179] Tissue samples were isolated from unfed or bovine blood-fed 1 st instar Ctenocephalides felis flea larvae; bovine blood-fed or cat blood-fed 3rd instar Ctenocephalides felis flea larvae; bovine blood-fed or cat blood-fed Ctenocephalides felis prepupal flea larvae; bovine blood-fed or cat blood-fed adult Ctenocephalides felis flea midgut tissue, and whole unfed, bovine blood-fed or cat blood-fed adult Ctenocephalides felis fleas. The 1 st instar, 3rd instar, prepupal and adult midgut tissues were then homogenized by freeze-fracture and sonicated in a Tris buffer comprising 50 mM Tris, pH 8.0 and 100 mM CaCl₂. The whole adult flea sample was then homogenized by freeze-fracture and ground with a microtube mortar and pestle. The extracts were centrifuged at about 14,000×g for 20 minutes (min.) and the soluble material recovered. The soluble material was then diluted to a final concentration of about 1 to about 1.2 tissue equivalents per microliter (μl) of Tris buffer. Each sample was labeled with [1,3- ³H]-diisopropylfluorophosphate (3H-DFP) (available from DuPont-NEN, Wilmington, Del.) using the method generally described in Borovsky, ibid. About 20 tissue equivalents of each tissue sample were mixed with about 1 μCi of ³H-DFP and incubated for about 18 hours at 4° C. Proteins contained in each sample were then resolved using a 14% Tris-glycine sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) (available from Novex, San Diego, Calif.) under reducing conditions. The gel was soaked in Entensify (available from DuPont-NEN) according to manufacturers instructions, and exposed to X-ray film (available from Kodak X-0mat AR, Rochester, N.Y.) for about 3 days at −70° C.

[0180] Analysis of the resulting autoradiogram (shown in FIG. 1) indicated that tissue samples from 3rd instar, prepupal larvae and whole adult flea contained proteins that labeled with DFP, having a molecular weight (MW) of about 60 kilodalton (kD). No proteins of this MW were labeled in tissue samples from unfed or fed 1st instar larvae and adult midgut. The results indicated preferred tissue distribution and stage-specific expression of DFP-labeled serine esterases in fleas.

Example 2

[0181] This example describes the identification of general CE activity in flea tissue extracts.

[0182] Tissue samples and soluble extracts were prepared as described above in Example 1, except not labelled, from unfed (UF) and bovine blood-fed 1st instar flea larvae, bovine blood-fed 3rd instar flea larvae, bovine blood-fed prepupal flea larvae, unfed whole adult fleas, cat blood-fed adult (ACF) whole fleas, cat blood-fed adult fleas that have had their heads and midguts removed (referred to herein as fed adult partial fleas), unfed adult flea midguts and cat blood-fed adult flea midguts. About 5 tissue equivalents of each tissue were assayed for general CE activity using the following method. Tissue samples of about 5 μl were added to separate wells of flat-bottomed microtiter plate (available from Becton Dickinson, Lincoln Park, N.J.). A control well was prepared by adding about 5 μl of Tris buffer to an empty well of the plate. About 95 μl of 25 mM Tris-HCl (pH 8.0) was then added to each sample to increase the volume in each well to about 100 ill. About 100 μl of 0.25 mM α-napthyl acetate (available from Sigma, St. Louis, Mo.) dissolved in 25 mM Tris-HCl (pH 8.0) was then added to each well. The plate was then incubated for about 15 min. at 37° C. Following the incubation, about 40 μl of 0.3% Fast Blue salt BN (tetrazotized o-dianisidine; available from Sigma) dissolved in 3.3% SDS in water was added to each well.

[0183] The microtiter plate was then analyzed using a Cambridge Technology, Inc. (Watertown, Pa.) model 7500 Microplate Reader set to 590 nm. The absorbance value for the control sample was subtracted from absorbance values of experimental samples, such that the background value was zero.

[0184] The results shown in FIG. 2 indicated that general CE activity was detected in all tissue samples. The level of activity varied, with unfed and fed 1st instar larvae, unfed adult flea midguts, and fed adult flea midguts having relatively lower activity than in the other tissues. Thus, the results indicated preferred tissue distribution and stage-specific expression of general CE activity in fleas.

Example 3

[0185] This example describes the determination of general CE activity using isoelectric focusing (IEF)-PAGE and non-reducing SDS-PAGE.

[0186] A. Non-Reducing SDS-PAGE.

[0187] Soluble extracts from unfed and bovine blood-fed 1st instar flea larvae, bovine blood-fed 3rd instar flea larvae, bovine blood-fed prepupal flea larvae, bovine blood-fed adult (ABF) whole fleas and cat blood-fed adult whole fleas were prepared using the method described in Example 1. Each soluble extract sample was combined with SDS sample buffer (available from Novex) and proteins in the samples were resolved by gel electrophoresis using 14% Tris-glycine SDS electrophoresis gels (available from Novex). The gels were run at room temperature for about 1 hour at 200 volts. After electrophoresis, the gels were soaked for about for 30 minutes in 50 mM Tris, pH 8.0, containing 2.5% Triton X-100 to renature the proteins. The gels were then soaked in 50 mM Tris, pH 8.0, for about 5 minutes and then stained for about 5 min. in 50 milliliters (ml) of 25 mM Tris, pH 8.0, containing 50 mg Fast blue salt BN and 10 mg α-napthyl acetate (dissolved in 1 ml acetone). Once protein was detected on the stained gels, the gels were rinsed with water and photographed.

[0188] B. IEF-PAGE.

[0189] Soluble extracts from unfed and bovine blood-fed 1st instar flea larvae, bovine blood-fed 3rd instar flea larvae, bovine blood-fed prepupal flea larvae, unfed and cat blood-fed whole fleas, cat blood-fed adult partial fleas and cat blood-fed adult midguts were prepared as described above in Section A. The extracts were each combined with IEF sample buffer pH 3-7 (available from Novex) and loaded onto pH 3-7 IEF electrophoresis gels (available from Novex). The gels were electrophoresed at room temperature first for about 1 hour at about 100 volts, then for about 1 hour at about 200 volts, and then for about 30 min. at about 500 volts. Following electrophoresis, the gels were soaked in 25 mM Tris buffer, pH 8.0, for about 5 min. and then stained for about 15 min. in 50 ml of 25 mM Tris buffer, pH 8.0, containing 50 mg Fast blue salt BN and 10 mg α-napthyl acetate (dissolved in 1 ml acetone). Once protein was detected on the stained gels, the gels were rinsed with water and photographed.

[0190] C. Results.

[0191] The results from gel electrophoresis experiments described above in Sections A and B are shown in FIGS. 3 and 4. The results indicated that certain flea tissues contain proteins having MW's of from about 60 to about 70 kD and native pI values of from about 4.7 to about 5.2 that have CE activity. In particular, CE activity was identified in prepupal larvae and fed adult flea extracts resolved by non-reduced SDS-PAGE. No CE activity was identified in unfed and fed 1st instar larvae or fed 3rd instar larvae extracts (see FIG. 3). When extracts were resolved by native IEF-PAGE, CE activity was identified in fed 3rd instar larvae, prepupal larvae, unfed and fed whole adult flea, and fed adult partial flea extracts (see FIG. 4, lanes 3-7)). No CE activity was identified in unfed or fed 1st instar larvae, or in fed adult flea midgut extracts (see FIG. 4, lanes 1, 2, and 8).

Example 4

[0192] This example describes the purification of CE protein from prepupal flea larvae.

[0193] About 15,000 bovine blood-fed prepupal flea larvae were collected and the larvae were homogenized in TBS by sonication in 50 ml Oak Ridge centrifuge tubes (available from Nalgene Co., Rochester, N.Y.) by sonicating 4 times 20 seconds each at a setting of 5 of a model W-380 Sonicator (available from Heat Systems-Ultrasonics, Inc.). The sonicates were clarified by centrifugation at 18,000 RPM for 30 minutes to produce an extract. Soluble protein in the extract was removed by aspiration and diluted to a volume of about 20 ml in TBS (equivalent to about 1 larva per μl TBS). The extract was then added to a column containing about 5 ml of p-aminobenzamidine linked to agarose beads (available from Sigma, St. Louis, Mo.) and incubated overnight at 4° C. The column was then washed with about 30 ml TBS to remove unbound protein. The collected unbound protein was then concentrated to a volume of about 20 ml using a Macrosep 10 centrifugal protein concentrator (Filtron Technology Corp., Northborough, Mass.) and filtered sequentially through a 1 μm syringe filter and then through a 0.2 μm syringe filter to clarify the sample for chromatography.

[0194] Aliquots of about 0.5 ml were loaded onto a 20 ml Superdex 200 HR gel filtration column (available from Pharmacia, Piscataway, N.J.) equilibrated in TBS, operated on a BioLogic liquid chromatography system (available from BioRad, Burlingame, Calif.). About 1 ml fractions were then collected. Repetitive runs were performed until about 30 ml of each fraction was collected. The fractions were analyzed for CE activity using the assay described above in Example 2. In preparation for cation exchange chromatography, fractions having CE activity (V_(e)=16−18 ml) were combined and dialyzed against about 2 liters of 20 mM MES buffer (2-(N-morpholino)ethanesulfonic acid), pH 6.0, containing 10 mM NaCl, for about 1.5 hours, and then against about 1 liter of the same buffer overnight at 4° C. Prior to loading onto the cation exchange chromatography column, the sample was again filtered through a 0.2 μm syringe filter to remove precipitated proteins. The sample was then applied to a Bio-Scale S2 cation exchange column (available from BioRad) at a rate of about 0.5 ml/min. The column was washed with MES buffer until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 20 mM MES buffer, pH 6. Fractions were assayed for CE activity using the assay described above in Example 2. The results indicated that CE activity was not retained on the cation exchange column using the above conditions, and all of the activity was found in the flow-through fractions.

[0195] Fractions containing CE activity were pooled and adjusted to pH 7 using 0.5 M Tris, pH 8.0, in preparation for anion exchange chromatography. The pooled fractions were then loaded onto a 4.5 mm×50 mm Poros 10 HQ anion exchange chromatography column (available from PerSeptive Biosystems, Cambridge, Mass.) equilibrated in 25 mM Tris buffer, pH 6.8. The column was washed with the loading buffer, and bound proteins were eluted with a linear gradient of 0 to 1 M NaCl in 25 mM Tris buffer, pH 6.8. Fractions were tested for CE activity using the assay described above in Example 2. The results indicated that CE activity was eluted at about 170 mM NaCl. Fractions containing CE activity were pooled and diafiltered into TBS.

Example 5

[0196] This example describes the determination of N-terminal amino acid sequences of carboxylesterases isolated from prepupal flea larvae.

[0197] A. Anion Exchange Chromatography Fractions.

[0198] Anion exchange chromatography fractions described above in Example 4 that contained proteins having CE activity were pooled, diafiltered into TBS buffer and concentrated 3-fold in a Speed-Vac Concentrator (available from Savant Instruments, Ho

ibrook, N.Y.). Proteins in the concentrated samples were then resolved on a reducing, 10% SDS-PAGE Tris-glycine gel (available from Novex) for 1 hour at about 200 V. The proteins on the gel were then blotted onto a polyvinylidene difluoride (PVDF) membrane (available from Novex) for about 70 min in 10 mM CAPS buffer (3[cyclohexylamino]-1-propanesulfonic acid; available from Sigma), pH 11, with 0.5 mM dithiothreitol (DTT). The membrane was then stained for 1 minute in 0.1% Coomassie Blue R-250 dissolved in 40% methanol and 1% acetic acid. The membrane was destained in 50% methanol for about 10 minutes, rinsed with MilliQ water and air dried. Three stained protein bands were identified having apparent molecular weights of about 64 kD, 65 kD, and 66 kD, respectively. The portion of the membrane containing each band was excised separately. Protein contained in each membrane segment was subjected to N-terminal amino acid sequencing using a 473A Protein Sequencer (available from Applied Biosystems, Foster City, Calif.) and using standard techniques.

[0199] The results indicated that the N-terminal amino acid sequence of the putative 64 kD protein was DPPTVTLPQGEL (denoted SEQ ID NO:39); the N-terminal amino acid sequence of the putative 65 kD protein was DPPTVTLPQGELVGKATNEnxk (denoted SEQ ID NO:40); and the N-terminal amino acid sequence of the putative 66 kD protein was DppTVTLPQGEL (denoted SEQ ID NO:41), in which the lower case letters designate uncertainties and “x” designates an undetermined residue.

[0200] B. Proteins Resolved by Native IEF-PAGE.

[0201] Proteins isolated by anion exchange chromatography as described above in Section A were further resolved by native IEF-PAGE. Proteins were loaded onto a pH 3-10 IEF gel (available from Novex) and separated in Novex's IEF buffers according to Novex's standard procedure (60 min at 100 V; then 60 min at 200 V; and then 30 min at 500 V). Following electrophoresis, part of the gel was stained for CE activity using the method described above in Example 2. The remaining portion of the gel was blotted onto PVDF membrane by reversing the orientation of the gel and membrane so that positively charged proteins migrated to the membrane, electrophoresing the protein for 60 min at 10 V, using 0.7% acetic acid as the transfer buffer. The membrane was stained as described above in Section A. After the membrane was dried, stained protein bands on the membrane were compared to bands on the gel tested for CE activity to identify corresponding bands. Protein bands on the membrane corresponding to proteins having CE activity were excised and submitted to N-terminal sequencing as described in Section A.

[0202] N-terminal amino acid sequence was obtained for protein contained in two bands having pI values of about pI 4.8 and about pI 4.9. N-terminal amino acid sequence of the pI 4.8 band was DPPTVTLPQGELVGKALSNen (denoted SEQ ID NO:42) and N-terminal amino acid sequence of the pI 4.9 band was DPPTVTLP (denoted SEQ ID NO:43). A comparison of the N-terminal amino acid sequences identified here and described in Section A indicates closely related proteins having a consensus sequence of DPPTVTLPQGELVGKALTNEnGk (denoted SEQ ID NO:44).

[0203] The amino acid sequences of SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43 and SEQ ID NO:44 are substantially contained within SEQ ID NO:5, SEQ ID NO:19 and SEQ ID NO:53, which are described below in Example 11.

Example 6

[0204] This example describes partial purification of CE from 3rd instar flea larvae.

[0205] Using the extract preparation methods described in Example 1 without labelling, extracts were prepared from about 50,000 bovine blood-fed 3rd instar flea larvae. The extract was then further purified over a p-aminobenzamidine linked agarose bead column using the method also described in Example 1. Collected unbound protein was concentrated to about 70 ml using a 200 ml stirred cell fitted with a YM-10 membrane (available from Amicon, Beverly, Mass.). Seven ml (about 5,000 3rd instar flea larval equivalents) of the concentrated extract was used for the remainder of the purification scheme described in Example 4. Resulting fractions from the anion exchange chromatography column were tested for CE activity using the assay described above in Example 2.

[0206] The results indicated that CE activity was eluted in two overlapping peaks at about 120 mM and about 210 mM NaCl.

Example 7

[0207] This example describes the identification of JHE activity in different flea tissues.

[0208] Tissue samples were prepared as described above in Example 1 from unfed and bovine blood-fed 1st instar flea larvae, bovine blood-fed 3rd instar flea larvae, bovine blood-fed prepupal flea larvae, unfed and cat blood-fed whole adult fleas, cat blood-fed adult partial fleas and cat blood-fed adult flea midguts. About 5 tissue equivalents of each tissue was assayed for JHE activity as follows.

[0209] Unlabeled juvenile hormone (JH; available from ICN Biomedicals, Inc., Aurora, Ohio) was diluted in hexane to concentration of about 0.025 M. Labeled 10⁻³H-juvenile hormone (³H-JH; available from Dupont-NEN) was diluted in hexane to concentration of about 80,000 cpm/μl. A JH substrate mixture was prepared by mixing about 20 μl of unlabeled JH with about 80 μl of ³H-JH (about 5 μCi) in a 4 ml screw cap vial. The substrate mixture was then covered with nitrogen (i.e., “blanketed”) and the solvent contained in the mixture was evaporated by heating the mixture at 35° C. When just dry, about 1 ml of absolute anhydrous ethanol (final concentration 5×10-4 M, or 6400 cpn/μl) was added to the vial. The substrate mixture was then stored at −200° C.

[0210] About 5 equivalents of each tissue (about 5 μl of protein) was added into the bottom of a small glass autosampler vial. About 95 μl of Tris-buffered saline (TBS) was added to each vial to bring the final volume in each vial to about 100 μl. Two control samples were also prepared by adding 100 μl TBS to two separate vials. About 1 μl of the substrate mixture described above was added to all of the vials including the control samples. The final JH concentration in each vial was about 5×10⁻⁶ M. The vials were then capped and spun in a microfuge to bring all of the liquid to the bottom of each vial. The vials were then transferred to a heat block and incubated at 35° C. for about 30 minutes. Following the incubation, enzyme activity was stopped by adding about 50 μl of methanol buffer (methanol:water:concentrated ammonium hydroxide at a 10:9:1 ratio, respectively) to each vial and removing the vials from the heat block.

[0211] To measure labeled juvenile hormone acid, about 250 μl isooctane was added to each vial. Each vial was vortexed for about 15 seconds or until an emulsion formed. Each vial was then centrifuged in a microfuge for about 1 minute to separate aqueous and organic phases. About 75 μl of the aqueous layer was removed from each vial and added to about 2 nl Eco-1-me scintillation fluid (available from ICN). The amount of ³H-juvenile hormone acid contained in each vial was determined using a Beckman LS-1801 liquid scintillation counter (available from Beckman, Fullerton, Calif.).

[0212] The results shown in FIG. 5 indicated that all flea tissues tested contain active JHE. Referring to Example 2, the level of CE activity differed from JHE activity in various tissue samples. The combined JHE and CE data indicated the differential expression of these two enzymatic activities during the development of a flea.

Example 8

[0213] This example describes the purification of JHE protein from cat blood-fed adult midguts.

[0214] About 23,000 cat blood-fed adult midguts were collected and prepared using the method described in Example 1. The extract was then added in 4 aliquots to columns containing about 3 to about 5 ml of p-aminobenzamidine linked agarose beads (available from Sigma), equilibrated in 50 mM Tris (pH 8.0), 100 mM CaCl₂, 400 mM NaCl, and incubated overnight at 4° C. The columns were then washed with about 15 to about 125 ml of the equilibration Tris buffer to remove unbound protein. The collected unbound protein was pooled and then concentrated to a volume of about 5 ml using an Ultrafree-20 10 kD centrifugal concentrator (available from Millipore, Bedford, Mass.) and filtered sequentially through a 0.2 μm centrifugal ultrafiltration membrane (available from Lida, Kenosha, Wis.) to clarify the sample for chromatography.

[0215] Aliquots of about 0.5 ml were loaded onto a Superdex 200 HR gel filtration column using the method described in Example 4. Repeated runs were performed until about 10 ml of each fraction was collected. The fractions were analyzed for JHE activity using the assay described in Example 7. In preparation for anion exchange chromatography, fractions having JHE activity (V_(e)=17-18 ml) were combined and dialyzed overnight against about 1 L of 20 mM Tris buffer, pH 8.0, containing 10 mM NaCl. The sample was then loaded onto a Poros 10 HQ anion exchange column using the method described in Example 4. Resulting fractions were tested for JHE activity as described in Example 7.

[0216] The results indicated that midgut JHE activity was eluted from the anion exchange column in a single peak at about 120 mM NaCl.

Example 9

[0217] This example describes partial purification of JHE from prepupal flea larvae and 3rd instar larvae.

[0218] A. JHE Purification from Prepupal Tissue.

[0219] Using the extract preparation methods described in Example 1, gel filtration fractions were obtained using a Superdex 200 HR gel filtration column (available from Pharmacia) using the method described in Example 4, from about 15,000 bovine blood-fed prepupal flea larvae. The fractions were analyzed for JHE activity using the assay described above in Example 7. Those fractions containing protein having JHE activity (V_(e)=16-18 ml) were combined and dialyzed using the method described in Example 8.

[0220] The fractions were then further purified by passing the fractions over a Bio-Scale S2 cation exchange column (available from BioRad) at a rate of about 0.5 ml/min. The column was washed with MES until all unbound protein was eluted. Bound protein was then eluted with a linear gradient of 20 mM MES buffer, pH 6.0, containing 10 mM NaCl to 1 M NaCl. Resulting fractions were assayed for JHE activity using the method described in Example 7. The results indicated that proteins having JHE activity using prepupal tissue eluted from the column in about 200 to 300 mM NaCl.

[0221] The fractions containing JHE activity were combined and the pH adjusted to pH 7 using 0.5 M Tris buffer (pH 8.0). The fractions were then dialyzed twice against about 1 liter of 10 mM phosphate buffer (pH 7.2) containing 10 mM NaCl at 4° C. The resulting dialyzed fractions were then loaded onto a Bio-Scale CHT2-I Hydroxyapatite Column (available from BioRad) at a rate of about 0.5 ml/min. Unbound protein was washed from the column using the dialysis buffer. Bound protein was then eluted with a linear gradient of from 10 mM phosphate buffer, pH 7.2, containing 10 mM NaCl to 0.5 M phosphate buffer pH 6.5 containing 10 mM NaCl. One ml fractions were collected and each tested for JHE activity by the method described in Example 7.

[0222] The results indicated that JHE eluted in 2 overlapping peaks at about 100 mM and 150 mM phosphate. These two JHE activities were designated PF JHE

I and PP JHE II, and were kept separate for the remainder of the purification. Both JHE samples were dialyzed overnight against 20 mM Tris buffer (pH 8.0) containing 10 mM NaCl. The two samples were then loaded, separately, onto a 4.5 mm×50 mm Poros 10 HQ anion exchange chromatography column (available from PerSeptive Biosystems) equilibrated with 20 mM Tris buffer, pH 8.0, containing 10 mM NaCl. Unbound proteins were washed from the column using the same buffer. Bound proteins were eluted with a linear gradient of from 10 mM to 1 M NaCl in 20 mM Tris buffer, pH 8.0. Resulting fractions were tested for JHE activity using the method described in Example 7.

[0223] The results indicated that in both samples, JHE activity was eluted from the column in a single peak at about 100 mM NaCl.

[0224] B. JHE Purification from 3^(rd) Instar Tissue

[0225] Using the procedure described above in Section A, proteins having JHE activity were obtained using about 5,000 bovine blood-fed 3^(rd) instar flea larvae. Following purification by cation exchange, proteins having JHE activity using 3^(rd) instar tissue were found to elute in 2 peaks. The first peak having JHE activity was not retained on the column and also exhibited CE activity (referred to herein as CE/JHE fractions). The second peak having JHE activity eluted from the column in about 100-200 mM NaCl and did not contain CE activity.

[0226] The CE/JHE fractions were pooled and adjusted to about pH 7 using 0.5 M Tris, pH 8.0. The fractions were then loaded onto a 4.5 mm×50 mm Poros 10 HQ anion exchange chromatography column (available from PerSeptive Biosystems) and the column was equilibrated in 25 mM Tris buffer, pH 6.8. The column was washed with the same buffer and bound proteins were eluted with a linear gradient of 0 to 1 M NaCl in 25 mM Tris buffer, pH 6.8. Fractions were then tested for JHE activity using the method described in Example 7. JHE activity was eluted in two overlapping peaks at about 120 mM and 210 mM NaCl. The fraction containing JHE activity also contained CE activity when tested using the method described in Example 2.

[0227] Fractions from the cation exchange column containing only JHE activity were combined, diluted in 20 mM Tris buffet, pH 8.0 containing 10 mM NaCl, and concentrated to about 5 ml. The fractions were purified on a Poros 10 HQ anion exchange chromatography column as described immediately above. Fractions were then tested for JHE activity using the method described in Example 7. The JHE activity was eluted in a single peak at about 120 mM. The peak contained no detectable CE activity.

Example 10

[0228] This example describes the purification of JHE protein from unfed adult midguts.

[0229] About 16,000 unfed adult midguts were collected in 20 mM Tris buffer (pH 7.7), containing 130 mM NaCl, 1 mM sodium EDTA, 1 mM Pefabloc® (available from Boehringer Mannheim, Indianapolis, Ind.), 1 microgram/ml (μg/ml) leupeptin and 1 μg/ml pepstatin. The midguts were homogenized by freeze-fracture and sonication, and then centrifuged at about 14,000×g for 20 min. The soluble material from the centrifugation step was recovered. The soluble material was then concentrated to about 1 ml using an Ultrafree-20 10 kD centrifugal concentrator (available from Millipore) and filtered sequentially through a 0.2 μm centrifugal ultrafiltration membrane to clarify the sample for chromatography. Aliquots of about 0.5 ml were loaded onto a Superdex 200 HR gel filtration column using the method described in Example 4. Repeated column runs were performed until about 2 ml of each fraction was collected. The fractions were analyzed for JHE activity using the assay described in Example 7. In preparation for cation exchange chromatography, fractions having JHE activity (V_(e)=15-17 ml) were combined and dialyzed overnight against about 1 L of 20 mM MES buffer, pH 6.0, containing 10 mM NaCl. The sample was then applied to a Bio-Scale S2 cation exchange column using the method described in Example 4. Fractions of eluate were assayed for JHE activity using the method described in Example 7.

[0230] The results indicate that JHE is present in unfed midguts in two forms, one that is not retained on the cation exchange column and one that is bound to the column under low salt conditions at about 100 mM NaCl. The form that was not retained under low salt conditions was shown to have general CE activity using the methods described in Example 2.

Example 11

[0231] This example describes the identification of certain esterase nucleic acid molecules of the present invention.

[0232] Several flea esterase nucleic acid molecules, representing one or more partial flea esterase genes, were PCR amplified from a flea mixed instar cDNA library or a flea prepupal cDNA library. The flea mixed instar cDNA library was produced using unfed 1 st instar, bovine blood-fed 1 st instar, bovine blood-fed 2^(nd) instar and bovine blood-fed 3^(rd) instar flea larvae (this combination of tissues is referred to herein as mixed instar larval tissues for purposes of this example). The flea prepupal cDNA library was produced using prepupal flea larvae. For each library, total RNA was extracted from mixed instar or prepupal tissue, respectfully, using an acid-guanidinium-phenol-chloroform method similar to that described by Chomczynski et al., 1987, Anal. Biochem. 162, p. 156-159. Approximately 5,164 mixed instar larvae or 3,653 prepupal larvae were used in each RNA preparation. Poly A+ selected RNA was separated from each total RNA preparation by oligo-dT cellulose chromatography using Poly(A)Quick® mRNA isolation kits (available from Stratagene Cloning Systems, La Jolla, Calif.), according to the method recommended by the manufacturer.

[0233] A mixed instar cDNA expression library and a prepupal cDNA expression library were constructed in lambda (λ) Uni-ZAP™XR vector (available from Stratagene Cloning Systems) using Stratagene's ZAP-cDNA Synthesis Kit® protocol. About 6.34 μg of mixed instar poly A+ RNA were used to produce the mixed instar library and about 6.72 μg of prepupal poly A+ RNA were used to produce the prepupal library. The resultant mixed instar library was amplified to a titer of about 2.17×1010 pfu/ml with about 97% recombinants. The resultant prepupal library was amplified to a titer of about 3.5×10¹⁰ pfu/ml with about 97% recombinants.

[0234] A pair of primers was used to amplify DNA from the cDNA libraries. A sense vector primer T-3× (corresponding to the vector in which nucleic acid molecules of the present invention had been ligated), having the nucleic acid sequence AATTAACCCT CACTAAAGGG (available from Gibco BRL, Gaithersburg, Md.; denoted SEQ ID NO:45), was used in combination with a degenerate primer, the design of which was based on a highly conserved esterase amino acid sequence (disclosed in Hanzlik et al., J. Biol. Chem. 264:12419-12423, 1989; I Y/H G G G F/L) located in a region downstream from the mature amino terminus in a number of known esterases. The degenerate primer, referred to herein as FCEF, is an anti-sense primer having the nucleic acid sequence ARDCCDCCDC CRTRDAT (R indicating an A or G; and D indicating an A, G or T; denoted SEQ ID NO:46). The resultant PCR products from the mixed instar cDNA library, obtained using standard PCR conditions (e.g., Sambrook et al., ibid.), were about 550 nucleotides. The resultant PCR products from the prepupal cDNA library were from about 500 nucleotides to about 860 nucleotides.

[0235] A. PCR Products.

[0236] PCR products were gel purified and cloned into the TA Vector™ (available from InVitrogen Corp., San Diego, Calif.). Approximately 8 clones were identified from the prepupal library and 6 clones were identified from the mixed instar library. These nucleic acid molecules were subjected to nucleic acid sequencing using the Sanger dideoxy chain termination method, as described in Sambrook et al., ibid.

[0237] 1. Flea esterase clone 1 isolated from the mixed instar cDNA library was determined to comprise nucleic acid molecule nfE1₄₀₁, the nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:1. Translation of SEQ ID NO:1 suggests that nucleic acid molecule nfE1₄₀₁, encodes a non-full-length flea esterase protein of about 103 amino acids, referred to herein as PfE1₁₀₃, having amino acid sequence SEQ ID NO:2, assuming an initiation codon spanning from nucleotide 92 through nucleotide 94 of SEQ ID NO:1. The complement of SEQ ID NO:1 is represented herein by SEQ ID NO:3. Comparison of amino acid sequence SEQ ID NO:2 (i.e., the amino acid sequence of PfE1₁₀₃) with amino acid sequences reported in GenBank indicates that SEQ ID NO:2, showed the most homology, i.e., about 33% identity, between SEQ ID NO:2 and alpha esterase protein from Drosophila melanogaster.

[0238] 2. Flea esterase clone 2 isolated from the mixed instar cDNA library was determined to comprise nucleic acid molecule nfE2₃₆₄, the nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:4. Translation of SEQ ID NO:4 suggests that nucleic acid molecule nfE2₃₆₄ encodes a non-full-length flea esterase protein of about 121 amino acids, referred to herein as PfE2₁₂₁, having amino acid sequence SEQ ID NO:5, assuming the first codon spans from nucleotide 2 through nucleotide 4 of SEQ ID NO:4. The complement of SEQ ID NO:4 is represented herein by SEQ ID NO:6. Comparison of nucleic acid sequence SEQ ID NO:4 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:4 showed the most homology, i.e., about 43% identity, between SEQ ID NO:4 and a H. virescens JHE gene. Comparison of amino acid sequence SEQ ID NO:5 (i.e., the amino acid sequence of PfE2₁₂₁) with amino acid sequences reported in GenBank indicates that SEQ ID NO:5, showed the most homology, i.e., about 38% identity, between SEQ ID NO:5 and alpha esterase protein from Drosophila melanogaster.

[0239] 3. Flea esterase clone 3 isolated from the prepupal cDNA library was determined to comprise nucleic acid molecule nfE3₄₂₁, the nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:7. Translation of SEQ ID NO:7 suggests that nucleic acid molecule nfE3₄₂₁ encodes a non-full-length flea esterase protein of about 103 amino acids, referred to herein as PfE3₁₀₃, having amino acid sequence SEQ ID NO:8, assuming an initiation codon spanning from nucleotide 113 through nucleotide 115 of SEQ ID NO:7. The complement of SEQ ID NO:7 is represented herein by SEQ ID NO:9. Comparison of nucleic acid sequence SEQ ID NO:7 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:7 showed the most homology, i.e., about 53% identity, between SEQ ID NO:7 and a Torpedo marmorata acetylcholinesterase gene. Comparison of amino acid sequence SEQ ID NO:8 (i.e., the amino acid sequence of PfE3₁₀₃) with amino acid sequences reported in GenBank indicates that SEQ ID NO:8, showed the most homology, i.e., about 39% identity, between SEQ ID NO:5 and alpha esterase protein from Drosophila melanogaster.

[0240] 4. Flea esterase clone 4 isolated from the prepupal cDNA library was determined to comprise nucleic acid molecule nfE4₅₂₄, the nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:10. Translation of SEQ ID NO:10 suggests that nucleic acid molecule nfE4₅₂₄ encodes a non-full-length flea esterase protein of about 137 amino acids, referred to herein as PfE4₁₃₇, having amino acid sequence SEQ ID NO:11, assuming an initiation codon spanning from nucleotide 113 through nucleotide 115 of SEQ ID NO:10. The complement of SEQ ID NO:10 is represented herein by SEQ ID NO:12. Comparison of nucleic acid sequence SEQ ID NO:10 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:10 showed the most homology, i.e., about 47% identity, between SEQ ID NO:10 and an Anas platyrhyncos thioesterase B gene. Comparison of amino acid sequence SEQ ID NO:11 (i.e., the amino acid sequence of PfE4₁₃₇) with amino acid sequences reported in GenBank indicates that SEQ ID NO:11, showed the most homology, i.e., about 30% identity, between SEQ ID NO:11 and Leptinotarsa decemlineata acetylcholinesterase.

[0241] B. cDNA Clones.

[0242] Certain amplified PCR fragments were used as probes to identify full-length flea esterase genes in the prepupal cDNA library.

[0243] 1. Nucleic acid molecule nfE2₃₆₄ was labeled with ³²P and used as a probe to screen the mixed instar cDNA library described in Section A, using standard hybridization techniques. Two clones were isolated. A first clone included about a 2300-nucleotide insert, referred to herein as nfE5₂₃₀₀. Nucleic acid sequence was obtained using standard techniques from nfE5₂₃00, to yield a flea esterase nucleic acid molecule named nfE5₉₈₂ having a nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:13. Translation of SEQ ID NO:13 suggests that nucleic acid molecule nfE5 ₁₉₈₂ encodes a non-full-length flea esterase protein of about 505 amino acids, referred to herein as PfE5₅₀₅, having amino acid sequence SEQ ID NO:14, assuming the first codon spans from nucleotide 1 through nucleotide 3 of SEQ ID NO:13 and the stop codon spans from nucleotide 1518 through nucleotide 1520 of SEQ ID NO:13. The complement of SEQ ID NO:13 is represented herein by SEQ ID NO:15. The amino acid sequence of PfE5₅₀₅ (i.e., SEQ ID NO:14) predicts that PfE5₅₀₅ has an estimated molecular weight of about 56.8 kD and an estimated pI of about 5.5. The nucleic acid molecule representing the coding region for PfE5₅₀₅ is referred to herein as nfE5₁₅₁₅; the nucleic acid sequences of the coding strand and the complementary strand are represented by SEQ ID NO:16 and SEQ ID NO:17, respectively.

[0244] The nucleic acid sequence of nfE5₁₉₈₂ was used to design primers to use in combination with a vector primer to PCR amplify the 5′ terminal fragment of the remainder of the flea esterase coding region from the flea mixed instar cDNA library. A pair of primers was used to amplify DNA from the cDNA library. A sense vector primer T3-X (corresponding to the vector in which nucleic acid molecules of the present invention had been ligated), having the nucleic acid sequence 5′ AATTAACCCT CACTAAAGCG 3′ (denoted SEQ ID NO:45), was used in combination with an anti-sense primer M6/M265′, having the nucleic acid sequence 5′ GTGCGTACAC GTTTACTACC 3′ (denoted SEQ ID NO:56). The resultant PCR product from the mixed instar cDNA library, obtained using standard PCR conditions (e.g., Sambrook et al., ibid.), were about 354 nucleotides.

[0245] The PCR product was subjected to DNA sequencing analysis, and a composite sequence representing a full-length flea esterase coding region was deduced. The nucleic acid sequence of the composite nucleic acid molecule, referred to herein as nfE5₂₁₄₄ is denoted herein as SEQ ID NO:57. Translation of SEQ ID NO:57 suggests that nucleic acid molecule nfE5₂₁₄₄ encodes a full-length flea esterase protein of about 550 amino acids, referred to herein as PfE5₅₅₀, having amino acid sequence SEQ ID NO:58, assuming an open reading frame in which the initiation codon spans from nucleotide 30 through nucleotide 32 of SEQ ID NO:57 and the stop codon spans from nucleotide 1680 through nucleotide 1682 of SEQ ID NO:57. The complement of SEQ ID NO:57 is represented herein by SEQ ID NO:59. The coding region encoding PfE5₅₅₀ is represented by the nucleic acid molecule nfE5₁₆₅₀, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:60 and a complementary strand with nucleic acid sequence SEQ ID NO:61. The amino acid sequence of PfE5₅₅₀ (i.e., SEQ ID NO:58) predicts that PfE5₅₅₀ has an estimated molecular weight of about 61.8 kD and an estimated pI of about 5.5.

[0246] Comparison of nucleic acid sequence SEQ ID NO:57 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:57 showed the most homology, i.e., about 41% identity, between SEQ ID NO:57 and a M. persicae esterase FE4 mRNA sequence. Comparison of amino acid sequence SEQ ID NO:58 (i.e., the amino acid sequence of PfE5₅₅₀) with amino acid sequences reported in GenBank indicates that SEQ ID NO:58 showed the most homology, i.e., about 36% identity between SEQ ID NO:58 and Drosophila melanogster alpha esterase protein.

[0247] A second clone included about a 1900 nucleotide insert, referred to herein as nfE6₁₉₀₀. Nucleic acid sequence was obtained using standard techniques from nfE6₁₉₀₀, to yield a flea esterase nucleic acid molecule named nfE6₁₇₉₂ having a nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:18. Translation of SEQ ID NO:18 suggests that nucleic acid molecule nfE6₁₇₉₂ encodes a full-length flea esterase protein of about 550 amino acids, referred to herein as PfE6₅₅₀, having amino acid sequence SEQ ID NO:19, assuming an open reading frame in which the initiation codon spans from nucleotide 49 through nucleotide 51 of SEQ ID NO:18 and a stop codon spanning from nucleotide 1699 through nucleotide 1701 of SEQ ID NO:18. The complement of SEQ ID NO:18 is represented herein by SEQ ID NO:20. The coding region encoding PfE6₅₅₀, is represented by nucleic acid molecule nfE6₁₆₅₀, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:21 and a complementary strand with nucleic acid sequence SEQ ID NO:22. The proposed mature protein, denoted herein as PfE6₅₃₀, contains about 530 amino acids which is represented herein as SEQ ID NO:53. The nucleic acid molecule encoding PfE6₅₃₀ is denoted herein as nfE6₅₉₀ and has a coding strand having the nucleic acid sequence SEQ ID NO:23. The amino acid sequence of PfE6₅₅₀ (i.e., SEQ ID NO:19) predicts that PfE6₅₅₀ has an estimated molecular weight of about 61.8 kD and an estimated pI of about 5.5. Comparison of nucleic acid sequence SEQ ID NO:18 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:18 showed the most homology, i.e., about 41% identity, between SEQ ID NO:18 and a Myzus pericae esterase gene. Comparison of amino acid sequence SEQ ID NO:19 (i.e., the amino acid sequence of PfE6₅₅₀) with amino acid sequences reported in GenBank indicates that SEQ ID NO:19 showed the most homology, i.e., about 28% identity between SEQ ID NO:19 and Drosophila melanogaster alpha esterase protein.

[0248] 2. Nucleic acid molecule nfE4₅₂₄ was labeled with ³²P and used as a probe to screen the prepupal cDNA library described in Example 11, using standard hybridization techniques (e.g., Sambrook et al., ibid.). Two clones were isolated. A first clone included about a 3000 nucleotide insert, referred to herein as nfE7₃₀₀₀. Nucleic acid sequence was obtained using standard techniques from nfE7₃₀₀₀, to yield a flea esterase nucleic acid molecule named nfE7₂₈₃₆ having a nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:24. Translation of SEQ ID NO:24 suggests that nucleic acid molecule nfE7₂₃₆ encodes a full-length flea esterase protein of about 596 amino acids, referred to herein as PfE7₅₉₆, having amino acid sequence SEQ ID NO:25, assuming an open reading frame in which the initiation codon spans from nucleotide 99 through nucleotide 101 of SEQ ID NO:24 and a stop codon spanning from nucleotide 1887 through nucleotide 1889 of SEQ ID NO:25. The complement of SEQ ID NO:24 is represented herein by SEQ ID NO:26. The coding region encoding PfE7₅₉₆, is represented by nucleic acid molecule nfE7₁₇₈₈, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:28 and a complementary strand with nucleic acid sequence SEQ ID NO:29. The proposed mature protein, denoted herein as PfE7₅₇₀, contains about 570 amino acids which is represented herein as SEQ ID NO:54. The nucleic acid molecule encoding PfE7₅₇₀ is denoted herein as nfE7₁₇₁₀ and has a coding strand having the nucleic acid sequence SEQ ID NO:27. The amino acid sequence of PfE7₅₉₆ (i.e., SEQ ID NO:25) predicts that PfE7₅₉₆ has an estimated molecular weight of about 68.7 kD and an estimated pI of about 6.1.

[0249] Comparison of nucleic acid sequence SEQ ID NO:24 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:24 showed the most homology, i.e., about 48% identity, between SEQ ID NO:24 and an Anas platychyncos thioesterase B gene. Comparison of amino acid sequence SEQ ID NO:25 (i.e., the amino acid sequence of PfE7₅₉₆) with amino acid sequences reported in GenBank indicates that SEQ ID NO:25 showed the most homology, i.e., about 27% identity between SEQ ID NO:25 and Drosophila melanogaster, alpha esterase protein.

[0250] A second clone included about a 3000 nucleotide insert, referred to herein as nfE8₃₀₀₀. Nucleic acid sequence was obtained using standard techniques from nfE8₃₀₀₀, to yield a flea esterase nucleic acid molecule named nfE8₂₈₀, having a nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:30. Translation of SEQ ID NO:30 suggests that nucleic acid molecule nfE8₂₈₀, encodes a full-length flea esterase protein of about 59: amino acids, referred to herein as PfE8₅₉₅, having amino acid sequence SEQ ID NO:31, assuming an open reading frame in which the initiation codon spans from nucleotide 99 through nucleotide 101 of SEQ ID NO:30 and a stop codon spanning from nucleotide 1884 through nucleotide 1886 of SEQ ID NO:30. The complement of SEQ ID NO:30 is represented herein by SEQ ID NO:32. The coding region encoding PfE8₅₉₅, is represented by nucleic acid molecule nfE8₁₇₈₅, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:34 and a complementary strand with nucleic acid sequence SEQ ID NO:35. The proposed mature protein, denoted herein as PfE8₅₇₀, contains about 570 amino acids which is represented herein as SEQ ID NO:55. The nucleic acid molecule encoding PfE8₅₇₀ is denoted herein as nfE8₁₇₁₀ and has a coding strand having the nucleic acid sequence SEQ ID NO:33. The amino acid sequence of PfE8₅₉₅ (i.e., SEQ ID NO:31) predicts that PfE8₅₉₅ has an estimated molecular weight of about 68.6 kD and an estimated pI of about 6.1.

[0251] Comparison of nucleic acid sequence SEQ ID NO:30 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:30 showed the most homology, i.e., about 46% identity, between SEQ ID NO:30 and a Mus musculus carboxyl ester lipase gene. Comparison of amino acid sequence SEQ ID NO:31 (i.e., the amino acid sequence of PfE8₅₉₅) with amino acid sequences reported in GenBank indicates that SEQ ID NO:31 showed the most homology, i.e., about 28% identity between SEQ ID NO:31 and estalpha-2 esterase of Culex pipens quinque fasciatus.

[0252] 3. Nucleic acid molecule nfE3₄₂₁ was labeled with ³²P and used as a probe to screen the prepupal cDNA library using standard hybridization techniques (e.g., Sambrook et al., ibid.). Two clones were isolated. One clone included about a 1900 nucleotide insert, referred to herein as nfE9₁₉₀₀. Nucleic acid sequence was obtained using standard techniques from nfE9₁₉₀₀, to yield a flea esterase nucleic acid molecule named nfE9₂₀₀₇ having nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:36. Translation of SEQ ID NO:36 suggests that nucleic acid molecule nfE9₂₀₀₇ encodes a full-length flea esterase protein of about 528 amino acids, referred to herein as PfE9₅₂₈, having amino acid sequence SEQ ID NO:37, assuming an open reading frame in which the initiation codon spans from nucleotide 11 through nucleotide 13 of SEQ ID NO:36 and a stop codon spanning from nucleotide 1595 through nucleotide 1597 of SEQ ID NO:36. The complement of SEQ ID NO:36 is represented herein by SEQ ID NO:38. The coding region encoding PfE9₅₂₈, is represented by nucleic acid molecule nfE9₁₅₈₄, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:51 and a complementary strand with nucleic acid sequence SEQ ID NO:52. The amino acid sequence of PfE9₅₂₈ (i.e., SEQ ID NO:37) predicts that PfE9₅₂₈ has an estimated molecular weight of about 60 kD and an estimated pI of about 5.43.

[0253] Comparison of nucleic acid sequence SEQ ID NO:36 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:36 showed the most homology, i.e., about 47% identity, between SEQ ID NO:36 and a hamster mRNA for carboxylesterase precursor gene. Comparison of amino acid sequence SEQ ID NO:37 (i.e., the amino acid sequence of PfE9₅₂₈) with amino acid sequences reported in GenBank indicates that SEQ ID NO:37 showed the most homology, i.e., about 37% identity between SEQ ID NO:37 and alpha esterase protein from Drosophila melanogaster.

[0254] As is the case for any of the nucleic acid molecules described in this example, variations between sequences may be due to a number of factors, such as but not limited to, sequencing errors or allelic variation.

[0255] 4. Nucleic acid molecule nfE1₄₀₁ was labeled with ³²P and used as a probe to screen the mixed instar cDNA library using standard hybridization techniques (e.g., Sambrook et al., ibid.). A clone was isolated that included about a 2000 nucleotide insert, referred to herein as nfE10₂₀₀₀. Nucleic acid sequence was obtained using standard techniques from nfE10₂₀₀₀, to yield a flea esterase nucleic acid molecule named nfE10₉₈₇ having nucleic acid sequence of the coding strand which is denoted herein as SEQ ID NO:67. Translation of SEQ ID NO:67 suggests that nucleic acid molecule nfE10₉₈₇ encodes a full-length flea esterase protein of about 530 amino acids, referred to herein as PfE10₅₃₀, having amino acid sequence SEQ ID NO:68, assuming an open reading frame in which the initiation codon spans from nucleotide 231 through nucleotide 233 of SEQ ID NO:67 and a stop codon spanning from nucleotide 1821 through nucleotide 1823 of SEQ ID NO:67. The complement of SEQ ID NO:67 is represented herein by SEQ ID NO:69. The coding region encoding PfE10₅₃₀, is represented by nucleic acid molecule nfE10₅₉₀, having a coding strand with the nucleic acid sequence represented by SEQ ID NO:70 and a complementary strand with nucleic acid sequence SEQ ID NO:71. The amino acid sequence of PfE10₅₃₀(i.e., SEQ ID NO:68) predicts that PfE10₅₃₀ has an estimated molecular weight of about 59.5 kD and an estimated pI of about 5.5.

[0256] Comparison of nucleic acid sequence SEQ ID NO:67 with nucleic acid sequences reported in GenBank indicates that SEQ ID NO:67 showed the most homology, i.e., about 48% identity, between SEQ ID NO:67 and a Lucilia cuprila alpha esterase gene (genembl #U56636) gene. Comparison of amino acid sequence SEQ ID NO:68 (i.e., the amino acid sequence of PfE10₅₃₀) with amino acid sequences reported in GenBank indicates that SEQ ID NO:68 showed the most homology, i.e., about 30% identity between SEQ ID NO:68 and Culex pipens esterase b1 precurser protein (swissprot #P16854).

[0257] As is the case for any of the nucleic acid molecules described in this example, variations between sequences may be due to a number of factors, such as but not limited to, sequencing errors or allelic variation.

Example 12

[0258] This Example demonstrates the production of esterase proteins of the present invention in E. coli cells.

[0259] A. Flea esterase protein PHIS-PfE7₅₇₀ and flea esterase protein PHIS-PfE8₅₇₀ were produced in the following manner. A pair of primers was used to amplify DNA from flea esterase nucleic acid molecule nfE7₂₈₃₆ or nfE8₂₈₀₁ produced as described in Example 11. A sense primer containing an XhoI site (shown in bold) having the nucleic acid sequence 5′ TGTGCTCGAG ATGGGATAAC CTAGATCAGC ATTTGTGC 3′ (denoted SEQ ID NO:47), was used in combination with an anti-sense primer containing a KpnI site (shown in bold) having the nucleic acid sequence 5′ TTAAGGTACC TCATCTAATA CTTCCTTCAT TACAG 3′ (denoted SEQ ID NO:48). A PCR product was derived from nfE7₂₈₃₆, and is referred to herein nfE7₁₇₁₀, having nucleic acid sequence SEQ ID NO:27. The PCR product was digested with XhoI and KpnI restriction endonucleases, gel purified and subcloned into expression vector pTrcHisB (available from InVitrogen). The resultant recombinant molecule, referred to herein as pTrc-nfE7₁₇₁₀, was transformed into E. coli HB101 competent cells (available from Gibco BRL) to form recombinant cell E. coli:pTrc-nfE7₁₇₁₀.

[0260] The PCR product derived from nfE8₂₈₀₁ using the primers is referred to herein as nfE8₁₇₁₀, having nucleic acid sequence SEQ ID NO:33. PCR product nfE8₁₇₁₀ was digested with XhoI and KpnI restriction endonucleases, gel purified and subcloned into expression vector pTrcHisB. The resultant recombinant molecule, referred to herein as pTrc-nfE8₁₇₁₀, was transformed into E. coli HB101 competent cells to form recombinant cell E. coli:pTrc-nfE8₁₇₁₀.

[0261] The recombinant cells were cultured in enriched bacterial growth medium containing 0.1 mg/ml ampicillin and 0.1% glucose at about 32° C. When the cells reached an OD₆₀₀ of about 0.4-0.5, expression of recombinant protein was induced by the addition of 0.5 mM isopropyl-B-D-thiogalactoside (IPTG), and the cells were cultured for about 2 hours at about 32° C. Immunoblot analysis of recombinant cell E. coli:pTrcnfE7₁₇₁₀ and E. coli:pTrc-nfE8₁₇₁₀ lysates using a T7 tag monoclonal antibody (available from Novagen, Inc., Madison, Wis.) directed against the fusion portion of the recombinant PHIS-PfE7₅₇₀ and PHIS-PfE8₅₇₀ fusion proteins identified proteins of appropriate size, namely an about 65 kD protein for each fusion protein.

[0262] B. Flea esterase protein PHIS-PfE6₅₄₀ was produced in the following manner. A pair of primers was used to amplify DNA from flea esterase nucleic acid molecule nfE6₁₇₉₂ produced as described in Example 11. A sense primer containing an XhoI site having the nucleic acid sequence 5′ AAACTCGAGT CCCCCGACTG TAACTTTGC 3′ (denoted SEQ ID NO:62; XhoI site shown in bold), was used in combination with an anti-sense primer containing a PstI site having the nucleic acid sequence 5′ TCATCTGCAG TTATTGACTG TGCAAAGTTT TTGTGG 3′ (denoted SEQ ID NO:63; PstI site shown in bold). A PCR product was derived from nfE6₁₇₉₂, and is referred to herein as nfE6₁₄₈₈, having nucleic acid sequence SEQ ID NO:76. The PCR product was digested with XhoI and PstI restriction endonucleases, gel purified and subcloned into expression vector lambdaP_(R)/T²ori/S10HIS-RSET-A9, that had been digested with XhoI and PstI and dephosphorylated. The resultant recombinant molecule, referred to herein as pCro-nfE6₁₄₈₈, was transformed into E. coli HB101 competent cells (available from Gibco BRL) to form recombinant cell E. coli:pCro-nfE6₁₄₈₈.

[0263] The recombinant cells were cultured using the method generally described in Section A of this example, except that the cells were grown under heat shift conditions rather than in the presence of IPTG. The cells were grown at 32° C. for about 2 hours, and then grown at 42° C. Immunoblot analysis of recombinant cell E. coli:pCro-nfE6₁₄₈₈ lysate using a T7 tag monoclonal antibody directed against the fusion portion of the recombinant PHIS-PfE6₅₄₀ fusion protein identified proteins of appropriate size, namely an about 60 kD protein for each fusion protein.

[0264] Expression of the recombinant PHIS-PfE6₅₄₀ fusion protein was improved by transforming supercoiled plasmid pCro-nfE6₁₄₈₈ DNA harested from E. coli:pCronfE6₁₄₈₈ cells into the BL-21 strain of E. coli (available from Novagen). The amount of expression PHIS-PfE6₅₄₀ was confined by immunoblot using the method described immediately above.

[0265]E. coli cells expressing PHIS-PfE6₅₄₀ protein were harvested from about 2 liters of media and suspended in about 140 ml of 50 mM Tris, pH 8.0, 50 mM NaCl, 0.1 mM phenylmethylsulfonylfluoride (PMSF) (Solubilization Buffer). The cells were broken by passage through a microfluidizer at 30 psi for 30 cycles. The sample was centrifuged at about 16,000×g for 30 min at 40° C. The supernatant (S1) was recovered and the pellet was resuspended in about 80 ml of Solubilization Buffer and centrifuged at about 16,000× g for 30 min at 40° C. The supernatant (S2) was recovered and the pellet was resuspended in about 80 ml of Solubilization Buffer containing 0.1% Triton-X100 and centrifuged at about 16,000× g for 30 min at 40° C. The supernatant (S3) was recovered and the pellet was resuspended in about 140 mls 50 mM Tris, pH 8.0, 8 M Urea, 0.1 M PMSF and centrifuged at about 16,000× g. The supernatant (S4) was recovered and the pellet was resuspended in 40 mis 50 mM Tris, 8 M Urea, 0.1 M PMSF. Aliquots of each pellet and supernatant were analyzed by SDS-PAGE and immunoblot using the T7 tag monoclonal antibody described above. The results indicated that the PHIS-PfE6₅₄₀ protein was located in the final supernatant (S4). The PHIS-PfE6₅₄₀ protein was loaded onto a 5.0 ml, Metal chelating HiTrap column charged with NiCl₂ (obtained from Pharmacia Biotech Inc., Piscataway, N.J.), previously equilibrated with 50 mM Tris, 1 mM PMSF, 1 mM β-mercaptoethanol (OME), 8 M urea, pH 8.0 (Buffer A). The column was washed with 10 column volumes (cv) of Buffer A and then with 10 cv with 50 mM Tris, 25 mM sodium acetate, 1 mM PMSF, 1 mM βME, 8 M urea, pH 6.0 (Buffer B) to remove loosely bound proteins. Bound PHIS-PfE6₅₄₀ protein was eluted with 10 cv of 50 mM Tris, 25 mM sodium acetate, 1 mM PMSF, 1 mM βME, 8 M urea, pH 4.0 (Buffer C). Column fractions were analyzed for the presence of PHIS-PfE6₅₄₀ protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the majority of the PHIS-PfE6₅₄₀ protein was eluted by Buffer C. The fractions containing the PHIS-PfE6₅₄₀ protein were combined and loaded onto a 5 ml SP-Sepharose HiTrap column (obtained from Pharmacia Biotech Inc.) previously equilibrated with 50 mM Tris, 25 mM Sodium Acetate, 1 mM PMSF, 1 mM βME, 8 M Urea, pH 4.5 (SP-Sepharose Buffer). The column was washed with SP-Sepharose Buffer until most of the unbound protein was removed. Bound protein was eluted with an increasing salt gradient to 1 M NaCl over 100 ml (20 cv) in SP-sepharose buffer. Column fractions were analyzed for the presence of PHIS-PfE6₅₄₀ protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the PHIS-PfE6₅₄₀ protein was eluted at about 0.75 M NaCl.

[0266] The purified PHIS-PfE6₁₄₈ protein was used to produce an anti-M6 polyclonal antiserum as follows. Rabbits were immunized with PHIS-PfE6₁₄₈ g protein diluted to a concentration of about 0.1 mg/ml in PBS. One milliliter of the dilution was mixed 1:1 mix with Complete Freunds Adjuvant. In the primary immunization, about 500 μl of the 1:1 mix was injected subcutaneously into 5 different sites (0.1 ml/site) and 500 μl was injected intradermally into 5 different sites (0.1 ml/site) on the rabbit. Booster shots were administered to the rabbit intramuscularly in 4 sites using 250 μl/site of a 1:1 mix of PHIS-PfE6₁₄₈₈ protein with Incomplete Freunds Adjuvant. The booster shots were administered at days 14 and 35. Serum samples were obtained prior to immunization (pre-bleed), and at day 14 after primary immunization and day 14 after the first and second boost.

[0267] C. Flea esterase protein PHIS-PfE9₅₂₈ was produced in the following maruler. A pair of primers was used to amplify DNA from flea esterase nucleic acid molecule nfE9₂₀₀₇ produced as described in Example 11. A sense primer containing an BamHI site having the nucleic acid sequence 5′-TTC CGG ATC CGG CTG ATC TAC AAG TGA CTT TG-3′ (denoted SEQ ID NO:64; BamHI site shown in bold), was used in combination with an anti-sense primer containing a XhoI site having the nucleic acid sequence 5′ TGG TAC TCG AGT CAT AAA AAT TTA TTC CAA AAT C₃′ (denoted SEQ ID NO:65; XhoI site shown in bold). A PCR product was derived from nfE9₂₀₀₇, and is referred to herein as nfE9₁₅₄₀, having nucleic acid sequence SEQ ID NO:51. The PCR product was digested with BamI and XhoI restriction endonucleases, gel purified and subcloned into expression vector pTrcHisB (available from InVitrogen). The resultant recombinant molecule, referred to herein as pTrc-nfE9₅₄₀, was transformed into E. coli HB101 competent cells (available from Gibco BRL) to form recombinant cell E. coli:pTrc-nfE9₁₅₄₀.

[0268] The recombinant cells were cultured using the method described in Section A of this example. Immunoblot analysis of recombinant cell E. coli:pTrc-nfE9₁₅₄₀ lysate using a T7 tag monoclonal antibody directed against the fusion portion of the recombinant PHIS-PfE9₅₂₈ fusion protein identified proteins of appropriate size, namely an about 59 kD protein for each fusion protein.

[0269] Expression of the recombinant PHIS-PfE9₅₂₈ fusion protein was improved by transforming supercoiled plasmid pTrc-nfE9₁₅₈₄ DNA harvested from E. coli:pTrc-nfE9₁₅₄₀ cells into the BL-21 strain of E. coli. The amount of expression PHIS-PfE9₅₂₈ was confined by immunoblot using the method described immediately above.

[0270] Two liters of media from cultures of E. coli cells expressing PHIS-PfE9₅₂₈ protein were harvested and S4 supernatant was prepared using the method described above in section B. The PHIS-PfE9₅₂₈ protein contained in the S4 supernatant was loaded onto a 5.0 ml, Metal chelating HiTrap column charged with NiCl₂ (available from Pharmacia Biotech Inc., Piscataway, N.J.), previously equilibrated with 50 mM Tris, 1 mM PMSF, 1 mM βME, 8 M urea, pH 8.0 (Buffer A). The column was washed with 5 cv of Buffer A until all unbound protein was removed. Bound protein was eluted with a linear gradient from Buffer A to 50 mM Tris, 1 mM PMSF, 1 mM βME, 8 M urea, 1 M NaCl, pH 4.0. Column fractions were analyzed for the presence of PHIS-PfE9₅₂₈ protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the majority of the PHIS-PfE9₅₂₈ protein was eluted at about 250 mM NaCl. The fractions containing the PHIS-PfE9₅₂₈ protein were combined and loaded onto a C4-reversed phase column (obtained from Vydak, Hesperia, Calif.), previously equilibrated with 0.05% trifluoroacetic acid (TFA). The column was washed with 0.05% TFA until all unbound protein was removed. Bound proteins were eluted with a linear gradient from 0.05% TFA to 0.05% TFA in acetonitrile. Column fractions were analyzed for the presence of PHIS-PfE9₅₂₈ protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the PHIS-PfE9₅₂₈ protein was eluted at about 40% acetonitrile. The fractions containing the PHIS-PfE9₅₂₈ protein were combined and loaded onto a 5 ml Q-Sepharose HiTrap column previously equilibrated with 50 mM Tris, 25 mM Sodium Acetate, 1 mM PMSF, 1 mM βME, 8 M Urea, pH 8.5 (Q-Sepharose Buffer). The column was washed with Q-Sepharose Buffer until all unbound protein was removed. Bound protein was eluted with an increasing salt gradient to 1 M NaCl over 100 ml (20 cv) in Q-sepharose buffer. Column fractions were analyzed for the presence of PHIS-PfE9₅₂₈ protein by immunoblot using the T7 tag monoclonal antibody as described above. The results indicated that the PHIS-PfE9₅₂₈ protein was eluted at about 0.3 M NaCl.

[0271] The purified PHIS-PfE9₅₂₈ protein was used to produce an anti-P 1 polyclonal antiserum as follows. Rabbits were immunized with PHIS-PfE9₅₂₈ protein diluted to a concentration of about 0.1 mg/ml in PBS. One milliliter of the dilution was mixed 1:1 mix with Complete Freunds Adjuvant. In the primary immunization, about 500 μl of the 1:1 mix was injected subcutaneously into 5 different sites (0.1 ml/site) and 500 μl was injected intradermally into 5 different sites (0.1 ml/site) on the rabbit. Booster shots were administered to the rabbit intramuscularly in 4 sites using 250 μl/site of a 1:1 mix of PHIS-PfE9₅₂₈ protein with Incomplete Freunds Adjuvant The booster shots were administered at days 14 and 35. Serum samples were obtained prior to immunization (pre-bleed), and at day 14 after primary immunization and day 14 after the first and second boost.

[0272] D. Flea esterase protein PHIS-PfE7₂₇₅ was produced in the following manner. A 650-bp fragment was produced by digesting nfE7₂₈₃₆ DNA with the restriction enzymes BamHI and BglII. The BamHI and BglII fragment derived from nfE7₂₈₃₆ is referred to herein as nfE7₆₅₀, having nucleic acid sequence SEQ ID NO:72 and amino acid SEQ ID NO:73. The fragment was purified using a Qiaquick™ Kit (available from Qiagen, Santa Clarita, Calif.), according to methods provided by the manufacturer. The purified fragment was subcloned into expression vector pTrcHisC which had been digested with BamHI and BglII. The resultant recombinant molecule, referred to herein as pTrc-nfE7₆₅₀ was transformed into E. coli DH-5a competent cells (available from Gibco BRL) to form recombinant cell E. coli:pTrc-nfE7₆₅₀.

[0273] The recombinant cells were cultured using the method described above in section A. Immunoblot analysis of recombinant cell E. coli:pTrc-nfE7₆₅₀ lysate using a T7 tag monoclonal antibody directed against the fusion portion of the recombinant PHIS-PfE7₂₇₅ fusion protein identified proteins of appropriate size, namely an about 35 kD protein for each fusion protein.

[0274] Expression of the recombinant fusion protein was improved by transforming supercoiled plasmid pTrc-nfE7₆₅₀ DNA harvested from E. coli:pTrc-nfE7₆₅₀ cells into the BL-21 strain of E. coli. The amount of expression E. coli:pTrc-nfE7₆₅₀ was confined by immunoblot using the method described immediately above.

Example 13

[0275] This Example demonstrates the production of esterase proteins of the present invention in eukaryotic cells.

[0276] A. Recombinant molecule pBv-nfE7₁₇₈₈, containing a flea esterase nucleic acid molecule spanning nucleotides from about 99 through about 1886 of SEQ ID NO:24, and pBv-nfE8₁₇₈₅, containing a flea esterase nucleic acid molecule spanning nucleotides from about 99 through about 1883 of SEQ ID NO:30 each, operatively linked to baculovirus polyhedron transcription control sequences were produced in the following manner. In order to subclone a flea esterase nucleic acid molecule into baculovirus expression vectors, flea esterase nucleic acid molecule-containing fragments were separately PCR amplified from nfE7₂₈₃₆ or nfE8₂₈₀₁ DNA. A PCR fragment of 1858 nucleotides, named nfE7₁₈₅₈, was amplified from nfE7₂₈₃₆ using a sense primer E1113 FWD having the nucleic acid sequence 5′-AAAACTGCAG TATAAATATG TTACCTCACA GTAGTG-3′ (SEQ ID NO:49; PstI site shown in bold) and an antisense primer E 1113/2212 REV having the nucleic acid sequence 5′-TGCTCTAGAT TATCTAATAC TTCCTTCATT ACAG (SEQ ID NO:50; XbaI site shown in bold). A PCR fragment of 1858 nucleotides, named nfE8₁₈₅₈, was amplified from nfE8₂₈₀₁ using a sense primer E2212 FWD having the nucleic acid sequence 5′-AAAACTGCAG TATAAATATG TTACCTCACA GTGCATTAG-3′ (SEQ ID NO:66; PstI site shown in bold), and the antisense primer E 1113/2212 REV. The N-terminal primer was designed from the pol h sequence of baculovirus with modifications to enhance expression in the baculovirus system.

[0277] In order to produce a baculovirus recombinant molecule capable of directing the production of PfE7₅₉₆, the about 1,802 base pair PCR product (referred to as Bv-nfE7₁₈₀₂) was digested with PstI and XbaI and subcloned into unique PstI and XbaI sites of pVL1392 baculovirus shuttle plasmid (available from Pharmingen, San Diego, Calif.) to produce the recombinant molecule referred to herein as pVL-nfE7₁₈₀₂.

[0278] In order to produce a baculovirus recombinant molecule capable of directing the production of PfE8₅₉₅, the about 1,792 base pair PCR product (referred to as Bv-nfE8₁₇₉₂) was digested with PstI and XbaI and subcloned into PstI and XbaI digested to produce the recombinant molecule referred to herein as pVL-nfE8₁₇₉₂.

[0279] The resultant recombinant molecules, pVL-nfE7₁₉₀₂ and pVL-nfE8₁₇₉₂, were verified for proper insert orientation by restriction mapping. Such a recombinant molecule can be co-transfected with a linear Baculogold baculovirus DNA (available from Pharmingen) into S. frugiperda Sf9 cells (available from InVitrogen) to form the recombinant cells denoted S. frugiperda:pVL-nfE7₁₈₀₂ and S. frugiperda:pVL-nfE8₁₇₉₂ . S. frugiperda:pVL-nfE7₁₈₀₂ can be cultured in order to produce a flea esterase protein PfE7₅₉₆ . S. frugiperda:pVL-nfE8₁₇₉₂ can be cultured in order to produce a flea esterase protein PfE8_(595.)

[0280] B. Recombinant molecule pBv-PfE9₅₂₈, containing a flea esterase nucleic acid molecule spanning nucleotides from 14 through 1595 of SEQ ID NO:36, operatively linked to baculovirus polyhedron transcription control sequences were produced in the following manner. In order to subclone a flea esterase nucleic acid molecule into baculovirus expression vectors, a flea esterase nucleic acid molecule-containing fragment was PCR amplified from nfE9₂₀₀₇ DNA. A PCR fragment of about 1600 nucleotides, named nfE9₁₆₀₀, was amplified from nfE9₂₀₀₇ using a sense primer P121 B1 Sense having the nucleic acid sequence 5′-CGC GGA TCC GCT GAT CTA CAA GTG ACT TTG C-3′ (SEQ ID NO:75; BamHI site shown in bold) and an antisense primer P121B1 Anti having the nucleic acid sequence 5′-CCG AGC GGC CGC ATA AAA ATT TAT TCC AAA ATC TAA GTC G-3′ (SEQ ID NO:76; NotI site shown in bold). The N-terminal primer was designed from the pol h sequence of baculovirus with modifications to enhance expression in the baculovirus system.

[0281] In order to produce a baculovirus recombinant molecule capable of directing the production of PfE9₅₂₈, the about 1,600 base pair PCR product (referred to as Bv-nfE9₁₆₀₀) w % as digested with BamHI and NotI and subcloned into unique BamHI and NotI sites of pVL1393 baculovirus shuttle plasmid (available from Pharmingen, San Diego, Calif.) to produce the recombinant molecule referred to herein as pVL-nfE9₁₆₀₀.

[0282] The resultant recombinant molecule, pVL-nfE9₁₆₀₀, was verified for proper insert orientation by restriction mapping. Such a recombinant molecule can be co-transfected with a linear Baculogold baculovirus DNA into S. frugiperda Sf9 cells to form the recombinant cells denoted S. frugiperda:pVL-nfE9₁₆₀₀ . S. frugiperda:pVL-nfE9₁₆₀₀ can be cultured in order to produce a flea esterase protein PfE9₅₂₈.

[0283] An immunoblot of supernatant from cultures of S. frugiperda:pVL-nfE9₁₆₀₀ cells producing the flea esterase protein PfE9₅₂₈ was performed using the anti-P1 polyclonal antiserum described in detail in Example 12. Blots were incubated using serum samples from the pre-bleed or from serum collected 14 days after the first boost of the rabbit. Analysis of the supernatent from cultures of S. frugiperda:pVL-nfE9₁₆₀₀ cells identified an about 66 kD protein

[0284] C. Recombinant molecule pBv-PfE6₅₃₀, containing a flea esterase nucleic acid molecule spanning nucleotides from 50 through 1701 of SEQ ID NO:18, operatively linked to baculovirus polyhedron transcription control sequences were produced in the following manner. In order to subclone a flea esterase nucleic acid molecule into baculovirus expression vectors, a flea esterase nucleic acid molecule-containing fragment was PCR amplified from nfE6₁₇₉₂ DNA. A PCR fragment of about 1679 nucleotides, named nfE10₁₆₇₉, was amplified from nfE6₁₇₉₂ using a sense primer M6M32 Sense having the nucleic acid sequence 5′-GCG AGG CCT TAT AAA TAT GTC TCG TGT TAT TTT TTT AAG TTG-3′ (SEQ ID NO:75; StuI site shown in bold) and an antisense primer M6M32 Anti having the nucleic acid sequence 5′-GCA CTG CAG TTA TTG ACT GTG CAA AGT TTT TGT GG-3′ (SEQ ID NO:76; PstI site shown in bold). The N-terminal primer was designed from the pol h sequence of baculovirus with modifications to enhance expression in the baculovirus system.

[0285] In order to produce a baculovirus recombinant molecule capable of directing the production of PfE6₅₃₀, the about 1,679 base pair PCR product (referred to as Bv-nfE6₁₆₇₉) was digested with StuI and PstI and subcloned into unique StuI and PstI sites of FAST BAC™ baculovirus shuttle plasmid (obtained from Gibco-BRL) to produce the recombinant molecule referred to herein as pFB-nfE6₁₆₇₉.

[0286] The resultant recombinant molecule, pFB-nfE6₁₆₇₉, was verified for proper insert orientation by restriction mapping. Such a recombinant molecule can be transformed into E. coli strain DH10 (obtained from Gibco-BRL) according to the manufacturer's instructions. The pFB-nfE6₁₆₇₉ isolated from the transformed DH10 cells can then be co-transfected with a linear Baculogold baculovirus DNA into S. frugiperda Sf9 cells to form the recombinant cells denoted S. frugiperda:pFB-nfE6₁₆₇₉ . S. frugiperda:pFB-nfE6,679 can be cultured in order to produce a flea esterase protein PfE6_(530.)

[0287] An immunoblot of supernatant from cultures of S. frugiperda:pFB-nfE6₁₆₇₉ cells producing the flea esterase protein PfE6₅₃₀ was performed using the anti-M6 polyclonal antiserum described in detail in Example 12. Blots were incubated using serum samples from the pre-bleed or from serum collected 14 days after the first boost of the rabbit. Analysis of the supernatent from cultures of S. frugiperda:pFB-nfE6₁₆₇₉ cells identified an about 66 kD protein.

[0288] N-terminal amino acid sequence was obtained using standard methods for the about 66 kD protein identified using the anti-M6 polyclonal antiserum. The N-terminal amino acid sequence was determined to be identical to the N-terminal amino acid sequence of SEQ ID NO:44.

Example 14

[0289] This example describes the purification of carboxylesterase protein from fed flea midguts.

[0290] About 43,000 cat blood-fed adult flea midguts were collected and prepared as previously described in Example 1. The extract was then added in 2 aliquots to columns containing about 1 to about 2 ml of p-aminobenzamidine linked agarose beads (available from Sigma), equilibrated in 50 mM Tris (pH 8.0), 400 mM NaCl, and incubated overnight at 4° C. The columns were then drained to remove unbound protein and the two aliquots of unbound protein were combined. The collected unbound protein was then concentrated and diafiltered into a total volume of about 16 ml of 25 mM Tris (pH 8), 10 mM NaCl using an Ultrafree-20 10 kD centrifugal concentrator (available from Millipore, Bedford, Mass.).

[0291] Aliquots of about 8 ml were loaded onto an Uno Q6 anion exchange column (available from Bio-Rad, Hercules, Calif.) equilibrated in 25 mM Tris (pH 8), 10 mM NaCl, operated on a BioLogic liquid chromatography system (available from Bio-Rad). The column was washed with 25 mM Tris (pH 8), 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 25 mM Tris, pH 8. Fractions were assayed for CE activity using the assay described previously. The results indicated that CE activity was eluted at about 220 mM NaCl.

[0292] Fractions containing CE activity were pooled and diafiltered into a total volume of about 3 ml of 20 mM MES buffer (2-(N-morpholino)ethanesulfonic acid), pH 6.0, containing 10 mM NaCl, in preparation for cation exchange chromatography. The sample was then applied to an Uno SI cation exchange column (available from Bio-Rad) equilibrated in MFS buffer. The column was washed with MES buffer until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 20 mM MES buffer, pH 6. Fractions were assayed for CE activity using the assay described previously. The results indicated that CE activity was not retained on the cation exchange column using the above conditions, and all of the activity was found in the flow-through fractions.

[0293] Fractions containing CE activity were pooled and diafiltered into a total volume of about 3 ml of 25 mM Tris (pH 8), 10 mM NaCl, in preparation for an additional anion exchange chromatography step. The sample was then applied to a Bio-Scale Q2 anion exchange column (available from Bio-Rad). The column was washed with 25 mM Tris (pH 8), 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 25 mM Tris, pH 8. Fractions were assayed for CE activity using the assay described previously. The results indicated that CE activity was eluted at about 130 mM NaCl.

[0294] A fraction containing CE activity was diluted into a total volume of about 4 ml of 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl, in preparation for hydroxyapatite chromatography. The sample was then applied to a Bio-Scale CHT2-I column (available from Bio-Rad) at a flow rate of about 0.5 ml/min. The column was washed with 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl to 0.5 M 10 nM phosphate buffer, pH 6.5 containing 10 mM NaCl. Fractions were assayed for CE activity using the assay described previously. The results indicated that CE activity was eluted at about 200 mM phosphate.

Example 15

[0295] This example describes the purification of a carboxylesterase protein from wandering flea larvae.

[0296] About 120,000 bovine blood-fed adult wandering flea larvae were homogenized in 3 batches of about 40,000 wandering larvae in each batch, in Tris buffered saline (TBS), pH 8.0 as previously described, except that about 1.2 mg of phenylthiourea was added to each ml of TBS during the extraction procedure to inhibit cross linking reactions. The extracts were dialyzed against 2 changes of about 2 L of 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl in preparation for hydroxyapatite batch chromatography. The samples were then filtered through glass Acrodiscs® (available from Gelman Sciences, Ann Arbor, Mich.) and added to 14 g of Macro-Prep Ceramic Hydroxyapatite, Type 1,40 μm beads (available from Bio-Rad), previously equilibrated in 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl. The extracts and beads were rocked at room temperature for about 30 minutes. Following incubation, the beads were centrifuged for about 5 minutes at 500×g and the supernatants removed. The beads were washed with about 40 ml 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl, centrifuged as above, and washed and centrifuged again to eliminate all unbound protein. Bound proteins were eluted by washing the beads with about 40 ml of each of-100 mM, 200 mM, 300 mM, and 400 mM phosphate buffer, pH 6.5 containing 10 mM NaCl. Following elution, the supernatants from each concentration of phosphate buffer were tested for juvenile hormone esterase activity as described previously in Example 7. The juvenile hormone esterase activity eluted at different phosphate concentrations in each batch, but the activity was generally found in the 200 mM to 300 mM phosphate fractions.

[0297] The fractions that contained the highest juvenile hormone esterase activity were combined and diafiltered into a total volume of about 50 ml of 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl using a stirred cell concentrator fitted with a YM10 ultrafiltration membrane (available from Amicon, Beverly, Mass.). Aliquots of about 5 ml to 10 ml were applied to a chromatography column containing about 10 ml of Macro-Prep Ceramic Hydroxyapatite, Type 1,20 μm beads, previously equilibrated with 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl. The column was washed with 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM phosphate buffer, pH 7.2 containing 10 mM NaCl to 0.5 M 10 mM phosphate buffer, pH 6.5 containing 10 mM NaCl. Fractions were assayed for carboxylesterase activity using the assay described previously. The results indicated that carboxylesterase activity was eluted at about 160 mM phosphate.

[0298] The fractions that contained the highest carboxylesterase activity w ere combined and diafiltered into a total volume of about 15 ml of 20 mM sodium acetate buffer, pH 4.0 in preparation for cation exchange chromatography. Aliquots of about 3 ml were applied to a PolyCat A cation exchange column (available from PolyLC, Columbia, Md.) equilibrated in 20 mM sodium acetate buffer, pH 6.0, operated on a Waters high performance liquid chromatography system (available from Waters Corporation, Milford, Mass.). The column was washed with 20 mM sodium acetate buffer, pH 6.0 until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 20 mM sodium acetate buffer, pH 6.0 to 20 mM sodium acetate buffer, pH 6.0 containing 1 M NaCl. Fractions were assayed for CE activity using the assay described previously. The results indicated that there were two pools of CE activity. The first pool was not retained on the cation exchange column, and the second pool was eluted at about 170 mM NaCl.

[0299] The fractions from the second pool that contained the highest carboxylesterase activity were combined and diafiltered into a total volume of about 10 ml of 25 mM Tris (pH 8), 10 mM NaCl, in preparation for anion exchange chromatography. The sample was then applied to a Bio-Scale Q2 anion exchange column (available from Bio-Rad). The column was washed with 25 mM Tris (pH 8), 10 mM NaCl until all unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 25 mM Tris, pH S. Fractions were assayed for carboxylesterase activity using the assay described previously. The results indicated that carboxylesterase activity was eluted at about 350 mM NaCl.

[0300] Fractions containing carboxylesterase activity were combined and concentrated to about 175 μl using a Centricon 10 centrifugal concentrator (available from Amicon, Beverly, Mass.) in preparation for size exclusion chromatography. The sample was applied to a Bio-Select SEC 125-5 size exclusion chromatography column (available from Bio-Rad), previously equilibrated in TBS, pH 7.2. About 250 μl fractions were then collected. The fractions were assayed for carboxylesterase activity using the assay described previously. The results indicated that the carboxylesterase activity was eluted in about 5.5 to u

iil of buffer, corresponding to a molecular weight of about 40 to 100 kDa based on the elution volumes of gel filtration molecular weight standard proteins (available from Sigma, St. Louis, Mo.).

Example 16

[0301] This example describes the purification of juvenile hormone esterase activity from unfed adult flea midguts by affinity chromatography.

[0302] About 16,000 unfed adult flea midguts were collected in 20 mM Tris buffer (pH 7.7), containing 130 mM NaCl, 1 mM sodium EDTA, 1 mM Pefabloc® (available from Boehringer Mannheim, Indianapolis, Ind.), 1 microgram/ml (μg/ml) leupeptin and 1 μg/ml pepstatin. The midguts were homogenized by freeze-fracture and sonication, and then centrifuged at about 14,000× g for 20 min. The soluble material from the centrifugation step was recovered, diafiltered into Tris buffered saline (TBS), and applied to a disposable plastic column containing about 1 ml of 3-[(4′-mercapto)butylthio]-1,1,1-trifluoropropan-2-one linked Sepharose 6B beads, prepared similarly to the method described by Venkateshi et al. (J. Biol. Chem., Vol. 265, No. 35, 21727-21732, 1990) (the 3-[(4′-mercapto)butylthio]-1,1,1-trifluoropropan-2-one was a gift from Novartis Corp., Basel, Switzerland; and the Epoxy-activated Sepharose 6B is available from Pharmacia Biotech Inc., Piscataway, N.J.). After overnight incubation at 4° C., the column was drained and the beads were washed with about 10 ml TBS, then about 10 ml TBS containing 0.1% (w/v) n-octylglucoside (OG; available from Boehringer Mannheim). The pre-column, flow-through, and wash fractions were tested for juvenile hormone esterase activity by the method previously described above in Example 7. The results indicate that the flow-through fraction contained approximately 40% less juvenile hormone esterase activity than the pre-column material, and that the washes contained very little activity.

[0303] Bound protein was eluted from the beads by adding about 10 ml of TBS containing 0.1% (w/v) OG and 1 mM 3-octylthio-1,1,1-trifluoropropan-2-one (OTFP; a gift from Novartis Corp.). After a 2 hour incubation at 4° C., about 5 ml of the eluate was collected, and the remaining 5 ml was incubated with the beads overnight at 4° C. The following day, the beads were drained, the eluate collected, and an additional 10 ml of TBS containing 0.1% (w/v) OG and 1 mM OTFP was added to the beads. After an overnight incubation at 4° C., the beads were drained and the eluate collected. The final 10 ml elution step was repeated 3 additional times so that we had 6 eluted fractions. The first elution fraction was dialyzed overnight twice against 1 liter of fresh TBS to remove excess OTFP. The second elution fraction was also dialyzed overnight against 1 liter of fresh TBS to remove OTFP. The third through sixth elution fractions were not dialyzed. All six eluted fractions were tested for juvenile hormone esterase activity by the method previously described above in Example 7. The results indicate that only the third elution fraction contained detectable juvenile hormone esterase activity. Analysis of the eluted fractions by silver-stained SDS-PAGE indicated that several proteins were specifically bound to the affinity beads and were eluted by OTFP. The apparent molecular weights of these proteins, as determined by SDS-PAGE, were about 66 kDa, 55 kDa, and 33 kDa. About 3.5 ml of each elution fraction were combined and concentrated to about 110 μl using a Centriplus 10 centrifugal concentrator (available from Anicon, Beverly, Mass.). This pool was separated by SDS-PAGE and blotted onto a polyvinylidene difluoride (PVDF) membrane as described previously in Example 5. The stained protein band at about 66 kDa was excised and subjected to N-terminal sequence analysis as described previously.

[0304] The results indicated that the N-terminal amino acid sequence of the putative 66 kDa juvenile hormone esterase protein was DL y/g V k/y/g v/q/n LQGTLKGKE (denoted herein as SEQ ID NO:74), in which the lower case letters designate uncertainties. Below is shown a comparison between different esterase amino acid sequences of the present invention. SEQ ID NO:74: DL (y/g) V (k/y/g) (v/q/n) LQGTLKGKE SEQ ID NO:37: DL    Q  V    T       L    LQGTLKGKE (Residues 3-17)

Example 17

[0305] This example describes the purification of an active recombinant juvenile hormone esterase protein from baculovirus supernatants.

[0306] About 1 liter of supernatant from cultures of S. frugiperda:pVL-nfE9₁₆₀₀ cells producing the flea esterase protein PfE9₅₂₈ was brought to about 50% salutation with ammonium sulfate and centrifuged at about 20000×g for about 30 minutes at 4° C. to pellet the precipitated material. After centrifugation, the pellet was retained and the supernatant was brought to about 100% saturation with ammonium sulfate and centrifuged as above. The material in both pellets were resuspended separately in about 35 ml of Tris buffered saline (TBS), pH 8.0. The resuspended pellets were assayed for the presence of flea esterase protein PfE9₅₂₈ g using standard Western blot techniques and a polyclonal antiserum that binds specifically to PfE9₅₂₈ protein. Briefly, a rabbit was immunized with PHIS-PfE9₅₂₈ protein purified from E. coli:pTrc-nfE9₁₅₈₄ cells (described above in Example 12C) and boosted using standard procedures. The results indicated that the flea esterase protein PfE9₅₂₈ was present in the S. frugiperda:pVL-nfE9₁₆₀₀ supernatants and the protein was precipitated by adjusting the ammonium sulfate concentration from about 50% saturation to about 100% saturation.

[0307] The resuspended flea protein PfE9₅₂₈ was diafiltered into about 10 ml of 25 mM Tris (pH 8.0), 10 mM NaCl using an Ultrafree-20 10 kD centrifugal concentrator in preparation for anion exchange chromatography. Aliquots of about 5 ml were loaded onto an Uno Q6 anion exchange column equilibrated in 25 mM Tris (pH 8.0), 10 mM NaCl. The column was washed with 25 mM Tris (pH 8.0), 10 mM NaCl until most of the unbound protein was removed. Protein bound to the column was then eluted with a linear gradient from 10 mM to 1 M NaCl in 25 mM Tris buffer (pH 8.0). Fractions were assayed for the presence of flea esterase protein PfE9₅₂₈ by the immunoblot method described above. The results indicated that the flea esterase protein PfE9₅₂₈ was eluted at about 200 mM NaCl.

[0308] Fractions containing the flea esterase protein PfE9₅₂₈ were pooled and concentrated to about 440 μl using a Centricon 10 kD centrifugal concentrator in preparation for size exclusion chromatography. The sample was applied in 3 aliquots to a Bio-Select SEC 125-5 size exclusion chromatography column (available from Bio-Rad), previously equilibrated in TBS, pH 7.2. The column was eluted with TBS, pH 7.2 at a flow rate of about 0.5 ml/min, and fractions of about 250 μl were collected. The fractions were assayed for the presence of flea esterase protein PfE9₅₂₈ by the immunoblot method described above. The results indicated that the flea esterase protein PfE9₅₂₈ was eluted with about 6 ml of buffer, corresponding to a molecular weight of about 40 to 100 kDa based on the elution volumes of gel filtration molecular weight standard proteins (available from Sigma, St. Louis, Mo.).

[0309] Fractions containing flea esterase protein PfE9₅₂₈ were then assayed for juvenile hormone esterase activity as described in Example 7 and carboxylesterase activity as described in Example 2. The results indicated that the purified flea esterase protein PfE9₅₂₈ had both juvenile hormone esterase activity and carboxylesterase activity.

[0310] While various embodiments of the present invention have been described in detail, it is apparent that modifications and adaptations of those embodiments will occur to those skilled in the art. It is to be expressly understood, however, that such modifications and adaptations are within the scope of the present invention, as set forth in the following claims.

1 76 1 401 DNA Ctenocephalides felis CDS (92)..(400) 1 tttacatcat taataaacat aaatctaata aatcttgtgg atcaagatca agtttattag 60 tgagagtgtt ggatttgtga aatatttcaa a atg aat tct tta att gta aaa 112 Met Asn Ser Leu Ile Val Lys 1 5 att tct caa gga gct att gag ggg aag gaa atg att aat gat aat gga 160 Ile Ser Gln Gly Ala Ile Glu Gly Lys Glu Met Ile Asn Asp Asn Gly 10 15 20 aag tcg ttt aga gga ttt ttg ggt ata cct tat gct aaa ccg cct ata 208 Lys Ser Phe Arg Gly Phe Leu Gly Ile Pro Tyr Ala Lys Pro Pro Ile 25 30 35 gga aat ctt ana ttt aag cct cct caa aag cct gat gat tgg aat gat 256 Gly Asn Leu Xaa Phe Lys Pro Pro Gln Lys Pro Asp Asp Trp Asn Asp 40 45 50 55 gtt cga cca gct act gaa naa gca aat ggt tgt aga tcg aaa cat atg 304 Val Arg Pro Ala Thr Glu Xaa Ala Asn Gly Cys Arg Ser Lys His Met 60 65 70 ctg cag cat cat att att gga gac naa nat tgt cta tac cta aac gtn 352 Leu Gln His His Ile Ile Gly Asp Xaa Xaa Cys Leu Tyr Leu Asn Val 75 80 85 tat gtt cca ttg act tcc aaa ttg gag aaa cta cca gta atg ttc tgg g 401 Tyr Val Pro Leu Thr Ser Lys Leu Glu Lys Leu Pro Val Met Phe Trp 90 95 100 2 103 PRT Ctenocephalides felis misc_feature (43)..(43) The ′Xaa′ at location 43 stands for Lys, Arg, Thr, or Ile. 2 Met Asn Ser Leu Ile Val Lys Ile Ser Gln Gly Ala Ile Glu Gly Lys 1 5 10 15 Glu Met Ile Asn Asp Asn Gly Lys Ser Phe Arg Gly Phe Leu Gly Ile 20 25 30 Pro Tyr Ala Lys Pro Pro Ile Gly Asn Leu Xaa Phe Lys Pro Pro Gln 35 40 45 Lys Pro Asp Asp Trp Asn Asp Val Arg Pro Ala Thr Glu Xaa Ala Asn 50 55 60 Gly Cys Arg Ser Lys His Met Leu Gln His His Ile Ile Gly Asp Xaa 65 70 75 80 Xaa Cys Leu Tyr Leu Asn Val Tyr Val Pro Leu Thr Ser Lys Leu Glu 85 90 95 Lys Leu Pro Val Met Phe Trp 100 3 401 DNA Ctenocephalides felis misc_feature (50)..(50) n = unknown 3 cccagaacat tactggtagt ttctccaatt tggaagtcaa tggaacatan acgtttaggt 60 atagacaatn ttngtctcca ataatatgat gctgcagcat atgtttcgat ctacaaccat 120 ttgcttnttc agtagctggt cgaacatcat tccaatcatc aggcttttga ggaggcttaa 180 atntaagatt tcctataggc ggtttagcat aaggtatacc caaaaatcct ctaaacgact 240 ttccattatc attaatcatt tccttcccct caatagctcc ttgagaaatt tttacaatta 300 aagaattcat tttgaaatat ttcacaaatc caacactctc actaataaac ttgatcttga 360 tccacaagat ttattagatt tatgtttatt aatgatgtaa a 401 4 364 DNA Ctenocephalides felis CDS (2)..(364) 4 g tct cgt gtt att ttt tta agt tgt att ttt ttg ttt agt ttt aat ttt 49 Ser Arg Val Ile Phe Leu Ser Cys Ile Phe Leu Phe Ser Phe Asn Phe 1 5 10 15 ata aac tgt gat tcc ccg act gta act ttg ccc caa ggc gaa ttg gtt 97 Ile Asn Cys Asp Ser Pro Thr Val Thr Leu Pro Gln Gly Glu Leu Val 20 25 30 gga aaa gct ttg acg aac gaa aat gga aaa gag tat ttt agc tac aca 145 Gly Lys Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr Thr 35 40 45 ggt gta cct tat gct aaa cct cct gtt gga gaa ctt aga ttt aag cct 193 Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg Phe Lys Pro 50 55 60 cca cag aaa gct gag cca tgg caa ggt gtt ttc aac gcc aca tta tac 241 Pro Gln Lys Ala Glu Pro Trp Gln Gly Val Phe Asn Ala Thr Leu Tyr 65 70 75 80 gga aat gtg tgt aaa tct tta aat ttc ttc ttg aag aaa att gaa gga 289 Gly Asn Val Cys Lys Ser Leu Asn Phe Phe Leu Lys Lys Ile Glu Gly 85 90 95 gac gaa gac tgc ttg gta gta aac gtg tac gca cca aaa aca act tct 337 Asp Glu Asp Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr Ser 100 105 110 gat aaa aaa ctt cca gta ttt ttc tgg 364 Asp Lys Lys Leu Pro Val Phe Phe Trp 115 120 5 121 PRT Ctenocephalides felis 5 Ser Arg Val Ile Phe Leu Ser Cys Ile Phe Leu Phe Ser Phe Asn Phe 1 5 10 15 Ile Asn Cys Asp Ser Pro Thr Val Thr Leu Pro Gln Gly Glu Leu Val 20 25 30 Gly Lys Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr Thr 35 40 45 Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg Phe Lys Pro 50 55 60 Pro Gln Lys Ala Glu Pro Trp Gln Gly Val Phe Asn Ala Thr Leu Tyr 65 70 75 80 Gly Asn Val Cys Lys Ser Leu Asn Phe Phe Leu Lys Lys Ile Glu Gly 85 90 95 Asp Glu Asp Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr Ser 100 105 110 Asp Lys Lys Leu Pro Val Phe Phe Trp 115 120 6 364 DNA Ctenocephalides felis 6 ccagaaaaat actggaagtt ttttatcaga agttgttttt ggtgcgtaca cgtttactac 60 caagcagtct tcgtctcctt caattttctt caagaagaaa tttaaagatt tacacacatt 120 tccgtataat gtggcgttga aaacaccttg ccatggctca gctttctgtg gaggcttaaa 180 tctaagttct ccaacaggag gtttagcata aggtacacct gtgtagctaa aatactcttt 240 tccattttcg ttcgtcaaag cttttccaac caattcgcct tggggcaaag ttacagtcgg 300 ggaatcacag tttataaaat taaaactaaa caaaaaaata caacttaaaa aaataacacg 360 agac 364 7 421 DNA Ctenocephalides felis CDS (113)..(421) 7 tttacattac atcaaatcat atttttatta gtatattttt tagaagaacc tagccaaaaa 60 atatggactt tagactgtga ttaatttatt ttacctgaga ttttccttta ca atg ggt 118 Met Gly 1 gat ctt caa gtg act ttg tta caa ggt tct ttg aga gga aaa gag caa 166 Asp Leu Gln Val Thr Leu Leu Gln Gly Ser Leu Arg Gly Lys Glu Gln 5 10 15 att aat gaa aag gga aat gtg ttt tat agt tat tct gga att cca tat 214 Ile Asn Glu Lys Gly Asn Val Phe Tyr Ser Tyr Ser Gly Ile Pro Tyr 20 25 30 gcc aaa cct cca gtt ggt gat cta aga ttc aag cca cct caa cct gca 262 Ala Lys Pro Pro Val Gly Asp Leu Arg Phe Lys Pro Pro Gln Pro Ala 35 40 45 50 gaa cct tgg tca ggt gtc ctt gat gct act aaa gaa ggg aat agt tgt 310 Glu Pro Trp Ser Gly Val Leu Asp Ala Thr Lys Glu Gly Asn Ser Cys 55 60 65 aga tct gta cat ttt att aaa aag att aaa gta ggg gct gaa gat tgt 358 Arg Ser Val His Phe Ile Lys Lys Ile Lys Val Gly Ala Glu Asp Cys 70 75 80 cta tac ctc aat gtc tat gta cca aaa aca tca gag aaa tcc ctt ctt 406 Leu Tyr Leu Asn Val Tyr Val Pro Lys Thr Ser Glu Lys Ser Leu Leu 85 90 95 cca gta atg gta tgg 421 Pro Val Met Val Trp 100 8 103 PRT Ctenocephalides felis 8 Met Gly Asp Leu Gln Val Thr Leu Leu Gln Gly Ser Leu Arg Gly Lys 1 5 10 15 Glu Gln Ile Asn Glu Lys Gly Asn Val Phe Tyr Ser Tyr Ser Gly Ile 20 25 30 Pro Tyr Ala Lys Pro Pro Val Gly Asp Leu Arg Phe Lys Pro Pro Gln 35 40 45 Pro Ala Glu Pro Trp Ser Gly Val Leu Asp Ala Thr Lys Glu Gly Asn 50 55 60 Ser Cys Arg Ser Val His Phe Ile Lys Lys Ile Lys Val Gly Ala Glu 65 70 75 80 Asp Cys Leu Tyr Leu Asn Val Tyr Val Pro Lys Thr Ser Glu Lys Ser 85 90 95 Leu Leu Pro Val Met Val Trp 100 9 421 DNA Ctenocephalides felis 9 ccataccatt actggaagaa gggatttctc tgatgttttt ggtacataga cattgaggta 60 tagacaatct tcagccccta ctttaatctt tttaataaaa tgtacagatc tacaactatt 120 cccttcttta gtagcatcaa ggacacctga ccaaggttct gcaggttgag gtggcttgaa 180 tcttagatca ccaactggag gtttggcata tggaattcca gaataactat aaaacacatt 240 tcccttttca ttaatttgct cttttcctct caaagaacct tgtaacaaag tcacttgaag 300 atcacccatt gtaaaggaaa atctcaggta aaataaatta atcacagtct aaagtccata 360 ttttttggct aggttcttct aaaaaatata ctaataaaaa tatgatttga tgtaatgtaa 420 a 421 10 524 DNA Ctenocephalides felis CDS (113)..(523) 10 gaacgttgat acgatagaca tgtcgtcttc aaaacgtcta ttttatcata aacaaaacga 60 gataaataat aacaattaag caaccaaaat gcattaaaaa acacaataaa aa atg tta 118 Met Leu 1 cct cac agt agt gca tta gtt tta ttt tta ttt ttt tta ttt ttc tta 166 Pro His Ser Ser Ala Leu Val Leu Phe Leu Phe Phe Leu Phe Phe Leu 5 10 15 ttt aca cct atc ttg tgc ata cta tgg gat aac cta gat cag cat ttg 214 Phe Thr Pro Ile Leu Cys Ile Leu Trp Asp Asn Leu Asp Gln His Leu 20 25 30 tgc aga gtt caa ttt aac agg atc acg gaa gga aaa ccg ttc cga tat 262 Cys Arg Val Gln Phe Asn Arg Ile Thr Glu Gly Lys Pro Phe Arg Tyr 35 40 45 50 aaa gat cat agg aat gat gta tat tgt tct tat ttg gga att cct tat 310 Lys Asp His Arg Asn Asp Val Tyr Cys Ser Tyr Leu Gly Ile Pro Tyr 55 60 65 gcc gaa ccg cct att gga cca tta cga ttt cag tct cca aaa cca ata 358 Ala Glu Pro Pro Ile Gly Pro Leu Arg Phe Gln Ser Pro Lys Pro Ile 70 75 80 tca aat cca aaa aca gga ttc gta cag gct cga act ttg gga gac aaa 406 Ser Asn Pro Lys Thr Gly Phe Val Gln Ala Arg Thr Leu Gly Asp Lys 85 90 95 tgt ttc cag gaa agt cta ata tat tct tat gca gga agc gaa gat tgc 454 Cys Phe Gln Glu Ser Leu Ile Tyr Ser Tyr Ala Gly Ser Glu Asp Cys 100 105 110 tta tat ctg aat ata ttc acg cca gag act gtt aat tct gcg aac aat 502 Leu Tyr Leu Asn Ile Phe Thr Pro Glu Thr Val Asn Ser Ala Asn Asn 115 120 125 130 aca aaa tat cct gta atg ttc t 524 Thr Lys Tyr Pro Val Met Phe 135 11 137 PRT Ctenocephalides felis 11 Met Leu Pro His Ser Ser Ala Leu Val Leu Phe Leu Phe Phe Leu Phe 1 5 10 15 Phe Leu Phe Thr Pro Ile Leu Cys Ile Leu Trp Asp Asn Leu Asp Gln 20 25 30 His Leu Cys Arg Val Gln Phe Asn Arg Ile Thr Glu Gly Lys Pro Phe 35 40 45 Arg Tyr Lys Asp His Arg Asn Asp Val Tyr Cys Ser Tyr Leu Gly Ile 50 55 60 Pro Tyr Ala Glu Pro Pro Ile Gly Pro Leu Arg Phe Gln Ser Pro Lys 65 70 75 80 Pro Ile Ser Asn Pro Lys Thr Gly Phe Val Gln Ala Arg Thr Leu Gly 85 90 95 Asp Lys Cys Phe Gln Glu Ser Leu Ile Tyr Ser Tyr Ala Gly Ser Glu 100 105 110 Asp Cys Leu Tyr Leu Asn Ile Phe Thr Pro Glu Thr Val Asn Ser Ala 115 120 125 Asn Asn Thr Lys Tyr Pro Val Met Phe 130 135 12 524 DNA Ctenocephalides felis 12 agaacattac aggatatttt gtattgttcg cagaattaac agtctctggc gtgaatatat 60 tcagatataa gcaatcttcg cttcctgcat aagaatatat tagactttcc tggaaacatt 120 tgtctcccaa agttcgagcc tgtacgaatc ctgtttttgg atttgatatt ggttttggag 180 actgaaatcg taatggtcca ataggcggtt cggcataagg aattcccaaa taagaacaat 240 atacatcatt cctatgatct ttatatcgga acggttttcc ttccgtgatc ctgttaaatt 300 gaactctgca caaatgctga tctaggttat cccatagtat gcacaagata ggtgtaaata 360 agaaaaataa aaaaaataaa aataaaacta atgcactact gtgaggtaac attttttatt 420 gtgtttttta atgcattttg gttgcttaat tgttattatt tatctcgttt tgtttatgat 480 aaaatagacg ttttgaagac gacatgtcta tcgtatcaac gttc 524 13 1982 DNA Ctenocephalides felis CDS (3)..(1517) 13 at ttt agc tac aca ggt gta cct tat gct aaa cct cct gtt gga gaa 47 Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu 1 5 10 15 ctt aga ttt aag cct cca cag aaa gct gag cca tgg caa ggt gtt ttc 95 Leu Arg Phe Lys Pro Pro Gln Lys Ala Glu Pro Trp Gln Gly Val Phe 20 25 30 aac gcc aca tta tac gga aat gtg tgt aaa tct tta aat ttc ttc ttg 143 Asn Ala Thr Leu Tyr Gly Asn Val Cys Lys Ser Leu Asn Phe Phe Leu 35 40 45 aag aaa att gaa gga gac gaa gac tgc ttg gta gta aac gtg tac gca 191 Lys Lys Ile Glu Gly Asp Glu Asp Cys Leu Val Val Asn Val Tyr Ala 50 55 60 cca aaa aca act tct gat aaa aaa ctt cca gta ttt ttc tgg gtt cat 239 Pro Lys Thr Thr Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His 65 70 75 ggt ggt ggt ttt gtg act gga tcc gga aat tta gaa ttc caa agc cca 287 Gly Gly Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gln Ser Pro 80 85 90 95 gat tat tta gta rat ttt gat gtt att ttc gta act ttc aat tac cga 335 Asp Tyr Leu Val Xaa Phe Asp Val Ile Phe Val Thr Phe Asn Tyr Arg 100 105 110 ttg gga cct ctc gga ttt ctg aat ttg gag ttg gag ggt gct cca gga 383 Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly 115 120 125 aat gta gga tta ttg gat cag gtg gca gct ctg aaa tgg acc aaa gaa 431 Asn Val Gly Leu Leu Asp Gln Val Ala Ala Leu Lys Trp Thr Lys Glu 130 135 140 aac att gag aaa ttt ggt gga gat cca gaa aat att aca att ggt ggt 479 Asn Ile Glu Lys Phe Gly Gly Asp Pro Glu Asn Ile Thr Ile Gly Gly 145 150 155 gtt tct gct ggt gga gca agt gtt cat tat ctt ttg tta tct cat aca 527 Val Ser Ala Gly Gly Ala Ser Val His Tyr Leu Leu Leu Ser His Thr 160 165 170 175 acc act gga ctt tac aaa agg gca att gct caa agt gga agt gct ttt 575 Thr Thr Gly Leu Tyr Lys Arg Ala Ile Ala Gln Ser Gly Ser Ala Phe 180 185 190 aat cca tgg gcc ttc caa aga cat cca gta aag cgt agt ctt caa ctt 623 Asn Pro Trp Ala Phe Gln Arg His Pro Val Lys Arg Ser Leu Gln Leu 195 200 205 gct gag ata ttg ggt cat ccc aca aac aat act caa gat gct tta gaa 671 Ala Glu Ile Leu Gly His Pro Thr Asn Asn Thr Gln Asp Ala Leu Glu 210 215 220 ttc tta caa aaa gcc ccc gta gac agt ctc ctg aag aaa atg cca gct 719 Phe Leu Gln Lys Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala 225 230 235 gaa aca gaa ggt gaa ata ata gaa gag ttt gtc ttc gta cca tca att 767 Glu Thr Glu Gly Glu Ile Ile Glu Glu Phe Val Phe Val Pro Ser Ile 240 245 250 255 gaa aaa gtt ttc cca tcc cac caa cct ttc ttg gaa gaa tca cca ttg 815 Glu Lys Val Phe Pro Ser His Gln Pro Phe Leu Glu Glu Ser Pro Leu 260 265 270 gcc aga atg aaa tcc gga tcc ttt aac aaa gta cct tta tta gtt gga 863 Ala Arg Met Lys Ser Gly Ser Phe Asn Lys Val Pro Leu Leu Val Gly 275 280 285 ttt aac agt gca gaa gga ctt ttg ttc aaa ttc ttc atg aaa gaa aaa 911 Phe Asn Ser Ala Glu Gly Leu Leu Phe Lys Phe Phe Met Lys Glu Lys 290 295 300 cca gag atg ctg aac caa gct gaa gca gat ttt gaa aga ctc gta cca 959 Pro Glu Met Leu Asn Gln Ala Glu Ala Asp Phe Glu Arg Leu Val Pro 305 310 315 gcc gaa ttt gaa tta gtc cat gga tca gag gaa tcg aaa aaa ctt gca 1007 Ala Glu Phe Glu Leu Val His Gly Ser Glu Glu Ser Lys Lys Leu Ala 320 325 330 335 gaa aaa atc agg aag ttt tac ttt gac gat aaa ccc gtt cca gaa aat 1055 Glu Lys Ile Arg Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn 340 345 350 gaa cag aaa ttt att gac ttg ata gga gat att tgg ttt act aga ggt 1103 Glu Gln Lys Phe Ile Asp Leu Ile Gly Asp Ile Trp Phe Thr Arg Gly 355 360 365 gtt gac aag cat gtc aag ttg tct gtg gag aaa caa gac gaa cca gtt 1151 Val Asp Lys His Val Lys Leu Ser Val Glu Lys Gln Asp Glu Pro Val 370 375 380 tat tat tat gaa tat tcc ttc tcg gaa agt cat cct gca aaa gga aca 1199 Tyr Tyr Tyr Glu Tyr Ser Phe Ser Glu Ser His Pro Ala Lys Gly Thr 385 390 395 ttt ggt gat cat aat ctg act ggt gca tgc cat gga gaa gaa ctt gtg 1247 Phe Gly Asp His Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val 400 405 410 415 aat tta ttc aaa gtc gag atg atg aag ctg gaa aaa gat aaa cct aat 1295 Asn Leu Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn 420 425 430 gtt cta tta aca aaa gat aga gta ctt gcc atg tgg act aac ttc atc 1343 Val Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe Ile 435 440 445 aaa aat gga aat cct act cct gaa gta aca gaa tta ttg cca gtt aaa 1391 Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys 450 455 460 tgg gaa cct gcc aca aaa gac aag ttg aat tat ttg aac att gat gcc 1439 Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu Asn Ile Asp Ala 465 470 475 acc tta act ttg gga aca aat cct gag gca aac cga gtc aaa ttt tgg 1487 Thr Leu Thr Leu Gly Thr Asn Pro Glu Ala Asn Arg Val Lys Phe Trp 480 485 490 495 gaa gac gcc aca aaa tct ttg cac ggt caa taataattta tgaaaattgt 1537 Glu Asp Ala Thr Lys Ser Leu His Gly Gln 500 505 tttaaatact ttaggtaata tattaggtaa ataaaaatta aaaaataaca atttttatgt 1597 tttatgtatt ggcttatgtg tatcagttct aattttattt atttattctt gttttgcttg 1657 ttttgaaata tcatggtttt aattttcaaa acacaacgtc gtttgttttt agcaaaattt 1717 ccaatagata tgttatatta agtactctga agtattttta tatatacact aaaatcagta 1777 aaaatacatt aactaaaaat ataagatatt ttcaataatt ttttttaaag aaaataccaa 1837 aaataaagta aaattccaaa cggaattttt gtttaactta aaaataaaat taactcttca 1897 ataattttga taattagtat ttctgatatc attagtgaaa attatatttt gataatacgt 1957 atttatattt aaaataaaat tatgt 1982 14 505 PRT Ctenocephalides felis misc_feature (100)..(100) The ′Xaa′ at location 100 stands for Asp, or Asn. 14 Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu 1 5 10 15 Arg Phe Lys Pro Pro Gln Lys Ala Glu Pro Trp Gln Gly Val Phe Asn 20 25 30 Ala Thr Leu Tyr Gly Asn Val Cys Lys Ser Leu Asn Phe Phe Leu Lys 35 40 45 Lys Ile Glu Gly Asp Glu Asp Cys Leu Val Val Asn Val Tyr Ala Pro 50 55 60 Lys Thr Thr Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly 65 70 75 80 Gly Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gln Ser Pro Asp 85 90 95 Tyr Leu Val Xaa Phe Asp Val Ile Phe Val Thr Phe Asn Tyr Arg Leu 100 105 110 Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn 115 120 125 Val Gly Leu Leu Asp Gln Val Ala Ala Leu Lys Trp Thr Lys Glu Asn 130 135 140 Ile Glu Lys Phe Gly Gly Asp Pro Glu Asn Ile Thr Ile Gly Gly Val 145 150 155 160 Ser Ala Gly Gly Ala Ser Val His Tyr Leu Leu Leu Ser His Thr Thr 165 170 175 Thr Gly Leu Tyr Lys Arg Ala Ile Ala Gln Ser Gly Ser Ala Phe Asn 180 185 190 Pro Trp Ala Phe Gln Arg His Pro Val Lys Arg Ser Leu Gln Leu Ala 195 200 205 Glu Ile Leu Gly His Pro Thr Asn Asn Thr Gln Asp Ala Leu Glu Phe 210 215 220 Leu Gln Lys Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala Glu 225 230 235 240 Thr Glu Gly Glu Ile Ile Glu Glu Phe Val Phe Val Pro Ser Ile Glu 245 250 255 Lys Val Phe Pro Ser His Gln Pro Phe Leu Glu Glu Ser Pro Leu Ala 260 265 270 Arg Met Lys Ser Gly Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe 275 280 285 Asn Ser Ala Glu Gly Leu Leu Phe Lys Phe Phe Met Lys Glu Lys Pro 290 295 300 Glu Met Leu Asn Gln Ala Glu Ala Asp Phe Glu Arg Leu Val Pro Ala 305 310 315 320 Glu Phe Glu Leu Val His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu 325 330 335 Lys Ile Arg Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn Glu 340 345 350 Gln Lys Phe Ile Asp Leu Ile Gly Asp Ile Trp Phe Thr Arg Gly Val 355 360 365 Asp Lys His Val Lys Leu Ser Val Glu Lys Gln Asp Glu Pro Val Tyr 370 375 380 Tyr Tyr Glu Tyr Ser Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe 385 390 395 400 Gly Asp His Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn 405 410 415 Leu Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn Val 420 425 430 Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe Ile Lys 435 440 445 Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys Trp 450 455 460 Glu Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu Asn Ile Asp Ala Thr 465 470 475 480 Leu Thr Leu Gly Thr Asn Pro Glu Ala Asn Arg Val Lys Phe Trp Glu 485 490 495 Asp Ala Thr Lys Ser Leu His Gly Gln 500 505 15 1982 DNA Ctenocephalides felis 15 acataatttt attttaaata taaatacgta ttatcaaaat ataattttca ctaatgatat 60 cagaaatact aattatcaaa attattgaag agttaatttt atttttaagt taaacaaaaa 120 ttccgtttgg aattttactt tatttttggt attttcttta aaaaaaatta ttgaaaatat 180 cttatatttt tagttaatgt atttttactg attttagtgt atatataaaa atacttcaga 240 gtacttaata taacatatct attggaaatt ttgctaaaaa caaacgacgt tgtgttttga 300 aaattaaaac catgatattt caaaacaagc aaaacaagaa taaataaata aaattagaac 360 tgatacacat aagccaatac ataaaacata aaaattgtta ttttttaatt tttatttacc 420 taatatatta cctaaagtat ttaaaacaat tttcataaat tattattgac cgtgcaaaga 480 ttttgtggcg tcttcccaaa atttgactcg gtttgcctca ggatttgttc ccaaagttaa 540 ggtggcatca atgttcaaat aattcaactt gtcttttgtg gcaggttccc atttaactgg 600 caataattct gttacttcag gagtaggatt tccatttttg atgaagttag tccacatggc 660 aagtactcta tcttttgtta atagaacatt aggtttatct ttttccagct tcatcatctc 720 gactttgaat aaattcacaa gttcttctcc atggcatgca ccagtcagat tatgatcacc 780 aaatgttcct tttgcaggat gactttccga gaaggaatat tcataataat aaactggttc 840 gtcttgtttc tccacagaca acttgacatg cttgtcaaca cctctagtaa accaaatatc 900 tcctatcaag tcaataaatt tctgttcatt ttctggaacg ggtttatcgt caaagtaaaa 960 cttcctgatt ttttctgcaa gttttttcga ttcctctgat ccatggacta attcaaattc 1020 ggctggtacg agtctttcaa aatctgcttc agcttggttc agcatctctg gtttttcttt 1080 catgaagaat ttgaacaaaa gtccttctgc actgttaaat ccaactaata aaggtacttt 1140 gttaaaggat ccggatttca ttctggccaa tggtgattct tccaagaaag gttggtggga 1200 tgggaaaact ttttcaattg atggtacgaa gacaaactct tctattattt caccttctgt 1260 ttcagctggc attttcttca ggagactgtc tacgggggct ttttgtaaga attctaaagc 1320 atcttgagta ttgtttgtgg gatgacccaa tatctcagca agttgaagac tacgctttac 1380 tggatgtctt tggaaggccc atggattaaa agcacttcca ctttgagcaa ttgccctttt 1440 gtaaagtcca gtggttgtat gagataacaa aagataatga acacttgctc caccagcaga 1500 aacaccacca attgtaatat tttctggatc tccaccaaat ttctcaatgt tttctttggt 1560 ccatttcaga gctgccacct gatccaataa tcctacattt cctggagcac cctccaactc 1620 caaattcaga aatccgagag gtcccaatcg gtaattgaaa gttacgaaaa taacatcaaa 1680 atytactaaa taatctgggc tttggaattc taaatttccg gatccagtca caaaaccacc 1740 accatgaacc cagaaaaata ctggaagttt tttatcagaa gttgtttttg gtgcgtacac 1800 gtttactacc aagcagtctt cgtctccttc aattttcttc aagaagaaat ttaaagattt 1860 acacacattt ccgtataatg tggcgttgaa aacaccttgc catggctcag ctttctgtgg 1920 aggcttaaat ctaagttctc caacaggagg tttagcataa ggtacacctg tgtagctaaa 1980 at 1982 16 1515 DNA Ctenocephalides felis exon (1)..(1515) 16 ttt agc tac aca ggt gta cct tat gct aaa cct cct gtt gga gaa ctt 48 Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu 1 5 10 15 aga ttt aag cct cca cag aaa gct gag cca tgg caa ggt gtt ttc aac 96 Arg Phe Lys Pro Pro Gln Lys Ala Glu Pro Trp Gln Gly Val Phe Asn 20 25 30 gcc aca tta tac gga aat gtg tgt aaa tct tta aat ttc ttc ttg aag 144 Ala Thr Leu Tyr Gly Asn Val Cys Lys Ser Leu Asn Phe Phe Leu Lys 35 40 45 aaa att gaa gga gac gaa gac tgc ttg gta gta aac gtg tac gca cca 192 Lys Ile Glu Gly Asp Glu Asp Cys Leu Val Val Asn Val Tyr Ala Pro 50 55 60 aaa aca act tct gat aaa aaa ctt cca gta ttt ttc tgg gtt cat ggt 240 Lys Thr Thr Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly 65 70 75 80 ggt ggt ttt gtg act gga tcc gga aat tta gaa ttc caa agc cca gat 288 Gly Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gln Ser Pro Asp 85 90 95 tat tta gta rat ttt gat gtt att ttc gta act ttc aat tac cga ttg 336 Tyr Leu Val Xaa Phe Asp Val Ile Phe Val Thr Phe Asn Tyr Arg Leu 100 105 110 gga cct ctc gga ttt ctg aat ttg gag ttg gag ggt gct cca gga aat 384 Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn 115 120 125 gta gga tta ttg gat cag gtg gca gct ctg aaa tgg acc aaa gaa aac 432 Val Gly Leu Leu Asp Gln Val Ala Ala Leu Lys Trp Thr Lys Glu Asn 130 135 140 att gag aaa ttt ggt gga gat cca gaa aat att aca att ggt ggt gtt 480 Ile Glu Lys Phe Gly Gly Asp Pro Glu Asn Ile Thr Ile Gly Gly Val 145 150 155 160 tct gct ggt gga gca agt gtt cat tat ctt ttg tta tct cat aca acc 528 Ser Ala Gly Gly Ala Ser Val His Tyr Leu Leu Leu Ser His Thr Thr 165 170 175 act gga ctt tac aaa agg gca att gct caa agt gga agt gct ttt aat 576 Thr Gly Leu Tyr Lys Arg Ala Ile Ala Gln Ser Gly Ser Ala Phe Asn 180 185 190 cca tgg gcc ttc caa aga cat cca gta aag cgt agt ctt caa ctt gct 624 Pro Trp Ala Phe Gln Arg His Pro Val Lys Arg Ser Leu Gln Leu Ala 195 200 205 gag ata ttg ggt cat ccc aca aac aat act caa gat gct tta gaa ttc 672 Glu Ile Leu Gly His Pro Thr Asn Asn Thr Gln Asp Ala Leu Glu Phe 210 215 220 tta caa aaa gcc ccc gta gac agt ctc ctg aag aaa atg cca gct gaa 720 Leu Gln Lys Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala Glu 225 230 235 240 aca gaa ggt gaa ata ata gaa gag ttt gtc ttc gta cca tca att gaa 768 Thr Glu Gly Glu Ile Ile Glu Glu Phe Val Phe Val Pro Ser Ile Glu 245 250 255 aaa gtt ttc cca tcc cac caa cct ttc ttg gaa gaa tca cca ttg gcc 816 Lys Val Phe Pro Ser His Gln Pro Phe Leu Glu Glu Ser Pro Leu Ala 260 265 270 aga atg aaa tcc gga tcc ttt aac aaa gta cct tta tta gtt gga ttt 864 Arg Met Lys Ser Gly Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe 275 280 285 aac agt gca gaa gga ctt ttg ttc aaa ttc ttc atg aaa gaa aaa cca 912 Asn Ser Ala Glu Gly Leu Leu Phe Lys Phe Phe Met Lys Glu Lys Pro 290 295 300 gag atg ctg aac caa gct gaa gca gat ttt gaa aga ctc gta cca gcc 960 Glu Met Leu Asn Gln Ala Glu Ala Asp Phe Glu Arg Leu Val Pro Ala 305 310 315 320 gaa ttt gaa tta gtc cat gga tca gag gaa tcg aaa aaa ctt gca gaa 1008 Glu Phe Glu Leu Val His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu 325 330 335 aaa atc agg aag ttt tac ttt gac gat aaa ccc gtt cca gaa aat gaa 1056 Lys Ile Arg Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn Glu 340 345 350 cag aaa ttt att gac ttg ata gga gat att tgg ttt act aga ggt gtt 1104 Gln Lys Phe Ile Asp Leu Ile Gly Asp Ile Trp Phe Thr Arg Gly Val 355 360 365 gac aag cat gtc aag ttg tct gtg gag aaa caa gac gaa cca gtt tat 1152 Asp Lys His Val Lys Leu Ser Val Glu Lys Gln Asp Glu Pro Val Tyr 370 375 380 tat tat gaa tat tcc ttc tcg gaa agt cat cct gca aaa gga aca ttt 1200 Tyr Tyr Glu Tyr Ser Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe 385 390 395 400 ggt gat cat aat ctg act ggt gca tgc cat gga gaa gaa ctt gtg aat 1248 Gly Asp His Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn 405 410 415 tta ttc aaa gtc gag atg atg aag ctg gaa aaa gat aaa cct aat gtt 1296 Leu Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn Val 420 425 430 cta tta aca aaa gat aga gta ctt gcc atg tgg act aac ttc atc aaa 1344 Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe Ile Lys 435 440 445 aat gga aat cct act cct gaa gta aca gaa tta ttg cca gtt aaa tgg 1392 Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys Trp 450 455 460 gaa cct gcc aca aaa gac aag ttg aat tat ttg aac att gat gcc acc 1440 Glu Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu Asn Ile Asp Ala Thr 465 470 475 480 tta act ttg gga aca aat cct gag gca aac cga gtc aaa ttt tgg gaa 1488 Leu Thr Leu Gly Thr Asn Pro Glu Ala Asn Arg Val Lys Phe Trp Glu 485 490 495 gac gcc aca aaa tct ttg cac ggt caa 1515 Asp Ala Thr Lys Ser Leu His Gly Gln 500 505 17 1515 DNA Ctenocephalides felis 17 ttgaccgtgc aaagattttg tggcgtcttc ccaaaatttg actcggtttg cctcaggatt 60 tgttcccaaa gttaaggtgg catcaatgtt caaataattc aacttgtctt ttgtggcagg 120 ttcccattta actggcaata attctgttac ttcaggagta ggatttccat ttttgatgaa 180 gttagtccac atggcaagta ctctatcttt tgttaataga acattaggtt tatctttttc 240 cagcttcatc atctcgactt tgaataaatt cacaagttct tctccatggc atgcaccagt 300 cagattatga tcaccaaatg ttccttttgc aggatgactt tccgagaagg aatattcata 360 ataataaact ggttcgtctt gtttctccac agacaacttg acatgcttgt caacacctct 420 agtaaaccaa atatctccta tcaagtcaat aaatttctgt tcattttctg gaacgggttt 480 atcgtcaaag taaaacttcc tgattttttc tgcaagtttt ttcgattcct ctgatccatg 540 gactaattca aattcggctg gtacgagtct ttcaaaatct gcttcagctt ggttcagcat 600 ctctggtttt tctttcatga agaatttgaa caaaagtcct tctgcactgt taaatccaac 660 taataaaggt actttgttaa aggatccgga tttcattctg gccaatggtg attcttccaa 720 gaaaggttgg tgggatggga aaactttttc aattgatggt acgaagacaa actcttctat 780 tatttcacct tctgtttcag ctggcatttt cttcaggaga ctgtctacgg gggctttttg 840 taagaattct aaagcatctt gagtattgtt tgtgggatga cccaatatct cagcaagttg 900 aagactacgc tttactggat gtctttggaa ggcccatgga ttaaaagcac ttccactttg 960 agcaattgcc cttttgtaaa gtccagtggt tgtatgagat aacaaaagat aatgaacact 1020 tgctccacca gcagaaacac caccaattgt aatattttct ggatctccac caaatttctc 1080 aatgttttct ttggtccatt tcagagctgc cacctgatcc aataatccta catttcctgg 1140 agcaccctcc aactccaaat tcagaaatcc gagaggtccc aatcggtaat tgaaagttac 1200 gaaaataaca tcaaaatyta ctaaataatc tgggctttgg aattctaaat ttccggatcc 1260 agtcacaaaa ccaccaccat gaacccagaa aaatactgga agttttttat cagaagttgt 1320 ttttggtgcg tacacgttta ctaccaagca gtcttcgtct ccttcaattt tcttcaagaa 1380 gaaatttaaa gatttacaca catttccgta taatgtggcg ttgaaaacac cttgccatgg 1440 ctcagctttc tgtggaggct taaatctaag ttctccaaca ggaggtttag cataaggtac 1500 acctgtgtag ctaaa 1515 18 1792 DNA Ctenocephalides felis CDS (49)..(1701) 18 actgtgtgct aataattcag tacacacagt caatagtcta gatccaag atg tct cgt 57 Met Ser Arg 1 gtt att ttt tta agt tgt att ttt ttg ttt agt ttt aat ttt ata aaa 105 Val Ile Phe Leu Ser Cys Ile Phe Leu Phe Ser Phe Asn Phe Ile Lys 5 10 15 tgt gat ccc ccg act gta act ttg ccc cag ggc gaa ttg gtt gga aaa 153 Cys Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu Val Gly Lys 20 25 30 35 gct ttg acg aac gaa aat gga aaa gag tat ttt agc tac aca ggt gtg 201 Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr Thr Gly Val 40 45 50 cct tat gct aaa cct cca gtt gga gaa ctt aga ttt aag cct cca cag 249 Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gln 55 60 65 aaa gct gag cca tgg aat ggt gtt ttc aac gcc aca tca cat gga aat 297 Lys Ala Glu Pro Trp Asn Gly Val Phe Asn Ala Thr Ser His Gly Asn 70 75 80 gtg tgc aaa gct ttg aat ttc ttc ttg aaa aaa att gaa gga gac gaa 345 Val Cys Lys Ala Leu Asn Phe Phe Leu Lys Lys Ile Glu Gly Asp Glu 85 90 95 gac tgc ttg ttg gtg aat gtg tac gca cca aaa aca act tct gac aaa 393 Asp Cys Leu Leu Val Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp Lys 100 105 110 115 aaa ctt cca gta ttt ttc tgg gtt cat ggt ggc ggt ttt gtg act gga 441 Lys Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe Val Thr Gly 120 125 130 tcc gga aat tta gaa ttt caa agc cca gat tat tta gta aat tat gat 489 Ser Gly Asn Leu Glu Phe Gln Ser Pro Asp Tyr Leu Val Asn Tyr Asp 135 140 145 gtt att ttt gta act ttc aat tac cga ttg gga cca ctc gga ttt ttg 537 Val Ile Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu Gly Phe Leu 150 155 160 aat ttg gag ttg gaa ggt gct cct gga aat gta gga tta ttg gat cag 585 Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gln 165 170 175 gta gca gct ttg aaa tgg acc aaa gaa aat att gag aaa ttt ggt gga 633 Val Ala Ala Leu Lys Trp Thr Lys Glu Asn Ile Glu Lys Phe Gly Gly 180 185 190 195 gat cca gaa aat att aca att ggt ggt gtt tct gct ggt gga gca agt 681 Asp Pro Glu Asn Ile Thr Ile Gly Gly Val Ser Ala Gly Gly Ala Ser 200 205 210 gtt cat tat ctt tta ttg tca cat aca acc act gga ctt tac aaa agg 729 Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu Tyr Lys Arg 215 220 225 gca att gct caa agt gga agt gct tta aat cca tgg gcc ttc caa aga 777 Ala Ile Ala Gln Ser Gly Ser Ala Leu Asn Pro Trp Ala Phe Gln Arg 230 235 240 cat cca gta aag cgt agt ctt caa ctt gct gag ata tta ggt cat ccc 825 His Pro Val Lys Arg Ser Leu Gln Leu Ala Glu Ile Leu Gly His Pro 245 250 255 aca aac aac act caa gat gct tta gaa ttc tta caa aaa gcc cca gta 873 Thr Asn Asn Thr Gln Asp Ala Leu Glu Phe Leu Gln Lys Ala Pro Val 260 265 270 275 gac agt ctc ctg aaa aaa atg cca gct gaa aca gaa ggt gaa ata ata 921 Asp Ser Leu Leu Lys Lys Met Pro Ala Glu Thr Glu Gly Glu Ile Ile 280 285 290 gaa gag ttc gtc ttc gta cca tca att gaa aaa gtt ttc cca tcc cac 969 Glu Glu Phe Val Phe Val Pro Ser Ile Glu Lys Val Phe Pro Ser His 295 300 305 caa cct ttc ttg gaa gaa tca cca ttg gcc aga atg aaa tct gga tcc 1017 Gln Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly Ser 310 315 320 ttt aac aaa gta cct tta tta gtt gga ttc aac agc gca gaa gga ctt 1065 Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala Glu Gly Leu 325 330 335 ttg tac aaa ttc ttt atg aaa gaa aaa cca gag atg ctg aac caa gct 1113 Leu Tyr Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu Asn Gln Ala 340 345 350 355 gaa gca gat ttc gaa aga ctc gta cca gcc gaa ttt gaa tta gcc cat 1161 Glu Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu Leu Ala His 360 365 370 gga tca gaa gaa tcg aaa aaa ctt gca gaa aaa atc agg aag ttt tac 1209 Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys Ile Arg Lys Phe Tyr 375 380 385 ttt gac gat aaa ccc gtt cct gaa aat gag cag aaa ttt att gac ttg 1257 Phe Asp Asp Lys Pro Val Pro Glu Asn Glu Gln Lys Phe Ile Asp Leu 390 395 400 ata gga gat att tgg ttt act aga ggc att gac aag cat gtc aag ttg 1305 Ile Gly Asp Ile Trp Phe Thr Arg Gly Ile Asp Lys His Val Lys Leu 405 410 415 tct gta gaa aaa caa gac gag cca gta tat tat tat gaa tat tct ttc 1353 Ser Val Glu Lys Gln Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe 420 425 430 435 tct gaa agt cat cct gca aaa gga aca ttt ggt gac cat aac ttg act 1401 Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His Asn Leu Thr 440 445 450 gga gca tgt cat ggt gaa gaa ctt gtg aat tta ttc aaa gtc gag atg 1449 Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys Val Glu Met 455 460 465 atg aag ctg gaa aaa gat aaa ccg aat gtt tta tta aca aaa gat agg 1497 Met Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr Lys Asp Arg 470 475 480 gta ctt gct atg tgg acg aac ttc atc aaa aat gga aat cct act cct 1545 Val Leu Ala Met Trp Thr Asn Phe Ile Lys Asn Gly Asn Pro Thr Pro 485 490 495 gaa gta act gaa tta ttg cca gtt aaa tgg gaa cct gcc aca aaa gac 1593 Glu Val Thr Glu Leu Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp 500 505 510 515 aag ttg aat tat ttg aac att gat gcc acc tta act ttg gga aca aat 1641 Lys Leu Asn Tyr Leu Asn Ile Asp Ala Thr Leu Thr Leu Gly Thr Asn 520 525 530 cca gaa gaa acc cga gtc aaa tty tgg gaa gat gcc aca aaa act ttg 1689 Pro Glu Glu Thr Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Thr Leu 535 540 545 cac agt caa taa aaatgtatga aaattgtttt aattatttta ggtaatacat 1741 His Ser Gln 550 taggtaaata aaaattnaaa aataacnaaa aaaaaaaaaa aaaaaaaaaa a 1792 19 550 PRT Ctenocephalides felis 19 Met Ser Arg Val Ile Phe Leu Ser Cys Ile Phe Leu Phe Ser Phe Asn 1 5 10 15 Phe Ile Lys Cys Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu 20 25 30 Val Gly Lys Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr 35 40 45 Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg Phe Lys 50 55 60 Pro Pro Gln Lys Ala Glu Pro Trp Asn Gly Val Phe Asn Ala Thr Ser 65 70 75 80 His Gly Asn Val Cys Lys Ala Leu Asn Phe Phe Leu Lys Lys Ile Glu 85 90 95 Gly Asp Glu Asp Cys Leu Leu Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe 115 120 125 Val Thr Gly Ser Gly Asn Leu Glu Phe Gln Ser Pro Asp Tyr Leu Val 130 135 140 Asn Tyr Asp Val Ile Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu 145 150 155 160 Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn Val Gly Leu 165 170 175 Leu Asp Gln Val Ala Ala Leu Lys Trp Thr Lys Glu Asn Ile Glu Lys 180 185 190 Phe Gly Gly Asp Pro Glu Asn Ile Thr Ile Gly Gly Val Ser Ala Gly 195 200 205 Gly Ala Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 210 215 220 Tyr Lys Arg Ala Ile Ala Gln Ser Gly Ser Ala Leu Asn Pro Trp Ala 225 230 235 240 Phe Gln Arg His Pro Val Lys Arg Ser Leu Gln Leu Ala Glu Ile Leu 245 250 255 Gly His Pro Thr Asn Asn Thr Gln Asp Ala Leu Glu Phe Leu Gln Lys 260 265 270 Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala Glu Thr Glu Gly 275 280 285 Glu Ile Ile Glu Glu Phe Val Phe Val Pro Ser Ile Glu Lys Val Phe 290 295 300 Pro Ser His Gln Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys 305 310 315 320 Ser Gly Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 325 330 335 Glu Gly Leu Leu Tyr Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu 340 345 350 Asn Gln Ala Glu Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu 355 360 365 Leu Ala His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys Ile Arg 370 375 380 Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn Glu Gln Lys Phe 385 390 395 400 Ile Asp Leu Ile Gly Asp Ile Trp Phe Thr Arg Gly Ile Asp Lys His 405 410 415 Val Lys Leu Ser Val Glu Lys Gln Asp Glu Pro Val Tyr Tyr Tyr Glu 420 425 430 Tyr Ser Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 435 440 445 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys 450 455 460 Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr 465 470 475 480 Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe Ile Lys Asn Gly Asn 485 490 495 Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys Trp Glu Pro Ala 500 505 510 Thr Lys Asp Lys Leu Asn Tyr Leu Asn Ile Asp Ala Thr Leu Thr Leu 515 520 525 Gly Thr Asn Pro Glu Glu Thr Arg Val Lys Phe Trp Glu Asp Ala Thr 530 535 540 Lys Thr Leu His Ser Gln 545 550 20 1792 DNA Ctenocephalides felis misc_feature (25)..(25) n = unknown 20 tttttttttt tttttttttt ttttngttat ttttnaattt ttatttacct aatgtattac 60 ctaaaataat taaaacaatt ttcatacatt tttattgact gtgcaaagtt tttgtggcat 120 cttcccaraa tttgactcgg gtttcttctg gatttgttcc caaagttaag gtggcatcaa 180 tgttcaaata attcaacttg tcttttgtgg caggttccca tttaactggc aataattcag 240 ttacttcagg agtaggattt ccatttttga tgaagttcgt ccacatagca agtaccctat 300 cttttgttaa taaaacattc ggtttatctt tttccagctt catcatctcg actttgaata 360 aattcacaag ttcttcacca tgacatgctc cagtcaagtt atggtcacca aatgttcctt 420 ttgcaggatg actttcagag aaagaatatt cataataata tactggctcg tcttgttttt 480 ctacagacaa cttgacatgc ttgtcaatgc ctctagtaaa ccaaatatct cctatcaagt 540 caataaattt ctgctcattt tcaggaacgg gtttatcgtc aaagtaaaac ttcctgattt 600 tttctgcaag ttttttcgat tcttctgatc catgggctaa ttcaaattcg gctggtacga 660 gtctttcgaa atctgcttca gcttggttca gcatctctgg tttttctttc ataaagaatt 720 tgtacaaaag tccttctgcg ctgttgaatc caactaataa aggtactttg ttaaaggatc 780 cagatttcat tctggccaat ggtgattctt ccaagaaagg ttggtgggat gggaaaactt 840 tttcaattga tggtacgaag acgaactctt ctattatttc accttctgtt tcagctggca 900 tttttttcag gagactgtct actggggctt tttgtaagaa ttctaaagca tcttgagtgt 960 tgtttgtggg atgacctaat atctcagcaa gttgaagact acgctttact ggatgtcttt 1020 ggaaggccca tggatttaaa gcacttccac tttgagcaat tgcccttttg taaagtccag 1080 tggttgtatg tgacaataaa agataatgaa cacttgctcc accagcagaa acaccaccaa 1140 ttgtaatatt ttctggatct ccaccaaatt tctcaatatt ttctttggtc catttcaaag 1200 ctgctacctg atccaataat cctacatttc caggagcacc ttccaactcc aaattcaaaa 1260 atccgagtgg tcccaatcgg taattgaaag ttacaaaaat aacatcataa tttactaaat 1320 aatctgggct ttgaaattct aaatttccgg atccagtcac aaaaccgcca ccatgaaccc 1380 agaaaaatac tggaagtttt ttgtcagaag ttgtttttgg tgcgtacaca ttcaccaaca 1440 agcagtcttc gtctccttca atttttttca agaagaaatt caaagctttg cacacatttc 1500 catgtgatgt ggcgttgaaa acaccattcc atggctcagc tttctgtgga ggcttaaatc 1560 taagttctcc aactggaggt ttagcataag gcacacctgt gtagctaaaa tactcttttc 1620 cattttcgtt cgtcaaagct tttccaacca attcgccctg gggcaaagtt acagtcgggg 1680 gatcacattt tataaaatta aaactaaaca aaaaaataca acttaaaaaa ataacacgag 1740 acatcttgga tctagactat tgactgtgtg tactgaatta ttagcacaca gt 1792 21 1650 DNA Ctenocephalides felis exon (1)..(1650) 21 atg tct cgt gtt att ttt tta agt tgt att ttt ttg ttt agt ttt aat 48 Met Ser Arg Val Ile Phe Leu Ser Cys Ile Phe Leu Phe Ser Phe Asn 1 5 10 15 ttt ata aaa tgt gat ccc ccg act gta act ttg ccc cag ggc gaa ttg 96 Phe Ile Lys Cys Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu 20 25 30 gtt gga aaa gct ttg acg aac gaa aat gga aaa gag tat ttt agc tac 144 Val Gly Lys Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr 35 40 45 aca ggt gtg cct tat gct aaa cct cca gtt gga gaa ctt aga ttt aag 192 Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg Phe Lys 50 55 60 cct cca cag aaa gct gag cca tgg aat ggt gtt ttc aac gcc aca tca 240 Pro Pro Gln Lys Ala Glu Pro Trp Asn Gly Val Phe Asn Ala Thr Ser 65 70 75 80 cat gga aat gtg tgc aaa gct ttg aat ttc ttc ttg aaa aaa att gaa 288 His Gly Asn Val Cys Lys Ala Leu Asn Phe Phe Leu Lys Lys Ile Glu 85 90 95 gga gac gaa gac tgc ttg ttg gtg aat gtg tac gca cca aaa aca act 336 Gly Asp Glu Asp Cys Leu Leu Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 tct gac aaa aaa ctt cca gta ttt ttc tgg gtt cat ggt ggc ggt ttt 384 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe 115 120 125 gtg act gga tcc gga aat tta gaa ttt caa agc cca gat tat tta gta 432 Val Thr Gly Ser Gly Asn Leu Glu Phe Gln Ser Pro Asp Tyr Leu Val 130 135 140 aat tat gat gtt att ttt gta act ttc aat tac cga ttg gga cca ctc 480 Asn Tyr Asp Val Ile Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu 145 150 155 160 gga ttt ttg aat ttg gag ttg gaa ggt gct cct gga aat gta gga tta 528 Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn Val Gly Leu 165 170 175 ttg gat cag gta gca gct ttg aaa tgg acc aaa gaa aat att gag aaa 576 Leu Asp Gln Val Ala Ala Leu Lys Trp Thr Lys Glu Asn Ile Glu Lys 180 185 190 ttt ggt gga gat cca gaa aat att aca att ggt ggt gtt tct gct ggt 624 Phe Gly Gly Asp Pro Glu Asn Ile Thr Ile Gly Gly Val Ser Ala Gly 195 200 205 gga gca agt gtt cat tat ctt tta ttg tca cat aca acc act gga ctt 672 Gly Ala Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 210 215 220 tac aaa agg gca att gct caa agt gga agt gct tta aat cca tgg gcc 720 Tyr Lys Arg Ala Ile Ala Gln Ser Gly Ser Ala Leu Asn Pro Trp Ala 225 230 235 240 ttc caa aga cat cca gta aag cgt agt ctt caa ctt gct gag ata tta 768 Phe Gln Arg His Pro Val Lys Arg Ser Leu Gln Leu Ala Glu Ile Leu 245 250 255 ggt cat ccc aca aac aac act caa gat gct tta gaa ttc tta caa aaa 816 Gly His Pro Thr Asn Asn Thr Gln Asp Ala Leu Glu Phe Leu Gln Lys 260 265 270 gcc cca gta gac agt ctc ctg aaa aaa atg cca gct gaa aca gaa ggt 864 Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala Glu Thr Glu Gly 275 280 285 gaa ata ata gaa gag ttc gtc ttc gta cca tca att gaa aaa gtt ttc 912 Glu Ile Ile Glu Glu Phe Val Phe Val Pro Ser Ile Glu Lys Val Phe 290 295 300 cca tcc cac caa cct ttc ttg gaa gaa tca cca ttg gcc aga atg aaa 960 Pro Ser His Gln Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys 305 310 315 320 tct gga tcc ttt aac aaa gta cct tta tta gtt gga ttc aac agc gca 1008 Ser Gly Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 325 330 335 gaa gga ctt ttg tac aaa ttc ttt atg aaa gaa aaa cca gag atg ctg 1056 Glu Gly Leu Leu Tyr Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu 340 345 350 aac caa gct gaa gca gat ttc gaa aga ctc gta cca gcc gaa ttt gaa 1104 Asn Gln Ala Glu Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu 355 360 365 tta gcc cat gga tca gaa gaa tcg aaa aaa ctt gca gaa aaa atc agg 1152 Leu Ala His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys Ile Arg 370 375 380 aag ttt tac ttt gac gat aaa ccc gtt cct gaa aat gag cag aaa ttt 1200 Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn Glu Gln Lys Phe 385 390 395 400 att gac ttg ata gga gat att tgg ttt act aga ggc att gac aag cat 1248 Ile Asp Leu Ile Gly Asp Ile Trp Phe Thr Arg Gly Ile Asp Lys His 405 410 415 gtc aag ttg tct gta gaa aaa caa gac gag cca gta tat tat tat gaa 1296 Val Lys Leu Ser Val Glu Lys Gln Asp Glu Pro Val Tyr Tyr Tyr Glu 420 425 430 tat tct ttc tct gaa agt cat cct gca aaa gga aca ttt ggt gac cat 1344 Tyr Ser Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 435 440 445 aac ttg act gga gca tgt cat ggt gaa gaa ctt gtg aat tta ttc aaa 1392 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys 450 455 460 gtc gag atg atg aag ctg gaa aaa gat aaa ccg aat gtt tta tta aca 1440 Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr 465 470 475 480 aaa gat agg gta ctt gct atg tgg acg aac ttc atc aaa aat gga aat 1488 Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe Ile Lys Asn Gly Asn 485 490 495 cct act cct gaa gta act gaa tta ttg cca gtt aaa tgg gaa cct gcc 1536 Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys Trp Glu Pro Ala 500 505 510 aca aaa gac aag ttg aat tat ttg aac att gat gcc acc tta act ttg 1584 Thr Lys Asp Lys Leu Asn Tyr Leu Asn Ile Asp Ala Thr Leu Thr Leu 515 520 525 gga aca aat cca gaa gaa acc cga gtc aaa tty tgg gaa gat gcc aca 1632 Gly Thr Asn Pro Glu Glu Thr Arg Val Lys Phe Trp Glu Asp Ala Thr 530 535 540 aaa act ttg cac agt caa 1650 Lys Thr Leu His Ser Gln 545 550 22 1650 DNA Ctenocephalides felis 22 ttgactgtgc aaagtttttg tggcatcttc ccaraatttg actcgggttt cttctggatt 60 tgttcccaaa gttaaggtgg catcaatgtt caaataattc aacttgtctt ttgtggcagg 120 ttcccattta actggcaata attcagttac ttcaggagta ggatttccat ttttgatgaa 180 gttcgtccac atagcaagta ccctatcttt tgttaataaa acattcggtt tatctttttc 240 cagcttcatc atctcgactt tgaataaatt cacaagttct tcaccatgac atgctccagt 300 caagttatgg tcaccaaatg ttccttttgc aggatgactt tcagagaaag aatattcata 360 ataatatact ggctcgtctt gtttttctac agacaacttg acatgcttgt caatgcctct 420 agtaaaccaa atatctccta tcaagtcaat aaatttctgc tcattttcag gaacgggttt 480 atcgtcaaag taaaacttcc tgattttttc tgcaagtttt ttcgattctt ctgatccatg 540 ggctaattca aattcggctg gtacgagtct ttcgaaatct gcttcagctt ggttcagcat 600 ctctggtttt tctttcataa agaatttgta caaaagtcct tctgcgctgt tgaatccaac 660 taataaaggt actttgttaa aggatccaga tttcattctg gccaatggtg attcttccaa 720 gaaaggttgg tgggatggga aaactttttc aattgatggt acgaagacga actcttctat 780 tatttcacct tctgtttcag ctggcatttt tttcaggaga ctgtctactg gggctttttg 840 taagaattct aaagcatctt gagtgttgtt tgtgggatga cctaatatct cagcaagttg 900 aagactacgc tttactggat gtctttggaa ggcccatgga tttaaagcac ttccactttg 960 agcaattgcc cttttgtaaa gtccagtggt tgtatgtgac aataaaagat aatgaacact 1020 tgctccacca gcagaaacac caccaattgt aatattttct ggatctccac caaatttctc 1080 aatattttct ttggtccatt tcaaagctgc tacctgatcc aataatccta catttccagg 1140 agcaccttcc aactccaaat tcaaaaatcc gagtggtccc aatcggtaat tgaaagttac 1200 aaaaataaca tcataattta ctaaataatc tgggctttga aattctaaat ttccggatcc 1260 agtcacaaaa ccgccaccat gaacccagaa aaatactgga agttttttgt cagaagttgt 1320 ttttggtgcg tacacattca ccaacaagca gtcttcgtct ccttcaattt ttttcaagaa 1380 gaaattcaaa gctttgcaca catttccatg tgatgtggcg ttgaaaacac cattccatgg 1440 ctcagctttc tgtggaggct taaatctaag ttctccaact ggaggtttag cataaggcac 1500 acctgtgtag ctaaaatact cttttccatt ttcgttcgtc aaagcttttc caaccaattc 1560 gccctggggc aaagttacag tcgggggatc acattttata aaattaaaac taaacaaaaa 1620 aatacaactt aaaaaaataa cacgagacat 1650 23 1590 DNA Ctenocephalides felis exon (1)..(1590) 23 gat ccc ccg act gta act ttg ccc cag ggc gaa ttg gtt gga aaa gct 48 Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu Val Gly Lys Ala 1 5 10 15 ttg acg aac gaa aat gga aaa gag tat ttt agc tac aca ggt gtg cct 96 Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro 20 25 30 tat gct aaa cct cca gtt gga gaa ctt aga ttt aag cct cca cag aaa 144 Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gln Lys 35 40 45 gct gag cca tgg aat ggt gtt ttc aac gcc aca tca cat gga aat gtg 192 Ala Glu Pro Trp Asn Gly Val Phe Asn Ala Thr Ser His Gly Asn Val 50 55 60 tgc aaa gct ttg aat ttc ttc ttg aaa aaa att gaa gga gac gaa gac 240 Cys Lys Ala Leu Asn Phe Phe Leu Lys Lys Ile Glu Gly Asp Glu Asp 65 70 75 80 tgc ttg ttg gtg aat gtg tac gca cca aaa aca act tct gac aaa aaa 288 Cys Leu Leu Val Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp Lys Lys 85 90 95 ctt cca gta ttt ttc tgg gtt cat ggt ggc ggt ttt gtg act gga tcc 336 Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe Val Thr Gly Ser 100 105 110 gga aat tta gaa ttt caa agc cca gat tat tta gta aat tat gat gtt 384 Gly Asn Leu Glu Phe Gln Ser Pro Asp Tyr Leu Val Asn Tyr Asp Val 115 120 125 att ttt gta act ttc aat tac cga ttg gga cca ctc gga ttt ttg aat 432 Ile Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn 130 135 140 ttg gag ttg gaa ggt gct cct gga aat gta gga tta ttg gat cag gta 480 Leu Glu Leu Glu Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gln Val 145 150 155 160 gca gct ttg aaa tgg acc aaa gaa aat att gag aaa ttt ggt gga gat 528 Ala Ala Leu Lys Trp Thr Lys Glu Asn Ile Glu Lys Phe Gly Gly Asp 165 170 175 cca gaa aat att aca att ggt ggt gtt tct gct ggt gga gca agt gtt 576 Pro Glu Asn Ile Thr Ile Gly Gly Val Ser Ala Gly Gly Ala Ser Val 180 185 190 cat tat ctt tta ttg tca cat aca acc act gga ctt tac aaa agg gca 624 His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu Tyr Lys Arg Ala 195 200 205 att gct caa agt gga agt gct tta aat cca tgg gcc ttc caa aga cat 672 Ile Ala Gln Ser Gly Ser Ala Leu Asn Pro Trp Ala Phe Gln Arg His 210 215 220 cca gta aag cgt agt ctt caa ctt gct gag ata tta ggt cat ccc aca 720 Pro Val Lys Arg Ser Leu Gln Leu Ala Glu Ile Leu Gly His Pro Thr 225 230 235 240 aac aac act caa gat gct tta gaa ttc tta caa aaa gcc cca gta gac 768 Asn Asn Thr Gln Asp Ala Leu Glu Phe Leu Gln Lys Ala Pro Val Asp 245 250 255 agt ctc ctg aaa aaa atg cca gct gaa aca gaa ggt gaa ata ata gaa 816 Ser Leu Leu Lys Lys Met Pro Ala Glu Thr Glu Gly Glu Ile Ile Glu 260 265 270 gag ttc gtc ttc gta cca tca att gaa aaa gtt ttc cca tcc cac caa 864 Glu Phe Val Phe Val Pro Ser Ile Glu Lys Val Phe Pro Ser His Gln 275 280 285 cct ttc ttg gaa gaa tca cca ttg gcc aga atg aaa tct gga tcc ttt 912 Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly Ser Phe 290 295 300 aac aaa gta cct tta tta gtt gga ttc aac agc gca gaa gga ctt ttg 960 Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala Glu Gly Leu Leu 305 310 315 320 tac aaa ttc ttt atg aaa gaa aaa cca gag atg ctg aac caa gct gaa 1008 Tyr Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu Asn Gln Ala Glu 325 330 335 gca gat ttc gaa aga ctc gta cca gcc gaa ttt gaa tta gcc cat gga 1056 Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu Leu Ala His Gly 340 345 350 tca gaa gaa tcg aaa aaa ctt gca gaa aaa atc agg aag ttt tac ttt 1104 Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys Ile Arg Lys Phe Tyr Phe 355 360 365 gac gat aaa ccc gtt cct gaa aat gag cag aaa ttt att gac ttg ata 1152 Asp Asp Lys Pro Val Pro Glu Asn Glu Gln Lys Phe Ile Asp Leu Ile 370 375 380 gga gat att tgg ttt act aga ggc att gac aag cat gtc aag ttg tct 1200 Gly Asp Ile Trp Phe Thr Arg Gly Ile Asp Lys His Val Lys Leu Ser 385 390 395 400 gta gaa aaa caa gac gag cca gta tat tat tat gaa tat tct ttc tct 1248 Val Glu Lys Gln Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser 405 410 415 gaa agt cat cct gca aaa gga aca ttt ggt gac cat aac ttg act gga 1296 Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His Asn Leu Thr Gly 420 425 430 gca tgt cat ggt gaa gaa ctt gtg aat tta ttc aaa gtc gag atg atg 1344 Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys Val Glu Met Met 435 440 445 aag ctg gaa aaa gat aaa ccg aat gtt tta tta aca aaa gat agg gta 1392 Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr Lys Asp Arg Val 450 455 460 ctt gct atg tgg acg aac ttc atc aaa aat gga aat cct act cct gaa 1440 Leu Ala Met Trp Thr Asn Phe Ile Lys Asn Gly Asn Pro Thr Pro Glu 465 470 475 480 gta act gaa tta ttg cca gtt aaa tgg gaa cct gcc aca aaa gac aag 1488 Val Thr Glu Leu Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp Lys 485 490 495 ttg aat tat ttg aac att gat gcc acc tta act ttg gga aca aat cca 1536 Leu Asn Tyr Leu Asn Ile Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro 500 505 510 gaa gaa acc cga gtc aaa tty tgg gaa gat gcc aca aaa act ttg cac 1584 Glu Glu Thr Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Thr Leu His 515 520 525 agt caa 1590 Ser Gln 530 24 2836 DNA Ctenocephalides felis CDS (99)..(1889) 24 tagacatgtc gtcttcaaaa cgtctatttt atcataaaca aaacgagata aataataaca 60 attaagcaac caaaatgcat taaaaaacac aataaaaa atg tta cct cac agt agt 116 Met Leu Pro His Ser Ser 1 5 gca tta gtt tta ttt tta ttt ttt tta ttt ttc tta ttt aca cct atc 164 Ala Leu Val Leu Phe Leu Phe Phe Leu Phe Phe Leu Phe Thr Pro Ile 10 15 20 ttg tgc ata cta tgg gat aac cta gat cag cat ttg tgc aga gtt caa 212 Leu Cys Ile Leu Trp Asp Asn Leu Asp Gln His Leu Cys Arg Val Gln 25 30 35 ttt aac ggg atc acg gaa gga aaa ccg ttc cga tat aaa gat cat agg 260 Phe Asn Gly Ile Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Arg 40 45 50 aat gat gta tat tgt tct tat ttg gga att cct tat gcc gaa ccg cct 308 Asn Asp Val Tyr Cys Ser Tyr Leu Gly Ile Pro Tyr Ala Glu Pro Pro 55 60 65 70 ttt gga cca tta cga ttt cag tct cca aaa cca ata tca aat cca aaa 356 Phe Gly Pro Leu Arg Phe Gln Ser Pro Lys Pro Ile Ser Asn Pro Lys 75 80 85 aca gga ttc gta cag gct cga act ttg gga gac aaa tgt ttc cag gaa 404 Thr Gly Phe Val Gln Ala Arg Thr Leu Gly Asp Lys Cys Phe Gln Glu 90 95 100 agt cta ata tat tct tat gca gga agc gaa gat tgc tta tat ctg aat 452 Ser Leu Ile Tyr Ser Tyr Ala Gly Ser Glu Asp Cys Leu Tyr Leu Asn 105 110 115 ata ttc acg cca gag act gtt aat tct gcg aac aat aca aaa tat cct 500 Ile Phe Thr Pro Glu Thr Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro 120 125 130 gta atg ttc tgg atc cat gga ggc gca ttc aac caa gga tca gga tct 548 Val Met Phe Trp Ile His Gly Gly Ala Phe Asn Gln Gly Ser Gly Ser 135 140 145 150 tat aat ttt ttt gga cct gat tat ttg atc agg gaa gga att att ttg 596 Tyr Asn Phe Phe Gly Pro Asp Tyr Leu Ile Arg Glu Gly Ile Ile Leu 155 160 165 gtc act atc aac tat aga tta gga gtt ttc ggt ttt cta tca gcg ccg 644 Val Thr Ile Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro 170 175 180 gaa tgg gat atc cat gga aat atg ggt cta aaa gac cag aga ttg gca 692 Glu Trp Asp Ile His Gly Asn Met Gly Leu Lys Asp Gln Arg Leu Ala 185 190 195 cta aaa tgg gtt tac gac aac atc gaa aag ttt ggt gga gac aga gaa 740 Leu Lys Trp Val Tyr Asp Asn Ile Glu Lys Phe Gly Gly Asp Arg Glu 200 205 210 aaa att aca att gct gga gaa tct gct gga gca gca agt gtc cat ttt 788 Lys Ile Thr Ile Ala Gly Glu Ser Ala Gly Ala Ala Ser Val His Phe 215 220 225 230 ctg atg atg gac aac tcg act aga aaa tac tac caa agg gcc att ttg 836 Leu Met Met Asp Asn Ser Thr Arg Lys Tyr Tyr Gln Arg Ala Ile Leu 235 240 245 cag agt ggg aca tta cta aat ccg act gct aat caa att caa ctt ctg 884 Gln Ser Gly Thr Leu Leu Asn Pro Thr Ala Asn Gln Ile Gln Leu Leu 250 255 260 cat aga ttt gaa aaa ctc aaa caa gtg cta aac atc acg caa aaa caa 932 His Arg Phe Glu Lys Leu Lys Gln Val Leu Asn Ile Thr Gln Lys Gln 265 270 275 gaa ctc cta aac ctg gat aaa aac cta att tta cga gca gcc tta aac 980 Glu Leu Leu Asn Leu Asp Lys Asn Leu Ile Leu Arg Ala Ala Leu Asn 280 285 290 aga gtt cct gat agc aac gac cat gac cga gac aca gta cca gta ttt 1028 Arg Val Pro Asp Ser Asn Asp His Asp Arg Asp Thr Val Pro Val Phe 295 300 305 310 aat cca gtc tta gaa tca cca gaa tct cca gat cca ata aca ttt cca 1076 Asn Pro Val Leu Glu Ser Pro Glu Ser Pro Asp Pro Ile Thr Phe Pro 315 320 325 tct gcc ttg gaa aga atg aga aat ggt gaa ttt cct gat gtc gat gtc 1124 Ser Ala Leu Glu Arg Met Arg Asn Gly Glu Phe Pro Asp Val Asp Val 330 335 340 atc att ggt ttc aat agt gct gaa ggt tta aga tct atg gca aga gta 1172 Ile Ile Gly Phe Asn Ser Ala Glu Gly Leu Arg Ser Met Ala Arg Val 345 350 355 acc aga gga aac atg gaa gtt cac aag act ttg aca aat ata gaa agg 1220 Thr Arg Gly Asn Met Glu Val His Lys Thr Leu Thr Asn Ile Glu Arg 360 365 370 gct ata cct aga gat gct aat att tgg aaa aat cca aat ggt att gag 1268 Ala Ile Pro Arg Asp Ala Asn Ile Trp Lys Asn Pro Asn Gly Ile Glu 375 380 385 390 gag aaa aaa cta ata aaa atg ctt aca gag ttt tat gac caa gtg aaa 1316 Glu Lys Lys Leu Ile Lys Met Leu Thr Glu Phe Tyr Asp Gln Val Lys 395 400 405 gaa caa aac gat gac att gaa gcc tac gtc caa cta aaa ggc gat gct 1364 Glu Gln Asn Asp Asp Ile Glu Ala Tyr Val Gln Leu Lys Gly Asp Ala 410 415 420 ggt tac ctc caa gga atc tac cgt acc ttg aaa gcc ata ttt ttc aat 1412 Gly Tyr Leu Gln Gly Ile Tyr Arg Thr Leu Lys Ala Ile Phe Phe Asn 425 430 435 gaa ttc aga agg aat tcc aat ttg tat ttg tac agg tta tca gac gat 1460 Glu Phe Arg Arg Asn Ser Asn Leu Tyr Leu Tyr Arg Leu Ser Asp Asp 440 445 450 acg tat agt gta tat aaa agt tat atc ttg ccc tat cga tgg ggt tcc 1508 Thr Tyr Ser Val Tyr Lys Ser Tyr Ile Leu Pro Tyr Arg Trp Gly Ser 455 460 465 470 ttg cca gga gtt agt cat ggt gat gat tta gga tat ctt ttt gca aac 1556 Leu Pro Gly Val Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn 475 480 485 tcg ttg gat gtt cct att ttg gga aca acg cac att tct ata ccg caa 1604 Ser Leu Asp Val Pro Ile Leu Gly Thr Thr His Ile Ser Ile Pro Gln 490 495 500 gat gct atg cag act ctg gaa agg atg gtc agg atc tgg acc aat ttt 1652 Asp Ala Met Gln Thr Leu Glu Arg Met Val Arg Ile Trp Thr Asn Phe 505 510 515 gta aag aat gga aaa cct aca tca aac act gaa gat gca tca tgt gat 1700 Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser Cys Asp 520 525 530 aca aaa aga cat tta aac gac att ttt tgg gaa cca tac aac gac gaa 1748 Thr Lys Arg His Leu Asn Asp Ile Phe Trp Glu Pro Tyr Asn Asp Glu 535 540 545 550 gaa cca aaa tat ttg gac atg gga aaa gaa aat ttt gaa atg aaa aat 1796 Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu Asn Phe Glu Met Lys Asn 555 560 565 att ttg gaa cta aaa cgc atg atg ctt tgg gat gaa gtt tat aga aat 1844 Ile Leu Glu Leu Lys Arg Met Met Leu Trp Asp Glu Val Tyr Arg Asn 570 575 580 gcg aat ttg cgg ttt aga gtc tgt aat gaa gaa agt att aga tga 1889 Ala Asn Leu Arg Phe Arg Val Cys Asn Glu Glu Ser Ile Arg 585 590 595 gtttttttaa ttttacatac agccgagagg aaacatgact aaaattggaa agaaaaatca 1949 gaaaaagaaa aatcacatgg accatagtaa ctttattaca tgatttagtt tcaagtgtat 2009 caagaaaact tattgcatca aagaaaatat tattttgcca aaattcttgg aaaaacactt 2069 tttatgactg acatggccca taattgaagc tttttcttct tttaccaaat cgccaaattt 2129 tgtagcgtca gacacattta tttatgacat ggcaattaat gtgttaaaca ttcaactcta 2189 tattaaaaat ggtagtattt tctaataaga aggttatata aaaagacttg aaaataataa 2249 gatttgctcg gctatatata aaaacttanc gtctcgttat gctaaacttt tttgatggta 2309 aaaatatgtt gattttccta ataatctaag atattatatt ttagattaaa ttaaaatatg 2369 atattttcaa ttaattaatt ttagttttaa atgtactata tttaccagta ctatgaaact 2429 attttaaata tattttttat tacaatattt atttctcaaa aatgtttagt gtaacaagac 2489 cattaaatta gagttaatgt tgtaaattaa actatttttt atctatcaca accgcttaat 2549 tggtgcaaag aaaaatttta ctgtgataat atttgacatt tacacaatat tacgaattgt 2609 aaactcacaa ttatgtgaat attgtttttt gttaaaaaaa catacatgac ttttctatat 2669 cattttatat tacggtgata tggattaatg tcaacatgta aaatacaaat gcggttgtta 2729 aaaataatct gtattaaaat tgttatataa aatctgaata aatgtacttt taagtaaaaa 2789 aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaa 2836 25 596 PRT Ctenocephalides felis 25 Met Leu Pro His Ser Ser Ala Leu Val Leu Phe Leu Phe Phe Leu Phe 1 5 10 15 Phe Leu Phe Thr Pro Ile Leu Cys Ile Leu Trp Asp Asn Leu Asp Gln 20 25 30 His Leu Cys Arg Val Gln Phe Asn Gly Ile Thr Glu Gly Lys Pro Phe 35 40 45 Arg Tyr Lys Asp His Arg Asn Asp Val Tyr Cys Ser Tyr Leu Gly Ile 50 55 60 Pro Tyr Ala Glu Pro Pro Phe Gly Pro Leu Arg Phe Gln Ser Pro Lys 65 70 75 80 Pro Ile Ser Asn Pro Lys Thr Gly Phe Val Gln Ala Arg Thr Leu Gly 85 90 95 Asp Lys Cys Phe Gln Glu Ser Leu Ile Tyr Ser Tyr Ala Gly Ser Glu 100 105 110 Asp Cys Leu Tyr Leu Asn Ile Phe Thr Pro Glu Thr Val Asn Ser Ala 115 120 125 Asn Asn Thr Lys Tyr Pro Val Met Phe Trp Ile His Gly Gly Ala Phe 130 135 140 Asn Gln Gly Ser Gly Ser Tyr Asn Phe Phe Gly Pro Asp Tyr Leu Ile 145 150 155 160 Arg Glu Gly Ile Ile Leu Val Thr Ile Asn Tyr Arg Leu Gly Val Phe 165 170 175 Gly Phe Leu Ser Ala Pro Glu Trp Asp Ile His Gly Asn Met Gly Leu 180 185 190 Lys Asp Gln Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn Ile Glu Lys 195 200 205 Phe Gly Gly Asp Arg Glu Lys Ile Thr Ile Ala Gly Glu Ser Ala Gly 210 215 220 Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg Lys Tyr 225 230 235 240 Tyr Gln Arg Ala Ile Leu Gln Ser Gly Thr Leu Leu Asn Pro Thr Ala 245 250 255 Asn Gln Ile Gln Leu Leu His Arg Phe Glu Lys Leu Lys Gln Val Leu 260 265 270 Asn Ile Thr Gln Lys Gln Glu Leu Leu Asn Leu Asp Lys Asn Leu Ile 275 280 285 Leu Arg Ala Ala Leu Asn Arg Val Pro Asp Ser Asn Asp His Asp Arg 290 295 300 Asp Thr Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro 305 310 315 320 Asp Pro Ile Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu 325 330 335 Phe Pro Asp Val Asp Val Ile Ile Gly Phe Asn Ser Ala Glu Gly Leu 340 345 350 Arg Ser Met Ala Arg Val Thr Arg Gly Asn Met Glu Val His Lys Thr 355 360 365 Leu Thr Asn Ile Glu Arg Ala Ile Pro Arg Asp Ala Asn Ile Trp Lys 370 375 380 Asn Pro Asn Gly Ile Glu Glu Lys Lys Leu Ile Lys Met Leu Thr Glu 385 390 395 400 Phe Tyr Asp Gln Val Lys Glu Gln Asn Asp Asp Ile Glu Ala Tyr Val 405 410 415 Gln Leu Lys Gly Asp Ala Gly Tyr Leu Gln Gly Ile Tyr Arg Thr Leu 420 425 430 Lys Ala Ile Phe Phe Asn Glu Phe Arg Arg Asn Ser Asn Leu Tyr Leu 435 440 445 Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr Ile Leu 450 455 460 Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His Gly Asp Asp Leu 465 470 475 480 Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val Pro Ile Leu Gly Thr Thr 485 490 495 His Ile Ser Ile Pro Gln Asp Ala Met Gln Thr Leu Glu Arg Met Val 500 505 510 Arg Ile Trp Thr Asn Phe Val Lys Asn Gly Lys Pro Thr Ser Asn Thr 515 520 525 Glu Asp Ala Ser Cys Asp Thr Lys Arg His Leu Asn Asp Ile Phe Trp 530 535 540 Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu 545 550 555 560 Asn Phe Glu Met Lys Asn Ile Leu Glu Leu Lys Arg Met Met Leu Trp 565 570 575 Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg Val Cys Asn Glu 580 585 590 Glu Ser Ile Arg 595 26 2836 DNA Ctenocephalides felis misc_feature (559)..(559) n = unknown 26 tttttttttt tttttttttt tttttttttt tttttttttt tttttttttt ttacttaaaa 60 gtacatttat tcagatttta tataacaatt ttaatacaga ttatttttaa caaccgcatt 120 tgtattttac atgttgacat taatccatat caccgtaata taaaatgata tagaaaagtc 180 atgtatgttt ttttaacaaa aaacaatatt cacataattg tgagtttaca attcgtaata 240 ttgtgtaaat gtcaaatatt atcacagtaa aatttttctt tgcaccaatt aagcggttgt 300 gatagataaa aaatagttta atttacaaca ttaactctaa tttaatggtc ttgttacact 360 aaacattttt gagaaataaa tattgtaata aaaaatatat ttaaaatagt ttcatagtac 420 tggtaaatat agtacattta aaactaaaat taattaattg aaaatatcat attttaattt 480 aatctaaaat ataatatctt agattattag gaaaatcaac atatttttac catcaaaaaa 540 gtttagcata acgagacgnt aagtttttat atatagccga gcaaatctta ttattttcaa 600 gtctttttat ataaccttct tattagaaaa tactaccatt tttaatatag agttgaatgt 660 ttaacacatt aattgccatg tcataaataa atgtgtctga cgctacaaaa tttggcgatt 720 tggtaaaaga agaaaaagct tcaattatgg gccatgtcag tcataaaaag tgtttttcca 780 agaattttgg caaaataata ttttctttga tgcaataagt tttcttgata cacttgaaac 840 taaatcatgt aataaagtta ctatggtcca tgtgattttt ctttttctga tttttctttc 900 caattttagt catgtttcct ctcggctgta tgtaaaatta aaaaaactca tctaatactt 960 tcttcattac agactctaaa ccgcaaattc gcatttctat aaacttcatc ccaaagcatc 1020 atgcgtttta gttccaaaat atttttcatt tcaaaatttt cttttcccat gtccaaatat 1080 tttggttctt cgtcgttgta tggttcccaa aaaatgtcgt ttaaatgtct ttttgtatca 1140 catgatgcat cttcagtgtt tgatgtaggt tttccattct ttacaaaatt ggtccagatc 1200 ctgaccatcc tttccagagt ctgcatagca tcttgcggta tagaaatgtg cgttgttccc 1260 aaaataggaa catccaacga gtttgcaaaa agatatccta aatcatcacc atgactaact 1320 cctggcaagg aaccccatcg atagggcaag atataacttt tatatacact atacgtatcg 1380 tctgataacc tgtacaaata caaattggaa ttccttctga attcattgaa aaatatggct 1440 ttcaaggtac ggtagattcc ttggaggtaa ccagcatcgc cttttagttg gacgtaggct 1500 tcaatgtcat cgttttgttc tttcacttgg tcataaaact ctgtaagcat ttttattagt 1560 tttttctcct caataccatt tggatttttc caaatattag catctctagg tatagccctt 1620 tctatatttg tcaaagtctt gtgaacttcc atgtttcctc tggttactct tgccatagat 1680 cttaaacctt cagcactatt gaaaccaatg atgacatcga catcaggaaa ttcaccattt 1740 ctcattcttt ccaaggcaga tggaaatgtt attggatctg gagattctgg tgattctaag 1800 actggattaa atactggtac tgtgtctcgg tcatggtcgt tgctatcagg aactctgttt 1860 aaggctgctc gtaaaattag gtttttatcc aggtttagga gttcttgttt ttgcgtgatg 1920 tttagcactt gtttgagttt ttcaaatcta tgcagaagtt gaatttgatt agcagtcgga 1980 tttagtaatg tcccactctg caaaatggcc ctttggtagt attttctagt cgagttgtcc 2040 atcatcagaa aatggacact tgctgctcca gcagattctc cagcaattgt aattttttct 2100 ctgtctccac caaacttttc gatgttgtcg taaacccatt ttagtgccaa tctctggtct 2160 tttagaccca tatttccatg gatatcccat tccggcgctg atagaaaacc gaaaactcct 2220 aatctatagt tgatagtgac caaaataatt ccttccctga tcaaataatc aggtccaaaa 2280 aaattataag atcctgatcc ttggttgaat gcgcctccat ggatccagaa cattacagga 2340 tattttgtat tgttcgcaga attaacagtc tctggcgtga atatattcag atataagcaa 2400 tcttcgcttc ctgcataaga atatattaga ctttcctgga aacatttgtc tcccaaagtt 2460 cgagcctgta cgaatcctgt ttttggattt gatattggtt ttggagactg aaatcgtaat 2520 ggtccaaaag gcggttcggc ataaggaatt cccaaataag aacaatatac atcattccta 2580 tgatctttat atcggaacgg ttttccttcc gtgatcccgt taaattgaac tctgcacaaa 2640 tgctgatcta ggttatccca tagtatgcac aagataggtg taaataagaa aaataaaaaa 2700 aataaaaata aaactaatgc actactgtga ggtaacattt tttattgtgt tttttaatgc 2760 attttggttg cttaattgtt attatttatc tcgttttgtt tatgataaaa tagacgtttt 2820 gaagacgaca tgtcta 2836 27 1710 DNA Ctenocephalides felis exon (1)..(1710) 27 tgg gat aac cta gat cag cat ttg tgc aga gtt caa ttt aac ggg atc 48 Trp Asp Asn Leu Asp Gln His Leu Cys Arg Val Gln Phe Asn Gly Ile 1 5 10 15 acg gaa gga aaa ccg ttc cga tat aaa gat cat agg aat gat gta tat 96 Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Arg Asn Asp Val Tyr 20 25 30 tgt tct tat ttg gga att cct tat gcc gaa ccg cct ttt gga cca tta 144 Cys Ser Tyr Leu Gly Ile Pro Tyr Ala Glu Pro Pro Phe Gly Pro Leu 35 40 45 cga ttt cag tct cca aaa cca ata tca aat cca aaa aca gga ttc gta 192 Arg Phe Gln Ser Pro Lys Pro Ile Ser Asn Pro Lys Thr Gly Phe Val 50 55 60 cag gct cga act ttg gga gac aaa tgt ttc cag gaa agt cta ata tat 240 Gln Ala Arg Thr Leu Gly Asp Lys Cys Phe Gln Glu Ser Leu Ile Tyr 65 70 75 80 tct tat gca gga agc gaa gat tgc tta tat ctg aat ata ttc acg cca 288 Ser Tyr Ala Gly Ser Glu Asp Cys Leu Tyr Leu Asn Ile Phe Thr Pro 85 90 95 gag act gtt aat tct gcg aac aat aca aaa tat cct gta atg ttc tgg 336 Glu Thr Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp 100 105 110 atc cat gga ggc gca ttc aac caa gga tca gga tct tat aat ttt ttt 384 Ile His Gly Gly Ala Phe Asn Gln Gly Ser Gly Ser Tyr Asn Phe Phe 115 120 125 gga cct gat tat ttg atc agg gaa gga att att ttg gtc act atc aac 432 Gly Pro Asp Tyr Leu Ile Arg Glu Gly Ile Ile Leu Val Thr Ile Asn 130 135 140 tat aga tta gga gtt ttc ggt ttt cta tca gcg ccg gaa tgg gat atc 480 Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu Trp Asp Ile 145 150 155 160 cat gga aat atg ggt cta aaa gac cag aga ttg gca cta aaa tgg gtt 528 His Gly Asn Met Gly Leu Lys Asp Gln Arg Leu Ala Leu Lys Trp Val 165 170 175 tac gac aac atc gaa aag ttt ggt gga gac aga gaa aaa att aca att 576 Tyr Asp Asn Ile Glu Lys Phe Gly Gly Asp Arg Glu Lys Ile Thr Ile 180 185 190 gct gga gaa tct gct gga gca gca agt gtc cat ttt ctg atg atg gac 624 Ala Gly Glu Ser Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp 195 200 205 aac tcg act aga aaa tac tac caa agg gcc att ttg cag agt ggg aca 672 Asn Ser Thr Arg Lys Tyr Tyr Gln Arg Ala Ile Leu Gln Ser Gly Thr 210 215 220 tta cta aat ccg act gct aat caa att caa ctt ctg cat aga ttt gaa 720 Leu Leu Asn Pro Thr Ala Asn Gln Ile Gln Leu Leu His Arg Phe Glu 225 230 235 240 aaa ctc aaa caa gtg cta aac atc acg caa aaa caa gaa ctc cta aac 768 Lys Leu Lys Gln Val Leu Asn Ile Thr Gln Lys Gln Glu Leu Leu Asn 245 250 255 ctg gat aaa aac cta att tta cga gca gcc tta aac aga gtt cct gat 816 Leu Asp Lys Asn Leu Ile Leu Arg Ala Ala Leu Asn Arg Val Pro Asp 260 265 270 agc aac gac cat gac cga gac aca gta cca gta ttt aat cca gtc tta 864 Ser Asn Asp His Asp Arg Asp Thr Val Pro Val Phe Asn Pro Val Leu 275 280 285 gaa tca cca gaa tct cca gat cca ata aca ttt cca tct gcc ttg gaa 912 Glu Ser Pro Glu Ser Pro Asp Pro Ile Thr Phe Pro Ser Ala Leu Glu 290 295 300 aga atg aga aat ggt gaa ttt cct gat gtc gat gtc atc att ggt ttc 960 Arg Met Arg Asn Gly Glu Phe Pro Asp Val Asp Val Ile Ile Gly Phe 305 310 315 320 aat agt gct gaa ggt tta aga tct atg gca aga gta acc aga gga aac 1008 Asn Ser Ala Glu Gly Leu Arg Ser Met Ala Arg Val Thr Arg Gly Asn 325 330 335 atg gaa gtt cac aag act ttg aca aat ata gaa agg gct ata cct aga 1056 Met Glu Val His Lys Thr Leu Thr Asn Ile Glu Arg Ala Ile Pro Arg 340 345 350 gat gct aat att tgg aaa aat cca aat ggt att gag gag aaa aaa cta 1104 Asp Ala Asn Ile Trp Lys Asn Pro Asn Gly Ile Glu Glu Lys Lys Leu 355 360 365 ata aaa atg ctt aca gag ttt tat gac caa gtg aaa gaa caa aac gat 1152 Ile Lys Met Leu Thr Glu Phe Tyr Asp Gln Val Lys Glu Gln Asn Asp 370 375 380 gac att gaa gcc tac gtc caa cta aaa ggc gat gct ggt tac ctc caa 1200 Asp Ile Glu Ala Tyr Val Gln Leu Lys Gly Asp Ala Gly Tyr Leu Gln 385 390 395 400 gga atc tac cgt acc ttg aaa gcc ata ttt ttc aat gaa ttc aga agg 1248 Gly Ile Tyr Arg Thr Leu Lys Ala Ile Phe Phe Asn Glu Phe Arg Arg 405 410 415 aat tcc aat ttg tat ttg tac agg tta tca gac gat acg tat agt gta 1296 Asn Ser Asn Leu Tyr Leu Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val 420 425 430 tat aaa agt tat atc ttg ccc tat cga tgg ggt tcc ttg cca gga gtt 1344 Tyr Lys Ser Tyr Ile Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val 435 440 445 agt cat ggt gat gat tta gga tat ctt ttt gca aac tcg ttg gat gtt 1392 Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val 450 455 460 cct att ttg gga aca acg cac att tct ata ccg caa gat gct atg cag 1440 Pro Ile Leu Gly Thr Thr His Ile Ser Ile Pro Gln Asp Ala Met Gln 465 470 475 480 act ctg gaa agg atg gtc agg atc tgg acc aat ttt gta aag aat gga 1488 Thr Leu Glu Arg Met Val Arg Ile Trp Thr Asn Phe Val Lys Asn Gly 485 490 495 aaa cct aca tca aac act gaa gat gca tca tgt gat aca aaa aga cat 1536 Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser Cys Asp Thr Lys Arg His 500 505 510 tta aac gac att ttt tgg gaa cca tac aac gac gaa gaa cca aaa tat 1584 Leu Asn Asp Ile Phe Trp Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr 515 520 525 ttg gac atg gga aaa gaa aat ttt gaa atg aaa aat att ttg gaa cta 1632 Leu Asp Met Gly Lys Glu Asn Phe Glu Met Lys Asn Ile Leu Glu Leu 530 535 540 aaa cgc atg atg ctt tgg gat gaa gtt tat aga aat gcg aat ttg cgg 1680 Lys Arg Met Met Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg 545 550 555 560 ttt aga gtc tgt aat gaa gaa agt att aga 1710 Phe Arg Val Cys Asn Glu Glu Ser Ile Arg 565 570 28 1788 DNA Ctenocephalides felis exon (1)..(1788) 28 atg tta cct cac agt agt gca tta gtt tta ttt tta ttt ttt tta ttt 48 Met Leu Pro His Ser Ser Ala Leu Val Leu Phe Leu Phe Phe Leu Phe 1 5 10 15 ttc tta ttt aca cct atc ttg tgc ata cta tgg gat aac cta gat cag 96 Phe Leu Phe Thr Pro Ile Leu Cys Ile Leu Trp Asp Asn Leu Asp Gln 20 25 30 cat ttg tgc aga gtt caa ttt aac ggg atc acg gaa gga aaa ccg ttc 144 His Leu Cys Arg Val Gln Phe Asn Gly Ile Thr Glu Gly Lys Pro Phe 35 40 45 cga tat aaa gat cat agg aat gat gta tat tgt tct tat ttg gga att 192 Arg Tyr Lys Asp His Arg Asn Asp Val Tyr Cys Ser Tyr Leu Gly Ile 50 55 60 cct tat gcc gaa ccg cct ttt gga cca tta cga ttt cag tct cca aaa 240 Pro Tyr Ala Glu Pro Pro Phe Gly Pro Leu Arg Phe Gln Ser Pro Lys 65 70 75 80 cca ata tca aat cca aaa aca gga ttc gta cag gct cga act ttg gga 288 Pro Ile Ser Asn Pro Lys Thr Gly Phe Val Gln Ala Arg Thr Leu Gly 85 90 95 gac aaa tgt ttc cag gaa agt cta ata tat tct tat gca gga agc gaa 336 Asp Lys Cys Phe Gln Glu Ser Leu Ile Tyr Ser Tyr Ala Gly Ser Glu 100 105 110 gat tgc tta tat ctg aat ata ttc acg cca gag act gtt aat tct gcg 384 Asp Cys Leu Tyr Leu Asn Ile Phe Thr Pro Glu Thr Val Asn Ser Ala 115 120 125 aac aat aca aaa tat cct gta atg ttc tgg atc cat gga ggc gca ttc 432 Asn Asn Thr Lys Tyr Pro Val Met Phe Trp Ile His Gly Gly Ala Phe 130 135 140 aac caa gga tca gga tct tat aat ttt ttt gga cct gat tat ttg atc 480 Asn Gln Gly Ser Gly Ser Tyr Asn Phe Phe Gly Pro Asp Tyr Leu Ile 145 150 155 160 agg gaa gga att att ttg gtc act atc aac tat aga tta gga gtt ttc 528 Arg Glu Gly Ile Ile Leu Val Thr Ile Asn Tyr Arg Leu Gly Val Phe 165 170 175 ggt ttt cta tca gcg ccg gaa tgg gat atc cat gga aat atg ggt cta 576 Gly Phe Leu Ser Ala Pro Glu Trp Asp Ile His Gly Asn Met Gly Leu 180 185 190 aaa gac cag aga ttg gca cta aaa tgg gtt tac gac aac atc gaa aag 624 Lys Asp Gln Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn Ile Glu Lys 195 200 205 ttt ggt gga gac aga gaa aaa att aca att gct gga gaa tct gct gga 672 Phe Gly Gly Asp Arg Glu Lys Ile Thr Ile Ala Gly Glu Ser Ala Gly 210 215 220 gca gca agt gtc cat ttt ctg atg atg gac aac tcg act aga aaa tac 720 Ala Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg Lys Tyr 225 230 235 240 tac caa agg gcc att ttg cag agt ggg aca tta cta aat ccg act gct 768 Tyr Gln Arg Ala Ile Leu Gln Ser Gly Thr Leu Leu Asn Pro Thr Ala 245 250 255 aat caa att caa ctt ctg cat aga ttt gaa aaa ctc aaa caa gtg cta 816 Asn Gln Ile Gln Leu Leu His Arg Phe Glu Lys Leu Lys Gln Val Leu 260 265 270 aac atc acg caa aaa caa gaa ctc cta aac ctg gat aaa aac cta att 864 Asn Ile Thr Gln Lys Gln Glu Leu Leu Asn Leu Asp Lys Asn Leu Ile 275 280 285 tta cga gca gcc tta aac aga gtt cct gat agc aac gac cat gac cga 912 Leu Arg Ala Ala Leu Asn Arg Val Pro Asp Ser Asn Asp His Asp Arg 290 295 300 gac aca gta cca gta ttt aat cca gtc tta gaa tca cca gaa tct cca 960 Asp Thr Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro 305 310 315 320 gat cca ata aca ttt cca tct gcc ttg gaa aga atg aga aat ggt gaa 1008 Asp Pro Ile Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu 325 330 335 ttt cct gat gtc gat gtc atc att ggt ttc aat agt gct gaa ggt tta 1056 Phe Pro Asp Val Asp Val Ile Ile Gly Phe Asn Ser Ala Glu Gly Leu 340 345 350 aga tct atg gca aga gta acc aga gga aac atg gaa gtt cac aag act 1104 Arg Ser Met Ala Arg Val Thr Arg Gly Asn Met Glu Val His Lys Thr 355 360 365 ttg aca aat ata gaa agg gct ata cct aga gat gct aat att tgg aaa 1152 Leu Thr Asn Ile Glu Arg Ala Ile Pro Arg Asp Ala Asn Ile Trp Lys 370 375 380 aat cca aat ggt att gag gag aaa aaa cta ata aaa atg ctt aca gag 1200 Asn Pro Asn Gly Ile Glu Glu Lys Lys Leu Ile Lys Met Leu Thr Glu 385 390 395 400 ttt tat gac caa gtg aaa gaa caa aac gat gac att gaa gcc tac gtc 1248 Phe Tyr Asp Gln Val Lys Glu Gln Asn Asp Asp Ile Glu Ala Tyr Val 405 410 415 caa cta aaa ggc gat gct ggt tac ctc caa gga atc tac cgt acc ttg 1296 Gln Leu Lys Gly Asp Ala Gly Tyr Leu Gln Gly Ile Tyr Arg Thr Leu 420 425 430 aaa gcc ata ttt ttc aat gaa ttc aga agg aat tcc aat ttg tat ttg 1344 Lys Ala Ile Phe Phe Asn Glu Phe Arg Arg Asn Ser Asn Leu Tyr Leu 435 440 445 tac agg tta tca gac gat acg tat agt gta tat aaa agt tat atc ttg 1392 Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr Ile Leu 450 455 460 ccc tat cga tgg ggt tcc ttg cca gga gtt agt cat ggt gat gat tta 1440 Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His Gly Asp Asp Leu 465 470 475 480 gga tat ctt ttt gca aac tcg ttg gat gtt cct att ttg gga aca acg 1488 Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val Pro Ile Leu Gly Thr Thr 485 490 495 cac att tct ata ccg caa gat gct atg cag act ctg gaa agg atg gtc 1536 His Ile Ser Ile Pro Gln Asp Ala Met Gln Thr Leu Glu Arg Met Val 500 505 510 agg atc tgg acc aat ttt gta aag aat gga aaa cct aca tca aac act 1584 Arg Ile Trp Thr Asn Phe Val Lys Asn Gly Lys Pro Thr Ser Asn Thr 515 520 525 gaa gat gca tca tgt gat aca aaa aga cat tta aac gac att ttt tgg 1632 Glu Asp Ala Ser Cys Asp Thr Lys Arg His Leu Asn Asp Ile Phe Trp 530 535 540 gaa cca tac aac gac gaa gaa cca aaa tat ttg gac atg gga aaa gaa 1680 Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu 545 550 555 560 aat ttt gaa atg aaa aat att ttg gaa cta aaa cgc atg atg ctt tgg 1728 Asn Phe Glu Met Lys Asn Ile Leu Glu Leu Lys Arg Met Met Leu Trp 565 570 575 gat gaa gtt tat aga aat gcg aat ttg cgg ttt aga gtc tgt aat gaa 1776 Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg Val Cys Asn Glu 580 585 590 gaa agt att aga 1788 Glu Ser Ile Arg 595 29 1788 DNA Ctenocephalides felis 29 tctaatactt tcttcattac agactctaaa ccgcaaattc gcatttctat aaacttcatc 60 ccaaagcatc atgcgtttta gttccaaaat atttttcatt tcaaaatttt cttttcccat 120 gtccaaatat tttggttctt cgtcgttgta tggttcccaa aaaatgtcgt ttaaatgtct 180 ttttgtatca catgatgcat cttcagtgtt tgatgtaggt tttccattct ttacaaaatt 240 ggtccagatc ctgaccatcc tttccagagt ctgcatagca tcttgcggta tagaaatgtg 300 cgttgttccc aaaataggaa catccaacga gtttgcaaaa agatatccta aatcatcacc 360 atgactaact cctggcaagg aaccccatcg atagggcaag atataacttt tatatacact 420 atacgtatcg tctgataacc tgtacaaata caaattggaa ttccttctga attcattgaa 480 aaatatggct ttcaaggtac ggtagattcc ttggaggtaa ccagcatcgc cttttagttg 540 gacgtaggct tcaatgtcat cgttttgttc tttcacttgg tcataaaact ctgtaagcat 600 ttttattagt tttttctcct caataccatt tggatttttc caaatattag catctctagg 660 tatagccctt tctatatttg tcaaagtctt gtgaacttcc atgtttcctc tggttactct 720 tgccatagat cttaaacctt cagcactatt gaaaccaatg atgacatcga catcaggaaa 780 ttcaccattt ctcattcttt ccaaggcaga tggaaatgtt attggatctg gagattctgg 840 tgattctaag actggattaa atactggtac tgtgtctcgg tcatggtcgt tgctatcagg 900 aactctgttt aaggctgctc gtaaaattag gtttttatcc aggtttagga gttcttgttt 960 ttgcgtgatg tttagcactt gtttgagttt ttcaaatcta tgcagaagtt gaatttgatt 1020 agcagtcgga tttagtaatg tcccactctg caaaatggcc ctttggtagt attttctagt 1080 cgagttgtcc atcatcagaa aatggacact tgctgctcca gcagattctc cagcaattgt 1140 aattttttct ctgtctccac caaacttttc gatgttgtcg taaacccatt ttagtgccaa 1200 tctctggtct tttagaccca tatttccatg gatatcccat tccggcgctg atagaaaacc 1260 gaaaactcct aatctatagt tgatagtgac caaaataatt ccttccctga tcaaataatc 1320 aggtccaaaa aaattataag atcctgatcc ttggttgaat gcgcctccat ggatccagaa 1380 cattacagga tattttgtat tgttcgcaga attaacagtc tctggcgtga atatattcag 1440 atataagcaa tcttcgcttc ctgcataaga atatattaga ctttcctgga aacatttgtc 1500 tcccaaagtt cgagcctgta cgaatcctgt ttttggattt gatattggtt ttggagactg 1560 aaatcgtaat ggtccaaaag gcggttcggc ataaggaatt cccaaataag aacaatatac 1620 atcattccta tgatctttat atcggaacgg ttttccttcc gtgatcccgt taaattgaac 1680 tctgcacaaa tgctgatcta ggttatccca tagtatgcac aagataggtg taaataagaa 1740 aaataaaaaa aataaaaata aaactaatgc actactgtga ggtaacat 1788 30 2801 DNA Ctenocephalides felis CDS (99)..(1886) 30 gacatgtcgt cttcaaaacg tctattttat cataaacaaa acgagataaa taataacaat 60 taagcatcca aaatgcatta aaaaaaacat cataaaaa atg tta cct cac agt gca 116 Met Leu Pro His Ser Ala 1 5 tta gtt tta ttt tta ttt ttt tta ttt ttc tta ttt aca cct gtc ttg 164 Leu Val Leu Phe Leu Phe Phe Leu Phe Phe Leu Phe Thr Pro Val Leu 10 15 20 tgc ata cta tgg gat aac cta gat cag cat ttg tgc aga gtt caa ttt 212 Cys Ile Leu Trp Asp Asn Leu Asp Gln His Leu Cys Arg Val Gln Phe 25 30 35 aac ggg atc acg gaa gga aaa ccg ttc cga tat aaa gat cat aaa aat 260 Asn Gly Ile Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Lys Asn 40 45 50 gat gta tat tgt tcc tat ttg gga att cct tat gca gaa ccg cct att 308 Asp Val Tyr Cys Ser Tyr Leu Gly Ile Pro Tyr Ala Glu Pro Pro Ile 55 60 65 70 gga cca ttg cga ttt cag tct cca aaa cca ata tca aat cca aaa aca 356 Gly Pro Leu Arg Phe Gln Ser Pro Lys Pro Ile Ser Asn Pro Lys Thr 75 80 85 gga ttc gtt cag gct cgg tct tta gga gac aaa tgt ttc cag gaa agt 404 Gly Phe Val Gln Ala Arg Ser Leu Gly Asp Lys Cys Phe Gln Glu Ser 90 95 100 cta ata tat tct tat gca gga agc gaa gat tgc tta tat ctg aat ata 452 Leu Ile Tyr Ser Tyr Ala Gly Ser Glu Asp Cys Leu Tyr Leu Asn Ile 105 110 115 ttc acg cca gag act gtt aat tct gcg aac aat aca aaa tat cct gta 500 Phe Thr Pro Glu Thr Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val 120 125 130 atg ttc tgg atc cat gga ggc gca ttc aac caa gga tca gga tct tat 548 Met Phe Trp Ile His Gly Gly Ala Phe Asn Gln Gly Ser Gly Ser Tyr 135 140 145 150 aat ttt ttt gga cct gat tat ttg atc agg gaa gga att att ttg gtc 596 Asn Phe Phe Gly Pro Asp Tyr Leu Ile Arg Glu Gly Ile Ile Leu Val 155 160 165 act atc aac tat aga tta gga gtt ttc ggt ttt cta tca gcg ccg gaa 644 Thr Ile Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu 170 175 180 tgg gat atc cat gga aat atg ggt cta aaa gac cag aga ttg gca cta 692 Trp Asp Ile His Gly Asn Met Gly Leu Lys Asp Gln Arg Leu Ala Leu 185 190 195 aaa tgg gtt tat gac aac atc gaa aaa ttt ggt gga gac aga gat aaa 740 Lys Trp Val Tyr Asp Asn Ile Glu Lys Phe Gly Gly Asp Arg Asp Lys 200 205 210 atc act ata gct gga gaa tct gct gga gca gca agt gtt cat ttt ctg 788 Ile Thr Ile Ala Gly Glu Ser Ala Gly Ala Ala Ser Val His Phe Leu 215 220 225 230 atg atg gac aat tct act aga aaa tac tac caa agg gca att ttg cag 836 Met Met Asp Asn Ser Thr Arg Lys Tyr Tyr Gln Arg Ala Ile Leu Gln 235 240 245 agt ggg aca tta ctc aat ccg act gct aat caa att caa cct ctg cat 884 Ser Gly Thr Leu Leu Asn Pro Thr Ala Asn Gln Ile Gln Pro Leu His 250 255 260 aga ttt gaa aaa cta aaa caa gtg ctg aac atc acg caa aaa caa gaa 932 Arg Phe Glu Lys Leu Lys Gln Val Leu Asn Ile Thr Gln Lys Gln Glu 265 270 275 ctc cta aat ctg gac aaa aat caa att ttg cga gca gcc tta aac aga 980 Leu Leu Asn Leu Asp Lys Asn Gln Ile Leu Arg Ala Ala Leu Asn Arg 280 285 290 gtc cca gat aac aac gac cac gaa agg gac aca gta cca gta ttt aat 1028 Val Pro Asp Asn Asn Asp His Glu Arg Asp Thr Val Pro Val Phe Asn 295 300 305 310 cca gtc cta gaa tca cca gaa tct cca gac cca ata aca ttt cca tct 1076 Pro Val Leu Glu Ser Pro Glu Ser Pro Asp Pro Ile Thr Phe Pro Ser 315 320 325 gct tta gaa aga atg aga aat ggt gaa ttt cct gac gtt gat gtc atc 1124 Ala Leu Glu Arg Met Arg Asn Gly Glu Phe Pro Asp Val Asp Val Ile 330 335 340 att gga ttc aat agt gct gaa ggt tta aga tct atg cca aga gta acc 1172 Ile Gly Phe Asn Ser Ala Glu Gly Leu Arg Ser Met Pro Arg Val Thr 345 350 355 aga gga aac atg gaa gtt tac aag act ttg aca aat ata gag aga gct 1220 Arg Gly Asn Met Glu Val Tyr Lys Thr Leu Thr Asn Ile Glu Arg Ala 360 365 370 ata cct aga gat gct aat att tgg aaa aat cct aat ggc att gag gag 1268 Ile Pro Arg Asp Ala Asn Ile Trp Lys Asn Pro Asn Gly Ile Glu Glu 375 380 385 390 aaa aaa ctt ata aaa atg ctt aca gag ttt tat gac caa gtt aaa gaa 1316 Lys Lys Leu Ile Lys Met Leu Thr Glu Phe Tyr Asp Gln Val Lys Glu 395 400 405 caa aac gat gac atc gaa gcc tat gtc caa cta aaa ggc gat gct ggt 1364 Gln Asn Asp Asp Ile Glu Ala Tyr Val Gln Leu Lys Gly Asp Ala Gly 410 415 420 tat ctc caa gga att tac cgt acc ttg aaa gcc ata ttt ttc aat gaa 1412 Tyr Leu Gln Gly Ile Tyr Arg Thr Leu Lys Ala Ile Phe Phe Asn Glu 425 430 435 atc aaa aga aat tcc aac ttg tat ttg tat agg tta tca gat gat acg 1460 Ile Lys Arg Asn Ser Asn Leu Tyr Leu Tyr Arg Leu Ser Asp Asp Thr 440 445 450 tat agt gta tat aaa agt tat atc ttg ccc tat cga tgg ggt tcc ttg 1508 Tyr Ser Val Tyr Lys Ser Tyr Ile Leu Pro Tyr Arg Trp Gly Ser Leu 455 460 465 470 cca gga gtt agt cat ggt gat gat tta gga tat ctt ttt gca aac tct 1556 Pro Gly Val Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser 475 480 485 ttg gat gtt cct att ttg gga aca acg cac att tct ata ccg caa gat 1604 Leu Asp Val Pro Ile Leu Gly Thr Thr His Ile Ser Ile Pro Gln Asp 490 495 500 gct atg cag act ctg gaa agg atg gtc agg atc tgg acc aat ttt gta 1652 Ala Met Gln Thr Leu Glu Arg Met Val Arg Ile Trp Thr Asn Phe Val 505 510 515 aag aat gga aaa cct aca tca aac act gaa gat gca tca tgt gat aca 1700 Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser Cys Asp Thr 520 525 530 aaa aga cat tta aac gac att ttt tgg gaa cca tac aac gac gaa gaa 1748 Lys Arg His Leu Asn Asp Ile Phe Trp Glu Pro Tyr Asn Asp Glu Glu 535 540 545 550 cca aaa tat ttg gac atg gga aaa gaa cat ttt gaa atg aaa aat att 1796 Pro Lys Tyr Leu Asp Met Gly Lys Glu His Phe Glu Met Lys Asn Ile 555 560 565 ttg gaa cta aaa cgc atg atg ctt tgg gat gaa gtt tat aga aat gcg 1844 Leu Glu Leu Lys Arg Met Met Leu Trp Asp Glu Val Tyr Arg Asn Ala 570 575 580 aat ttg cgg ttt aga gtc tgt aat gaa gaa agt att aga tga 1886 Asn Leu Arg Phe Arg Val Cys Asn Glu Glu Ser Ile Arg 585 590 595 gtttttttaa ttttacatac agccgagagg aaacatgact aaaattggaa agaaaaatca 1946 gaaaaagaaa aatcacatgg accatagtaa ctttattaca tgatttagtt tcaagtgtat 2006 caagaaaact tattgcatca aagaaaatat tattttgcca aaattcttgg aaaaacactt 2066 tttatgactg acatggccca taattgaagc tttttcttct tttaccaaat cgccaaattt 2126 tgtagcgtca gacacattta tttatgacat ggcaattaat gtgttaaaca ttcaactcta 2186 tattaaaaat ggtagtattt tctaataaga aggttatata aaaagacttg aaaataataa 2246 gatttgctcg gctatatata aaaacttanc gtctcgttat gctaaacttt tttgatggta 2306 aaaatatgtt gattttccta ataatctaag atattatatt ttagattaaa ttaaaatatg 2366 atattttcaa ttaattaatt ttagttttaa atgtactata tttaccagta ctatgaaact 2426 attttaaata tattttttat tacaatattt atttctcaaa aatgtttagt gtaacaagac 2486 cattaaatta gagttaatgt tgtaaattaa actatttttt atctatcaca accgcttaat 2546 tggtgcaaag aaaaatttta ctgtgataat atttgacatt tacacaatat tacgaattgt 2606 aaactcacaa ttatgtgaat attgtttttt gttaaaaaaa catacatgac ttttctatat 2666 cattttatat tacggtgata tggattaatg tcaacatgta aaatacaaat gcggttgtta 2726 aaaataatct gtattaaaat tgttatataa aatctgaata aatgtacttt taagtaaaaa 2786 aaaaaaaaaa aaaaa 2801 31 595 PRT Ctenocephalides felis 31 Met Leu Pro His Ser Ala Leu Val Leu Phe Leu Phe Phe Leu Phe Phe 1 5 10 15 Leu Phe Thr Pro Val Leu Cys Ile Leu Trp Asp Asn Leu Asp Gln His 20 25 30 Leu Cys Arg Val Gln Phe Asn Gly Ile Thr Glu Gly Lys Pro Phe Arg 35 40 45 Tyr Lys Asp His Lys Asn Asp Val Tyr Cys Ser Tyr Leu Gly Ile Pro 50 55 60 Tyr Ala Glu Pro Pro Ile Gly Pro Leu Arg Phe Gln Ser Pro Lys Pro 65 70 75 80 Ile Ser Asn Pro Lys Thr Gly Phe Val Gln Ala Arg Ser Leu Gly Asp 85 90 95 Lys Cys Phe Gln Glu Ser Leu Ile Tyr Ser Tyr Ala Gly Ser Glu Asp 100 105 110 Cys Leu Tyr Leu Asn Ile Phe Thr Pro Glu Thr Val Asn Ser Ala Asn 115 120 125 Asn Thr Lys Tyr Pro Val Met Phe Trp Ile His Gly Gly Ala Phe Asn 130 135 140 Gln Gly Ser Gly Ser Tyr Asn Phe Phe Gly Pro Asp Tyr Leu Ile Arg 145 150 155 160 Glu Gly Ile Ile Leu Val Thr Ile Asn Tyr Arg Leu Gly Val Phe Gly 165 170 175 Phe Leu Ser Ala Pro Glu Trp Asp Ile His Gly Asn Met Gly Leu Lys 180 185 190 Asp Gln Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn Ile Glu Lys Phe 195 200 205 Gly Gly Asp Arg Asp Lys Ile Thr Ile Ala Gly Glu Ser Ala Gly Ala 210 215 220 Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg Lys Tyr Tyr 225 230 235 240 Gln Arg Ala Ile Leu Gln Ser Gly Thr Leu Leu Asn Pro Thr Ala Asn 245 250 255 Gln Ile Gln Pro Leu His Arg Phe Glu Lys Leu Lys Gln Val Leu Asn 260 265 270 Ile Thr Gln Lys Gln Glu Leu Leu Asn Leu Asp Lys Asn Gln Ile Leu 275 280 285 Arg Ala Ala Leu Asn Arg Val Pro Asp Asn Asn Asp His Glu Arg Asp 290 295 300 Thr Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro Asp 305 310 315 320 Pro Ile Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu Phe 325 330 335 Pro Asp Val Asp Val Ile Ile Gly Phe Asn Ser Ala Glu Gly Leu Arg 340 345 350 Ser Met Pro Arg Val Thr Arg Gly Asn Met Glu Val Tyr Lys Thr Leu 355 360 365 Thr Asn Ile Glu Arg Ala Ile Pro Arg Asp Ala Asn Ile Trp Lys Asn 370 375 380 Pro Asn Gly Ile Glu Glu Lys Lys Leu Ile Lys Met Leu Thr Glu Phe 385 390 395 400 Tyr Asp Gln Val Lys Glu Gln Asn Asp Asp Ile Glu Ala Tyr Val Gln 405 410 415 Leu Lys Gly Asp Ala Gly Tyr Leu Gln Gly Ile Tyr Arg Thr Leu Lys 420 425 430 Ala Ile Phe Phe Asn Glu Ile Lys Arg Asn Ser Asn Leu Tyr Leu Tyr 435 440 445 Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr Ile Leu Pro 450 455 460 Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His Gly Asp Asp Leu Gly 465 470 475 480 Tyr Leu Phe Ala Asn Ser Leu Asp Val Pro Ile Leu Gly Thr Thr His 485 490 495 Ile Ser Ile Pro Gln Asp Ala Met Gln Thr Leu Glu Arg Met Val Arg 500 505 510 Ile Trp Thr Asn Phe Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu 515 520 525 Asp Ala Ser Cys Asp Thr Lys Arg His Leu Asn Asp Ile Phe Trp Glu 530 535 540 Pro Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu His 545 550 555 560 Phe Glu Met Lys Asn Ile Leu Glu Leu Lys Arg Met Met Leu Trp Asp 565 570 575 Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg Val Cys Asn Glu Glu 580 585 590 Ser Ile Arg 595 32 2801 DNA Ctenocephalides felis misc_feature (527)..(527) n = unknown at position 527 32 tttttttttt tttttttttt acttaaaagt acatttattc agattttata taacaatttt 60 aatacagatt atttttaaca accgcatttg tattttacat gttgacatta atccatatca 120 ccgtaatata aaatgatata gaaaagtcat gtatgttttt ttaacaaaaa acaatattca 180 cataattgtg agtttacaat tcgtaatatt gtgtaaatgt caaatattat cacagtaaaa 240 tttttctttg caccaattaa gcggttgtga tagataaaaa atagtttaat ttacaacatt 300 aactctaatt taatggtctt gttacactaa acatttttga gaaataaata ttgtaataaa 360 aaatatattt aaaatagttt catagtactg gtaaatatag tacatttaaa actaaaatta 420 attaattgaa aatatcatat tttaatttaa tctaaaatat aatatcttag attattagga 480 aaatcaacat atttttacca tcaaaaaagt ttagcataac gagacgntaa gtttttatat 540 atagccgagc aaatcttatt attttcaagt ctttttatat aaccttctta ttagaaaata 600 ctaccatttt taatatagag ttgaatgttt aacacattaa ttgccatgtc ataaataaat 660 gtgtctgacg ctacaaaatt tggcgatttg gtaaaagaag aaaaagcttc aattatgggc 720 catgtcagtc ataaaaagtg tttttccaag aattttggca aaataatatt ttctttgatg 780 caataagttt tcttgataca cttgaaacta aatcatgtaa taaagttact atggtccatg 840 tgatttttct ttttctgatt tttctttcca attttagtca tgtttcctct cggctgtatg 900 taaaattaaa aaaactcatc taatactttc ttcattacag actctaaacc gcaaattcgc 960 atttctataa acttcatccc aaagcatcat gcgttttagt tccaaaatat ttttcatttc 1020 aaaatgttct tttcccatgt ccaaatattt tggttcttcg tcgttgtatg gttcccaaaa 1080 aatgtcgttt aaatgtcttt ttgtatcaca tgatgcatct tcagtgtttg atgtaggttt 1140 tccattcttt acaaaattgg tccagatcct gaccatcctt tccagagtct gcatagcatc 1200 ttgcggtata gaaatgtgcg ttgttcccaa aataggaaca tccaaagagt ttgcaaaaag 1260 atatcctaaa tcatcaccat gactaactcc tggcaaggaa ccccatcgat agggcaagat 1320 ataactttta tatacactat acgtatcatc tgataaccta tacaaataca agttggaatt 1380 tcttttgatt tcattgaaaa atatggcttt caaggtacgg taaattcctt ggagataacc 1440 agcatcgcct tttagttgga cataggcttc gatgtcatcg ttttgttctt taacttggtc 1500 ataaaactct gtaagcattt ttataagttt tttctcctca atgccattag gatttttcca 1560 aatattagca tctctaggta tagctctctc tatatttgtc aaagtcttgt aaacttccat 1620 gtttcctctg gttactcttg gcatagatct taaaccttca gcactattga atccaatgat 1680 gacatcaacg tcaggaaatt caccatttct cattctttct aaagcagatg gaaatgttat 1740 tgggtctgga gattctggtg attctaggac tggattaaat actggtactg tgtccctttc 1800 gtggtcgttg ttatctggga ctctgtttaa ggctgctcgc aaaatttgat ttttgtccag 1860 atttaggagt tcttgttttt gcgtgatgtt cagcacttgt tttagttttt caaatctatg 1920 cagaggttga atttgattag cagtcggatt gagtaatgtc ccactctgca aaattgccct 1980 ttggtagtat tttctagtag aattgtccat catcagaaaa tgaacacttg ctgctccagc 2040 agattctcca gctatagtga ttttatctct gtctccacca aatttttcga tgttgtcata 2100 aacccatttt agtgccaatc tctggtcttt tagacccata tttccatgga tatcccattc 2160 cggcgctgat agaaaaccga aaactcctaa tctatagttg atagtgacca aaataattcc 2220 ttccctgatc aaataatcag gtccaaaaaa attataagat cctgatcctt ggttgaatgc 2280 gcctccatgg atccagaaca ttacaggata ttttgtattg ttcgcagaat taacagtctc 2340 tggcgtgaat atattcagat ataagcaatc ttcgcttcct gcataagaat atattagact 2400 ttcctggaaa catttgtctc ctaaagaccg agcctgaacg aatcctgttt ttggatttga 2460 tattggtttt ggagactgaa atcgcaatgg tccaataggc ggttctgcat aaggaattcc 2520 caaataggaa caatatacat catttttatg atctttatat cggaacggtt ttccttccgt 2580 gatcccgtta aattgaactc tgcacaaatg ctgatctagg ttatcccata gtatgcacaa 2640 gacaggtgta aataagaaaa ataaaaaaaa taaaaataaa actaatgcac tgtgaggtaa 2700 cattttttat gatgtttttt ttaatgcatt ttggatgctt aattgttatt atttatctcg 2760 ttttgtttat gataaaatag acgttttgaa gacgacatgt c 2801 33 1710 DNA Ctenocephalides felis exon (1)..(1710) 33 tgg gat aac cta gat cag cat ttg tgc aga gtt caa ttt aac ggg atc 48 Trp Asp Asn Leu Asp Gln His Leu Cys Arg Val Gln Phe Asn Gly Ile 1 5 10 15 acg gaa gga aaa ccg ttc cga tat aaa gat cat aaa aat gat gta tat 96 Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Lys Asn Asp Val Tyr 20 25 30 tgt tcc tat ttg gga att cct tat gca gaa ccg cct att gga cca ttg 144 Cys Ser Tyr Leu Gly Ile Pro Tyr Ala Glu Pro Pro Ile Gly Pro Leu 35 40 45 cga ttt cag tct cca aaa cca ata tca aat cca aaa aca gga ttc gtt 192 Arg Phe Gln Ser Pro Lys Pro Ile Ser Asn Pro Lys Thr Gly Phe Val 50 55 60 cag gct cgg tct tta gga gac aaa tgt ttc cag gaa agt cta ata tat 240 Gln Ala Arg Ser Leu Gly Asp Lys Cys Phe Gln Glu Ser Leu Ile Tyr 65 70 75 80 tct tat gca gga agc gaa gat tgc tta tat ctg aat ata ttc acg cca 288 Ser Tyr Ala Gly Ser Glu Asp Cys Leu Tyr Leu Asn Ile Phe Thr Pro 85 90 95 gag act gtt aat tct gcg aac aat aca aaa tat cct gta atg ttc tgg 336 Glu Thr Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp 100 105 110 atc cat gga ggc gca ttc aac caa gga tca gga tct tat aat ttt ttt 384 Ile His Gly Gly Ala Phe Asn Gln Gly Ser Gly Ser Tyr Asn Phe Phe 115 120 125 gga cct gat tat ttg atc agg gaa gga att att ttg gtc act atc aac 432 Gly Pro Asp Tyr Leu Ile Arg Glu Gly Ile Ile Leu Val Thr Ile Asn 130 135 140 tat aga tta gga gtt ttc ggt ttt cta tca gcg ccg gaa tgg gat atc 480 Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu Trp Asp Ile 145 150 155 160 cat gga aat atg ggt cta aaa gac cag aga ttg gca cta aaa tgg gtt 528 His Gly Asn Met Gly Leu Lys Asp Gln Arg Leu Ala Leu Lys Trp Val 165 170 175 tat gac aac atc gaa aaa ttt ggt gga gac aga gat aaa atc act ata 576 Tyr Asp Asn Ile Glu Lys Phe Gly Gly Asp Arg Asp Lys Ile Thr Ile 180 185 190 gct gga gaa tct gct gga gca gca agt gtt cat ttt ctg atg atg gac 624 Ala Gly Glu Ser Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp 195 200 205 aat tct act aga aaa tac tac caa agg gca att ttg cag agt ggg aca 672 Asn Ser Thr Arg Lys Tyr Tyr Gln Arg Ala Ile Leu Gln Ser Gly Thr 210 215 220 tta ctc aat ccg act gct aat caa att caa cct ctg cat aga ttt gaa 720 Leu Leu Asn Pro Thr Ala Asn Gln Ile Gln Pro Leu His Arg Phe Glu 225 230 235 240 aaa cta aaa caa gtg ctg aac atc acg caa aaa caa gaa ctc cta aat 768 Lys Leu Lys Gln Val Leu Asn Ile Thr Gln Lys Gln Glu Leu Leu Asn 245 250 255 ctg gac aaa aat caa att ttg cga gca gcc tta aac aga gtc cca gat 816 Leu Asp Lys Asn Gln Ile Leu Arg Ala Ala Leu Asn Arg Val Pro Asp 260 265 270 aac aac gac cac gaa agg gac aca gta cca gta ttt aat cca gtc cta 864 Asn Asn Asp His Glu Arg Asp Thr Val Pro Val Phe Asn Pro Val Leu 275 280 285 gaa tca cca gaa tct cca gac cca ata aca ttt cca tct gct tta gaa 912 Glu Ser Pro Glu Ser Pro Asp Pro Ile Thr Phe Pro Ser Ala Leu Glu 290 295 300 aga atg aga aat ggt gaa ttt cct gac gtt gat gtc atc att gga ttc 960 Arg Met Arg Asn Gly Glu Phe Pro Asp Val Asp Val Ile Ile Gly Phe 305 310 315 320 aat agt gct gaa ggt tta aga tct atg cca aga gta acc aga gga aac 1008 Asn Ser Ala Glu Gly Leu Arg Ser Met Pro Arg Val Thr Arg Gly Asn 325 330 335 atg gaa gtt tac aag act ttg aca aat ata gag aga gct ata cct aga 1056 Met Glu Val Tyr Lys Thr Leu Thr Asn Ile Glu Arg Ala Ile Pro Arg 340 345 350 gat gct aat att tgg aaa aat cct aat ggc att gag gag aaa aaa ctt 1104 Asp Ala Asn Ile Trp Lys Asn Pro Asn Gly Ile Glu Glu Lys Lys Leu 355 360 365 ata aaa atg ctt aca gag ttt tat gac caa gtt aaa gaa caa aac gat 1152 Ile Lys Met Leu Thr Glu Phe Tyr Asp Gln Val Lys Glu Gln Asn Asp 370 375 380 gac atc gaa gcc tat gtc caa cta aaa ggc gat gct ggt tat ctc caa 1200 Asp Ile Glu Ala Tyr Val Gln Leu Lys Gly Asp Ala Gly Tyr Leu Gln 385 390 395 400 gga att tac cgt acc ttg aaa gcc ata ttt ttc aat gaa atc aaa aga 1248 Gly Ile Tyr Arg Thr Leu Lys Ala Ile Phe Phe Asn Glu Ile Lys Arg 405 410 415 aat tcc aac ttg tat ttg tat agg tta tca gat gat acg tat agt gta 1296 Asn Ser Asn Leu Tyr Leu Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val 420 425 430 tat aaa agt tat atc ttg ccc tat cga tgg ggt tcc ttg cca gga gtt 1344 Tyr Lys Ser Tyr Ile Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val 435 440 445 agt cat ggt gat gat tta gga tat ctt ttt gca aac tct ttg gat gtt 1392 Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val 450 455 460 cct att ttg gga aca acg cac att tct ata ccg caa gat gct atg cag 1440 Pro Ile Leu Gly Thr Thr His Ile Ser Ile Pro Gln Asp Ala Met Gln 465 470 475 480 act ctg gaa agg atg gtc agg atc tgg acc aat ttt gta aag aat gga 1488 Thr Leu Glu Arg Met Val Arg Ile Trp Thr Asn Phe Val Lys Asn Gly 485 490 495 aaa cct aca tca aac act gaa gat gca tca tgt gat aca aaa aga cat 1536 Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser Cys Asp Thr Lys Arg His 500 505 510 tta aac gac att ttt tgg gaa cca tac aac gac gaa gaa cca aaa tat 1584 Leu Asn Asp Ile Phe Trp Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr 515 520 525 ttg gac atg gga aaa gaa cat ttt gaa atg aaa aat att ttg gaa cta 1632 Leu Asp Met Gly Lys Glu His Phe Glu Met Lys Asn Ile Leu Glu Leu 530 535 540 aaa cgc atg atg ctt tgg gat gaa gtt tat aga aat gcg aat ttg cgg 1680 Lys Arg Met Met Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg 545 550 555 560 ttt aga gtc tgt aat gaa gaa agt att aga 1710 Phe Arg Val Cys Asn Glu Glu Ser Ile Arg 565 570 34 1785 DNA Ctenocephalides felis exon (1)..(1785) 34 atg tta cct cac agt gca tta gtt tta ttt tta ttt ttt tta ttt ttc 48 Met Leu Pro His Ser Ala Leu Val Leu Phe Leu Phe Phe Leu Phe Phe 1 5 10 15 tta ttt aca cct gtc ttg tgc ata cta tgg gat aac cta gat cag cat 96 Leu Phe Thr Pro Val Leu Cys Ile Leu Trp Asp Asn Leu Asp Gln His 20 25 30 ttg tgc aga gtt caa ttt aac ggg atc acg gaa gga aaa ccg ttc cga 144 Leu Cys Arg Val Gln Phe Asn Gly Ile Thr Glu Gly Lys Pro Phe Arg 35 40 45 tat aaa gat cat aaa aat gat gta tat tgt tcc tat ttg gga att cct 192 Tyr Lys Asp His Lys Asn Asp Val Tyr Cys Ser Tyr Leu Gly Ile Pro 50 55 60 tat gca gaa ccg cct att gga cca ttg cga ttt cag tct cca aaa cca 240 Tyr Ala Glu Pro Pro Ile Gly Pro Leu Arg Phe Gln Ser Pro Lys Pro 65 70 75 80 ata tca aat cca aaa aca gga ttc gtt cag gct cgg tct tta gga gac 288 Ile Ser Asn Pro Lys Thr Gly Phe Val Gln Ala Arg Ser Leu Gly Asp 85 90 95 aaa tgt ttc cag gaa agt cta ata tat tct tat gca gga agc gaa gat 336 Lys Cys Phe Gln Glu Ser Leu Ile Tyr Ser Tyr Ala Gly Ser Glu Asp 100 105 110 tgc tta tat ctg aat ata ttc acg cca gag act gtt aat tct gcg aac 384 Cys Leu Tyr Leu Asn Ile Phe Thr Pro Glu Thr Val Asn Ser Ala Asn 115 120 125 aat aca aaa tat cct gta atg ttc tgg atc cat gga ggc gca ttc aac 432 Asn Thr Lys Tyr Pro Val Met Phe Trp Ile His Gly Gly Ala Phe Asn 130 135 140 caa gga tca gga tct tat aat ttt ttt gga cct gat tat ttg atc agg 480 Gln Gly Ser Gly Ser Tyr Asn Phe Phe Gly Pro Asp Tyr Leu Ile Arg 145 150 155 160 gaa gga att att ttg gtc act atc aac tat aga tta gga gtt ttc ggt 528 Glu Gly Ile Ile Leu Val Thr Ile Asn Tyr Arg Leu Gly Val Phe Gly 165 170 175 ttt cta tca gcg ccg gaa tgg gat atc cat gga aat atg ggt cta aaa 576 Phe Leu Ser Ala Pro Glu Trp Asp Ile His Gly Asn Met Gly Leu Lys 180 185 190 gac cag aga ttg gca cta aaa tgg gtt tat gac aac atc gaa aaa ttt 624 Asp Gln Arg Leu Ala Leu Lys Trp Val Tyr Asp Asn Ile Glu Lys Phe 195 200 205 ggt gga gac aga gat aaa atc act ata gct gga gaa tct gct gga gca 672 Gly Gly Asp Arg Asp Lys Ile Thr Ile Ala Gly Glu Ser Ala Gly Ala 210 215 220 gca agt gtt cat ttt ctg atg atg gac aat tct act aga aaa tac tac 720 Ala Ser Val His Phe Leu Met Met Asp Asn Ser Thr Arg Lys Tyr Tyr 225 230 235 240 caa agg gca att ttg cag agt ggg aca tta ctc aat ccg act gct aat 768 Gln Arg Ala Ile Leu Gln Ser Gly Thr Leu Leu Asn Pro Thr Ala Asn 245 250 255 caa att caa cct ctg cat aga ttt gaa aaa cta aaa caa gtg ctg aac 816 Gln Ile Gln Pro Leu His Arg Phe Glu Lys Leu Lys Gln Val Leu Asn 260 265 270 atc acg caa aaa caa gaa ctc cta aat ctg gac aaa aat caa att ttg 864 Ile Thr Gln Lys Gln Glu Leu Leu Asn Leu Asp Lys Asn Gln Ile Leu 275 280 285 cga gca gcc tta aac aga gtc cca gat aac aac gac cac gaa agg gac 912 Arg Ala Ala Leu Asn Arg Val Pro Asp Asn Asn Asp His Glu Arg Asp 290 295 300 aca gta cca gta ttt aat cca gtc cta gaa tca cca gaa tct cca gac 960 Thr Val Pro Val Phe Asn Pro Val Leu Glu Ser Pro Glu Ser Pro Asp 305 310 315 320 cca ata aca ttt cca tct gct tta gaa aga atg aga aat ggt gaa ttt 1008 Pro Ile Thr Phe Pro Ser Ala Leu Glu Arg Met Arg Asn Gly Glu Phe 325 330 335 cct gac gtt gat gtc atc att gga ttc aat agt gct gaa ggt tta aga 1056 Pro Asp Val Asp Val Ile Ile Gly Phe Asn Ser Ala Glu Gly Leu Arg 340 345 350 tct atg cca aga gta acc aga gga aac atg gaa gtt tac aag act ttg 1104 Ser Met Pro Arg Val Thr Arg Gly Asn Met Glu Val Tyr Lys Thr Leu 355 360 365 aca aat ata gag aga gct ata cct aga gat gct aat att tgg aaa aat 1152 Thr Asn Ile Glu Arg Ala Ile Pro Arg Asp Ala Asn Ile Trp Lys Asn 370 375 380 cct aat ggc att gag gag aaa aaa ctt ata aaa atg ctt aca gag ttt 1200 Pro Asn Gly Ile Glu Glu Lys Lys Leu Ile Lys Met Leu Thr Glu Phe 385 390 395 400 tat gac caa gtt aaa gaa caa aac gat gac atc gaa gcc tat gtc caa 1248 Tyr Asp Gln Val Lys Glu Gln Asn Asp Asp Ile Glu Ala Tyr Val Gln 405 410 415 cta aaa ggc gat gct ggt tat ctc caa gga att tac cgt acc ttg aaa 1296 Leu Lys Gly Asp Ala Gly Tyr Leu Gln Gly Ile Tyr Arg Thr Leu Lys 420 425 430 gcc ata ttt ttc aat gaa atc aaa aga aat tcc aac ttg tat ttg tat 1344 Ala Ile Phe Phe Asn Glu Ile Lys Arg Asn Ser Asn Leu Tyr Leu Tyr 435 440 445 agg tta tca gat gat acg tat agt gta tat aaa agt tat atc ttg ccc 1392 Arg Leu Ser Asp Asp Thr Tyr Ser Val Tyr Lys Ser Tyr Ile Leu Pro 450 455 460 tat cga tgg ggt tcc ttg cca gga gtt agt cat ggt gat gat tta gga 1440 Tyr Arg Trp Gly Ser Leu Pro Gly Val Ser His Gly Asp Asp Leu Gly 465 470 475 480 tat ctt ttt gca aac tct ttg gat gtt cct att ttg gga aca acg cac 1488 Tyr Leu Phe Ala Asn Ser Leu Asp Val Pro Ile Leu Gly Thr Thr His 485 490 495 att tct ata ccg caa gat gct atg cag act ctg gaa agg atg gtc agg 1536 Ile Ser Ile Pro Gln Asp Ala Met Gln Thr Leu Glu Arg Met Val Arg 500 505 510 atc tgg acc aat ttt gta aag aat gga aaa cct aca tca aac act gaa 1584 Ile Trp Thr Asn Phe Val Lys Asn Gly Lys Pro Thr Ser Asn Thr Glu 515 520 525 gat gca tca tgt gat aca aaa aga cat tta aac gac att ttt tgg gaa 1632 Asp Ala Ser Cys Asp Thr Lys Arg His Leu Asn Asp Ile Phe Trp Glu 530 535 540 cca tac aac gac gaa gaa cca aaa tat ttg gac atg gga aaa gaa cat 1680 Pro Tyr Asn Asp Glu Glu Pro Lys Tyr Leu Asp Met Gly Lys Glu His 545 550 555 560 ttt gaa atg aaa aat att ttg gaa cta aaa cgc atg atg ctt tgg gat 1728 Phe Glu Met Lys Asn Ile Leu Glu Leu Lys Arg Met Met Leu Trp Asp 565 570 575 gaa gtt tat aga aat gcg aat ttg cgg ttt aga gtc tgt aat gaa gaa 1776 Glu Val Tyr Arg Asn Ala Asn Leu Arg Phe Arg Val Cys Asn Glu Glu 580 585 590 agt att aga 1785 Ser Ile Arg 595 35 1785 DNA Ctenocephalides felis 35 tctaatactt tcttcattac agactctaaa ccgcaaattc gcatttctat aaacttcatc 60 ccaaagcatc atgcgtttta gttccaaaat atttttcatt tcaaaatgtt cttttcccat 120 gtccaaatat tttggttctt cgtcgttgta tggttcccaa aaaatgtcgt ttaaatgtct 180 ttttgtatca catgatgcat cttcagtgtt tgatgtaggt tttccattct ttacaaaatt 240 ggtccagatc ctgaccatcc tttccagagt ctgcatagca tcttgcggta tagaaatgtg 300 cgttgttccc aaaataggaa catccaaaga gtttgcaaaa agatatccta aatcatcacc 360 atgactaact cctggcaagg aaccccatcg atagggcaag atataacttt tatatacact 420 atacgtatca tctgataacc tatacaaata caagttggaa tttcttttga tttcattgaa 480 aaatatggct ttcaaggtac ggtaaattcc ttggagataa ccagcatcgc cttttagttg 540 gacataggct tcgatgtcat cgttttgttc tttaacttgg tcataaaact ctgtaagcat 600 ttttataagt tttttctcct caatgccatt aggatttttc caaatattag catctctagg 660 tatagctctc tctatatttg tcaaagtctt gtaaacttcc atgtttcctc tggttactct 720 tggcatagat cttaaacctt cagcactatt gaatccaatg atgacatcaa cgtcaggaaa 780 ttcaccattt ctcattcttt ctaaagcaga tggaaatgtt attgggtctg gagattctgg 840 tgattctagg actggattaa atactggtac tgtgtccctt tcgtggtcgt tgttatctgg 900 gactctgttt aaggctgctc gcaaaatttg atttttgtcc agatttagga gttcttgttt 960 ttgcgtgatg ttcagcactt gttttagttt ttcaaatcta tgcagaggtt gaatttgatt 1020 agcagtcgga ttgagtaatg tcccactctg caaaattgcc ctttggtagt attttctagt 1080 agaattgtcc atcatcagaa aatgaacact tgctgctcca gcagattctc cagctatagt 1140 gattttatct ctgtctccac caaatttttc gatgttgtca taaacccatt ttagtgccaa 1200 tctctggtct tttagaccca tatttccatg gatatcccat tccggcgctg atagaaaacc 1260 gaaaactcct aatctatagt tgatagtgac caaaataatt ccttccctga tcaaataatc 1320 aggtccaaaa aaattataag atcctgatcc ttggttgaat gcgcctccat ggatccagaa 1380 cattacagga tattttgtat tgttcgcaga attaacagtc tctggcgtga atatattcag 1440 atataagcaa tcttcgcttc ctgcataaga atatattaga ctttcctgga aacatttgtc 1500 tcctaaagac cgagcctgaa cgaatcctgt ttttggattt gatattggtt ttggagactg 1560 aaatcgcaat ggtccaatag gcggttctgc ataaggaatt cccaaatagg aacaatatac 1620 atcattttta tgatctttat atcggaacgg ttttccttcc gtgatcccgt taaattgaac 1680 tctgcacaaa tgctgatcta ggttatccca tagtatgcac aagacaggtg taaataagaa 1740 aaataaaaaa aataaaaata aaactaatgc actgtgaggt aacat 1785 36 2007 DNA Ctenocephalides felis CDS (11)..(1594) 36 agttccaacg atg gct gat cta caa gtg act ttg ctt caa ggt act tta 49 Met Ala Asp Leu Gln Val Thr Leu Leu Gln Gly Thr Leu 1 5 10 aaa gga aaa gag caa att agt gaa aaa gga aat gtg ttc cat agt tat 97 Lys Gly Lys Glu Gln Ile Ser Glu Lys Gly Asn Val Phe His Ser Tyr 15 20 25 tct gga att cca tat gcc aaa cct cct gta ggt gat cta aga ttt aag 145 Ser Gly Ile Pro Tyr Ala Lys Pro Pro Val Gly Asp Leu Arg Phe Lys 30 35 40 45 cca cct caa cct gca gaa cct tgg tca ggt gtt ctt gat gct agt aaa 193 Pro Pro Gln Pro Ala Glu Pro Trp Ser Gly Val Leu Asp Ala Ser Lys 50 55 60 gaa ggg aat agt tgt aga tca gta cat ttt att aaa aaa att aaa gta 241 Glu Gly Asn Ser Cys Arg Ser Val His Phe Ile Lys Lys Ile Lys Val 65 70 75 ggg gct gaa gat tgt tta tac ctc aat gtc tat gta cca aaa aca tca 289 Gly Ala Glu Asp Cys Leu Tyr Leu Asn Val Tyr Val Pro Lys Thr Ser 80 85 90 gag aaa tca ctt ctt cca gta atg gta tgg ata cat gga gga ggc ttc 337 Glu Lys Ser Leu Leu Pro Val Met Val Trp Ile His Gly Gly Gly Phe 95 100 105 ttc atg gga tct gga aat agt gat atg tat ggt cct gaa tat ttg atg 385 Phe Met Gly Ser Gly Asn Ser Asp Met Tyr Gly Pro Glu Tyr Leu Met 110 115 120 125 gat tat gga att gtt ctg gtt act ttc aat tat cga tta ggt gtt ttg 433 Asp Tyr Gly Ile Val Leu Val Thr Phe Asn Tyr Arg Leu Gly Val Leu 130 135 140 gga ttt ttg aac ctg gga ata gaa gaa gcg cct ggc aat gtt ggt ttg 481 Gly Phe Leu Asn Leu Gly Ile Glu Glu Ala Pro Gly Asn Val Gly Leu 145 150 155 atg gac cag gtt gaa gct cta aaa tgg gta aaa aac aat att gca tcc 529 Met Asp Gln Val Glu Ala Leu Lys Trp Val Lys Asn Asn Ile Ala Ser 160 165 170 ttt ggt ggt gac ccc aac aat gtg act att ttt gga gaa tca gca ggt 577 Phe Gly Gly Asp Pro Asn Asn Val Thr Ile Phe Gly Glu Ser Ala Gly 175 180 185 ggt gca agt gtt cat tat ttg atg tta tca gat ctt tcc aaa gga ctt 625 Gly Ala Ser Val His Tyr Leu Met Leu Ser Asp Leu Ser Lys Gly Leu 190 195 200 205 ttt cat aaa gcg atc tca caa agt gga agt gct ttt aat cct tgg gca 673 Phe His Lys Ala Ile Ser Gln Ser Gly Ser Ala Phe Asn Pro Trp Ala 210 215 220 ctt caa cat gat aat aat aaa gaa aat gca ttc cgc ctc tgc aaa ctt 721 Leu Gln His Asp Asn Asn Lys Glu Asn Ala Phe Arg Leu Cys Lys Leu 225 230 235 ctg ggt cat cct gtc gat aac gag aca gaa gct cta aaa atc ctt cgt 769 Leu Gly His Pro Val Asp Asn Glu Thr Glu Ala Leu Lys Ile Leu Arg 240 245 250 caa gcc ccc ata gat gat ctt ata gac aac aga ata aaa cca aaa gac 817 Gln Ala Pro Ile Asp Asp Leu Ile Asp Asn Arg Ile Lys Pro Lys Asp 255 260 265 aaa ggc caa ctt att ata gac tat cct ttt cta cca aca ata gaa aaa 865 Lys Gly Gln Leu Ile Ile Asp Tyr Pro Phe Leu Pro Thr Ile Glu Lys 270 275 280 285 cgt tat caa aat ttt gaa cca ttc ttg gac cag tct cca tta tca aaa 913 Arg Tyr Gln Asn Phe Glu Pro Phe Leu Asp Gln Ser Pro Leu Ser Lys 290 295 300 atg caa tca ggc aat ttc aca aaa gtc cca ttt ata tgt gga tac aac 961 Met Gln Ser Gly Asn Phe Thr Lys Val Pro Phe Ile Cys Gly Tyr Asn 305 310 315 agt gct gaa gga att tta ggt tta atg gac ttc aag gat gac cca aat 1009 Ser Ala Glu Gly Ile Leu Gly Leu Met Asp Phe Lys Asp Asp Pro Asn 320 325 330 ata ttt gag aag ttt gaa gct gat ttt gaa aga ttt gta cca gta gat 1057 Ile Phe Glu Lys Phe Glu Ala Asp Phe Glu Arg Phe Val Pro Val Asp 335 340 345 ttg aat cta act tta agg tct aag gaa tct aaa aaa ttg gct gaa gaa 1105 Leu Asn Leu Thr Leu Arg Ser Lys Glu Ser Lys Lys Leu Ala Glu Glu 350 355 360 365 atg aga aag ttt tat tac caa gac gaa cct gtt tct tca gac aac aaa 1153 Met Arg Lys Phe Tyr Tyr Gln Asp Glu Pro Val Ser Ser Asp Asn Lys 370 375 380 gaa aaa ttt gtc agt gtt att agt gat act tgg ttt ttg aga ggg att 1201 Glu Lys Phe Val Ser Val Ile Ser Asp Thr Trp Phe Leu Arg Gly Ile 385 390 395 aaa aat act gca aga tat ata att gaa cat tcc tca gaa ccg tta tat 1249 Lys Asn Thr Ala Arg Tyr Ile Ile Glu His Ser Ser Glu Pro Leu Tyr 400 405 410 tta tat gtt tat agt ttt gat gat ttt ggt ttt ttg aag aaa ctt gta 1297 Leu Tyr Val Tyr Ser Phe Asp Asp Phe Gly Phe Leu Lys Lys Leu Val 415 420 425 tta gat cct aat att gaa gga gca gct cat gga gat gag ctg gga tat 1345 Leu Asp Pro Asn Ile Glu Gly Ala Ala His Gly Asp Glu Leu Gly Tyr 430 435 440 445 ctt ttc aag atg agt ttt aca gaa ttt cca aaa gat tta cca agt gca 1393 Leu Phe Lys Met Ser Phe Thr Glu Phe Pro Lys Asp Leu Pro Ser Ala 450 455 460 gtg gtg aat agg gaa cga ttg ttg caa ctt tgg aca aat ttt gca aaa 1441 Val Val Asn Arg Glu Arg Leu Leu Gln Leu Trp Thr Asn Phe Ala Lys 465 470 475 aca gga aat ccc act cct gaa atc aat gat gtt ata aca aca aaa tgg 1489 Thr Gly Asn Pro Thr Pro Glu Ile Asn Asp Val Ile Thr Thr Lys Trp 480 485 490 gat aaa gct act gag gaa aaa tca gat cat atg gat atc gat aat act 1537 Asp Lys Ala Thr Glu Glu Lys Ser Asp His Met Asp Ile Asp Asn Thr 495 500 505 ttg aga atg att cca gat cct gat gca aaa cga ctt aga ttt tgg aat 1585 Leu Arg Met Ile Pro Asp Pro Asp Ala Lys Arg Leu Arg Phe Trp Asn 510 515 520 525 aaa ttt tta tgataaatat accaattatc gattttatta tagagtttct 1634 Lys Phe Leu gtattagtat aattatcacg tttagatgta cgagattcaa ttggctctaa ttgaagtata 1694 tttcgatttc aaatttactc tgattattgg aaaaaaagct tttacagttg taataatcaa 1754 gaagtaggtg gtaaatttag aacaaattct gttttagtga tttgcgcatt caacagatgg 1814 tgtactgtgc ctaaatttgt cgctcttctt gaagaactga actaaaaatg tgattaatgg 1874 acgccacatt atttatattt gatattatta ccatctttgt atcatatttg cttttatttt 1934 ttcatttttt ttttatttca aatatattgt ttttttataa aaaaaaaaaa aaaaaaaaaa 1994 aaaaaaaaaa aaa 2007 37 528 PRT Ctenocephalides felis 37 Met Ala Asp Leu Gln Val Thr Leu Leu Gln Gly Thr Leu Lys Gly Lys 1 5 10 15 Glu Gln Ile Ser Glu Lys Gly Asn Val Phe His Ser Tyr Ser Gly Ile 20 25 30 Pro Tyr Ala Lys Pro Pro Val Gly Asp Leu Arg Phe Lys Pro Pro Gln 35 40 45 Pro Ala Glu Pro Trp Ser Gly Val Leu Asp Ala Ser Lys Glu Gly Asn 50 55 60 Ser Cys Arg Ser Val His Phe Ile Lys Lys Ile Lys Val Gly Ala Glu 65 70 75 80 Asp Cys Leu Tyr Leu Asn Val Tyr Val Pro Lys Thr Ser Glu Lys Ser 85 90 95 Leu Leu Pro Val Met Val Trp Ile His Gly Gly Gly Phe Phe Met Gly 100 105 110 Ser Gly Asn Ser Asp Met Tyr Gly Pro Glu Tyr Leu Met Asp Tyr Gly 115 120 125 Ile Val Leu Val Thr Phe Asn Tyr Arg Leu Gly Val Leu Gly Phe Leu 130 135 140 Asn Leu Gly Ile Glu Glu Ala Pro Gly Asn Val Gly Leu Met Asp Gln 145 150 155 160 Val Glu Ala Leu Lys Trp Val Lys Asn Asn Ile Ala Ser Phe Gly Gly 165 170 175 Asp Pro Asn Asn Val Thr Ile Phe Gly Glu Ser Ala Gly Gly Ala Ser 180 185 190 Val His Tyr Leu Met Leu Ser Asp Leu Ser Lys Gly Leu Phe His Lys 195 200 205 Ala Ile Ser Gln Ser Gly Ser Ala Phe Asn Pro Trp Ala Leu Gln His 210 215 220 Asp Asn Asn Lys Glu Asn Ala Phe Arg Leu Cys Lys Leu Leu Gly His 225 230 235 240 Pro Val Asp Asn Glu Thr Glu Ala Leu Lys Ile Leu Arg Gln Ala Pro 245 250 255 Ile Asp Asp Leu Ile Asp Asn Arg Ile Lys Pro Lys Asp Lys Gly Gln 260 265 270 Leu Ile Ile Asp Tyr Pro Phe Leu Pro Thr Ile Glu Lys Arg Tyr Gln 275 280 285 Asn Phe Glu Pro Phe Leu Asp Gln Ser Pro Leu Ser Lys Met Gln Ser 290 295 300 Gly Asn Phe Thr Lys Val Pro Phe Ile Cys Gly Tyr Asn Ser Ala Glu 305 310 315 320 Gly Ile Leu Gly Leu Met Asp Phe Lys Asp Asp Pro Asn Ile Phe Glu 325 330 335 Lys Phe Glu Ala Asp Phe Glu Arg Phe Val Pro Val Asp Leu Asn Leu 340 345 350 Thr Leu Arg Ser Lys Glu Ser Lys Lys Leu Ala Glu Glu Met Arg Lys 355 360 365 Phe Tyr Tyr Gln Asp Glu Pro Val Ser Ser Asp Asn Lys Glu Lys Phe 370 375 380 Val Ser Val Ile Ser Asp Thr Trp Phe Leu Arg Gly Ile Lys Asn Thr 385 390 395 400 Ala Arg Tyr Ile Ile Glu His Ser Ser Glu Pro Leu Tyr Leu Tyr Val 405 410 415 Tyr Ser Phe Asp Asp Phe Gly Phe Leu Lys Lys Leu Val Leu Asp Pro 420 425 430 Asn Ile Glu Gly Ala Ala His Gly Asp Glu Leu Gly Tyr Leu Phe Lys 435 440 445 Met Ser Phe Thr Glu Phe Pro Lys Asp Leu Pro Ser Ala Val Val Asn 450 455 460 Arg Glu Arg Leu Leu Gln Leu Trp Thr Asn Phe Ala Lys Thr Gly Asn 465 470 475 480 Pro Thr Pro Glu Ile Asn Asp Val Ile Thr Thr Lys Trp Asp Lys Ala 485 490 495 Thr Glu Glu Lys Ser Asp His Met Asp Ile Asp Asn Thr Leu Arg Met 500 505 510 Ile Pro Asp Pro Asp Ala Lys Arg Leu Arg Phe Trp Asn Lys Phe Leu 515 520 525 38 2007 DNA Ctenocephalides felis 38 tttttttttt tttttttttt tttttttttt tttttataaa aaaacaatat atttgaaata 60 aaaaaaaaat gaaaaaataa aagcaaatat gatacaaaga tggtaataat atcaaatata 120 aataatgtgg cgtccattaa tcacattttt agttcagttc ttcaagaaga gcgacaaatt 180 taggcacagt acaccatctg ttgaatgcgc aaatcactaa aacagaattt gttctaaatt 240 taccacctac ttcttgatta ttacaactgt aaaagctttt tttccaataa tcagagtaaa 300 tttgaaatcg aaatatactt caattagagc caattgaatc tcgtacatct aaacgtgata 360 attatactaa tacagaaact ctataataaa atcgataatt ggtatattta tcataaaaat 420 ttattccaaa atctaagtcg ttttgcatca ggatctggaa tcattctcaa agtattatcg 480 atatccatat gatctgattt ttcctcagta gctttatccc attttgttgt tataacatca 540 ttgatttcag gagtgggatt tcctgttttt gcaaaatttg tccaaagttg caacaatcgt 600 tccctattca ccactgcact tggtaaatct tttggaaatt ctgtaaaact catcttgaaa 660 agatatccca gctcatctcc atgagctgct ccttcaatat taggatctaa tacaagtttc 720 ttcaaaaaac caaaatcatc aaaactataa acatataaat ataacggttc tgaggaatgt 780 tcaattatat atcttgcagt atttttaatc cctctcaaaa accaagtatc actaataaca 840 ctgacaaatt tttctttgtt gtctgaagaa acaggttcgt cttggtaata aaactttctc 900 atttcttcag ccaatttttt agattcctta gaccttaaag ttagattcaa atctactggt 960 acaaatcttt caaaatcagc ttcaaacttc tcaaatatat ttgggtcatc cttgaagtcc 1020 attaaaccta aaattccttc agcactgttg tatccacata taaatgggac ttttgtgaaa 1080 ttgcctgatt gcatttttga taatggagac tggtccaaga atggttcaaa attttgataa 1140 cgtttttcta ttgttggtag aaaaggatag tctataataa gttggccttt gtcttttggt 1200 tttattctgt tgtctataag atcatctatg ggggcttgac gaaggatttt tagagcttct 1260 gtctcgttat cgacaggatg acccagaagt ttgcagaggc ggaatgcatt ttctttatta 1320 ttatcatgtt gaagtgccca aggattaaaa gcacttccac tttgtgagat cgctttatga 1380 aaaagtcctt tggaaagatc tgataacatc aaataatgaa cacttgcacc acctgctgat 1440 tctccaaaaa tagtcacatt gttggggtca ccaccaaagg atgcaatatt gttttttacc 1500 cattttagag cttcaacctg gtccatcaaa ccaacattgc caggcgcttc ttctattccc 1560 aggttcaaaa atcccaaaac acctaatcga taattgaaag taaccagaac aattccataa 1620 tccatcaaat attcaggacc atacatatca ctatttccag atcccatgaa gaagcctcct 1680 ccatgtatcc ataccattac tggaagaagt gatttctctg atgtttttgg tacatagaca 1740 ttgaggtata aacaatcttc agcccctact ttaatttttt taataaaatg tactgatcta 1800 caactattcc cttctttact agcatcaaga acacctgacc aaggttctgc aggttgaggt 1860 ggcttaaatc ttagatcacc tacaggaggt ttggcatatg gaattccaga ataactatgg 1920 aacacatttc ctttttcact aatttgctct tttcctttta aagtaccttg aagcaaagtc 1980 acttgtagat cagccatcgt tggaact 2007 39 12 PRT Peptide 39 Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu 1 5 10 40 22 PRT Peptide MISC_FEATURE (21)..(21) Xaa = unknown 40 Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu Val Gly Lys Ala 1 5 10 15 Thr Asn Glu Asn Xaa Lys 20 41 12 PRT Peptide 41 Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu 1 5 10 42 21 PRT Peptide 42 Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu Val Gly Lys Ala 1 5 10 15 Leu Ser Asn Glu Asn 20 43 8 PRT Peptide 43 Asp Pro Pro Thr Val Thr Leu Pro 1 5 44 23 PRT Peptide 44 Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu Val Gly Lys Ala 1 5 10 15 Leu Thr Asn Glu Asn Gly Lys 20 45 20 DNA Artificial sequence Synthetic Primer 45 aattaaccct cactaaaggg 20 46 17 DNA Artificial sequence Synthetic Primer 46 ardccdccdc crtrdat 17 47 38 DNA Artificial sequence Synthetic Primer 47 tgtgctcgag atgggataac ctagatcagc atttgtgc 38 48 35 DNA Artificial sequence Synthetic Primer 48 ttaaggtacc tcatctaata cttccttcat tacag 35 49 36 DNA Artificial sequence Synthetic Primer 49 aaaactgcag tataaatatg ttacctcaca gtagtg 36 50 34 DNA Artificial sequence Synthetic Primer 50 tgctctagat tatctaatac ttccttcatt acag 34 51 1584 DNA Ctenocephalides felis exon (1)..(1584) 51 atg gct gat cta caa gtg act ttg ctt caa ggt act tta aaa gga aaa 48 Met Ala Asp Leu Gln Val Thr Leu Leu Gln Gly Thr Leu Lys Gly Lys 1 5 10 15 gag caa att agt gaa aaa gga aat gtg ttc cat agt tat tct gga att 96 Glu Gln Ile Ser Glu Lys Gly Asn Val Phe His Ser Tyr Ser Gly Ile 20 25 30 cca tat gcc aaa cct cct gta ggt gat cta aga ttt aag cca cct caa 144 Pro Tyr Ala Lys Pro Pro Val Gly Asp Leu Arg Phe Lys Pro Pro Gln 35 40 45 cct gca gaa cct tgg tca ggt gtt ctt gat gct agt aaa gaa ggg aat 192 Pro Ala Glu Pro Trp Ser Gly Val Leu Asp Ala Ser Lys Glu Gly Asn 50 55 60 agt tgt aga tca gta cat ttt att aaa aaa att aaa gta ggg gct gaa 240 Ser Cys Arg Ser Val His Phe Ile Lys Lys Ile Lys Val Gly Ala Glu 65 70 75 80 gat tgt tta tac ctc aat gtc tat gta cca aaa aca tca gag aaa tca 288 Asp Cys Leu Tyr Leu Asn Val Tyr Val Pro Lys Thr Ser Glu Lys Ser 85 90 95 ctt ctt cca gta atg gta tgg ata cat gga gga ggc ttc ttc atg gga 336 Leu Leu Pro Val Met Val Trp Ile His Gly Gly Gly Phe Phe Met Gly 100 105 110 tct gga aat agt gat atg tat ggt cct gaa tat ttg atg gat tat gga 384 Ser Gly Asn Ser Asp Met Tyr Gly Pro Glu Tyr Leu Met Asp Tyr Gly 115 120 125 att gtt ctg gtt act ttc aat tat cga tta ggt gtt ttg gga ttt ttg 432 Ile Val Leu Val Thr Phe Asn Tyr Arg Leu Gly Val Leu Gly Phe Leu 130 135 140 aac ctg gga ata gaa gaa gcg cct ggc aat gtt ggt ttg atg gac cag 480 Asn Leu Gly Ile Glu Glu Ala Pro Gly Asn Val Gly Leu Met Asp Gln 145 150 155 160 gtt gaa gct cta aaa tgg gta aaa aac aat att gca tcc ttt ggt ggt 528 Val Glu Ala Leu Lys Trp Val Lys Asn Asn Ile Ala Ser Phe Gly Gly 165 170 175 gac ccc aac aat gtg act att ttt gga gaa tca gca ggt ggt gca agt 576 Asp Pro Asn Asn Val Thr Ile Phe Gly Glu Ser Ala Gly Gly Ala Ser 180 185 190 gtt cat tat ttg atg tta tca gat ctt tcc aaa gga ctt ttt cat aaa 624 Val His Tyr Leu Met Leu Ser Asp Leu Ser Lys Gly Leu Phe His Lys 195 200 205 gcg atc tca caa agt gga agt gct ttt aat cct tgg gca ctt caa cat 672 Ala Ile Ser Gln Ser Gly Ser Ala Phe Asn Pro Trp Ala Leu Gln His 210 215 220 gat aat aat aaa gaa aat gca ttc cgc ctc tgc aaa ctt ctg ggt cat 720 Asp Asn Asn Lys Glu Asn Ala Phe Arg Leu Cys Lys Leu Leu Gly His 225 230 235 240 cct gtc gat aac gag aca gaa gct cta aaa atc ctt cgt caa gcc ccc 768 Pro Val Asp Asn Glu Thr Glu Ala Leu Lys Ile Leu Arg Gln Ala Pro 245 250 255 ata gat gat ctt ata gac aac aga ata aaa cca aaa gac aaa ggc caa 816 Ile Asp Asp Leu Ile Asp Asn Arg Ile Lys Pro Lys Asp Lys Gly Gln 260 265 270 ctt att ata gac tat cct ttt cta cca aca ata gaa aaa cgt tat caa 864 Leu Ile Ile Asp Tyr Pro Phe Leu Pro Thr Ile Glu Lys Arg Tyr Gln 275 280 285 aat ttt gaa cca ttc ttg gac cag tct cca tta tca aaa atg caa tca 912 Asn Phe Glu Pro Phe Leu Asp Gln Ser Pro Leu Ser Lys Met Gln Ser 290 295 300 ggc aat ttc aca aaa gtc cca ttt ata tgt gga tac aac agt gct gaa 960 Gly Asn Phe Thr Lys Val Pro Phe Ile Cys Gly Tyr Asn Ser Ala Glu 305 310 315 320 gga att tta ggt tta atg gac ttc aag gat gac cca aat ata ttt gag 1008 Gly Ile Leu Gly Leu Met Asp Phe Lys Asp Asp Pro Asn Ile Phe Glu 325 330 335 aag ttt gaa gct gat ttt gaa aga ttt gta cca gta gat ttg aat cta 1056 Lys Phe Glu Ala Asp Phe Glu Arg Phe Val Pro Val Asp Leu Asn Leu 340 345 350 act tta agg tct aag gaa tct aaa aaa ttg gct gaa gaa atg aga aag 1104 Thr Leu Arg Ser Lys Glu Ser Lys Lys Leu Ala Glu Glu Met Arg Lys 355 360 365 ttt tat tac caa gac gaa cct gtt tct tca gac aac aaa gaa aaa ttt 1152 Phe Tyr Tyr Gln Asp Glu Pro Val Ser Ser Asp Asn Lys Glu Lys Phe 370 375 380 gtc agt gtt att agt gat act tgg ttt ttg aga ggg att aaa aat act 1200 Val Ser Val Ile Ser Asp Thr Trp Phe Leu Arg Gly Ile Lys Asn Thr 385 390 395 400 gca aga tat ata att gaa cat tcc tca gaa ccg tta tat tta tat gtt 1248 Ala Arg Tyr Ile Ile Glu His Ser Ser Glu Pro Leu Tyr Leu Tyr Val 405 410 415 tat agt ttt gat gat ttt ggt ttt ttg aag aaa ctt gta tta gat cct 1296 Tyr Ser Phe Asp Asp Phe Gly Phe Leu Lys Lys Leu Val Leu Asp Pro 420 425 430 aat att gaa gga gca gct cat gga gat gag ctg gga tat ctt ttc aag 1344 Asn Ile Glu Gly Ala Ala His Gly Asp Glu Leu Gly Tyr Leu Phe Lys 435 440 445 atg agt ttt aca gaa ttt cca aaa gat tta cca agt gca gtg gtg aat 1392 Met Ser Phe Thr Glu Phe Pro Lys Asp Leu Pro Ser Ala Val Val Asn 450 455 460 agg gaa cga ttg ttg caa ctt tgg aca aat ttt gca aaa aca gga aat 1440 Arg Glu Arg Leu Leu Gln Leu Trp Thr Asn Phe Ala Lys Thr Gly Asn 465 470 475 480 ccc act cct gaa atc aat gat gtt ata aca aca aaa tgg gat aaa gct 1488 Pro Thr Pro Glu Ile Asn Asp Val Ile Thr Thr Lys Trp Asp Lys Ala 485 490 495 act gag gaa aaa tca gat cat atg gat atc gat aat act ttg aga atg 1536 Thr Glu Glu Lys Ser Asp His Met Asp Ile Asp Asn Thr Leu Arg Met 500 505 510 att cca gat cct gat gca aaa cga ctt aga ttt tgg aat aaa ttt tta 1584 Ile Pro Asp Pro Asp Ala Lys Arg Leu Arg Phe Trp Asn Lys Phe Leu 515 520 525 52 1584 DNA Ctenocephalides felis 52 taaaaattta ttccaaaatc taagtcgttt tgcatcagga tctggaatca ttctcaaagt 60 attatcgata tccatatgat ctgatttttc ctcagtagct ttatcccatt ttgttgttat 120 aacatcattg atttcaggag tgggatttcc tgtttttgca aaatttgtcc aaagttgcaa 180 caatcgttcc ctattcacca ctgcacttgg taaatctttt ggaaattctg taaaactcat 240 cttgaaaaga tatcccagct catctccatg agctgctcct tcaatattag gatctaatac 300 aagtttcttc aaaaaaccaa aatcatcaaa actataaaca tataaatata acggttctga 360 ggaatgttca attatatatc ttgcagtatt tttaatccct ctcaaaaacc aagtatcact 420 aataacactg acaaattttt ctttgttgtc tgaagaaaca ggttcgtctt ggtaataaaa 480 ctttctcatt tcttcagcca attttttaga ttccttagac cttaaagtta gattcaaatc 540 tactggtaca aatctttcaa aatcagcttc aaacttctca aatatatttg ggtcatcctt 600 gaagtccatt aaacctaaaa ttccttcagc actgttgtat ccacatataa atgggacttt 660 tgtgaaattg cctgattgca tttttgataa tggagactgg tccaagaatg gttcaaaatt 720 ttgataacgt ttttctattg ttggtagaaa aggatagtct ataataagtt ggcctttgtc 780 ttttggtttt attctgttgt ctataagatc atctatgggg gcttgacgaa ggatttttag 840 agcttctgtc tcgttatcga caggatgacc cagaagtttg cagaggcgga atgcattttc 900 tttattatta tcatgttgaa gtgcccaagg attaaaagca cttccacttt gtgagatcgc 960 tttatgaaaa agtcctttgg aaagatctga taacatcaaa taatgaacac ttgcaccacc 1020 tgctgattct ccaaaaatag tcacattgtt ggggtcacca ccaaaggatg caatattgtt 1080 ttttacccat tttagagctt caacctggtc catcaaacca acattgccag gcgcttcttc 1140 tattcccagg ttcaaaaatc ccaaaacacc taatcgataa ttgaaagtaa ccagaacaat 1200 tccataatcc atcaaatatt caggaccata catatcacta tttccagatc ccatgaagaa 1260 gcctcctcca tgtatccata ccattactgg aagaagtgat ttctctgatg tttttggtac 1320 atagacattg aggtataaac aatcttcagc ccctacttta atttttttaa taaaatgtac 1380 tgatctacaa ctattccctt ctttactagc atcaagaaca cctgaccaag gttctgcagg 1440 ttgaggtggc ttaaatctta gatcacctac aggaggtttg gcatatggaa ttccagaata 1500 actatggaac acatttcctt tttcactaat ttgctctttt ccttttaaag taccttgaag 1560 caaagtcact tgtagatcag ccat 1584 53 530 PRT Ctenocephalides felis 53 Asp Pro Pro Thr Val Thr Leu Pro Gln Gly Glu Leu Val Gly Lys Ala 1 5 10 15 Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro 20 25 30 Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gln Lys 35 40 45 Ala Glu Pro Trp Asn Gly Val Phe Asn Ala Thr Ser His Gly Asn Val 50 55 60 Cys Lys Ala Leu Asn Phe Phe Leu Lys Lys Ile Glu Gly Asp Glu Asp 65 70 75 80 Cys Leu Leu Val Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp Lys Lys 85 90 95 Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe Val Thr Gly Ser 100 105 110 Gly Asn Leu Glu Phe Gln Ser Pro Asp Tyr Leu Val Asn Tyr Asp Val 115 120 125 Ile Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn 130 135 140 Leu Glu Leu Glu Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gln Val 145 150 155 160 Ala Ala Leu Lys Trp Thr Lys Glu Asn Ile Glu Lys Phe Gly Gly Asp 165 170 175 Pro Glu Asn Ile Thr Ile Gly Gly Val Ser Ala Gly Gly Ala Ser Val 180 185 190 His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu Tyr Lys Arg Ala 195 200 205 Ile Ala Gln Ser Gly Ser Ala Leu Asn Pro Trp Ala Phe Gln Arg His 210 215 220 Pro Val Lys Arg Ser Leu Gln Leu Ala Glu Ile Leu Gly His Pro Thr 225 230 235 240 Asn Asn Thr Gln Asp Ala Leu Glu Phe Leu Gln Lys Ala Pro Val Asp 245 250 255 Ser Leu Leu Lys Lys Met Pro Ala Glu Thr Glu Gly Glu Ile Ile Glu 260 265 270 Glu Phe Val Phe Val Pro Ser Ile Glu Lys Val Phe Pro Ser His Gln 275 280 285 Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys Ser Gly Ser Phe 290 295 300 Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala Glu Gly Leu Leu 305 310 315 320 Tyr Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu Asn Gln Ala Glu 325 330 335 Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu Leu Ala His Gly 340 345 350 Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys Ile Arg Lys Phe Tyr Phe 355 360 365 Asp Asp Lys Pro Val Pro Glu Asn Glu Gln Lys Phe Ile Asp Leu Ile 370 375 380 Gly Asp Ile Trp Phe Thr Arg Gly Ile Asp Lys His Val Lys Leu Ser 385 390 395 400 Val Glu Lys Gln Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser 405 410 415 Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His Asn Leu Thr Gly 420 425 430 Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys Val Glu Met Met 435 440 445 Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr Lys Asp Arg Val 450 455 460 Leu Ala Met Trp Thr Asn Phe Ile Lys Asn Gly Asn Pro Thr Pro Glu 465 470 475 480 Val Thr Glu Leu Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp Lys 485 490 495 Leu Asn Tyr Leu Asn Ile Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro 500 505 510 Glu Glu Thr Arg Val Lys Phe Trp Glu Asp Ala Thr Lys Thr Leu His 515 520 525 Ser Gln 530 54 570 PRT Ctenocephalides felis 54 Trp Asp Asn Leu Asp Gln His Leu Cys Arg Val Gln Phe Asn Gly Ile 1 5 10 15 Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Arg Asn Asp Val Tyr 20 25 30 Cys Ser Tyr Leu Gly Ile Pro Tyr Ala Glu Pro Pro Phe Gly Pro Leu 35 40 45 Arg Phe Gln Ser Pro Lys Pro Ile Ser Asn Pro Lys Thr Gly Phe Val 50 55 60 Gln Ala Arg Thr Leu Gly Asp Lys Cys Phe Gln Glu Ser Leu Ile Tyr 65 70 75 80 Ser Tyr Ala Gly Ser Glu Asp Cys Leu Tyr Leu Asn Ile Phe Thr Pro 85 90 95 Glu Thr Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp 100 105 110 Ile His Gly Gly Ala Phe Asn Gln Gly Ser Gly Ser Tyr Asn Phe Phe 115 120 125 Gly Pro Asp Tyr Leu Ile Arg Glu Gly Ile Ile Leu Val Thr Ile Asn 130 135 140 Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu Trp Asp Ile 145 150 155 160 His Gly Asn Met Gly Leu Lys Asp Gln Arg Leu Ala Leu Lys Trp Val 165 170 175 Tyr Asp Asn Ile Glu Lys Phe Gly Gly Asp Arg Glu Lys Ile Thr Ile 180 185 190 Ala Gly Glu Ser Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp 195 200 205 Asn Ser Thr Arg Lys Tyr Tyr Gln Arg Ala Ile Leu Gln Ser Gly Thr 210 215 220 Leu Leu Asn Pro Thr Ala Asn Gln Ile Gln Leu Leu His Arg Phe Glu 225 230 235 240 Lys Leu Lys Gln Val Leu Asn Ile Thr Gln Lys Gln Glu Leu Leu Asn 245 250 255 Leu Asp Lys Asn Leu Ile Leu Arg Ala Ala Leu Asn Arg Val Pro Asp 260 265 270 Ser Asn Asp His Asp Arg Asp Thr Val Pro Val Phe Asn Pro Val Leu 275 280 285 Glu Ser Pro Glu Ser Pro Asp Pro Ile Thr Phe Pro Ser Ala Leu Glu 290 295 300 Arg Met Arg Asn Gly Glu Phe Pro Asp Val Asp Val Ile Ile Gly Phe 305 310 315 320 Asn Ser Ala Glu Gly Leu Arg Ser Met Ala Arg Val Thr Arg Gly Asn 325 330 335 Met Glu Val His Lys Thr Leu Thr Asn Ile Glu Arg Ala Ile Pro Arg 340 345 350 Asp Ala Asn Ile Trp Lys Asn Pro Asn Gly Ile Glu Glu Lys Lys Leu 355 360 365 Ile Lys Met Leu Thr Glu Phe Tyr Asp Gln Val Lys Glu Gln Asn Asp 370 375 380 Asp Ile Glu Ala Tyr Val Gln Leu Lys Gly Asp Ala Gly Tyr Leu Gln 385 390 395 400 Gly Ile Tyr Arg Thr Leu Lys Ala Ile Phe Phe Asn Glu Phe Arg Arg 405 410 415 Asn Ser Asn Leu Tyr Leu Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val 420 425 430 Tyr Lys Ser Tyr Ile Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val 435 440 445 Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val 450 455 460 Pro Ile Leu Gly Thr Thr His Ile Ser Ile Pro Gln Asp Ala Met Gln 465 470 475 480 Thr Leu Glu Arg Met Val Arg Ile Trp Thr Asn Phe Val Lys Asn Gly 485 490 495 Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser Cys Asp Thr Lys Arg His 500 505 510 Leu Asn Asp Ile Phe Trp Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr 515 520 525 Leu Asp Met Gly Lys Glu Asn Phe Glu Met Lys Asn Ile Leu Glu Leu 530 535 540 Lys Arg Met Met Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg 545 550 555 560 Phe Arg Val Cys Asn Glu Gly Ser Ile Arg 565 570 55 570 PRT Ctenocephalides felis 55 Trp Asp Asn Leu Asp Gln His Leu Cys Arg Val Gln Phe Asn Gly Ile 1 5 10 15 Thr Glu Gly Lys Pro Phe Arg Tyr Lys Asp His Lys Asn Asp Val Tyr 20 25 30 Cys Ser Tyr Leu Gly Ile Pro Tyr Ala Glu Pro Pro Ile Gly Pro Leu 35 40 45 Arg Phe Gln Ser Pro Lys Pro Ile Ser Asn Pro Lys Thr Gly Phe Val 50 55 60 Gln Ala Arg Ser Leu Gly Asp Lys Cys Phe Gln Glu Ser Leu Ile Tyr 65 70 75 80 Ser Tyr Ala Gly Ser Glu Asp Cys Leu Tyr Leu Asn Ile Phe Thr Pro 85 90 95 Glu Thr Val Asn Ser Ala Asn Asn Thr Lys Tyr Pro Val Met Phe Trp 100 105 110 Ile His Gly Gly Ala Phe Asn Gln Gly Ser Gly Ser Tyr Asn Phe Phe 115 120 125 Gly Pro Asp Tyr Leu Ile Arg Glu Gly Ile Ile Leu Val Thr Ile Asn 130 135 140 Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu Trp Asp Ile 145 150 155 160 His Gly Asn Met Gly Leu Lys Asp Gln Arg Leu Ala Leu Lys Trp Val 165 170 175 Tyr Asp Asn Ile Glu Lys Phe Gly Gly Asp Arg Asp Lys Ile Thr Ile 180 185 190 Ala Gly Glu Ser Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp 195 200 205 Asn Ser Thr Arg Lys Tyr Tyr Gln Arg Ala Ile Leu Gln Ser Gly Thr 210 215 220 Leu Leu Asn Pro Thr Ala Asn Gln Ile Gln Pro Leu His Arg Phe Glu 225 230 235 240 Lys Leu Lys Gln Val Leu Asn Ile Thr Gln Lys Gln Glu Leu Leu Asn 245 250 255 Leu Asp Lys Asn Gln Ile Leu Arg Ala Ala Leu Asn Arg Val Pro Asp 260 265 270 Asn Asn Asp His Glu Arg Asp Thr Val Pro Val Phe Asn Pro Val Leu 275 280 285 Glu Ser Pro Glu Ser Pro Asp Pro Ile Thr Phe Pro Ser Ala Leu Glu 290 295 300 Arg Met Arg Asn Gly Glu Phe Pro Asp Val Asp Val Ile Ile Gly Phe 305 310 315 320 Asn Ser Ala Glu Gly Leu Arg Ser Met Pro Arg Val Thr Arg Gly Asn 325 330 335 Met Glu Val Tyr Lys Thr Leu Thr Asn Ile Glu Arg Ala Ile Pro Arg 340 345 350 Asp Ala Asn Ile Trp Lys Asn Pro Asn Gly Ile Glu Glu Lys Lys Leu 355 360 365 Ile Lys Met Leu Thr Glu Phe Tyr Asp Gln Val Lys Glu Gln Asn Asp 370 375 380 Asp Ile Glu Ala Tyr Val Gln Leu Lys Gly Asp Ala Gly Tyr Leu Gln 385 390 395 400 Gly Ile Tyr Arg Thr Leu Lys Ala Ile Phe Phe Asn Glu Ile Lys Arg 405 410 415 Asn Ser Asn Leu Tyr Leu Tyr Arg Leu Ser Asp Asp Thr Tyr Ser Val 420 425 430 Tyr Lys Ser Tyr Ile Leu Pro Tyr Arg Trp Gly Ser Leu Pro Gly Val 435 440 445 Ser His Gly Asp Asp Leu Gly Tyr Leu Phe Ala Asn Ser Leu Asp Val 450 455 460 Pro Ile Leu Gly Thr Thr His Ile Ser Ile Pro Gln Asp Ala Met Gln 465 470 475 480 Thr Leu Glu Arg Met Val Arg Ile Trp Thr Asn Phe Val Lys Asn Gly 485 490 495 Lys Pro Thr Ser Asn Thr Glu Asp Ala Ser Cys Asp Thr Lys Arg His 500 505 510 Leu Asn Asp Ile Phe Trp Glu Pro Tyr Asn Asp Glu Glu Pro Lys Tyr 515 520 525 Leu Asp Met Gly Lys Glu His Phe Glu Met Lys Asn Ile Leu Glu Leu 530 535 540 Lys Arg Met Met Leu Trp Asp Glu Val Tyr Arg Asn Ala Asn Leu Arg 545 550 555 560 Phe Arg Val Cys Asn Glu Gly Ser Ile Arg 565 570 56 20 DNA Artificial sequence Synthetic Primer 56 gtgcgtacac gtttactacc 20 57 2144 DNA Ctenocephalides felis CDS (30)..(1682) 57 gtacacatag tcaatagtct agatccaag atg tct cgt gtt att ttt tta agt 53 Met Ser Arg Val Ile Phe Leu Ser 1 5 tgt att ttt ttg ttt agt ttt aat ttt ata aaa tgt gat tcc ccg act 101 Cys Ile Phe Leu Phe Ser Phe Asn Phe Ile Lys Cys Asp Ser Pro Thr 10 15 20 gta act ttg ccc caa ggc gaa ttg gtt gga aaa gct ttg acg aac gaa 149 Val Thr Leu Pro Gln Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu 25 30 35 40 aat gga aaa gag tat ttt agc tac aca ggt gta cct tat gct aaa cct 197 Asn Gly Lys Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro 45 50 55 cct gtt gga gaa ctt aga ttt aag cct cca cag aaa gct gag cca tgg 245 Pro Val Gly Glu Leu Arg Phe Lys Pro Pro Gln Lys Ala Glu Pro Trp 60 65 70 caa ggt gtt ttc aac gcc aca tta tac gga aat gtg tgt aaa tct tta 293 Gln Gly Val Phe Asn Ala Thr Leu Tyr Gly Asn Val Cys Lys Ser Leu 75 80 85 aat ttc ttc ttg aag aaa att gaa gga gac gaa gac tgc ttg gta gta 341 Asn Phe Phe Leu Lys Lys Ile Glu Gly Asp Glu Asp Cys Leu Val Val 90 95 100 aac gtg tac gca cca aaa aca act tct gat aaa aaa ctt cca gta ttt 389 Asn Val Tyr Ala Pro Lys Thr Thr Ser Asp Lys Lys Leu Pro Val Phe 105 110 115 120 ttc tgg gtt cat ggt ggt ggt ttt gtg act gga tcc gga aat tta gaa 437 Phe Trp Val His Gly Gly Gly Phe Val Thr Gly Ser Gly Asn Leu Glu 125 130 135 ttc caa agc cca gat tat tta gta rat ttt gat gtt att ttc gta act 485 Phe Gln Ser Pro Asp Tyr Leu Val Xaa Phe Asp Val Ile Phe Val Thr 140 145 150 ttc aat tac cga ttg gga cct ctc gga ttt ctg aat ttg gag ttg gag 533 Phe Asn Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu 155 160 165 ggt gct cca gga aat gta gga tta ttg gat cag gtg gca gct ctg aaa 581 Gly Ala Pro Gly Asn Val Gly Leu Leu Asp Gln Val Ala Ala Leu Lys 170 175 180 tgg acc aaa gaa aac att gag aaa ttt ggt gga gat cca gaa aat att 629 Trp Thr Lys Glu Asn Ile Glu Lys Phe Gly Gly Asp Pro Glu Asn Ile 185 190 195 200 aca att ggt ggt gtt tct gct ggt gga gca agt gtt cat tat ctt ttg 677 Thr Ile Gly Gly Val Ser Ala Gly Gly Ala Ser Val His Tyr Leu Leu 205 210 215 tta tct cat aca acc act gga ctt tac aaa agg gca att gct caa agt 725 Leu Ser His Thr Thr Thr Gly Leu Tyr Lys Arg Ala Ile Ala Gln Ser 220 225 230 gga agt gct ttt aat cca tgg gcc ttc caa aga cat cca gta aag cgt 773 Gly Ser Ala Phe Asn Pro Trp Ala Phe Gln Arg His Pro Val Lys Arg 235 240 245 agt ctt caa ctt gct gag ata ttg ggt cat ccc aca aac aat act caa 821 Ser Leu Gln Leu Ala Glu Ile Leu Gly His Pro Thr Asn Asn Thr Gln 250 255 260 gat gct tta gaa ttc tta caa aaa gcc ccc gta gac agt ctc ctg aag 869 Asp Ala Leu Glu Phe Leu Gln Lys Ala Pro Val Asp Ser Leu Leu Lys 265 270 275 280 aaa atg cca gct gaa aca gaa ggt gaa ata ata gaa gag ttt gtc ttc 917 Lys Met Pro Ala Glu Thr Glu Gly Glu Ile Ile Glu Glu Phe Val Phe 285 290 295 gta cca tca att gaa aaa gtt ttc cca tcc cac caa cct ttc ttg gaa 965 Val Pro Ser Ile Glu Lys Val Phe Pro Ser His Gln Pro Phe Leu Glu 300 305 310 gaa tca cca ttg gcc aga atg aaa tcc gga tcc ttt aac aaa gta cct 1013 Glu Ser Pro Leu Ala Arg Met Lys Ser Gly Ser Phe Asn Lys Val Pro 315 320 325 tta tta gtt gga ttt aac agt gca gaa gga ctt ttg ttc aaa ttc ttc 1061 Leu Leu Val Gly Phe Asn Ser Ala Glu Gly Leu Leu Phe Lys Phe Phe 330 335 340 atg aaa gaa aaa cca gag atg ctg aac caa gct gaa gca gat ttt gaa 1109 Met Lys Glu Lys Pro Glu Met Leu Asn Gln Ala Glu Ala Asp Phe Glu 345 350 355 360 aga ctc gta cca gcc gaa ttt gaa tta gtc cat gga tca gag gaa tcg 1157 Arg Leu Val Pro Ala Glu Phe Glu Leu Val His Gly Ser Glu Glu Ser 365 370 375 aaa aaa ctt gca gaa aaa atc agg aag ttt tac ttt gac gat aaa ccc 1205 Lys Lys Leu Ala Glu Lys Ile Arg Lys Phe Tyr Phe Asp Asp Lys Pro 380 385 390 gtt cca gaa aat gaa cag aaa ttt att gac ttg ata gga gat att tgg 1253 Val Pro Glu Asn Glu Gln Lys Phe Ile Asp Leu Ile Gly Asp Ile Trp 395 400 405 ttt act aga ggt gtt gac aag cat gtc aag ttg tct gtg gag aaa caa 1301 Phe Thr Arg Gly Val Asp Lys His Val Lys Leu Ser Val Glu Lys Gln 410 415 420 gac gaa cca gtt tat tat tat gaa tat tcc ttc tcg gaa agt cat cct 1349 Asp Glu Pro Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser Glu Ser His Pro 425 430 435 440 gca aaa gga aca ttt ggt gat cat aat ctg act ggt gca tgc cat gga 1397 Ala Lys Gly Thr Phe Gly Asp His Asn Leu Thr Gly Ala Cys His Gly 445 450 455 gaa gaa ctt gtg aat tta ttc aaa gtc gag atg atg aag ctg gaa aaa 1445 Glu Glu Leu Val Asn Leu Phe Lys Val Glu Met Met Lys Leu Glu Lys 460 465 470 gat aaa cct aat gtt cta tta aca aaa gat aga gta ctt gcc atg tgg 1493 Asp Lys Pro Asn Val Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp 475 480 485 act aac ttc atc aaa aat gga aat cct act cct gaa gta aca gaa tta 1541 Thr Asn Phe Ile Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu 490 495 500 ttg cca gtt aaa tgg gaa cct gcc aca aaa gac aag ttg aat tat ttg 1589 Leu Pro Val Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu 505 510 515 520 aac att gat gcc acc tta act ttg gga aca aat cct gag gca aac cga 1637 Asn Ile Asp Ala Thr Leu Thr Leu Gly Thr Asn Pro Glu Ala Asn Arg 525 530 535 gtc aaa ttt tgg gaa gac gcc aca aaa tct ttg cac ggt caa taa 1682 Val Lys Phe Trp Glu Asp Ala Thr Lys Ser Leu His Gly Gln 540 545 550 taatttatga aaattgtttt aaatacttta ggtaatatat taggtaaata aaaattaaaa 1742 aataacaatt tttatgtttt atgtattggc ttatgtgtat cagttctaat tttatttatt 1802 tattcttgtt ttgcttgttt tgaaatatca tggttttaat tttcaaaaca caacgtcgtt 1862 tgtttttagc aaaatttcca atagatatgt tatattaagt actctgaagt atttttatat 1922 atacactaaa atcagtaaaa atacattaac taaaaatata agatattttc aataattttt 1982 tttaaagaaa ataccaaaaa taaagtaaaa ttccaaacgg aatttttgtt taacttaaaa 2042 ataaaattaa ctcttcaata attttgataa ttagtatttc tgatatcatt agtgaaaatt 2102 atattttgat aatacgtatt tatatttaaa ataaaattat gt 2144 58 550 PRT Ctenocephalides felis misc_feature (145)..(145) The ′Xaa′ at location 145 stands for Asp, or Asn. 58 Met Ser Arg Val Ile Phe Leu Ser Cys Ile Phe Leu Phe Ser Phe Asn 1 5 10 15 Phe Ile Lys Cys Asp Ser Pro Thr Val Thr Leu Pro Gln Gly Glu Leu 20 25 30 Val Gly Lys Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr 35 40 45 Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg Phe Lys 50 55 60 Pro Pro Gln Lys Ala Glu Pro Trp Gln Gly Val Phe Asn Ala Thr Leu 65 70 75 80 Tyr Gly Asn Val Cys Lys Ser Leu Asn Phe Phe Leu Lys Lys Ile Glu 85 90 95 Gly Asp Glu Asp Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe 115 120 125 Val Thr Gly Ser Gly Asn Leu Glu Phe Gln Ser Pro Asp Tyr Leu Val 130 135 140 Xaa Phe Asp Val Ile Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu 145 150 155 160 Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn Val Gly Leu 165 170 175 Leu Asp Gln Val Ala Ala Leu Lys Trp Thr Lys Glu Asn Ile Glu Lys 180 185 190 Phe Gly Gly Asp Pro Glu Asn Ile Thr Ile Gly Gly Val Ser Ala Gly 195 200 205 Gly Ala Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 210 215 220 Tyr Lys Arg Ala Ile Ala Gln Ser Gly Ser Ala Phe Asn Pro Trp Ala 225 230 235 240 Phe Gln Arg His Pro Val Lys Arg Ser Leu Gln Leu Ala Glu Ile Leu 245 250 255 Gly His Pro Thr Asn Asn Thr Gln Asp Ala Leu Glu Phe Leu Gln Lys 260 265 270 Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala Glu Thr Glu Gly 275 280 285 Glu Ile Ile Glu Glu Phe Val Phe Val Pro Ser Ile Glu Lys Val Phe 290 295 300 Pro Ser His Gln Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys 305 310 315 320 Ser Gly Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 325 330 335 Glu Gly Leu Leu Phe Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu 340 345 350 Asn Gln Ala Glu Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu 355 360 365 Leu Val His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys Ile Arg 370 375 380 Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn Glu Gln Lys Phe 385 390 395 400 Ile Asp Leu Ile Gly Asp Ile Trp Phe Thr Arg Gly Val Asp Lys His 405 410 415 Val Lys Leu Ser Val Glu Lys Gln Asp Glu Pro Val Tyr Tyr Tyr Glu 420 425 430 Tyr Ser Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 435 440 445 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys 450 455 460 Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr 465 470 475 480 Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe Ile Lys Asn Gly Asn 485 490 495 Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys Trp Glu Pro Ala 500 505 510 Thr Lys Asp Lys Leu Asn Tyr Leu Asn Ile Asp Ala Thr Leu Thr Leu 515 520 525 Gly Thr Asn Pro Glu Ala Asn Arg Val Lys Phe Trp Glu Asp Ala Thr 530 535 540 Lys Ser Leu His Gly Gln 545 550 59 2144 DNA Ctenocephalides felis 59 acataatttt attttaaata taaatacgta ttatcaaaat ataattttca ctaatgatat 60 cagaaatact aattatcaaa attattgaag agttaatttt atttttaagt taaacaaaaa 120 ttccgtttgg aattttactt tatttttggt attttcttta aaaaaaatta ttgaaaatat 180 cttatatttt tagttaatgt atttttactg attttagtgt atatataaaa atacttcaga 240 gtacttaata taacatatct attggaaatt ttgctaaaaa caaacgacgt tgtgttttga 300 aaattaaaac catgatattt caaaacaagc aaaacaagaa taaataaata aaattagaac 360 tgatacacat aagccaatac ataaaacata aaaattgtta ttttttaatt tttatttacc 420 taatatatta cctaaagtat ttaaaacaat tttcataaat tattattgac cgtgcaaaga 480 ttttgtggcg tcttcccaaa atttgactcg gtttgcctca ggatttgttc ccaaagttaa 540 ggtggcatca atgttcaaat aattcaactt gtcttttgtg gcaggttccc atttaactgg 600 caataattct gttacttcag gagtaggatt tccatttttg atgaagttag tccacatggc 660 aagtactcta tcttttgtta atagaacatt aggtttatct ttttccagct tcatcatctc 720 gactttgaat aaattcacaa gttcttctcc atggcatgca ccagtcagat tatgatcacc 780 aaatgttcct tttgcaggat gactttccga gaaggaatat tcataataat aaactggttc 840 gtcttgtttc tccacagaca acttgacatg cttgtcaaca cctctagtaa accaaatatc 900 tcctatcaag tcaataaatt tctgttcatt ttctggaacg ggtttatcgt caaagtaaaa 960 cttcctgatt ttttctgcaa gttttttcga ttcctctgat ccatggacta attcaaattc 1020 ggctggtacg agtctttcaa aatctgcttc agcttggttc agcatctctg gtttttcttt 1080 catgaagaat ttgaacaaaa gtccttctgc actgttaaat ccaactaata aaggtacttt 1140 gttaaaggat ccggatttca ttctggccaa tggtgattct tccaagaaag gttggtggga 1200 tgggaaaact ttttcaattg atggtacgaa gacaaactct tctattattt caccttctgt 1260 ttcagctggc attttcttca ggagactgtc tacgggggct ttttgtaaga attctaaagc 1320 atcttgagta ttgtttgtgg gatgacccaa tatctcagca agttgaagac tacgctttac 1380 tggatgtctt tggaaggccc atggattaaa agcacttcca ctttgagcaa ttgccctttt 1440 gtaaagtcca gtggttgtat gagataacaa aagataatga acacttgctc caccagcaga 1500 aacaccacca attgtaatat tttctggatc tccaccaaat ttctcaatgt tttctttggt 1560 ccatttcaga gctgccacct gatccaataa tcctacattt cctggagcac cctccaactc 1620 caaattcaga aatccgagag gtcccaatcg gtaattgaaa gttacgaaaa taacatcaaa 1680 atytactaaa taatctgggc tttggaattc taaatttccg gatccagtca caaaaccacc 1740 accatgaacc cagaaaaata ctggaagttt tttatcagaa gttgtttttg gtgcgtacac 1800 gtttactacc aagcagtctt cgtctccttc aattttcttc aagaagaaat ttaaagattt 1860 acacacattt ccgtataatg tggcgttgaa aacaccttgc catggctcag ctttctgtgg 1920 aggcttaaat ctaagttctc caacaggagg tttagcataa ggtacacctg tgtagctaaa 1980 atactctttt ccattttcgt tcgtcaaagc ttttccaacc aattcgcctt ggggcaaagt 2040 tacagtcggg gaatcacatt ttataaaatt aaaactaaac aaaaaaatac aacttaaaaa 2100 aataacacga gacatcttgg atctagacta ttgactatgt gtac 2144 60 1650 DNA Ctenocephalides felis exon (1)..(1650) 60 atg tct cgt gtt att ttt tta agt tgt att ttt ttg ttt agt ttt aat 48 Met Ser Arg Val Ile Phe Leu Ser Cys Ile Phe Leu Phe Ser Phe Asn 1 5 10 15 ttt ata aaa tgt gat tcc ccg act gta act ttg ccc caa ggc gaa ttg 96 Phe Ile Lys Cys Asp Ser Pro Thr Val Thr Leu Pro Gln Gly Glu Leu 20 25 30 gtt gga aaa gct ttg acg aac gaa aat gga aaa gag tat ttt agc tac 144 Val Gly Lys Ala Leu Thr Asn Glu Asn Gly Lys Glu Tyr Phe Ser Tyr 35 40 45 aca ggt gta cct tat gct aaa cct cct gtt gga gaa ctt aga ttt aag 192 Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly Glu Leu Arg Phe Lys 50 55 60 cct cca cag aaa gct gag cca tgg caa ggt gtt ttc aac gcc aca tta 240 Pro Pro Gln Lys Ala Glu Pro Trp Gln Gly Val Phe Asn Ala Thr Leu 65 70 75 80 tac gga aat gtg tgt aaa tct tta aat ttc ttc ttg aag aaa att gaa 288 Tyr Gly Asn Val Cys Lys Ser Leu Asn Phe Phe Leu Lys Lys Ile Glu 85 90 95 gga gac gaa gac tgc ttg gta gta aac gtg tac gca cca aaa aca act 336 Gly Asp Glu Asp Cys Leu Val Val Asn Val Tyr Ala Pro Lys Thr Thr 100 105 110 tct gat aaa aaa ctt cca gta ttt ttc tgg gtt cat ggt ggt ggt ttt 384 Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val His Gly Gly Gly Phe 115 120 125 gtg act gga tcc gga aat tta gaa ttc caa agc cca gat tat tta gta 432 Val Thr Gly Ser Gly Asn Leu Glu Phe Gln Ser Pro Asp Tyr Leu Val 130 135 140 rat ttt gat gtt att ttc gta act ttc aat tac cga ttg gga cct ctc 480 Xaa Phe Asp Val Ile Phe Val Thr Phe Asn Tyr Arg Leu Gly Pro Leu 145 150 155 160 gga ttt ctg aat ttg gag ttg gag ggt gct cca gga aat gta gga tta 528 Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro Gly Asn Val Gly Leu 165 170 175 ttg gat cag gtg gca gct ctg aaa tgg acc aaa gaa aac att gag aaa 576 Leu Asp Gln Val Ala Ala Leu Lys Trp Thr Lys Glu Asn Ile Glu Lys 180 185 190 ttt ggt gga gat cca gaa aat att aca att ggt ggt gtt tct gct ggt 624 Phe Gly Gly Asp Pro Glu Asn Ile Thr Ile Gly Gly Val Ser Ala Gly 195 200 205 gga gca agt gtt cat tat ctt ttg tta tct cat aca acc act gga ctt 672 Gly Ala Ser Val His Tyr Leu Leu Leu Ser His Thr Thr Thr Gly Leu 210 215 220 tac aaa agg gca att gct caa agt gga agt gct ttt aat cca tgg gcc 720 Tyr Lys Arg Ala Ile Ala Gln Ser Gly Ser Ala Phe Asn Pro Trp Ala 225 230 235 240 ttc caa aga cat cca gta aag cgt agt ctt caa ctt gct gag ata ttg 768 Phe Gln Arg His Pro Val Lys Arg Ser Leu Gln Leu Ala Glu Ile Leu 245 250 255 ggt cat ccc aca aac aat act caa gat gct tta gaa ttc tta caa aaa 816 Gly His Pro Thr Asn Asn Thr Gln Asp Ala Leu Glu Phe Leu Gln Lys 260 265 270 gcc ccc gta gac agt ctc ctg aag aaa atg cca gct gaa aca gaa ggt 864 Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro Ala Glu Thr Glu Gly 275 280 285 gaa ata ata gaa gag ttt gtc ttc gta cca tca att gaa aaa gtt ttc 912 Glu Ile Ile Glu Glu Phe Val Phe Val Pro Ser Ile Glu Lys Val Phe 290 295 300 cca tcc cac caa cct ttc ttg gaa gaa tca cca ttg gcc aga atg aaa 960 Pro Ser His Gln Pro Phe Leu Glu Glu Ser Pro Leu Ala Arg Met Lys 305 310 315 320 tcc gga tcc ttt aac aaa gta cct tta tta gtt gga ttt aac agt gca 1008 Ser Gly Ser Phe Asn Lys Val Pro Leu Leu Val Gly Phe Asn Ser Ala 325 330 335 gaa gga ctt ttg ttc aaa ttc ttc atg aaa gaa aaa cca gag atg ctg 1056 Glu Gly Leu Leu Phe Lys Phe Phe Met Lys Glu Lys Pro Glu Met Leu 340 345 350 aac caa gct gaa gca gat ttt gaa aga ctc gta cca gcc gaa ttt gaa 1104 Asn Gln Ala Glu Ala Asp Phe Glu Arg Leu Val Pro Ala Glu Phe Glu 355 360 365 tta gtc cat gga tca gag gaa tcg aaa aaa ctt gca gaa aaa atc agg 1152 Leu Val His Gly Ser Glu Glu Ser Lys Lys Leu Ala Glu Lys Ile Arg 370 375 380 aag ttt tac ttt gac gat aaa ccc gtt cca gaa aat gaa cag aaa ttt 1200 Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu Asn Glu Gln Lys Phe 385 390 395 400 att gac ttg ata gga gat att tgg ttt act aga ggt gtt gac aag cat 1248 Ile Asp Leu Ile Gly Asp Ile Trp Phe Thr Arg Gly Val Asp Lys His 405 410 415 gtc aag ttg tct gtg gag aaa caa gac gaa cca gtt tat tat tat gaa 1296 Val Lys Leu Ser Val Glu Lys Gln Asp Glu Pro Val Tyr Tyr Tyr Glu 420 425 430 tat tcc ttc tcg gaa agt cat cct gca aaa gga aca ttt ggt gat cat 1344 Tyr Ser Phe Ser Glu Ser His Pro Ala Lys Gly Thr Phe Gly Asp His 435 440 445 aat ctg act ggt gca tgc cat gga gaa gaa ctt gtg aat tta ttc aaa 1392 Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu Val Asn Leu Phe Lys 450 455 460 gtc gag atg atg aag ctg gaa aaa gat aaa cct aat gtt cta tta aca 1440 Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro Asn Val Leu Leu Thr 465 470 475 480 aaa gat aga gta ctt gcc atg tgg act aac ttc atc aaa aat gga aat 1488 Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe Ile Lys Asn Gly Asn 485 490 495 cct act cct gaa gta aca gaa tta ttg cca gtt aaa tgg gaa cct gcc 1536 Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val Lys Trp Glu Pro Ala 500 505 510 aca aaa gac aag ttg aat tat ttg aac att gat gcc acc tta act ttg 1584 Thr Lys Asp Lys Leu Asn Tyr Leu Asn Ile Asp Ala Thr Leu Thr Leu 515 520 525 gga aca aat cct gag gca aac cga gtc aaa ttt tgg gaa gac gcc aca 1632 Gly Thr Asn Pro Glu Ala Asn Arg Val Lys Phe Trp Glu Asp Ala Thr 530 535 540 aaa tct ttg cac ggt caa 1650 Lys Ser Leu His Gly Gln 545 550 61 1650 DNA Ctenocephalides felis 61 ttgaccgtgc aaagattttg tggcgtcttc ccaaaatttg actcggtttg cctcaggatt 60 tgttcccaaa gttaaggtgg catcaatgtt caaataattc aacttgtctt ttgtggcagg 120 ttcccattta actggcaata attctgttac ttcaggagta ggatttccat ttttgatgaa 180 gttagtccac atggcaagta ctctatcttt tgttaataga acattaggtt tatctttttc 240 cagcttcatc atctcgactt tgaataaatt cacaagttct tctccatggc atgcaccagt 300 cagattatga tcaccaaatg ttccttttgc aggatgactt tccgagaagg aatattcata 360 ataataaact ggttcgtctt gtttctccac agacaacttg acatgcttgt caacacctct 420 agtaaaccaa atatctccta tcaagtcaat aaatttctgt tcattttctg gaacgggttt 480 atcgtcaaag taaaacttcc tgattttttc tgcaagtttt ttcgattcct ctgatccatg 540 gactaattca aattcggctg gtacgagtct ttcaaaatct gcttcagctt ggttcagcat 600 ctctggtttt tctttcatga agaatttgaa caaaagtcct tctgcactgt taaatccaac 660 taataaaggt actttgttaa aggatccgga tttcattctg gccaatggtg attcttccaa 720 gaaaggttgg tgggatggga aaactttttc aattgatggt acgaagacaa actcttctat 780 tatttcacct tctgtttcag ctggcatttt cttcaggaga ctgtctacgg gggctttttg 840 taagaattct aaagcatctt gagtattgtt tgtgggatga cccaatatct cagcaagttg 900 aagactacgc tttactggat gtctttggaa ggcccatgga ttaaaagcac ttccactttg 960 agcaattgcc cttttgtaaa gtccagtggt tgtatgagat aacaaaagat aatgaacact 1020 tgctccacca gcagaaacac caccaattgt aatattttct ggatctccac caaatttctc 1080 aatgttttct ttggtccatt tcagagctgc cacctgatcc aataatccta catttcctgg 1140 agcaccctcc aactccaaat tcagaaatcc gagaggtccc aatcggtaat tgaaagttac 1200 gaaaataaca tcaaaatyta ctaaataatc tgggctttgg aattctaaat ttccggatcc 1260 agtcacaaaa ccaccaccat gaacccagaa aaatactgga agttttttat cagaagttgt 1320 ttttggtgcg tacacgttta ctaccaagca gtcttcgtct ccttcaattt tcttcaagaa 1380 gaaatttaaa gatttacaca catttccgta taatgtggcg ttgaaaacac cttgccatgg 1440 ctcagctttc tgtggaggct taaatctaag ttctccaaca ggaggtttag cataaggtac 1500 acctgtgtag ctaaaatact cttttccatt ttcgttcgtc aaagcttttc caaccaattc 1560 gccttggggc aaagttacag tcggggaatc acattttata aaattaaaac taaacaaaaa 1620 aatacaactt aaaaaaataa cacgagacat 1650 62 29 DNA Artificial sequence Synthetic Primer 62 aaactcgagt cccccgactg taactttgc 29 63 36 DNA Artificial sequence Synthetic Primer 63 tcatctgcag ttattgactg tgcaaagttt ttgtgg 36 64 32 DNA Artificial sequence Synthetic Primer 64 ttccggatcc ggctgatcta caagtgactt tg 32 65 34 DNA Artificial sequence Synthetic Primer 65 tggtactcga gtcataaaaa tttattccaa aatc 34 66 39 DNA Artificial sequence Synthetic Primer 66 aaaactgcag tataaatatg ttacctcaca gtgcattag 39 67 1987 DNA Ctenocephalides felis CDS (231)..(1820) 67 aattcacagt gtaaataatt ttatttgata taaatgtatt taatttttat tttaatctaa 60 ttttaattta aatatatata gttttattta taaaaaaata ttttttttat gatcgaaaag 120 aaatttttat ttatgtttat gagtgtgtgt tttggctatg atttacatta tttttgagct 180 agtataaaat taaaccatat tatattttgg atatataata acattttata atg tgt 236 Met Cys 1 gat cca tta cta aaa aca aca aca tat gga att ctg aaa ggc aag aaa 284 Asp Pro Leu Leu Lys Thr Thr Thr Tyr Gly Ile Leu Lys Gly Lys Lys 5 10 15 gtt gta aac gaa aat ggt aaa att tac tat agt tac aca ggt ata ccc 332 Val Val Asn Glu Asn Gly Lys Ile Tyr Tyr Ser Tyr Thr Gly Ile Pro 20 25 30 tat gca aaa tct cct gta aat gat ctc aga ttc aag cca cca caa aaa 380 Tyr Ala Lys Ser Pro Val Asn Asp Leu Arg Phe Lys Pro Pro Gln Lys 35 40 45 50 ctt gat cct tgg aat ggt gtt ttt gac gcc act cag tat gga aat aat 428 Leu Asp Pro Trp Asn Gly Val Phe Asp Ala Thr Gln Tyr Gly Asn Asn 55 60 65 tgt gct gct ggg aaa tgg ttt ttg aaa tca gct ggg ggt tgc gaa gat 476 Cys Ala Ala Gly Lys Trp Phe Leu Lys Ser Ala Gly Gly Cys Glu Asp 70 75 80 tgc ctt tac tta aat atc tat gtc cca caa aac act tca gaa aat cct 524 Cys Leu Tyr Leu Asn Ile Tyr Val Pro Gln Asn Thr Ser Glu Asn Pro 85 90 95 ttg cca gta atg ttt tgg att cat gga gga gca ttt gtg gtc gga tca 572 Leu Pro Val Met Phe Trp Ile His Gly Gly Ala Phe Val Val Gly Ser 100 105 110 gga aat tct gat ata cat ggt cct gat tat tta ata gaa tat gat att 620 Gly Asn Ser Asp Ile His Gly Pro Asp Tyr Leu Ile Glu Tyr Asp Ile 115 120 125 130 atc tta gta act att aat tat cgt cta gga cca ctt ggt ttt ctt aat 668 Ile Leu Val Thr Ile Asn Tyr Arg Leu Gly Pro Leu Gly Phe Leu Asn 135 140 145 ttg gaa atc gaa gat gcg cct ggg aat gtt gga ttg atg gat caa gtt 716 Leu Glu Ile Glu Asp Ala Pro Gly Asn Val Gly Leu Met Asp Gln Val 150 155 160 gca gcc cta aaa tgg gta aat gaa aat att gca acc ttt agt gga gac 764 Ala Ala Leu Lys Trp Val Asn Glu Asn Ile Ala Thr Phe Ser Gly Asp 165 170 175 cca aaa aat att aca att tgt gga gca act gct gga gct gca agt gta 812 Pro Lys Asn Ile Thr Ile Cys Gly Ala Thr Ala Gly Ala Ala Ser Val 180 185 190 cat tat cac att ttg tca caa ctt acc aaa ggt tta ttc cac aag gct 860 His Tyr His Ile Leu Ser Gln Leu Thr Lys Gly Leu Phe His Lys Ala 195 200 205 210 ata gca caa agt gga agt gct ttt aat ccc tgg gct ttc caa aaa aat 908 Ile Ala Gln Ser Gly Ser Ala Phe Asn Pro Trp Ala Phe Gln Lys Asn 215 220 225 cct gtt aag aat gca ctt cga cta tgc aaa acc tta ggc ctt acc aca 956 Pro Val Lys Asn Ala Leu Arg Leu Cys Lys Thr Leu Gly Leu Thr Thr 230 235 240 aac aac ctt caa gaa gcc ttg gat ttt ttg aaa aac cta cca gta gaa 1004 Asn Asn Leu Gln Glu Ala Leu Asp Phe Leu Lys Asn Leu Pro Val Glu 245 250 255 aca ttg tta aat acc aaa tta ccc caa gaa att gat ggt caa ctg ctg 1052 Thr Leu Leu Asn Thr Lys Leu Pro Gln Glu Ile Asp Gly Gln Leu Leu 260 265 270 gat gac ttc gtg ttt gta cct tcg att gaa aaa aca ttt cca gaa caa 1100 Asp Asp Phe Val Phe Val Pro Ser Ile Glu Lys Thr Phe Pro Glu Gln 275 280 285 290 gat tcg tac tta act gac ttg cca ata cca ata ata aat tca gga aaa 1148 Asp Ser Tyr Leu Thr Asp Leu Pro Ile Pro Ile Ile Asn Ser Gly Lys 295 300 305 ttc cac aaa gtt cca ttg ttg aca ggt tac aac agt gcc gaa ggc aat 1196 Phe His Lys Val Pro Leu Leu Thr Gly Tyr Asn Ser Ala Glu Gly Asn 310 315 320 cta ttt ttc atg tac tta aaa aca gat cca gat tta tta aat aaa ttt 1244 Leu Phe Phe Met Tyr Leu Lys Thr Asp Pro Asp Leu Leu Asn Lys Phe 325 330 335 gaa gct gat ttt gaa aga ttt ata cca act gac tta gaa tta cct ttg 1292 Glu Ala Asp Phe Glu Arg Phe Ile Pro Thr Asp Leu Glu Leu Pro Leu 340 345 350 cga tca caa aaa tct att gca ctg ggt gaa gca atc agg gaa ttt tat 1340 Arg Ser Gln Lys Ser Ile Ala Leu Gly Glu Ala Ile Arg Glu Phe Tyr 355 360 365 370 ttc caa aac aaa acc ata tca gaa aat atg cag aat ttt gta gat gtt 1388 Phe Gln Asn Lys Thr Ile Ser Glu Asn Met Gln Asn Phe Val Asp Val 375 380 385 tta agt gat aat tgg ttt aca cgt gga att gat gag caa gta aag tta 1436 Leu Ser Asp Asn Trp Phe Thr Arg Gly Ile Asp Glu Gln Val Lys Leu 390 395 400 act gtt aaa aat cag gaa gaa cca gtt ttt tat tat gtt tat aat ttt 1484 Thr Val Lys Asn Gln Glu Glu Pro Val Phe Tyr Tyr Val Tyr Asn Phe 405 410 415 gat gaa aat tct cca agt cgg aaa gtt ttt ggt gat ttt gga ata aaa 1532 Asp Glu Asn Ser Pro Ser Arg Lys Val Phe Gly Asp Phe Gly Ile Lys 420 425 430 ggc ggt ggt cat gct gat gaa ttg ggt aat ata ttt aaa gcc aaa agt 1580 Gly Gly Gly His Ala Asp Glu Leu Gly Asn Ile Phe Lys Ala Lys Ser 435 440 445 450 gca aat ttt ggg aag gaa aca cca aat gct gtg ttg gtt cag aga agg 1628 Ala Asn Phe Gly Lys Glu Thr Pro Asn Ala Val Leu Val Gln Arg Arg 455 460 465 atg ctg gag atg tgg act aat ttt gct aaa ttt gga aat cct act cca 1676 Met Leu Glu Met Trp Thr Asn Phe Ala Lys Phe Gly Asn Pro Thr Pro 470 475 480 gct att acg gat aca ctt cca ata aaa tgg gaa cct gct ttt aaa gaa 1724 Ala Ile Thr Asp Thr Leu Pro Ile Lys Trp Glu Pro Ala Phe Lys Glu 485 490 495 aat atg act ttt gtt caa att gac att gat tta aat ttg agt act gat 1772 Asn Met Thr Phe Val Gln Ile Asp Ile Asp Leu Asn Leu Ser Thr Asp 500 505 510 cca cta aaa agt cgt atg gaa ttt ggg aat aaa ata aaa tta tta aaa 1820 Pro Leu Lys Ser Arg Met Glu Phe Gly Asn Lys Ile Lys Leu Leu Lys 515 520 525 530 taagtaacta tacttagcta aaccataata taccaaataa tagtatagga atacttcaca 1880 attttttgtt acttcgttaa gtaaatttaa ttttttataa aaccaacttt tacgaataaa 1940 aaatgtaatt attttggaaa aaaaaaagaa aaaaaaaaaa aaaaaac 1987 68 530 PRT Ctenocephalides felis 68 Met Cys Asp Pro Leu Leu Lys Thr Thr Thr Tyr Gly Ile Leu Lys Gly 1 5 10 15 Lys Lys Val Val Asn Glu Asn Gly Lys Ile Tyr Tyr Ser Tyr Thr Gly 20 25 30 Ile Pro Tyr Ala Lys Ser Pro Val Asn Asp Leu Arg Phe Lys Pro Pro 35 40 45 Gln Lys Leu Asp Pro Trp Asn Gly Val Phe Asp Ala Thr Gln Tyr Gly 50 55 60 Asn Asn Cys Ala Ala Gly Lys Trp Phe Leu Lys Ser Ala Gly Gly Cys 65 70 75 80 Glu Asp Cys Leu Tyr Leu Asn Ile Tyr Val Pro Gln Asn Thr Ser Glu 85 90 95 Asn Pro Leu Pro Val Met Phe Trp Ile His Gly Gly Ala Phe Val Val 100 105 110 Gly Ser Gly Asn Ser Asp Ile His Gly Pro Asp Tyr Leu Ile Glu Tyr 115 120 125 Asp Ile Ile Leu Val Thr Ile Asn Tyr Arg Leu Gly Pro Leu Gly Phe 130 135 140 Leu Asn Leu Glu Ile Glu Asp Ala Pro Gly Asn Val Gly Leu Met Asp 145 150 155 160 Gln Val Ala Ala Leu Lys Trp Val Asn Glu Asn Ile Ala Thr Phe Ser 165 170 175 Gly Asp Pro Lys Asn Ile Thr Ile Cys Gly Ala Thr Ala Gly Ala Ala 180 185 190 Ser Val His Tyr His Ile Leu Ser Gln Leu Thr Lys Gly Leu Phe His 195 200 205 Lys Ala Ile Ala Gln Ser Gly Ser Ala Phe Asn Pro Trp Ala Phe Gln 210 215 220 Lys Asn Pro Val Lys Asn Ala Leu Arg Leu Cys Lys Thr Leu Gly Leu 225 230 235 240 Thr Thr Asn Asn Leu Gln Glu Ala Leu Asp Phe Leu Lys Asn Leu Pro 245 250 255 Val Glu Thr Leu Leu Asn Thr Lys Leu Pro Gln Glu Ile Asp Gly Gln 260 265 270 Leu Leu Asp Asp Phe Val Phe Val Pro Ser Ile Glu Lys Thr Phe Pro 275 280 285 Glu Gln Asp Ser Tyr Leu Thr Asp Leu Pro Ile Pro Ile Ile Asn Ser 290 295 300 Gly Lys Phe His Lys Val Pro Leu Leu Thr Gly Tyr Asn Ser Ala Glu 305 310 315 320 Gly Asn Leu Phe Phe Met Tyr Leu Lys Thr Asp Pro Asp Leu Leu Asn 325 330 335 Lys Phe Glu Ala Asp Phe Glu Arg Phe Ile Pro Thr Asp Leu Glu Leu 340 345 350 Pro Leu Arg Ser Gln Lys Ser Ile Ala Leu Gly Glu Ala Ile Arg Glu 355 360 365 Phe Tyr Phe Gln Asn Lys Thr Ile Ser Glu Asn Met Gln Asn Phe Val 370 375 380 Asp Val Leu Ser Asp Asn Trp Phe Thr Arg Gly Ile Asp Glu Gln Val 385 390 395 400 Lys Leu Thr Val Lys Asn Gln Glu Glu Pro Val Phe Tyr Tyr Val Tyr 405 410 415 Asn Phe Asp Glu Asn Ser Pro Ser Arg Lys Val Phe Gly Asp Phe Gly 420 425 430 Ile Lys Gly Gly Gly His Ala Asp Glu Leu Gly Asn Ile Phe Lys Ala 435 440 445 Lys Ser Ala Asn Phe Gly Lys Glu Thr Pro Asn Ala Val Leu Val Gln 450 455 460 Arg Arg Met Leu Glu Met Trp Thr Asn Phe Ala Lys Phe Gly Asn Pro 465 470 475 480 Thr Pro Ala Ile Thr Asp Thr Leu Pro Ile Lys Trp Glu Pro Ala Phe 485 490 495 Lys Glu Asn Met Thr Phe Val Gln Ile Asp Ile Asp Leu Asn Leu Ser 500 505 510 Thr Asp Pro Leu Lys Ser Arg Met Glu Phe Gly Asn Lys Ile Lys Leu 515 520 525 Leu Lys 530 69 1987 DNA Ctenocephalides felis 69 gttttttttt tttttttttc tttttttttt ccaaaataat tacatttttt attcgtaaaa 60 gttggtttta taaaaaatta aatttactta acgaagtaac aaaaaattgt gaagtattcc 120 tatactatta tttggtatat tatggtttag ctaagtatag ttacttattt taataatttt 180 attttattcc caaattccat acgacttttt agtggatcag tactcaaatt taaatcaatg 240 tcaatttgaa caaaagtcat attttcttta aaagcaggtt cccattttat tggaagtgta 300 tccgtaatag ctggagtagg atttccaaat ttagcaaaat tagtccacat ctccagcatc 360 cttctctgaa ccaacacagc atttggtgtt tccttcccaa aatttgcact tttggcttta 420 aatatattac ccaattcatc agcatgacca ccgcctttta ttccaaaatc accaaaaact 480 ttccgacttg gagaattttc atcaaaatta taaacataat aaaaaactgg ttcttcctga 540 tttttaacag ttaactttac ttgctcatca attccacgtg taaaccaatt atcacttaaa 600 acatctacaa aattctgcat attttctgat atggttttgt tttggaaata aaattccctg 660 attgcttcac ccagtgcaat agatttttgt gatcgcaaag gtaattctaa gtcagttggt 720 ataaatcttt caaaatcagc ttcaaattta tttaataaat ctggatctgt ttttaagtac 780 atgaaaaata gattgccttc ggcactgttg taacctgtca acaatggaac tttgtggaat 840 tttcctgaat ttattattgg tattggcaag tcagttaagt acgaatcttg ttctggaaat 900 gttttttcaa tcgaaggtac aaacacgaag tcatccagca gttgaccatc aatttcttgg 960 ggtaatttgg tatttaacaa tgtttctact ggtaggtttt tcaaaaaatc caaggcttct 1020 tgaaggttgt ttgtggtaag gcctaaggtt ttgcatagtc gaagtgcatt cttaacagga 1080 tttttttgga aagcccaggg attaaaagca cttccacttt gtgctatagc cttgtggaat 1140 aaacctttgg taagttgtga caaaatgtga taatgtacac ttgcagctcc agcagttgct 1200 ccacaaattg taatattttt tgggtctcca ctaaaggttg caatattttc atttacccat 1260 tttagggctg caacttgatc catcaatcca acattcccag gcgcatcttc gatttccaaa 1320 ttaagaaaac caagtggtcc tagacgataa ttaatagtta ctaagataat atcatattct 1380 attaaataat caggaccatg tatatcagaa tttcctgatc cgaccacaaa tgctcctcca 1440 tgaatccaaa acattactgg caaaggattt tctgaagtgt tttgtgggac atagatattt 1500 aagtaaaggc aatcttcgca acccccagct gatttcaaaa accatttccc agcagcacaa 1560 ttatttccat actgagtggc gtcaaaaaca ccattccaag gatcaagttt ttgtggtggc 1620 ttgaatctga gatcatttac aggagatttt gcatagggta tacctgtgta actatagtaa 1680 attttaccat tttcgtttac aactttcttg cctttcagaa ttccatatgt tgttgttttt 1740 agtaatggat cacacattat aaaatgttat tatatatcca aaatataata tggtttaatt 1800 ttatactagc tcaaaaataa tgtaaatcat agccaaaaca cacactcata aacataaata 1860 aaaatttctt ttcgatcata aaaaaaatat ttttttataa ataaaactat atatatttaa 1920 attaaaatta gattaaaata aaaattaaat acatttatat caaataaaat tatttacact 1980 gtgaatt 1987 70 1590 DNA Ctenocephalides felis exon (1)..(1590) 70 atg tgt gat cca tta cta aaa aca aca aca tat gga att ctg aaa ggc 48 Met Cys Asp Pro Leu Leu Lys Thr Thr Thr Tyr Gly Ile Leu Lys Gly 1 5 10 15 aag aaa gtt gta aac gaa aat ggt aaa att tac tat agt tac aca ggt 96 Lys Lys Val Val Asn Glu Asn Gly Lys Ile Tyr Tyr Ser Tyr Thr Gly 20 25 30 ata ccc tat gca aaa tct cct gta aat gat ctc aga ttc aag cca cca 144 Ile Pro Tyr Ala Lys Ser Pro Val Asn Asp Leu Arg Phe Lys Pro Pro 35 40 45 caa aaa ctt gat cct tgg aat ggt gtt ttt gac gcc act cag tat gga 192 Gln Lys Leu Asp Pro Trp Asn Gly Val Phe Asp Ala Thr Gln Tyr Gly 50 55 60 aat aat tgt gct gct ggg aaa tgg ttt ttg aaa tca gct ggg ggt tgc 240 Asn Asn Cys Ala Ala Gly Lys Trp Phe Leu Lys Ser Ala Gly Gly Cys 65 70 75 80 gaa gat tgc ctt tac tta aat atc tat gtc cca caa aac act tca gaa 288 Glu Asp Cys Leu Tyr Leu Asn Ile Tyr Val Pro Gln Asn Thr Ser Glu 85 90 95 aat cct ttg cca gta atg ttt tgg att cat gga gga gca ttt gtg gtc 336 Asn Pro Leu Pro Val Met Phe Trp Ile His Gly Gly Ala Phe Val Val 100 105 110 gga tca gga aat tct gat ata cat ggt cct gat tat tta ata gaa tat 384 Gly Ser Gly Asn Ser Asp Ile His Gly Pro Asp Tyr Leu Ile Glu Tyr 115 120 125 gat att atc tta gta act att aat tat cgt cta gga cca ctt ggt ttt 432 Asp Ile Ile Leu Val Thr Ile Asn Tyr Arg Leu Gly Pro Leu Gly Phe 130 135 140 ctt aat ttg gaa atc gaa gat gcg cct ggg aat gtt gga ttg atg gat 480 Leu Asn Leu Glu Ile Glu Asp Ala Pro Gly Asn Val Gly Leu Met Asp 145 150 155 160 caa gtt gca gcc cta aaa tgg gta aat gaa aat att gca acc ttt agt 528 Gln Val Ala Ala Leu Lys Trp Val Asn Glu Asn Ile Ala Thr Phe Ser 165 170 175 gga gac cca aaa aat att aca att tgt gga gca act gct gga gct gca 576 Gly Asp Pro Lys Asn Ile Thr Ile Cys Gly Ala Thr Ala Gly Ala Ala 180 185 190 agt gta cat tat cac att ttg tca caa ctt acc aaa ggt tta ttc cac 624 Ser Val His Tyr His Ile Leu Ser Gln Leu Thr Lys Gly Leu Phe His 195 200 205 aag gct ata gca caa agt gga agt gct ttt aat ccc tgg gct ttc caa 672 Lys Ala Ile Ala Gln Ser Gly Ser Ala Phe Asn Pro Trp Ala Phe Gln 210 215 220 aaa aat cct gtt aag aat gca ctt cga cta tgc aaa acc tta ggc ctt 720 Lys Asn Pro Val Lys Asn Ala Leu Arg Leu Cys Lys Thr Leu Gly Leu 225 230 235 240 acc aca aac aac ctt caa gaa gcc ttg gat ttt ttg aaa aac cta cca 768 Thr Thr Asn Asn Leu Gln Glu Ala Leu Asp Phe Leu Lys Asn Leu Pro 245 250 255 gta gaa aca ttg tta aat acc aaa tta ccc caa gaa att gat ggt caa 816 Val Glu Thr Leu Leu Asn Thr Lys Leu Pro Gln Glu Ile Asp Gly Gln 260 265 270 ctg ctg gat gac ttc gtg ttt gta cct tcg att gaa aaa aca ttt cca 864 Leu Leu Asp Asp Phe Val Phe Val Pro Ser Ile Glu Lys Thr Phe Pro 275 280 285 gaa caa gat tcg tac tta act gac ttg cca ata cca ata ata aat tca 912 Glu Gln Asp Ser Tyr Leu Thr Asp Leu Pro Ile Pro Ile Ile Asn Ser 290 295 300 gga aaa ttc cac aaa gtt cca ttg ttg aca ggt tac aac agt gcc gaa 960 Gly Lys Phe His Lys Val Pro Leu Leu Thr Gly Tyr Asn Ser Ala Glu 305 310 315 320 ggc aat cta ttt ttc atg tac tta aaa aca gat cca gat tta tta aat 1008 Gly Asn Leu Phe Phe Met Tyr Leu Lys Thr Asp Pro Asp Leu Leu Asn 325 330 335 aaa ttt gaa gct gat ttt gaa aga ttt ata cca act gac tta gaa tta 1056 Lys Phe Glu Ala Asp Phe Glu Arg Phe Ile Pro Thr Asp Leu Glu Leu 340 345 350 cct ttg cga tca caa aaa tct att gca ctg ggt gaa gca atc agg gaa 1104 Pro Leu Arg Ser Gln Lys Ser Ile Ala Leu Gly Glu Ala Ile Arg Glu 355 360 365 ttt tat ttc caa aac aaa acc ata tca gaa aat atg cag aat ttt gta 1152 Phe Tyr Phe Gln Asn Lys Thr Ile Ser Glu Asn Met Gln Asn Phe Val 370 375 380 gat gtt tta agt gat aat tgg ttt aca cgt gga att gat gag caa gta 1200 Asp Val Leu Ser Asp Asn Trp Phe Thr Arg Gly Ile Asp Glu Gln Val 385 390 395 400 aag tta act gtt aaa aat cag gaa gaa cca gtt ttt tat tat gtt tat 1248 Lys Leu Thr Val Lys Asn Gln Glu Glu Pro Val Phe Tyr Tyr Val Tyr 405 410 415 aat ttt gat gaa aat tct cca agt cgg aaa gtt ttt ggt gat ttt gga 1296 Asn Phe Asp Glu Asn Ser Pro Ser Arg Lys Val Phe Gly Asp Phe Gly 420 425 430 ata aaa ggc ggt ggt cat gct gat gaa ttg ggt aat ata ttt aaa gcc 1344 Ile Lys Gly Gly Gly His Ala Asp Glu Leu Gly Asn Ile Phe Lys Ala 435 440 445 aaa agt gca aat ttt ggg aag gaa aca cca aat gct gtg ttg gtt cag 1392 Lys Ser Ala Asn Phe Gly Lys Glu Thr Pro Asn Ala Val Leu Val Gln 450 455 460 aga agg atg ctg gag atg tgg act aat ttt gct aaa ttt gga aat cct 1440 Arg Arg Met Leu Glu Met Trp Thr Asn Phe Ala Lys Phe Gly Asn Pro 465 470 475 480 act cca gct att acg gat aca ctt cca ata aaa tgg gaa cct gct ttt 1488 Thr Pro Ala Ile Thr Asp Thr Leu Pro Ile Lys Trp Glu Pro Ala Phe 485 490 495 aaa gaa aat atg act ttt gtt caa att gac att gat tta aat ttg agt 1536 Lys Glu Asn Met Thr Phe Val Gln Ile Asp Ile Asp Leu Asn Leu Ser 500 505 510 act gat cca cta aaa agt cgt atg gaa ttt ggg aat aaa ata aaa tta 1584 Thr Asp Pro Leu Lys Ser Arg Met Glu Phe Gly Asn Lys Ile Lys Leu 515 520 525 tta aaa 1590 Leu Lys 530 71 1590 DNA Ctenocephalides felis 71 ttttaataat tttattttat tcccaaattc catacgactt tttagtggat cagtactcaa 60 atttaaatca atgtcaattt gaacaaaagt catattttct ttaaaagcag gttcccattt 120 tattggaagt gtatccgtaa tagctggagt aggatttcca aatttagcaa aattagtcca 180 catctccagc atccttctct gaaccaacac agcatttggt gtttccttcc caaaatttgc 240 acttttggct ttaaatatat tacccaattc atcagcatga ccaccgcctt ttattccaaa 300 atcaccaaaa actttccgac ttggagaatt ttcatcaaaa ttataaacat aataaaaaac 360 tggttcttcc tgatttttaa cagttaactt tacttgctca tcaattccac gtgtaaacca 420 attatcactt aaaacatcta caaaattctg catattttct gatatggttt tgttttggaa 480 ataaaattcc ctgattgctt cacccagtgc aatagatttt tgtgatcgca aaggtaattc 540 taagtcagtt ggtataaatc tttcaaaatc agcttcaaat ttatttaata aatctggatc 600 tgtttttaag tacatgaaaa atagattgcc ttcggcactg ttgtaacctg tcaacaatgg 660 aactttgtgg aattttcctg aatttattat tggtattggc aagtcagtta agtacgaatc 720 ttgttctgga aatgtttttt caatcgaagg tacaaacacg aagtcatcca gcagttgacc 780 atcaatttct tggggtaatt tggtatttaa caatgtttct actggtaggt ttttcaaaaa 840 atccaaggct tcttgaaggt tgtttgtggt aaggcctaag gttttgcata gtcgaagtgc 900 attcttaaca ggattttttt ggaaagccca gggattaaaa gcacttccac tttgtgctat 960 agccttgtgg aataaacctt tggtaagttg tgacaaaatg tgataatgta cacttgcagc 1020 tccagcagtt gctccacaaa ttgtaatatt ttttgggtct ccactaaagg ttgcaatatt 1080 ttcatttacc cattttaggg ctgcaacttg atccatcaat ccaacattcc caggcgcatc 1140 ttcgatttcc aaattaagaa aaccaagtgg tcctagacga taattaatag ttactaagat 1200 aatatcatat tctattaaat aatcaggacc atgtatatca gaatttcctg atccgaccac 1260 aaatgctcct ccatgaatcc aaaacattac tggcaaagga ttttctgaag tgttttgtgg 1320 gacatagata tttaagtaaa ggcaatcttc gcaaccccca gctgatttca aaaaccattt 1380 cccagcagca caattatttc catactgagt ggcgtcaaaa acaccattcc aaggatcaag 1440 tttttgtggt ggcttgaatc tgagatcatt tacaggagat tttgcatagg gtatacctgt 1500 gtaactatag taaattttac cattttcgtt tacaactttc ttgcctttca gaattccata 1560 tgttgttgtt tttagtaatg gatcacacat 1590 72 650 DNA Ctenocephalides felis CDS (3)..(650) 72 gg atc cat gga ggc gca ttc aac caa gga tca gga tct tat aat ttt 47 Ile His Gly Gly Ala Phe Asn Gln Gly Ser Gly Ser Tyr Asn Phe 1 5 10 15 ttt gga cct gat tat ttg atc agg gaa gga att att ttg gtc act atc 95 Phe Gly Pro Asp Tyr Leu Ile Arg Glu Gly Ile Ile Leu Val Thr Ile 20 25 30 aac tat aga tta gga gtt ttc ggt ttt cta tca gcg ccg gaa tgg gat 143 Asn Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu Trp Asp 35 40 45 atc cat gga aat atg ggt cta aaa gac cag aga ttg gca cta aaa tgg 191 Ile His Gly Asn Met Gly Leu Lys Asp Gln Arg Leu Ala Leu Lys Trp 50 55 60 gtt tac gac aac atc gaa aag ttt ggt gga gac aga gaa aaa att aca 239 Val Tyr Asp Asn Ile Glu Lys Phe Gly Gly Asp Arg Glu Lys Ile Thr 65 70 75 att gct gga gaa tct gct gga gca gca agt gtc cat ttt ctg atg atg 287 Ile Ala Gly Glu Ser Ala Gly Ala Ala Ser Val His Phe Leu Met Met 80 85 90 95 gac aac tcg act aga aaa tac tac caa agg gcc att ttg cag agt ggg 335 Asp Asn Ser Thr Arg Lys Tyr Tyr Gln Arg Ala Ile Leu Gln Ser Gly 100 105 110 aca tta cta aat ccg act gct aat caa att caa ctt ctg cat aga ttt 383 Thr Leu Leu Asn Pro Thr Ala Asn Gln Ile Gln Leu Leu His Arg Phe 115 120 125 gaa aaa ctc aaa caa gtg cta aac atc acg caa aaa caa gaa ctc cta 431 Glu Lys Leu Lys Gln Val Leu Asn Ile Thr Gln Lys Gln Glu Leu Leu 130 135 140 aac ctg gat aaa aac cta att tta cga gca gcc tta aac aga gtt cct 479 Asn Leu Asp Lys Asn Leu Ile Leu Arg Ala Ala Leu Asn Arg Val Pro 145 150 155 gat agc aac gac cat gac cga gac aca gta cca gta ttt aat cca gtc 527 Asp Ser Asn Asp His Asp Arg Asp Thr Val Pro Val Phe Asn Pro Val 160 165 170 175 tta gaa tca cca gaa tct cca gat cca ata aca ttt cca tct gcc ttg 575 Leu Glu Ser Pro Glu Ser Pro Asp Pro Ile Thr Phe Pro Ser Ala Leu 180 185 190 gaa aga atg aga aat ggt gaa ttt cct gat gtc gat gtc atc att ggt 623 Glu Arg Met Arg Asn Gly Glu Phe Pro Asp Val Asp Val Ile Ile Gly 195 200 205 ttc aat agt gct gaa ggt tta aga tct 650 Phe Asn Ser Ala Glu Gly Leu Arg Ser 210 215 73 216 PRT Ctenocephalides felis 73 Ile His Gly Gly Ala Phe Asn Gln Gly Ser Gly Ser Tyr Asn Phe Phe 1 5 10 15 Gly Pro Asp Tyr Leu Ile Arg Glu Gly Ile Ile Leu Val Thr Ile Asn 20 25 30 Tyr Arg Leu Gly Val Phe Gly Phe Leu Ser Ala Pro Glu Trp Asp Ile 35 40 45 His Gly Asn Met Gly Leu Lys Asp Gln Arg Leu Ala Leu Lys Trp Val 50 55 60 Tyr Asp Asn Ile Glu Lys Phe Gly Gly Asp Arg Glu Lys Ile Thr Ile 65 70 75 80 Ala Gly Glu Ser Ala Gly Ala Ala Ser Val His Phe Leu Met Met Asp 85 90 95 Asn Ser Thr Arg Lys Tyr Tyr Gln Arg Ala Ile Leu Gln Ser Gly Thr 100 105 110 Leu Leu Asn Pro Thr Ala Asn Gln Ile Gln Leu Leu His Arg Phe Glu 115 120 125 Lys Leu Lys Gln Val Leu Asn Ile Thr Gln Lys Gln Glu Leu Leu Asn 130 135 140 Leu Asp Lys Asn Leu Ile Leu Arg Ala Ala Leu Asn Arg Val Pro Asp 145 150 155 160 Ser Asn Asp His Asp Arg Asp Thr Val Pro Val Phe Asn Pro Val Leu 165 170 175 Glu Ser Pro Glu Ser Pro Asp Pro Ile Thr Phe Pro Ser Ala Leu Glu 180 185 190 Arg Met Arg Asn Gly Glu Phe Pro Asp Val Asp Val Ile Ile Gly Phe 195 200 205 Asn Ser Ala Glu Gly Leu Arg Ser 210 215 74 15 PRT Peptide MISC_FEATURE (3)..(3) Xaa = unknown 74 Asp Leu Xaa Val Xaa Xaa Leu Gln Gly Thr Leu Lys Gly Lys Glu 1 5 10 15 75 31 DNA Artificial sequence Synthetic Primer 75 cgcggatccg ctgatctaca agtgactttg c 31 76 1488 DNA Ctenocephalides felis exon (3)..(1487) 76 cc cag ggc gaa ttg gtt gga aaa gct ttg acg aac gaa aat gga aaa 47 Gln Gly Glu Leu Val Gly Lys Ala Leu Thr Asn Glu Asn Gly Lys 1 5 10 15 gag tat ttt agc tac aca ggt gtg cct tat gct aaa cct cca gtt gga 95 Glu Tyr Phe Ser Tyr Thr Gly Val Pro Tyr Ala Lys Pro Pro Val Gly 20 25 30 gaa ctt aga ttt aag cct cca cag aaa gct gag cca tgg aat ggt gtt 143 Glu Leu Arg Phe Lys Pro Pro Gln Lys Ala Glu Pro Trp Asn Gly Val 35 40 45 ttc aac gcc aca tca cat gga aat gtg tgc aaa gct ttg aat ttc ttc 191 Phe Asn Ala Thr Ser His Gly Asn Val Cys Lys Ala Leu Asn Phe Phe 50 55 60 ttg aaa aaa att gaa gga gac gaa gac tgc ttg ttg gtg aat gtg tac 239 Leu Lys Lys Ile Glu Gly Asp Glu Asp Cys Leu Leu Val Asn Val Tyr 65 70 75 gca cca aaa aca act tct gac aaa aaa ctt cca gta ttt ttc tgg gtt 287 Ala Pro Lys Thr Thr Ser Asp Lys Lys Leu Pro Val Phe Phe Trp Val 80 85 90 95 cat ggt ggc ggt ttt gtg act gga tcc gga aat tta gaa ttt caa agc 335 His Gly Gly Gly Phe Val Thr Gly Ser Gly Asn Leu Glu Phe Gln Ser 100 105 110 cca gat tat tta gta aat tat gat gtt att ttt gta act ttc aat tac 383 Pro Asp Tyr Leu Val Asn Tyr Asp Val Ile Phe Val Thr Phe Asn Tyr 115 120 125 cga ttg gga cca ctc gga ttt ttg aat ttg gag ttg gaa ggt gct cct 431 Arg Leu Gly Pro Leu Gly Phe Leu Asn Leu Glu Leu Glu Gly Ala Pro 130 135 140 gga aat gta gga tta ttg gat cag gta gca gct ttg aaa tgg acc aaa 479 Gly Asn Val Gly Leu Leu Asp Gln Val Ala Ala Leu Lys Trp Thr Lys 145 150 155 gaa aat att gag aaa ttt ggt gga gat cca gaa aat att aca att ggt 527 Glu Asn Ile Glu Lys Phe Gly Gly Asp Pro Glu Asn Ile Thr Ile Gly 160 165 170 175 ggt gtt tct gct ggt gga gca agt gtt cat tat ctt tta ttg tca cat 575 Gly Val Ser Ala Gly Gly Ala Ser Val His Tyr Leu Leu Leu Ser His 180 185 190 aca acc act gga ctt tac aaa agg gca att gct caa agt gga agt gct 623 Thr Thr Thr Gly Leu Tyr Lys Arg Ala Ile Ala Gln Ser Gly Ser Ala 195 200 205 tta aat cca tgg gcc ttc caa aga cat cca gta aag cgt agt ctt caa 671 Leu Asn Pro Trp Ala Phe Gln Arg His Pro Val Lys Arg Ser Leu Gln 210 215 220 ctt gct gag ata tta ggt cat ccc aca aac aac act caa gat gct tta 719 Leu Ala Glu Ile Leu Gly His Pro Thr Asn Asn Thr Gln Asp Ala Leu 225 230 235 gaa ttc tta caa aaa gcc cca gta gac agt ctc ctg aaa aaa atg cca 767 Glu Phe Leu Gln Lys Ala Pro Val Asp Ser Leu Leu Lys Lys Met Pro 240 245 250 255 gct gaa aca gaa ggt gaa ata ata gaa gag ttc gtc ttc gta cca tca 815 Ala Glu Thr Glu Gly Glu Ile Ile Glu Glu Phe Val Phe Val Pro Ser 260 265 270 att gaa aaa gtt ttc cca tcc cac caa cct ttc ttg gaa gaa tca cca 863 Ile Glu Lys Val Phe Pro Ser His Gln Pro Phe Leu Glu Glu Ser Pro 275 280 285 ttg gcc aga atg aaa tct gga tcc ttt aac aaa gta cct tta tta gtt 911 Leu Ala Arg Met Lys Ser Gly Ser Phe Asn Lys Val Pro Leu Leu Val 290 295 300 gga ttc aac agc gca gaa gga ctt ttg tac aaa ttc ttt atg aaa gaa 959 Gly Phe Asn Ser Ala Glu Gly Leu Leu Tyr Lys Phe Phe Met Lys Glu 305 310 315 aaa cca gag atg ctg aac caa gct gaa gca gat ttc gaa aga ctc gta 1007 Lys Pro Glu Met Leu Asn Gln Ala Glu Ala Asp Phe Glu Arg Leu Val 320 325 330 335 cca gcc gaa ttt gaa tta gcc cat gga tca gaa gaa tcg aaa aaa ctt 1055 Pro Ala Glu Phe Glu Leu Ala His Gly Ser Glu Glu Ser Lys Lys Leu 340 345 350 gca gaa aaa atc agg aag ttt tac ttt gac gat aaa ccc gtt cct gaa 1103 Ala Glu Lys Ile Arg Lys Phe Tyr Phe Asp Asp Lys Pro Val Pro Glu 355 360 365 aat gag cag aaa ttt att gac ttg ata gga gat att tgg ttt act aga 1151 Asn Glu Gln Lys Phe Ile Asp Leu Ile Gly Asp Ile Trp Phe Thr Arg 370 375 380 ggc att gac aag cat gtc aag ttg tct gta gaa aaa caa gac gag cca 1199 Gly Ile Asp Lys His Val Lys Leu Ser Val Glu Lys Gln Asp Glu Pro 385 390 395 gta tat tat tat gaa tat tct ttc tct gaa agt cat cct gca aaa gga 1247 Val Tyr Tyr Tyr Glu Tyr Ser Phe Ser Glu Ser His Pro Ala Lys Gly 400 405 410 415 aca ttt ggt gac cat aac ttg act gga gca tgt cat ggt gaa gaa ctt 1295 Thr Phe Gly Asp His Asn Leu Thr Gly Ala Cys His Gly Glu Glu Leu 420 425 430 gtg aat tta ttc aaa gtc gag atg atg aag ctg gaa aaa gat aaa ccg 1343 Val Asn Leu Phe Lys Val Glu Met Met Lys Leu Glu Lys Asp Lys Pro 435 440 445 aat gtt tta tta aca aaa gat agg gta ctt gct atg tgg acg aac ttc 1391 Asn Val Leu Leu Thr Lys Asp Arg Val Leu Ala Met Trp Thr Asn Phe 450 455 460 atc aaa aat gga aat cct act cct gaa gta act gaa tta ttg cca gtt 1439 Ile Lys Asn Gly Asn Pro Thr Pro Glu Val Thr Glu Leu Leu Pro Val 465 470 475 aaa tgg gaa cct gcc aca aaa gac aag ttg aat tat ttg aac att gat g 1488 Lys Trp Glu Pro Ala Thr Lys Asp Lys Leu Asn Tyr Leu Asn Ile Asp 480 485 490 495 

What is claimed is:
 1. An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a gene comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 and a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74.
 2. An isolated nucleic acid molecule that hybridizes under stringent hybridization conditions with a nucleic acid molecule having a nucleic acid sequence encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:1, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74.
 3. An isolated nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ. ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:67, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76 a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule comprising any of said nucleic acid sequences.
 4. An isolated protein encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions to a nucleic acid molecule selected from the group consisting of: a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:6, SEQ ID NO:9, SEQ ID NO:12, SEQ ID NO:15, SEQ ID NO:17, SEQ ID NO:20, SEQ ID NO:22, SEQ ID NO:26, SEQ ID NO:29, SEQ ID NO:32, SEQ ID NO:35, SEQ ID NO:38, SEQ ID NO:52, SEQ ID NO:59, SEQ ID NO:61, SEQ ID NO:69, SEQ ID NO:71; and a nucleic acid molecule encoding a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55 and SEQ ID NO:74.
 5. An isolated flea protein selected from the group consisting of: a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; and a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein comprising any of said amino acid sequences.
 6. A formulation of flea carboxylesterase proteins, wherein said proteins, when submitted to 14% Tris-glycine SDS-PAGE, comprise a fractionation profile as depicted in FIG. 3, wherein said proteins have carboxylesterase activity.
 7. A formulation of flea carboxylesterase proteins, wherein said proteins, when submitted to IEF-PAGE, comprise a fractionation profile as depicted in FIG. 4 in a lane selected from the group consisting of lane 3, lane 4, lane 5, lane 6 and lane 7, wherein said proteins have carboxylesterase activity.
 8. An isolated flea protein that hydrolyzes α-napthyl acetate to produce α-napthyl, when said protein is incubated in the presence of α-napthyl acetate contained in about 20 mM Tris at about pH 8.0 for about 15 minutes at about 37° C.
 9. A formulation comprising flea proteins that hydrolyze α-napthyl acetate to produce α-napthol, when said proteins are incubated in the presence of α-napthyl acetate contained in about 20 mM Tris at about pH 8.0 for about 15 minutes at about 37° C.
 10. An isolated flea protein that hydrolyzes the methyl ester group of juvenile hormone to produce a juvenile hormone acid.
 11. A formulation comprising flea proteins that hydrolyze the methyl ester group of juvenile hormone to produce a juvenile hormone acid.
 12. A therapeutic composition that, when administered to an animal, reduces hematophagous ectoparasite infestation, said therapeutic composition comprising an excipient and a protective compound selected from the group consisting of: an isolated hematophagous ectoparasite carboxylesterase protein; a mimetope of an isolated hematophagous ectoparasite carboxylesterase protein; an isolated hematophagous ectoparasite carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene; an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein; and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase.
 13. A method to reduce hematophagous ectoparasite infestation comprising treating an animal with a therapeutic composition comprising a protective compound selected from the group consisting of: an isolated hematophagous ectoparasite carboxylesterase protein; a mimetope of a hematophagous ectoparasite carboxylesterase protein; an isolated hematophagous ectoparasite carboxylesterase nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene; an isolated antibody that selectively binds to a hematophagous ectoparasite carboxylesterase protein; and an inhibitor of carboxylesterase activity identified by its ability to inhibit the activity of a flea carboxylesterase.
 14. A method to produce a carboxylesterase protein, said method comprising culturing a cell capable of expressing said protein, said protein being encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with a Ctenocephalides felis carboxylesterase gene.
 15. A method to identify a compound capable of inhibiting flea carboxylesterase activity, said method comprising: (a) contacting an isolated flea carboxylesterase with a putative inhibitory compound under conditions in which, in the absence of said compound, said protein has carboxylesterase activity; and (b) determining if said putative inhibitory compound inhibits said activity.
 16. A test kit to identify a compound capable of inhibiting flea carboxylesterase activity, said test kit comprising an isolated flea carboxylesterase protein having esterase activity and a means for determining the extent of inhibition of said activity in the presence of a putative inhibitory compound.
 17. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is a flea nucleic acid molecule.
 18. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule is selected from the group consisting of Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla nucleic acid molecules.
 19. The nucleic acid molecule of claims 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla (Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans nucleic acid molecules.
 20. The nucleic acid molecule of claims 1 or 2, wherein said nucleic acid molecule comprises a Ctenocephalides felis nucleic acid molecule.
 21. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule hybridizes under stringent hybridization conditions with a nucleic acid molecule selected from the group consisting of nfE1₄₀₁, nfE2₃₆₄, nfE3₄₂₁, nfE4₅₂₄, nfE5₁₉₈₂, nfE5₁₅₁₅, nfE5₂₁₄₄, nfE5₁₆₅₀, nfE6₁₄₈₈, nfE6₁₇₉₂, nfE6₁₆₅₀, nfE7₂₈₃₆, nfE7₁₇₈₈, nfE7₁₇₁₀, nfE7₆₅₀, nfE8₂₈₀₁, nfE8₁₇₈₅, nfE8₁₇₁₀, nfE9₂₀₀₇, nfE9₁₅₈₄, nfE9₁₅₄₀, nfE10₁₉₈₇ and nfE10₁₅₉₀.
 22. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a nucleic acid molecule selected from the group consisting of nfE1₄₀₁, nfE2₃₆₄, nfE3₄₂₁, nfE4₅₂₄, nfE5₁₉₈₂, nfE5₁₅₁₅, nfE5₂₁₄₄, nfE5₁₆₅₀, nfE6₁₄₈₈, nfE6₁₇₉₂, nfE6₁₆₅₀, nfE7₂₈₃₆, nfE7₁₇₈₈, nfE7₁₇₁₀, nfE7₆₅₀, nfE8₂₈₀₁, nfE8₁₇₈₅, nfE8₁₇₁₀, nfE9₂₀₀₇, nfE9₁₅₈₄, nfE9₁₅₄₀, nfE10₁₉₈₇ and nfE10₅₉₀.
 23. The nucleic acid molecule of claims 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule comprising a nucleic acid sequence that encodes a protein having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule encoding a protein having any of said amino acid sequences.
 24. The nucleic acid molecule of claims 1 or 2, wherein said nucleic acid molecule is selected from the group consisting of: a nucleic acid molecule comprising a nucleic acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:15, SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:20, SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:32, SEQ ID NO:33, SEQ ID NO:34, SEQ ID NO:35, SEQ ID NO:36, SEQ ID NO:38, SEQ ID NO:51, SEQ ID NO:52, SEQ ID NO:57, SEQ ID NO:59, SEQ ID NO:60, SEQ ID NO:61, SEQ ID NO:69, SEQ ID NO:70, SEQ ID NO:71, SEQ ID NO:72, SEQ ID NO:76, a nucleic acid molecule encoding a protein comprising amino acid sequence SEQ ID NO:74 SEQ ID NO:74; and a nucleic acid molecule comprising an allelic variant of a nucleic acid molecule comprising any of said nucleic acid sequences.
 25. The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises an oligonucleotide.
 26. A recombinant molecule comprising a nucleic acid molecule as set forth in claims 1 or 2 operatively linked to a transcription control sequence.
 27. A recombinant virus comprising a nucleic acid molecule as set forth in claims 1 or
 2. 28. A recombinant cell comprising a nucleic acid molecule as set forth in claims 1 or
 2. 29. The nucleic acid molecule of claim 2, wherein said nucleic acid molecule comprises a nucleic acid sequence that encodes a carboxylesterase protein.
 30. The nucleic acid molecule of claim 2, wherein said nucleic acid molecule hybridizes under stringent hybridization conditions with the complement of a nucleic acid sequence encoding said protein.
 31. The protein of claim 4, wherein said protein, when administered to an animal, elicits an immune response against a carboxylesterase protein.
 32. The protein of claim 4, wherein said protein is encoded by a nucleic acid molecule that hybridizes under stringent hybridization conditions with nucleic acid molecule nfE6₁₇₉₂.
 33. The protein of claim 4, wherein said protein is selected from the group consisting of: a protein comprising an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41. SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58 SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74; and a protein encoded by an allelic variant of a nucleic acid molecule encoding a protein selected from the group consisting of SEQ ID NO:2, SEQ ID NO:5, SEQ ID NO:8, SEQ ID NO:11, SEQ ID NO:14, SEQ ID NO:19, SEQ ID NO:25, SEQ ID NO:31, SEQ ID NO:37, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:53, SEQ ID NO:54, SEQ ID NO:55, SEQ ID NO:58, SEQ ID NO:68, SEQ ID NO:73 and SEQ ID NO:74.
 34. An isolated antibody that selectively binds to a protein as set forth in claim
 4. 35. The formulation of claim 6, wherein said proteins are selected from the group consisting of proteins having molecular weights ranging from about 60 kD to about 75 kD as determined by 14% Tris-glycine SDS-PAGE.
 36. The formulation of claim 6, wherein said proteins are isolated by the method comprising: (a) applying soluble proteins of a flea extract to a p-aminobenzamidine agarose bead column; (b) collecting unbound protein from said p-aminobenzamidine agarose bead column and applying said unbound protein to a gel filtration column; (c) eluting proteins bound to said gel filtration column and applying said eluted proteins to a cation exchange chromatography column; (d) eluting proteins bound to said cation exchange column and applying said eluted proteins to an anion exchange chromatography column; and (e) eluting proteins bound to said anion exchange column with about 170 mM NaCl to obtain said flea carboxylesterase proteins.
 37. The formulation of claim 7, wherein said proteins are selected from the group consisting of proteins having pI values ranging from about pI 4.7 to about pI 5.2 as determined by IEF-PAGE.
 38. The invention of claims 8 or 9, wherein said incubation results in the production of from about 0.3 to at least about 2.5 absorbance units in the presence of Fast Blue when measured at 590 nm.
 39. The protein of claim 8, wherein said protein does not hydrolyze the methyl ester group of juvenile hormone.
 40. The invention of claims 8 or 9 or 10 or 11, wherein the mature form of said protein has a molecular weight ranging from about 60 kD to about 75 kD.
 41. The invention of claims 8 or 9, wherein said protein comprises an amino acid sequence selected from the group consisting of SEQ ID NO:5, SEQ ID NO:19, SEQ ID NO:39, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44 and SEQ ID NO:53.
 42. The invention of claims 10 or 11, wherein hydrolyzation of said methyl ester group results in the release of at least about 120 counts per minute of ³H-juvenile hormone acid when determined by the method comprising: (a) incubating said flea protein in the presence of ³H-juvenile hormone to create a reaction mixture; (b) combining said reaction mixture with isooctane to produce an aqueous phase and an organic phase; (c) recovering said aqueous phase; and (d) determining the amount of ³H-juvenile hormone acid present in said aqueous phase.
 43. The protein of claim 10, wherein said protein does not hydrolyze α-napthyl acetate.
 44. The invention of claims 12 or 13, wherein said hematophagous ectoparasite carboxylesterase comprises a flea carboxylesterase.
 45. The invention of claims 12 or 13, wherein said hematophagous ectoparasite is a flea of a genus selected from the group consisting of Ctenocephalides, Ceratophyllus, Diamanus, Echidnophaga, Nosopsyllus, Pulex, Tunga, Oropsylla, Orchopeus and Xenopsylla.
 46. The invention of claims 12 or 13, wherein said hematophagous ectoparasite is a flea of a species selected from the group consisting of Ctenocephalides felis, Ctenocephalides canis, Ceratophyllus pulicidae, Pulex irritans, Oropsylla (Thrassis) bacchi, Oropsylla (Diamanus) montana, Orchopeus howardi, Xenopsylla cheopis and Pulex simulans.
 47. The invention of claims 12 or 13, wherein said hematophagous ectoparasite carboxylesterase comprises a juvenile hormone esterase.
 48. The invention of claims 12 or 13, wherein said composition further comprises a component selected from the group consisting of an adjuvant and a carrier.
 49. The invention of claims 12 or 13, wherein said composition further comprises a compound that reduces hematophagous ectoparasite burden by a method other than by reducing hematophagous ectoparasite carboxylesterase activity.
 50. The invention of claims 12 or 13, wherein said protective compound is selected from the group consisting of a naked nucleic acid vaccine, a recombinant virus vaccine and a recombinant cell vaccine.
 51. The invention of claims 12 or 13, wherein said inhibitor comprises a substrate analog of a hematophagous ectoparasite carboxylesterase.
 52. The method of claim 13, wherein said animal is selected from the group consisting of adult hematophagous ectoparasites, hematophagous ectoparasite larvae and animals susceptible to hematophagous ectoparasite infestation.
 53. The method of claim 13, wherein said animal is selected from the group consisting of adult fleas, flea larvae and animals susceptible to flea infestation.
 54. The method of claim 13, wherein hematophagous ectoparasite infestation is reduced by hematophagous ectoparasite larvae ingesting adult hematophagous ectoparasite feces comprising said therapeutic composition.
 55. The method of claim 13, wherein said adult hematophagous ectoparasite feces comprises anti-hematophagous ectoparasite carboxylesterase antibodies.
 56. The method of claim 13, wherein anti-hematophagous ectoparasite carboxylesterase antibodies are elicited in a host animal in response to administration of a reagent selected from the group consisting of one or more of said isolated hematophagous ectoparasite carboxylesterase proteins and one or more of said hematophagous ectoparasite carboxylesterase nucleic acid molecules, said adult hematophagous ectoparasite having fed from said host animal after said administration.
 57. The method of claim 13, wherein said animal is selected from the group consisting of mammals and birds.
 58. The method of claim 13, wherein said animal is selected from the group consisting of cats and dogs.
 59. The method of claim 14, wherein said cell expresses a nucleic acid molecule selected from the group consisting of pCro-nfE6₁₄₈₈, pTrc-nfE7₆₅₀, pTrc-nfE7₁₇₁₀, pTrc-nfE8₁₇₁₀, pTrc-nfE5₁₆₅₀, pTrc-nfE9₁₅₄₀, pFB-nfE6₁₆₇₉, pVL-nfE7₁₈₀₂, pVL-fE8₁₇₉₂ and pVL-nfE9₁₆₀₀. 